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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and livr failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms reveled in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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1. Background 
Bone is the basic element of the skeletal system and forms a major part of the 
framework of the body. Bone provides not only attachment points for most skeletal 
muscles, but also mechanical protection for the internal organs. Additionally, bone 
possesses the capacity for regeneration, remodeling and repair in response to 
injury caused by trauma, tumor resection or skeletal abnormalities. In some cases, 
bone injuries can heal without scar formation within a certain timeframe. 
Nevertheless, bone regeneration can be compromised when the required bone 
regeneration exceeds the self-healing potential, or if the regenerative process 
occurs in the presence of local or systemic diseases (e.g. avascular necrosis, 
osteoporosis or diabetes). 
Currently, the transplantation of autologous bone grafts has been considered as 
the “gold standard” for bone repair in clinics. Unfortunately, the limited availability 
of autografts and considerable morbidity at the donor site restricted their usage. 
The use of allografts can avoid these disadvantages but brings the risks of disease 
transmission or immunogenic rejection1. Bone tissue engineering (BTE), with the 
synergistic combination of scaffolds, cells and biomolecules (e.g. growth factors; 
Figure 1), has been applied as a promising alternative to engineer bone constructs2. 
However, the regenerative capacity using only scaffolds or biomaterials is limited 
and therefore not satisfying. Especially in critical situations (e.g. large bone defects 
or compromised medical conditions), additional empowerment of bone substitute 
materials with cells and/or biomolecules is necessary to obtain effective bone 
regeneration. In this thesis, we particularly focus on cell-based strategies for bone 
regeneration. 
2. Cellular strategies in BTE 
Among the various cell-types used in BTE, mesenchymal stem cells (MSCs) have 
attracted great attention because of their extensive proliferation potential and ability 
to differentiate into various cell types including osteoblasts3. Bone marrow (BM)- 
and adipose tissue (AT)-derived MSCs are the most frequently used MSCs in BTE, 
for which accounts that AT-MSCs have been mostly explored within the last 
decades for reasons of ease of cell harvesting with little donor site morbidity and 
high cell yield4. 
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Figure 1. Three key components for bone tissue engineering: cells, scaffolds and biomolecules. 
3. Cocultures of MSCs with angiogenic cells in BTE 
Notwithstanding the satisfactory results achieved in the animal studies by applying 
MSCs for bone regeneration, a big gap exists between the laboratory and the 
clinic5-6. Lack of sufficient vascular supply, resulting in immediate cell death after 
implantation, is generally suggested to be the cause of limited efficacy of cell-
based constructs for BTE in patients2. To simulate vascularization in cell-based 
constructs, coculture approaches of MSCs with angiogenic cells (e.g. endothelial 
cells, ECs) have been proposed to be effective7. Moreover, it has been 
demonstrated that such cocultures (with most studies using BM-MSCs) induced at 
least equal levels of mineralization in vitro8 and bone formation in vivo9 compared 
to MSCs monocultures, albeit lower numbers of MSCs are required in cocultures. 
4. Objectives of this thesis 
Although BM-MSCs and AT-MSCs are phenotypically similar, there are only few 
reports on the comparison of their osteogenic and angiogenic capacities in 
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regeneration exceeds the self-healing potential, or if the regenerative process 
occurs in the presence of local or systemic diseases (e.g. avascular necrosis, 
osteoporosis or diabetes). 
Currently, the transplantation of autologous bone grafts has been considered as 
the “gold standard” for bone repair in clinics. Unfortunately, the limited availability 
of autografts and considerable morbidity at the donor site restricted their usage. 
The use of allografts can avoid these disadvantages but brings the risks of disease 
transmission or immunogenic rejection1. Bone tissue engineering (BTE), with the 
synergistic combination of scaffolds, cells and biomolecules (e.g. growth factors; 
Figure 1), has been applied as a promising alternative to engineer bone constructs2. 
However, the regenerative capacity using only scaffolds or biomaterials is limited 
and therefore not satisfying. Especially in critical situations (e.g. large bone defects 
or compromised medical conditions), additional empowerment of bone substitute 
materials with cells and/or biomolecules is necessary to obtain effective bone 
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regeneration. 
2. Cellular strategies in BTE 
Among the various cell-types used in BTE, mesenchymal stem cells (MSCs) have 
attracted great attention because of their extensive proliferation potential and ability 
to differentiate into various cell types including osteoblasts3. Bone marrow (BM)- 
and adipose tissue (AT)-derived MSCs are the most frequently used MSCs in BTE, 
for which accounts that AT-MSCs have been mostly explored within the last 
decades for reasons of ease of cell harvesting with little donor site morbidity and 
high cell yield4. 
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Figure 1. Three key components for bone tissue engineering: cells, scaffolds and biomolecules. 
3. Cocultures of MSCs with angiogenic cells in BTE 
Notwithstanding the satisfactory results achieved in the animal studies by applying 
MSCs for bone regeneration, a big gap exists between the laboratory and the 
clinic5-6. Lack of sufficient vascular supply, resulting in immediate cell death after 
implantation, is generally suggested to be the cause of limited efficacy of cell-
based constructs for BTE in patients2. To simulate vascularization in cell-based 
constructs, coculture approaches of MSCs with angiogenic cells (e.g. endothelial 
cells, ECs) have been proposed to be effective7. Moreover, it has been 
demonstrated that such cocultures (with most studies using BM-MSCs) induced at 
least equal levels of mineralization in vitro8 and bone formation in vivo9 compared 
to MSCs monocultures, albeit lower numbers of MSCs are required in cocultures. 
4. Objectives of this thesis 
Although BM-MSCs and AT-MSCs are phenotypically similar, there are only few 
reports on the comparison of their osteogenic and angiogenic capacities in 
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monocultures or cocultures. Even within these few reports, no consensus has been 
reached. Consequently, two main questions need to be answered: (i) do AT-MSCs 
have an equal capacity as BM-MSCs in terms of osteogenesis and angiogenesis, 
and (ii) do cocultures of MSCs with angiogenic cells have higher osteogenic and 
angiogenic capacities than monocultures? Moreover, a prerequisite for such 
comparisons is knowing the optimal culture conditions (e.g. culture medium, cell 
ratio in cocultures, cell loading methods, etc.). 
In view of this, this thesis aimed to (i) optimize the (co)culture conditions in terms of 
culture medium and cell ratio; (ii) comparatively evaluate the osteogenic (in vitro) 
and angiogenic (both in vitro and in vivo) capacity of BM-MSCs and AT-MSCs, as 
well as their cocultures with ECs; (iii) evaluate the bone forming capacity of AT-
MSCs and their cocultures with ECs in vivo, in both ectopic (i.e. subcutaneous and 
intramuscular sites) and orthotopic (i.e. cranial defects) implantation models. In 
more detail, the following research questions were addressed: 
1. What is the current state of art for the use of BM-MSCs and AT-MSCs, and their 
cocultures with ECs in BTE (Chapter 2)? 
2. What is the optimal cell culture medium and cell ratio in cocultures of BM-
MSCs/ECs, in terms of osteogenesis and angiogenesis (Chapter 3)? 
3. Is human platelet lysate a suitable alternative for fetal bovine serum to be used 
as a supplementation in culture medium for both BM-MSCs and AT-MSCs, and 
their cocultures with ECs (Chapter 4)? 
4. What is the optimal cell loading method for osteogenesis of BM-MSCs and AT-
MSCs in hydrogels (Chapter 5)? 
5. Do cocultures of AT-MSCs/ECs form more bone compared to AT-MSCs 
monocultures in an orthotopic implantation model (Chapter 6)? 
6. What is the effect of ectopic implantation (i.e. subcutaneous and intramuscular) 
site on bone formation of cell-based and growth factor-based constructs (Chapter 
7)? 
7. Do AT-MSCs/ECs cocultures have equal angiogenic capacity compared to BM-
MSCs/ECs (Chapter 8)? 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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1. Introduction 
Bone is one of the most transplanted tissues with over 2.2 million bone graft 
procedures being performed annually worldwide1. Nowadays, bone tissue 
engineering/regenerative medicine (BTE/RM) approaches, with the triad principle 
of applying combinations of the three building blocks (i) supporting scaffolds, (ii) 
growth factors and (iii) functionally active cells in order to (re)generate biologically 
functional tissues, have been suggested as promising strategies to regenerate 
bone2. 
The potential of BTE/RM-constructs becomes especially challenging under 
compromised conditions, such as in elderly patients with suboptimal medical 
conditions (e.g. osteoporosis, diabetes and cancer), or in cases in which the bone 
defect dimensions are (far) beyond those that can spontaneously heal. Consensus 
on the difficulty of healing bone defects under such conditions illuminates that the 
bone regenerative capacity arising from only a scaffold material is often insufficient, 
and that additional empowerment of BTE/RM-approaches should arise from pre-
seeding the scaffold with cells or incorporating growth factors within the scaffolds. 
Small successes have been reported for in vitro experiments and even animal 
studies with cell-laden scaffolds, but translation of these results toward the clinics 
for bone regenerative applications has been insignificant so far3. Several issues 
can be attributed to the lack of this clinical success. Firstly, the quality and quantity 
of the used cells and the pre-culture conditions after cell seeding onto the scaffolds 
are variable and limited, and tiny variations within these procedures may 
substantially influence the outcome. Secondly, cells within a construct are 
subjected to inflammatory conditions and limited nutrient supply upon implantation, 
since surgical intervention generates tissue damage and the diffusion of nutrients 
and oxygen from the nearest capillary is limited to only 150-200 μm4. Researchers 
have pointed out that rapid vascularization into cell-based BTE/RM-constructs is 
pivotal to clinical success3. From a cellular point of view, the solution for insufficient 
vascularization is either coculture of osteogenic cells with angiogenic cells5 or 
changing the priming differentiation pathway of stem cells from osteogenic to 
chondrogenic, since cartilage is an avascular tissue with less susceptibility to 
limited vascularization6. 
The aim of this review is to summarize the current state-of-the-art in cell-based 
BTE/RM in terms of critical procedures and efficacy of monoculture (osteogenic) 
and coculture approaches. Although the authors are aware of the major importance 
of scaffold properties and the potential of growth factor incorporation and release, 
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the intention is to focus on the cellular component in BTE/RM approaches, and 
hence critically review the experimental, pre-clinical and clinical efforts on this topic. 
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2. Critical procedures 
To eventually restore the bone defects in clinical applications, some critical issues 
should be taken into consideration, which are inherently related to the cell quality 
and quantity (e.g. cell types/sources, cell isolation and yield), cell seeding 
efficiency and pre-culture conditions, and finally in vivo conditions. 
2.1. Stem cell sources 
A source of human cells that can be derived in large numbers from a small and 
easy initial harvest and differentiate into bone forming cells is preferable for cell-
based BTE/RM constructs7. Various cell types have been explored for BTE/RM, 
each with its own potential and premise. 
2.1.1. Non-adult stem cells 
Non-adult stem cells contain two categories: embryonic stem cells (ESCs) and 
stem cells isolated from perinatal tissue, such as aborted fetal tissue (fetal stem 
cells) and discarded tissue at birth (e.g. umbilical cord and placenta). ESCs are 
pluripotent, but consistency on bone formation capacity by ESCs progeny has not 
been achieved8-9 and ethical issues exist. The latter category, positioned between 
embryonic and adult stem cells, is multipotent. These cells have similar bone 
formation capacity compared to adult mesenchymal stem cells (MSCs)10. 
Nevertheless, the fact that they can form tumors11 upon in vivo implantation makes 
the use of these cell types controversial. 
2.1.2. Adult stem cells 
Adult MSCs play a predominant role in the field of BTE/RM and the most common 
sources are bone marrow (BM), adipose tissue (AT) and dental pulp (DP). 
2.1.2.1. BM-MSCs 
BM is the predominant source for adult MSCs. BM-derived MSCs (BM-MSCs) have 
multipotential differentiation capacity including osteogenic, and can perform 
pericyte-like functions by secreting both angiogenic and stabilization factors in the 
process of vessel formation12. Although BM-MSCs are widely used in laboratory 
and pre-clinical studies, they bring along several disadvantages, including donor 
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site morbidity and side effects, limited proliferation capacity and inferior 
differentiation potential in aged individuals13. Thus, alternatives to BM-MSCs have 
been explored. 
2.1.2.2. AT-MSCs 
AT is a popular alternative source for MSCs because of easy and less invasive 
harvest procedures and larger yield compared to BM14. AT-derived MSCs (AT-
MSCs) show large similarity with BM-MSCs regarding gene expression and 
osteogenic capacity15, and also can exert pericyte-like functions16. Nevertheless, 
the bone forming capacity of AT-MSCs needs further confirmation and whether AT-
MSCs exhibit a similar bone forming capacity to BM-MSCs is still controversial. 
Moreover, pre-clinical safety and efficacy as well as long-term in vivo studies are 
required before the promise of AT-MSCs can be evaluated clinically. 
2.1.2.3. DP-MSCs 
The non-invasive way of obtaining DP from deciduous/extracted teeth or even non-
extracted crown fractured teeth make it an ideal source for MSCs. DP-derived 
MSCs (DP-MSCs) have similar gene expression, faster proliferation rate and 
higher percentage of stem cells in the harvested population compared to BM-
MSCs17 and have demonstrated to express pericyte markers18. While some 
researchers reported that DP-MSCs have at least equal bone forming capacity 
compared to BM-MSCs19-20 , others showed only the formation of connective tissue 
from DP-MSCs21 or dentin-pulp-like complex formation22, suggesting the 
requirement for in-depth studies on the mechanism of bone forming capacity by 
DP-MSCs. 
2.2. Isolation and expansion 
Often, high-quality cells in relevant quantities are crucial to satisfy the clinical 
demands, i.e. the successful restoration of a bone defect. To achieve this, effective 
cell isolation and expansion of harvested cells are of utmost importance. 
Inadequate isolation methods can lead to „polluted‟ isolates and hence 
inconsistency in cell marker expression23. Further, long-term expansion has 
demonstrated to decrease stem cell proliferation and differentiation capacity24. 
Nevertheless, a broadly accepted protocol has not been established for isolation 
and large-scale expansion of human (mesenchymal stem) cells, which also makes 
the comparison among reported results from publicly available databanks difficult. 
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alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2. Critical procedures 
To eventually restore the bone defects in clinical applications, some critical issues 
should be taken into consideration, which are inherently related to the cell quality 
and quantity (e.g. cell types/sources, cell isolation and yield), cell seeding 
efficiency and pre-culture conditions, and finally in vivo conditions. 
2.1. Stem cell sources 
A source of human cells that can be derived in large numbers from a small and 
easy initial harvest and differentiate into bone forming cells is preferable for cell-
based BTE/RM constructs7. Various cell types have been explored for BTE/RM, 
each with its own potential and premise. 
2.1.1. Non-adult stem cells 
Non-adult stem cells contain two categories: embryonic stem cells (ESCs) and 
stem cells isolated from perinatal tissue, such as aborted fetal tissue (fetal stem 
cells) and discarded tissue at birth (e.g. umbilical cord and placenta). ESCs are 
pluripotent, but consistency on bone formation capacity by ESCs progeny has not 
been achieved8-9 and ethical issues exist. The latter category, positioned between 
embryonic and adult stem cells, is multipotent. These cells have similar bone 
formation capacity compared to adult mesenchymal stem cells (MSCs)10. 
Nevertheless, the fact that they can form tumors11 upon in vivo implantation makes 
the use of these cell types controversial. 
2.1.2. Adult stem cells 
Adult MSCs play a predominant role in the field of BTE/RM and the most common 
sources are bone marrow (BM), adipose tissue (AT) and dental pulp (DP). 
2.1.2.1. BM-MSCs 
BM is the predominant source for adult MSCs. BM-derived MSCs (BM-MSCs) have 
multipotential differentiation capacity including osteogenic, and can perform 
pericyte-like functions by secreting both angiogenic and stabilization factors in the 
process of vessel formation12. Although BM-MSCs are widely used in laboratory 
and pre-clinical studies, they bring along several disadvantages, including donor 
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site morbidi y and side effects, limited proliferati n capacity and inferior 
differentiation potential in aged i dividuals13. Thus, al ernatives to BM-MSCs have 
been explored. 
2.1.2.2. AT-MSCs 
AT is a popula  alternative source for MSCs bec use of easy a d less invasive 
harves  procedures and larger yi ld compared to BM14. AT-derived MSCs (AT-
MSCs) show l rge similarity with BM-MSCs regarding gene expression and 
osteogenic capacity15, and a so can exert pericyte-like fun tion 16. Neverthel ss, 
the bone forming capacity of AT-MSCs needs further confirmation and wh t er AT-
MSCs exhibit a similar bone forming c pacity to BM-MSCs is still controversial. 
Moreover, pre-clinical saf ty and efficacy as well as long-term i  vivo studies are 
required before the promise of AT-MSCs can be evaluated clinically. 
2.1.2.3. DP-MSCs 
The non-invasive way of obtaining DP from deciduous/extracted teeth or even non-
extracted crown fractured teeth make it an ideal source for MSCs. DP-derived 
MSCs (DP-MSCs) have similar gene expression, faster proliferation rate and 
higher percentage of stem cells in the harvested population compared to BM-
MSCs17 and have demonstrated to express pericyte markers18. While some 
researchers reported that DP-MSCs have at least equal bone forming capacity 
compared to BM-MSCs19-20 , others showed only the formation of connective tissue 
from DP-MSCs21 or dentin-pulp-like complex formation22, suggesting the 
requirement for in-depth studies on the mechanism of bone forming capacity by 
DP-MSCs. 
2.2. Isolation and expansion 
Often, high-quality cells in relevant quantities are crucial to satisfy the clinical 
demands, i.e. the successful restoration of a bone defect. To achieve this, effective 
cell isolation and expansion of harvested cells are of utmost importance. 
Inadequate isolation methods can lead to „polluted‟ isolates and hence 
inconsistency in cell marker expression23. Further, long-term expansion has 
demonstrated to decrease stem cell proliferation and differentiation capacity24. 
Nevertheless, a broadly accepted protocol has not been established for isolation 
and large-scale expansion of human (mesenchymal stem) cells, which also makes 
the comparison among reported results from publicly available databanks difficult. 
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2.2.1. Isolation of BM-, AT- and DP-MSCs 
The isolation of MSCs undergoes a general procedure, meaning tissue harvesting 
and treatment (mincing and/or enzymatic digestion), washing, filtering and 
centrifugation, and plating. BM-MSCs can be obtained from either bone chips 
(cortical or trabecular bone) or bone marrow, for which the stem cells isolated from 
these two sources have been shown to be identical in terms of phenotype and 
multilineage differentiation capacity25. AT-MSCs can be isolated from a resected 
adipose block or lipoaspirate, and the latter method is easier since a lipoaspirate 
consists of finely minced fat fragments with less volume and a more homogeneous 
population of cells. Isolation of MSCs from DP basically relies on two methods. The 
first one is the outgrowth method (i.e. cell migration out of the pulp fragments and 
adherence to cell culture plates), which is rarely applied nowadays as it takes 
substantially longer to obtain similar cell numbers compared to enzymatic digestion. 
This latter method is comparable to the earlier mentioned digestion method for BM-
MSCs (Figure 1). Next, bone chips, resected adipose tissue and dental pulp tissue 
require mincing, while bone marrow and lipoaspirate directly proceed to a washing 
procedure. After washing, enzymatic digestion is performed for all the tissues 
except for bone marrow aspirates, and followed by filtering and gradient density 
centrifugation. The isolated cells are plated for adhesion-dependent selection. To 
increase the purity of the isolated cells, cell separation methods such as cell 
sorting using cell surface markers (e.g. CD73, CD105 and Stro-1) are frequently 
used (Figure 1). 
 
Figure 1. Scheme for isolation of mesenchymal stem cells derived from bone, adipose tissue and dental 
pulp. Abbreviations: MACS/FACS, magnetic activated cell sorting/fluorescence activated cell sorting. 
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2.2.2. Expansion of BM-, AT- and DP-MSCs 
For expansion, essential culture parameters comprise the type of basic culture 
medium and the nutritional source (e.g. serum), cell passaging density and 
doubling numbers. Alpha-minimum essential medium (α-MEM) is the optimal bare 
culture medium for isolation and expansion of human BM-MSCs26, AT-MSCs27-28 
and DP-MSCs29-30. Human serum31 or human platelet lysate (PL)32-34 has been 
explored as a replacement for fetal bovine serum (FBS) since FBS brings along 
potential hazards related to bovine pathogens or immunological issues. No 
consensus regarding optimal cell seeding density for expansion exists, although 
low density cell seeding has been recommended (e.g. for BM-MSCs, 50~100 or 
1,000 cells/cm2 for expansion; for AT-MSCs, 100~200 cells/cm2 and for DP-MSCs, 
800~1,000 cells/cm2) because this is associated with higher proliferation rates26,35-
36. 
One needs to realize that small variations within each step of an isolation 
procedure, including enzyme type and enzymatic digestion time, centrifugation 
speed and time, washing liquid (either phosphate-buffered saline or sodium saline), 
may change the quality and quantity of the isolated stem cells and hence influence 
the experimental outcomes. Additionally, the site of tissue harvest can influence 
the phenotype of the isolated stem cells37, the percentage of stem cells in the 
whole population38 as well as their osteogenic differentiation capacity39. However, 
this review did not reach any significant conclusion as to standardized and 
optimized stem cell isolation and expansion procedures, which sheds light on the 
need for relative studies. 
2.3. Cell seeding techniques and pre-culture on scaffolds 
Cell seeding and pre-culture on scaffolds are essential procedures before in vivo 
implantation. Seeding requirements for cell-based BTE/RM constructs for potential 
clinical use should allow for (i) maximized utilization of donor cells, (ii) minimal time 
for anchorage-dependent and shear-sensitive cells (e.g. osteoblasts) in suspension, 
and (iii) spatially uniform distribution of attached cells40. 
2.3.1. Cell seeding efficiency 
Cell seeding efficiency, which might further correlate with bone forming capacity, 
can be increased by either selecting proper scaffolds and modifying the scaffold 
surface or optimizing cell seeding methods. For the former method, the criteria for 
three-dimensional scaffolds are explored in tandem with the properties such as 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2.2.1. Isolation of BM-, AT- and DP-MSCs 
The isolation of MSCs undergoes a general procedure, meaning tissue harvesting 
and treatment (mincing and/or enzymatic digestion), washing, filtering and 
centrifugation, and plating. BM-MSCs can be obtained from either bone chips 
(cortical or trabecular bone) or bone marrow, for which the stem cells isolated from 
these two sources have been shown to be identical in terms of phenotype and 
multilineage differentiation capacity25. AT-MSCs can be isolated from a resected 
adipose block or lipoaspirate, and the latter method is easier since a lipoaspirate 
consists of finely minced fat fragments with less volume and a more homogeneous 
population of cells. Isolation of MSCs from DP basically relies on two methods. The 
first one is the outgrowth method (i.e. cell migration out of the pulp fragments and 
adherence to cell culture plates), which is rarely applied nowadays as it takes 
substantially longer to obtain similar cell numbers compared to enzymatic digestion. 
This latter method is comparable to the earlier mentioned digestion method for BM-
MSCs (Figure 1). Next, bone chips, resected adipose tissue and dental pulp tissue 
require mincing, while bone marrow and lipoaspirate directly proceed to a washing 
procedure. After washing, enzymatic digestion is performed for all the tissues 
except for bone marrow aspirates, and followed by filtering and gradient density 
centrifugation. The isolated cells are plated for adhesion-dependent selection. To 
increase the purity of the isolated cells, cell separation methods such as cell 
sorting using cell surface markers (e.g. CD73, CD105 and Stro-1) are frequently 
used (Figure 1). 
 
Figure 1. Scheme for isolation of mesenchymal stem cells derived from bone, adipose tissue and dental 
pulp. Abbreviations: MACS/FACS, magnetic activated cell sorting/fluorescence activated cell sorting. 
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2.2.2. Expansi n of BM-, AT- and DP-MSCs 
For expansion, essential culture parameters comprise the type of basic culture 
medium and the nutritional source (e.g. serum), cell passaging density and 
doubling numbers. Alpha-minimum essential medium (α-MEM) is the optimal bare 
culture medium for isolation and expansion of human BM-MSCs26, AT-MSCs27-28 
and DP-MSCs29-30. Human serum31 or human platelet lysate (PL)32-34 has been 
explored as a replacement for fetal bovine serum (FBS) since FBS brings along 
potential hazards related to bovine pathogens or immunological issues. No 
consensus regarding optimal cell seeding density for expansion exists, although 
low density cell seeding has been recom ended (e.g. for BM-MSCs, 50~100 or 
1,000 cells/cm2 for expansion; for AT-MSCs, 100~200 cells/cm2 and for DP-MSCs, 
800~1,000 cells/cm2) because this is associated with higher proliferation rates26,35-
36. 
One needs to realize that small variations within each step of an isolation 
procedure, including enzyme type and enzymatic digestion time, centrifugation 
speed and time, washing liquid (either phosphate-buffered saline or sodium saline), 
may change the quality and quantity of the isolated stem cells and hence influence 
the experimental outcomes. Additionally, the site of tissue harvest can influence 
the phenotype of the isolated stem cells37, the percentage of stem cells in the 
whole population38 as well as their osteogenic differentiation capacity39. However, 
this review did not reach any significant conclusion as to standardized and 
optimized stem cell isolation and expansion procedures, which sheds light on the 
need for relative studies. 
2.3. Cell seeding techniques and pre-culture on scaffolds 
Cell seeding and pre-culture on scaffolds are essential procedures before in vivo 
implantation. Seeding requirements for cell-based BTE/RM constructs for potential 
clinical use should allow for (i) maximized utilization of donor cells, (ii) minimal time 
for anchorage-dependent and shear-sensitive cells (e.g. osteoblasts) in suspension, 
and (iii) spatially uniform distribution of attached cells40. 
2.3.1. Cell seeding efficiency 
Cell seeding efficiency, which might further correlate with bone forming capacity, 
can be increased by either selecting proper scaffolds and modifying the scaffold 
surface or optimizing cell seeding methods. For the former method, the criteria for 
three-dimensional scaffolds are explored in tandem with the properties such as 
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porosity, interconnectivity, biodegradability and mechanical integrity. As such, 
diverse forms of scaffolds (e.g. bulk vs. hydrogels; fibrous vs. foam) with different 
components (e.g. polymers, ceramics and metal) have been explored. Various 
scaffold properties affect cell seeding efficiency, for instance scaffolds that have 
more regular and homogeneous pores and are more accessible for the cell 
suspension during drop seeding have higher cell seeding efficiency (e.g. a fiber 
deposited vs. a foam scaffold) since they might avoid cell aggregate entrapment in 
the small and irregular internal pores41. Furthermore, scaffold surfaces can be 
modified through pre-treatment with adhesive proteins (e.g. pre-immersion in 
serum or fibronectin). For the latter method, cell seeding volume and cell seeding 
time significantly affect cell seeding efficacy as well as cell viability41. Moreover, the 
combination of low pressure (vacuum) with vibration can help removing potential 
air bubbles around scaffolds and allow more cells to penetrate deeply into the 
scaffolds to enhance bone formation, especially for porous scaffolds, in 
comparison with the common used static seeding methods42. Additionally, dynamic 
cell seeding (e.g. perfusion bioreactor) has shown to yield higher cell seeding 
efficiencies and more homogenous cell distribution compared to static cell 
seeding43. 
2.3.2. Cell seeding density and medium perfusion 
Cell proliferation after cell seeding is mainly regulated by (i) contact-inhibition 
between adjacent cells, which is determined by cell seeding density44 and (ii) 
nutrient transfer efficiency as a result of the medium perfusion rate, which also 
determines cell viability45. 
Initial seeding density can alter the expression of osteogenic genes by controlling 
the distance of paracrine signals among cells. Although no systematic studies on 
the optimal cell seeding density are available due to the variety of scaffold 
properties (Table 1), it has been agreed that a certain threshold of cell density is 
essential to achieve successful bone regeneration in vivo. Low seeding densities 
may compromise cellular contact and hence influence bone formation while high 
seeding densities do not necessarily benefit cell behavior since the overloaded 
cells may result in limited nutrient transport and insufficient waste removal from the 
internal structures46. In general, below a certain threshold (i.e. the optimal density), 
osteogenic marker expression and extracellular matrix production (i.e. 
mineralization) capacities are enhanced with increasing cell seeding density. In 
contrast, when the cell seeding density exceeds this optimal density, a further 
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increase in cell seeding density can reduce the bone regenerative capacity of 
cells46. 
Medium perfusion is increased in dynamic cultures using bioreactor systems, 
leading to an improved nutrient delivery and mechanical stimulation to the cells as 
well as enhanced osteogenic differentiation compared to static cultures47. Three 
classes of bioreactor systems have been widely utilized in BTE: spinner ﬂasks, 
rotating wall, and perfusion systems, with each of these being proven as an 
effective means to culture cells for BTE purposes. Nevertheless, compared to the 
former two methods, perfusion systems have been exhibited to effectively perfuse 
media throughout the scaffold rather than only creating a homogenous media 
solution on the exterior of a scaffold48. 
2.3.3. Pre-differentiation of cells 
Pre-differentiation of the cells into osteogenic49-50 or chondrogenic lineage6,51 prior 
to in vivo implantation has been assumed essential for enhancing osteogenesis in 
vitro and in vivo in comparison to non-predifferentiated (i.e. osteogenic or 
chondrogenic) cells. However, the optimal pre-culture time for bone regeneration is 
either controversial (for osteogenic differentiation) or lacking (for chondrogenic 
differentiation). Short time osteogenic induction is probably insufficient for inducing 
cell differentiation, while long time osteogenic induction leads to an apoptotic 
process52. Longer pre-culture time (2-weeks) has shown to induce more bone 
formation compared to shorter time (1-week) for both human BM-MSCs53 and 
human AT-MSCs54. From a clinical point of view, one-step surgical techniques, in 
which freshly isolated cells (without expansion) are used directly within the 
operation theatre, are recommendable for clinical applications of cell-based bone 
regenerative strategies55. This suggests that one needs to balance between the 
bone regeneration efficacy caused by the relatively longer pre-culture time and the 
benefits that patients gain from the one-step surgery. 
The aforementioned seeding techniques and pre-culture conditions (for 
monocultures) are also applied to cocultures. Besides, more parameters should be 
considered for cocultures, amongst which is the choice of cell origin and cell types, 
culture medium and cell ratio. The effects of origin of either MSCs (e.g. BM- or AT-
MSCs) or angiogenic cells (e.g. endothelial cells, ECs or endothelial progenitor 
cells, EPCs) need further investigation. Furthermore, it should be noted that 
cellular communication in cocultures is cell-type specific. For instance, when ECs 
were replaced by primary chondrocytes or fibroblasts in osteoblasts/ECs coculture, 
no increasing effects on ALP-activity were observed56. The culture medium used in 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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porosity, interconnectivity, biodegradability and mechanical integrity. As such, 
diverse forms of scaffolds (e.g. bulk vs. hydrogels; fibrous vs. foam) with different 
components (e.g. polymers, ceramics and metal) have been explored. Various 
scaffold properties affect cell seeding efficiency, for instance scaffolds that have 
more regular and homogeneous pores and are more accessible for the cell 
suspension during drop seeding have higher cell seeding efficiency (e.g. a fiber 
deposited vs. a foam scaffold) since they might avoid cell aggregate entrapment in 
the small and irregular internal pores41. Furthermore, scaffold surfaces can be 
modified through pre-treatment with adhesive proteins (e.g. pre-immersion in 
serum or fibronectin). For the latter method, cell seeding volume and cell seeding 
time significantly affect cell seeding efficacy as well as cell viability41. Moreover, the 
combination of low pressure (vacuum) with vibration can help removing potential 
air bubbles around scaffolds and allow more cells to penetrate deeply into the 
scaffolds to enhance bone formation, especially for porous scaffolds, in 
comparison with the common used static seeding methods42. Additionally, dynamic 
cell seeding (e.g. perfusion bioreactor) has shown to yield higher cell seeding 
efficiencies and more homogenous cell distribution compared to static cell 
seeding43. 
2.3.2. Cell seeding density and medium perfusion 
Cell proliferation after cell seeding is mainly regulated by (i) contact-inhibition 
between adjacent cells, which is determined by cell seeding density44 and (ii) 
nutrient transfer efficiency as a result of the medium perfusion rate, which also 
determines cell viability45. 
Initial seeding density can alter the expression of osteogenic genes by controlling 
the distance of paracrine signals among cells. Although no systematic studies on 
the optimal cell seeding density are available due to the variety of scaffold 
properties (Table 1), it has been agreed that a certain threshold of cell density is 
essential to achieve successful bone regeneration in vivo. Low seeding densities 
may compromise cellular contact and hence influence bone formation while high 
seeding densities do not necessarily benefit cell behavior since the overloaded 
cells may result in limited nutrient transport and insufficient waste removal from the 
internal structures46. In general, below a certain threshold (i.e. the optimal density), 
osteogenic marker expression and extracellular matrix production (i.e. 
mineralization) capacities are enhanced with increasing cell seeding density. In 
contrast, when the cell seeding density exceeds this optimal density, a further 
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increase in cell seeding density can reduce the bo e regenerative capacity of 
cells46. 
Medium perfusion i  increased in dynamic cultures using bioreac or syst ms, 
leading to an improved nutrient delivery and mechanical stimulation to the cells as 
well as enhanced osteogenic differentiation compared to static cultures47. Three 
classes of bioreactor systems have been widely utilized in BTE: spinner ﬂasks, 
rotating wall, and perfusion systems, with each of these being proven as an 
effective means to culture cells for BTE purposes. Nevertheless, compared to the 
former two methods, perfusion systems have been exhibited to effectively perfuse 
media throughout the scaffold rather than only creating a homogenous media 
solution on the exterior of a scaffold48. 
2.3.3. Pre-differentiation of cells 
Pre-differentiation of the cells into osteogenic49-50 or chondrogenic lineage6,51 prior 
to in vivo implantatio  has been assu ed essential for enhancing osteogenesis in 
vitro an  in vivo in comparison to non-predifferentiated (i.e. oste genic or 
chondrogenic) cells. However, the optimal pre-culture time for bone regeneration is 
either controversial (for osteogenic differentiation) or l cking (for chondrogenic 
differentiation). Short time steog nic induction is probably insufficient for inducing 
cell differentiation, while long time osteogenic induction leads to an apoptotic 
process52. Longer pre- ulture time (2-weeks) has shown to induce more bone 
formation compared to sh rter time (1-week) f r both hum n BM-MSCs53 and 
human AT-MSCs54. Fro  a c inical point of view, ne-step surgical techniques, in 
which freshly isolated cells (without expan ion) are used directly within the 
op r tion theatre, ar  recommendable for clinical appli ations of cell-based bone 
regenerative stra egies55. This suggests that on  ne ds to balance between the 
bone regeneration efficacy caused by the relatively longer pre-culture time nd the 
benefits that patien s gain from the one-step urgery. 
The aforementioned seeding techniques and pre-culture conditions (for 
monocultures) are also applied to cocultures. Besides, more parameters should be 
considered for cocultures, amongst which is the choice of cell origin nd cell types, 
culture medium and cell ratio. The effects of origin of either MSCs (e.g. BM- or AT-
MSCs) or angiogenic cells ( .g. endothelial cells, ECs r end thelial progenitor 
cells, EPCs) eed further inve tigation. Furthermore, it shoul  b  noted that 
cell lar communication in cocultures is cell-type specific. For insta ce, when ECs 
were repl ced by primary chondrocytes or fibr blasts in osteoblasts/ECs coculture, 
no increasing effects on ALP- ctivity were observed56. The culture medium used in 
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cocultures is different depending on the research aims (i.e. angiogenesis or 
osteogenesis). Endothelial cell culture medium (EM) has shown to be more 
suitable for vessel formation and stabilization, whereas osteogenic medium (OM) 
has shown to favor osteogenic differentiation of MSCs57. It was reported recently 
that more bone formation was observed for cells, cocultured continuously in OM 
compared to sequential culture medium variations (e.g. first culturing cells in EM 
and subsequently in OM) prior to in vivo implantation58. Further, it was recently 
shown that BM-MSCs/ECs cultured in OM achieved higher mineralization while 
maintaining angiogenic capacity in vitro59. This indicates that OM may be a more 
optimal culture medium for cocultures for future research on bone regeneration 
capacity of such cell-based constructs. A cell ratio of 1:1 is often chosen in 
cocultures, which was also demonstrated recently as optimal for both BM-
MSCs/ECs5 and AT-MSCs/ECs60 cocultures. 
One of the crucial aspects of BTE/RM is the evaluation/prediction of bone healing 
capacity for the tissue-engineered constructs. To further test such bone forming 
efficacy, in vivo studies including both pre-clinical research and clinical trials are 
necessary. 
2.4. Pre-clinical studies 
2.4.1. Monocultures 
Since MSCs from human (rather than other animal cell source) are the cell type 
essential for future clinical application and orthotopic implantation (i.e. bony defects) 
is the preferred model to mimic the clinical situation compared to ectopic 
implantation sites, a literature review on pre-clinical studies using BM-MSCs, AT-
MSCs and DP-MSCs from human origin for repair of bony defects was performed 
in Pubmed. A total number of 13 such pre-clinical studies were available, among 
which 7 for BM-MSCs, 6 for AT-MSCs (including one paper studying both BM-
MSCs and AT-MSCs) and 1 for DP-MSCs (Table 1). For human BM-MSCs, 3 
studies used rat cranial defects, 1 used mouse cranial defects, 1 used sheep tibial 
defects, and 2 used rat femoral defects. For human AT-MSCs, 4 studies used rat 
cranial defects, 1 used mouse cranial defects, and 1 used rat femoral defects. For 
human DP-MSCs, the only available study used rat parietal bone defects. Cell-
based constructs demonstrated obviously more efficacy in restoring bone defects 
in comparison to cell-free constructs, with a fold range of 1.4-3.8, 1.6-4.0 and 1.8 
compared to cell-free control constructs for BM-MSCs, AT-MSCs and DP-MSCs, 
respectively. 
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2.4.2. Cocultures 
Although animal studies confirmed the capability of cell-based constructs to form 
bone and integrate with the host tissues, the repair efficacy could be more 
promising once the key hurdle of insufficient vascularization can be overcome if 
clinically sized, fully viable bone grafts could be engineered and implanted. A 50% 
loss of viable cells in monoculture cell-based constructs, as shown by the presence 
of apoptotic cells, was observed within 2 days after implantation in vivo61, most 
likely because cells encountered an ischemic and inflammatory environment3. In 
view of this, coculture approaches have shown advantages in terms of both 
vascularization and bone formation compared to monocultures (Table 2). Up to 
now, 6 pre-clinical studies have been reported on orthotopic implantation using 
tissue-engineered constructs seeded with cocultures using human MSCs, i.e. 4 for 
BM-MSCs, 2 for AT-MSCs and 0 for DP-MSCs (Table 2). For human BM-MSCs, 1 
study used rat cranial defects, 2 used rat femoral defects, 1 used rabbit ulna 
defects; these studies demonstrated a range fold of bone-forming efficacy of 1.2-
1.4 (cocultures compared to MSCs monocultures) and vessel-forming efficacy of 
1.0-10.0 (compared to MSCs monocultures) or 2.5-2.7 (compared to ECs/EPCs 
monocultures). For human AT-MSCs, the studies demonstrated a range fold of 
bone-forming efficacy of 0.3-1.3 (cocultures compared to MSCs monocultures). 
Despite the fact that cocultures of human DP-MSCs with ECs enhance osteogenic 
and angiogenic potential in vitro62, in vivo studies using DP-MSCs in coculture 
approaches are still lacking. 
2.4.3. Fate of the implanted cells 
After in vivo implantation, the fate/contribution of the seeded cells (both MSCs and 
ECs/EPCs) and the possible mechanisms of their bone- (for MSCs) or vessel-
forming (for ECs/EPCs) capacity have been explored. For MSCs, there are a dual 
hint for their contribution to bone formation: on the one hand, the seeded MSCs 
can proliferate and differentiate into osteogenic lineages to contribute directly to 
bone formation63-64; and on the other hand, the seeded MSCs can have the 
potential to recruit cells from the host, which can be MSCs65 or ECs/EPCs65-66, to 
induce/enhance bone formation indirectly. Similarly, implanted EPCs may also act 
in this way on bone formation by either forming stable vasculature through 
coculturing with MSCs67 or secreting chemotactic factors (e.g. vascular endothelial 
growth factor) to recruit ECs/EPCs from the host and thereby stimulating 
vascularization in bone defects68. Several studies have shown the synergistic 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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cocultures is different depending on the research aims (i.e. angiogenesis or 
osteogenesis). Endothelial cell culture medium (EM) has shown to be more 
suitable for vessel formation and stabilization, whereas osteogenic medium (OM) 
has shown to favor osteogenic differentiation of MSCs57. It was reported recently 
that more bone formation was observed for cells, cocultured continuously in OM 
compared to sequential culture medium variations (e.g. first culturing cells in EM 
and subsequently in OM) prior to in vivo implantation58. Further, it was recently 
shown that BM-MSCs/ECs cultured in OM achieved higher mineralization while 
maintaining angiogenic capacity in vitro59. This indicates that OM may be a more 
optimal culture medium for cocultures for future research on bone regeneration 
capacity of such cell-based constructs. A cell ratio of 1:1 is often chosen in 
cocultures, which was also demonstrated recently as optimal for both BM-
MSCs/ECs5 and AT-MSCs/ECs60 cocultures. 
One of the crucial aspects of BTE/RM is the evaluation/prediction of bone healing 
capacity for the tissue-engineered constructs. To further test such bone forming 
efficacy, in vivo studies including both pre-clinical research and clinical trials are 
necessary. 
2.4. Pre-clinical studies 
2.4.1. Monocultures 
Since MSCs from human (rather than other animal cell source) are the cell type 
essential for future clinical application and orthotopic implantation (i.e. bony defects) 
is the preferred model to mimic the clinical situation compared to ectopic 
implantation sites, a literature review on pre-clinical studies using BM-MSCs, AT-
MSCs and DP-MSCs from human origin for repair of bony defects was performed 
in Pubmed. A total number of 13 such pre-clinical studies were available, among 
which 7 for BM-MSCs, 6 for AT-MSCs (including one paper studying both BM-
MSCs and AT-MSCs) and 1 for DP-MSCs (Table 1). For human BM-MSCs, 3 
studies used rat cranial defects, 1 used mouse cranial defects, 1 used sheep tibial 
defects, and 2 used rat femoral defects. For human AT-MSCs, 4 studies used rat 
cranial defects, 1 used mouse cranial defects, and 1 used rat femoral defects. For 
human DP-MSCs, the only available study used rat parietal bone defects. Cell-
based constructs demonstrated obviously more efficacy in restoring bone defects 
in comparison to cell-free constructs, with a fold range of 1.4-3.8, 1.6-4.0 and 1.8 
compared to cell-free control constructs for BM-MSCs, AT-MSCs and DP-MSCs, 
respectively. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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discrepancy between pre-clinical results and clinical outcomes is likely to be 
explained by several causes. Firstly, as aforementioned, due to the unstandardized 
cell preparation protocol, the cell populations used are often very heterogeneous, 
which makes the comparison between the outcomes from different studies difficult. 
Secondly, the long-term survival and proliferation of the implanted cells as well as 
to what extent these cells can contribute to bone formation remain largely unknown, 
especially in critical sized bone defects. In view of this, cell tracing such as 
luciferase labeling enables real time in vivo evaluation of the cells, which is 
particularly interesting to determine the contribution and distribution of the 
implanted cells. Lastly, the comparison of bone regeneration mechanisms between 
animals and human beings at a molecular level is necessary to further understand 
the underlying reasons. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
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fractures using human MSCs monocultures. Currently, some of these studies are 
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so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially le s pr mising compared to those f animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bon  regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-M Cs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-bas d constructs for bone repair are limited to ca e reports (Table 
3), which e phasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone d fects, jaw defects, 
alveolar cleft regeneratio  and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cell " AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bo e cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mllitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomizd control trials and systmatic clinical 
studies. The available case reports are about long one defects, jaw defects, 
alveolar cleft regeneration and sinus augmntation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeeration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunio 
fractures using human MSCs monocultures. Currntly, some of these studies are 
still in the sttus of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Abbreviations: polycaprolactone (PCL), β-tricalcium phosphate (TCP), poly lactic-co-glycolic acid 
(PLGA), hydroxyapatite (HA), titanium (Ti), biphasic calcium phosphate (BCP), demineralized bone 
matrix (DBM), bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose tissue-derived 
mesenchymal stem cells (AT-MSCs), dental pulp-derived mesenchymal stem cells (DP-MSCs), 
endothelial cells (ECs), endothelial progenitor cells (EPCs), platelet-rich-plasma (PRP), bone 
morphogenetic protein (BMP)-2, proliferation medium (PM), osteogenic medium (OM), Ø-diameter, H-
height. 
Search conditions for Table 1: 
For human BM-MSCs: 
(i) (human bone marrow mesenchymal stem cell* OR human bone marrow derived mesenchymal stem 
cell* OR human bone marrow mesenchymal stromal cell* OR human multipotential stromal cell*) AND 
(bone tissue engineering OR bone regenerat* OR bone form*) AND (spinal OR cranial OR cavarial OR 
femur OR femoral OR radial OR jaw OR mandible OR mandibular OR maxilla OR tibia), and 
(ii) (human bone marrow mesenchymal stem cell* OR human bone marrow derived mesenchymal stem 
cell* OR human bone marrow mesenchymal stromal cell* OR human multipotential stromal cell*) AND 
(bone tissue engineering OR bone regenerat* OR bone form*) AND (animal* OR in vivo). 
For human AT-MSCs: 
(i) (human fat derived mesenchymal stem cell* OR human fat tissue derived mesenchymal stem cell* 
OR human adipose tissue derived mesenchymal stem cell* OR human lipoaspiration) AND (spinal OR 
cranial OR cavarial OR femur OR femoral OR radial OR jaw OR mandible OR mandibular OR maxilla 
OR tibia), and 
(ii) (human fat derived mesenchymal stem cell* OR human fat tissue derived mesenchymal stem cell* 
OR human adipose tissue derived mesenchymal stem cell* OR human lipoaspiration) AND (animal* OR 
in vivo). 
For human DP-MSCs: 
(i) (human dental pulp mesenchymal stem cell* OR human dental pulp derived mesenchymal stem cell* 
OR human dental pulp stem cell*) AND (spinal OR cranial OR cavarial OR femur OR femoral OR radial 
OR jaw OR mandible OR mandibular OR maxilla OR tibia), and 
(ii) (human dental pulp mesenchymal stem cell* OR human dental pulp derived mesenchymal stem cell* 
OR human dental pulp stem cell*) AND (animal* OR in vivo). 
Search conditions for Table 2: 
Based on the search conditions from Table 1, additional search condition of (coculture* OR co-culture* 
OR co-seed* OR coseed* OR cotransplant* OR co-transplant* OR co-implant*) OR (endothelial cell* 
OR endothelial progenitor cell*) was added. 
Search conditions for Table 3: 
(human mesenchymal stem cell* OR human stem cell* OR human mesenchymal stromal cell* OR 
human marrow stromal cell*) AND (clinic* OR case report* OR clinical trial*) AND (bone tissue 
engineering OR bone regenerat* OR bone form*). 
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Table 4 Opportunities and threats for cell-based constructs in clinical application for BTE/RM 
Opportunities Threats 
 Various cell sources available, with 
osteogenic capacity. 
 Limited cell number for the clinical cases 
with big size defects, or for one-step 
surgery. 
 By long time expansion, sufficient cell 
numbers can be obtained. 
 Longer expansion may lead to cell 
deformation and decreased 
differentiation capacity. 
 Efficient cell seeding on scaffolds can 
be achieved prior to in vivo 
implantation. 
 Compromised cell survival after in vivo 
implantation. 
 Demonstrated successful bone 
regeneration using cell-based 
constructs in pre-clinical studies. 
 Less promising outcomes of bone 
regeneration using cell-based constructs 
in clinics. 
 In some clinical case reports using cell-
based strategies for BTE/RM, bone 
regeneration was observed. 
 Due to the lack of control groups, the 
contribution of the implanted cells 
cannot be distinguished. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
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 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
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Abbreviations: polycaprolactone (PCL), β-tricalcium phosphate (TCP), poly lactic-co-glycolic acid 
(PLGA), hydroxyapatite (HA), titanium (Ti), biphasic calcium phosphate (BCP), demineralized bone 
matrix (DBM), bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose tissue-derived 
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endothelial cells (ECs), endothelial progenitor cells (EPCs), platelet-rich-plasma (PRP), bone 
morphogenetic protein (BMP)-2, proliferation medium (PM), osteogenic medium (OM), Ø-diameter, H-
height. 
Search conditions for Table 1: 
For human BM-MSCs: 
(i) (human bone marrow mesenchymal stem cell* OR human bone marrow derived mesenchymal stem 
cell* OR human bone marrow mesenchymal stromal cell* OR human multipotential stromal cell*) AND 
(bone tissue engineering OR bone regenerat* OR bone form*) AND (spinal OR cranial OR cavarial OR 
femur OR femoral OR radial OR jaw OR mandible OR mandibular OR maxilla OR tibia), and 
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(bone tissue engineering OR bone regenerat* OR bone form*) AND (animal* OR in vivo). 
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in vivo). 
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OR human dental pulp stem cell*) AND (spinal OR cranial OR cavarial OR femur OR femoral OR radial 
OR jaw OR mandible OR mandibular OR maxilla OR tibia), and 
(ii) (human dental pulp mesenchymal stem cell* OR human dental pulp derived mesenchymal stem cell* 
OR human dental pulp stem cell*) AND (animal* OR in vivo). 
Search conditions for Table 2: 
Based on the search conditions from Table 1, additional search condition of (coculture* OR co-culture* 
OR co-seed* OR coseed* OR cotransplant* OR co-transplant* OR co-implant*) OR (endothelial cell* 
OR endothelial progenitor cell*) was added. 
Search conditions for Table 3: 
(human mesenchymal stem cell* OR human stem cell* OR human mesenchymal stromal cell* OR 
human marrow stromal cell*) AND (clinic* OR case report* OR clinical trial*) AND (bone tissue 
engineering OR bone regenerat* OR bone form*). 
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Table 4 Opportunities and threats for cell-based constructs in clinical application for BTE/RM 
Opportunities Threats 
 Various cell sources availabl , with 
osteogenic capacity. 
 Limited cell number for the clinical cases 
with big size defects, or for one-step 
surgery. 
 By long time expansion, sufficient cell 
numbers can be obtained. 
 Longer expansion may lead to cell 
deformation and decreased 
differentiation capacity. 
 Efficient cell seeding on scaffolds can 
be achieved prior to in vivo
implantation. 
 Compromised cell survival after in vivo 
implantation. 
 Demonstrated successful bone 
regeneration using cell-based 
constructs in pre-clinical studies. 
 Less promising outcomes of bone 
regeneration using cell-based constructs 
in clinics. 
 In some clinical case reports using cell-
based strategies for BTE/RM, bone 
regeneration was observed. 
 Due to the lack of control groups, the 
contribution of the implanted cells 
cannot be distinguished. 
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3. Conclusions and future perspectives 
Bone regeneration in clinics is compromised in some cases, for example, in 
patients with typical risk factors like smoking or diabetes and such risk is increasing 
from 5-10% (for healthy population) up to 40%98. Cell-based BTE/RM has emerged 
as an attractive approach for bone regeneration in pre-clinical studies, although no 
definite answer has been given for clinical studies yet. A standardized way of 
utilizing cell-based tissue engineering constructs in clinical work contains: 
protocolized cell isolation and culture method; valid characterization of the isolated 
cells and efficient cell seeding with optimized cell source, scaffold type and cell 
seeding parameters (e.g. density, time, and volume); and proper pre-differentiation 
method and time. 
Based on the promising outcomes from pre-clinical studies, in which cell-based 
constructs (irrespective of mono- and cocultures) enhanced bone formation 
compared to acellular ones and cocultures showed more pronounced vessel and 
bone formation than monocultures, it is logical and straightforward to proceed the 
translational step from bench to bedside. Nowadays, due to the limited number of 
systematic clinical studies and the lack of evidenced examination methods (e.g. 
biopsy), very few studies were able to demonstrate the efficacy of cell-based 
strategies for BTE/RM in a clinical setting. Therefore, a number of areas of ongoing 
active research are directly relevant to the translation of cell-based constructs for 
bone regeneration into clinics, including: development of bioreactor systems for 
standardized and scalable cell expansion methods; scale up to clinically sized 
(large) bone constructs with potential for further integration with host tissues; 
evaluation of engineered bone grafts in large animal models; rapid establishment 
of vascularization through the implanted bone graft; and marketing of off-the-shelf 
products. For the benefit of patients, intraoperative graft manufacture, also called 
one-step surgery, in which the graft is assembled during the surgical procedure, 
may be of interest. A prerequisite for this method is to obtain sufficient cell 
numbers for cell seeding and bone regeneration without expansion. Moreover, by 
the use of cocultures, the need of MSCs number can be reduced while at least 
equal vascularization and bone formation can be achieved. 
As an overview, the opportunities and threats for cell-based tissue engineered 
constructs for clinical application in BTE/RM are listed in Table 4. For clinical 
studies, still several aspects should be considered: 
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(i) a reduction of the time lapse from cell isolation to in vivo implantation to avoid 
long waiting time and patient discomfort and meanwhile ensure the multipotential 
differentiation capacity of MSCs, which can be lost during (long-term) expansion; 
(ii) due to the immunomodulatory properties of MSCs99, standardized off-the-shelf 
products containing allogeneic MSCs seem feasible; 
(iii) the contribution of the implanted MSCs to the regenerative process still is 
unclear because of the combination of osteoinductive scaffolds and/or growth 
factors and the lack of including control groups (e.g. bare scaffolds) in clinical trials; 
(iv) to determine the regeneration efficacy of cell-based constructs, quantitative 
measurement should be performed while the current assessment for bone 
formation is mostly radiological examination (e.g. X-ray and micro-CT); this makes 
it hard to distinguish between newly formed bone and the implanted scaffolds, 
especially when radiopaque scaffolds are used; 
(v) it is necessary to identify donors with appropriate osteogenic capacity before in 
vivo implantation. There is no certain correlation between osteogenic capacity in 
vitro and bone formation in vivo100, though researchers are seeking for indices to 
help predict the bone formation capacity; 
(vi) longer follow-up periods are recommended to evaluate the long term safety 
and efficacy of human MSCs-based tissue engineered constructs in bone 
regeneration. 
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 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3. Conclusions and future perspectives 
Bone regeneration in clinics is compromised in some cases, for example, in 
patients with typical risk factors like smoking or diabetes and such risk is increasing 
from 5-10% (for healthy population) up to 40%98. Cell-based BTE/RM has emerged 
as an attractive approach for bone regeneration in pre-clinical studies, although no 
definite answer has been given for clinical studies yet. A standardized way of 
utilizing cell-based tissue engineering constructs in clinical work contains: 
protocolized cell isolation and culture method; valid characterization of the isolated 
cells and efficient cell seeding with optimized cell source, scaffold type and cell 
seeding parameters (e.g. density, time, and volume); and proper pre-differentiation 
method and time. 
Based on the promising outcomes from pre-clinical studies, in which cell-based 
constructs (irrespective of mono- and cocultures) enhanced bone formation 
compared to acellular ones and cocultures showed more pronounced vessel and 
bone formation than monocultures, it is logical and straightforward to proceed the 
translational step from bench to bedside. Nowadays, due to the limited number of 
systematic clinical studies and the lack of evidenced examination methods (e.g. 
biopsy), very few studies were able to demonstrate the efficacy of cell-based 
strategies for BTE/RM in a clinical setting. Therefore, a number of areas of ongoing 
active research are directly relevant to the translation of cell-based constructs for 
bone regeneration into clinics, including: development of bioreactor systems for 
standardized and scalable cell expansion methods; scale up to clinically sized 
(large) bone constructs with potential for further integration with host tissues; 
evaluation of engineered bone grafts in large animal models; rapid establishment 
of vascularization through the implanted bone graft; and marketing of off-the-shelf 
products. For the benefit of patients, intraoperative graft manufacture, also called 
one-step surgery, in which the graft is assembled during the surgical procedure, 
may be of interest. A prerequisite for this method is to obtain sufficient cell 
numbers for cell seeding and bone regeneration without expansion. Moreover, by 
the use of cocultures, the need of MSCs number can be reduced while at least 
equal vascularization and bone formation can be achieved. 
As an overview, the opportunities and threats for cell-based tissue engineered 
constructs for clinical application in BTE/RM are listed in Table 4. For clinical 
studies, still several aspects should be considered: 
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(i) a reduction of the time lapse from cell isolation to in vivo implanta io  o avoid 
long waiting time and patient disco fort and m anwhile ensure the multipotential 
differentiation capacity of MSCs, which can be lost during (long-term) expansion; 
(ii) due to the immunomodulatory properties of MSCs99, standardized off-the-shelf 
products containing allogeneic MSCs seem feasible; 
(iii) the contribution of the implanted MSCs to the regenerative process still is 
unclear because of the combination of osteoinductive scaffolds and/or growth 
factors and the lack of including control groups (e.g. bare scaffolds) in clinical trials; 
(iv) to determine the regeneration efficacy of cell-based constructs, quantitative 
measurement should be performed while the current assessment for bone 
formation is mostly radiological examination (e.g. X-ray and micro-CT); this makes 
it hard to distinguish between newly formed bone and the implanted scaffolds, 
especially when radiopaque scaffolds are used; 
(v) it is necessary to identify donors with appropriate osteogenic capacity before in 
vivo implantation. There is no certain correlation between osteogenic capacity in 
vitro and bone formation in vivo100, though researchers are seeking for indices to 
help predict the bone formation capacity; 
(vi) longer follow-up periods are recommended to evaluate the long term safety 
and efficacy of human MSCs-based tissue engineered constructs in bone 
regeneration. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3), which emphasizes the need for randomized control trials and systematic clinical 
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still in the status of recruiting patients. To date, BM-MSCs are still the main source 
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but the outcomes are substantially less promising compared to those of animal 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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1. Introduction 
To date, bone tissue engineering has not yet resulted in a successful clinical 
approach. This lack of success is probably due to the insufficient vascular supply of 
the created tissue engineered construct1 because diffusion of nutrition and oxygen 
from surrounding tissues is limited to only 150 µm2. Implanted cells and tissues 
need oxygen and nutrients to survive, but the ingrowth of blood vessels proceeds 
too slowly, which results in cellular necrosis in the center of the construct. It is 
hypothesized that the solution to this problem is prevascularization, which aims at 
creating a biological vasculature inside a piece of engineered bone tissue prior to 
implantation3. The introduction of endothelial cells (ECs) in combination with 
osteoblastic cells (OBs) in a scaffold demonstrated the possibility to create tissue-
engineered and vascularized bone4. Furthermore, the OBs in coculture with ECs 
showed a higher alkaline phosphatase (ALP) activity than those in monocultures, 
indicating an enhanced osteogenic differentiation5-7. Additionally, vessel-like 
structures were observed in such cocultures, whereas they were absent in EC 
monocultures8-12. For those reasons, research in bone tissue engineering is 
increasingly focusing on this topic7-8,10,13-15. 
In view of the available literatures on coculture systems of OBs and ECs, it is 
remarkable that no consensus exists on the optimal conditions for such a culture. 
All reports dealing with this topic describe different experimental set-ups regarding 
cell ratio and culture medium (see Table 1). Generally, these set-ups compared 
cocultures with monocultures in terms of either osteogenesis or angiogenesis, and 
only a limited number of studies focused on both. It is commonly assumed that 
osteogenesis and angiogenesis benefit from coculture compared to monoculture in 
both in vitro6,8,10-11 and in vivo settings7,16-21. However, data on the optimal culture 
conditions for such cocultures are lacking, and more specifically data that take both 
osteogenic and angiogenic outcome parameters into account. The few studies that 
reported data on cocultures used a single type of culture medium in combination 
with either only osteogenic or angiogenic outcome parameters. For instance, 
Villars et al. cocultured different cell ratios (4:1 - 1:4) of human bone marrow 
derived mesenchymal stem cells (BM-MSCs)/ECs in proliferation medium (PM). 
The results demonstrated that higher ALP activity could be achieved with the ratios 
of 2:1 - 1:26. Kaigler et al. also cocultured various ratios (1:1 - 10:1) of BM-
MSCs/ECs in 1:1 mixture of PM/EM and found higher ALP activity in the ratio of 
1:17. Rouwkema et al. cultured cell pellets of BM-MSCs/ECs at different cell ratios 
(99:1 - 50:50) in osteogenic medium (OM) and found an optimal CD31-staining in 
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the 50:50 coculture, although they assumed that the ratios of 98:2 and 95:5 would 
be beneficial for the formation of vessel-like structures11. 
 
Table 1. Literature review of cell ratio and culture medium used for coculture experiments  
No. Cell  
types1 
Cell  
ratio 
Culture 
medium2 
References 
1 OBs+ECs 1:1 PM 10 
2 MSCs+ECs 4:1-1:4 PM 6 
3 MSCs+ECs 5:1 PM 28 
4 MSCs+EPCs 1:1 PM 16 
5 MSCs+ECs 99:1-50:50 OM 11 
6 OBs+ ECs 2:1 OM 19 
7 OBs+ECs 8:1 OM 20 
8 MSCs+ECs 1:1 OM 21 
9 OBs+ECs 3:2 EM 8 
10 OBs+ECs 1:1 EM 38 
11 OBs+ECs 1:1 Not 
mentioned 
17 
12 Bone marrow-derived 
fibroblasts+ECs 
1:1 MIX-1 14 
13 MSCs+EPCs 2:1 MIX-1 18 
14 MSCs+ECs 10:1-1:1 MIX-2 7 
1 OBs, osteoblastic cells; ECs, endothelial cells; MSCs, mesenchymal stem cells; EPCs, endothelial 
progenitor cells. 
2 PM, proliferation medium (for MSCs or OBs); OM, osteogenic medium; EM, endothelial cell culture 
medium; MIX-1, 1:1 mixture of OM/EM; MIX-2, 1:1 mixture of PM/EM. 
Based on the aforementioned, we aim to structurally evaluate both osteogenic and 
angiogenic outcome parameters for cocultures of OBs/ECs using different cell 
ratios and culture media, to elucidate optimal coculture conditions for OBs and ECs. 
Therefore, the experimental set-up involved coculture of BM-MSCs and human 
umbilical vein ECs (HUVECs) at different cell ratios (98:2 - 10:90) in different 
culture media in both 2D (well plates) and 3D (cell pellets) cultures. For comparison, 
monocultures of BM-MSCs (100:0) and HUVECs (0:100) were enrolled. Outcome 
parameters were cell differentiation and mineralization for osteogenesis and 
immunological staining of endothelial marker for angiogenesis. 
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2. Materials and methods 
2.1. Isolation, expansion and characterization of BM-MSCs 
BM-MSCs were isolated from bone blocks of human iliac crest biopsies of donors. 
The biopsies were discarded tissues during standard surgical procedures at 
Radboud University Nijmegen Medical Center (Nijmegen, the Netherlands). The 
bone blocks were cut into small pieces and subsequently placed in a 50 ml tube to 
which 20 ml alpha-MEM was added. After that the tube was shaken vigorously and 
the medium with cells was collected. This procedure was repeated several times. 
The collected medium with cells was plated in culture flasks (T175; Greiner Bio-one) 
and expanded in PM (see Table 2). Cells were cultured at 37°C in a humid 
atmosphere with 5% CO2 and passaged at ~80% confluency using trypsin EDTA 
(Gibco). After the first generation, cells were plated at a density of 5,000 cells/cm2 
in culture flasks (T175). The culture medium was changed twice a week. Cells from 
passage 3 or 4 were used in the experiment. Prior to coculture experiments, cells 
were retrieved by trypsin digestion and characterized by fluorescence-activated cell 
sorting (FACS; Becton Dickinson Biosciences (BD), Breda, the Netherlands) 
analysis. Cell aliquots (100,000 cells) were washed with FACS buffer (PBS 
containing 1% bovine serum albumin) and stained with allophycocyanin (APC)-, 
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated monoclonal 
antibodies against human CD29, CD44, CD90, CD105, CD31 and negative control 
isotypes IgG1 and IgG2b. CD105 was purchased from Ancell (Bayport MN, USA), 
and all the other antibodies were from BD. Additonally, the mineralization capacity 
of each BM-MSCs isolation was evaluated in T75 flasks by both observation using 
inverted light microscope (Leica DFC 290, UK) and von-Kossa staining. 
2.2. Culture of HUVECs 
HUVECs were purchased from BD. Cells were cultured in EM (see Table 2) at 
37 °C in a humid atmosphere with 5% CO2 according to the guidelines provided by 
BD. Medium was changed twice a week. Cells from passage 3 or 4 were used in 
the experiment. 
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Table 2. Cell culture media used in the experiment 
Abbreviated 
name 
Full name Constituents Origin of 
constituents 
PM proliferation 
medium (for 
MSCs or 
OBs) 
minimal essential medium (α-MEM) 
10% fetal bovine serum (FBS) 
0.2 mM ascorbic acid 
2mM L-glutamine 
100 U/ml penicillin 
10 μg/ml streptomycin 
10-3 μg/ml basic fibroblast growth factor (bFGF) 
Gibco-BRL 
Greiner Bio-one 
Sigma 
Gibco-BRL 
Gibco-BRL 
Gibco-BRL 
Invitrogen 
OM Osteogenic 
medium 
PM (without bFGF) 
10-8 M dexamethasone 
0.01 M β-glycerophosphate 
 
Sigma 
Sigma 
EM ECs culture 
medium 
basal Medium 200 + low serum growth 
supplements containing 2% FBS, 10 ng/ml 
epidermal growth factor, 3 ng/ml bFGF, 10 µg/ml 
heparin, 0.2 μg /ml bovine serum albumin, 1 
µg/ml hydrocortisone, and 0.2% 
gentamicin/amphotericin B 
Invitrogen 
MIX OM/EM 1:1 mixture of OM and EM  
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were retrieved by trypsin digestion and characterized by fluorescence-activated cell 
sorting (FACS; Becton Dickinson Biosciences (BD), Breda, the Netherlands) 
analysis. Cell aliquots (100,000 cells) were washed with FACS buffer (PBS 
containing 1% bovine serum albumin) and stained with allophycocyanin (APC)-, 
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated monoclonal 
antibodies against human CD29, CD44, CD90, CD105, CD31 and negative control 
isotypes IgG1 and IgG2b. CD105 was purchased from Ancell (Bayport MN, USA), 
and all the other antibodies were from BD. Additonally, the mineralization capacity 
of each BM-MSCs isolation was evaluated in T75 flasks by both observation using 
inverted light microscope (Leica DFC 290, UK) and von-Kossa staining. 
2.2. Culture of HUVECs 
HUVECs were purchased from BD. Cells were cultured in EM (see Table 2) at 
37 °C in a humid atmosphere with 5% CO2 according to the guidelines provided by 
BD. Medium was changed twice a week. Cells from passage 3 or 4 were used in 
the experiment. 
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Table 2. Cell culture media used in the experiment 
Abbreviated 
name 
Full name Constituents Origin of 
constituents 
PM proliferation 
medium (for 
MSCs or 
OBs) 
minimal essential medium (α-MEM) 
10% fetal bovine serum (FBS) 
0.2 mM ascorbic acid 
2mM L-glutamine 
100 U/ml penicillin 
10 μg/ml streptomycin 
10-3 μg/ml basic fibroblast growth factor (bFGF) 
Gibco-BRL 
Greiner Bio-one 
Sigma 
Gibco-BRL 
Gibco-BRL 
Gibco-BRL 
Invitrogen 
OM Osteogenic 
medium 
PM (without bFGF) 
10-8 M dexamethasone 
0.01 M β-glycerophosphate 
 
Sigma 
Sigma 
EM ECs culture 
medium 
basal Medium 200 + low serum growth 
supplements containing 2% FBS, 10 ng/ml 
epidermal growth factor, 3 ng/ml bFGF, 10 µg/ml 
heparin, 0.2 μg /ml bovine serum albumin, 1 
µg/ml hydrocortisone, and 0.2% 
gentamicin/amphotericin B 
Invitrogen 
MIX OM/EM 1:1 mixture of OM and EM  
P lif r ti
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2.3. 2D culture experiments 
2.3.1. Groups and cell seeding 
BM-MSCs and HUVECs were cultured at different cell ratios (BM-MSCs:HUVECs 
 100:0, 98:2, 95:5, 90:10, 80:20, 50:50, 40:60, 20:80, 10:90 and 0:100) in 4 
different culture media (detailed information on the content of the media is listed in 
Table 2); monocultures of BM-MSCs (100:0) or HUVECs (0:100) served as 
controls. Cell suspensions were prepared at appropriate ratio and cells were 
seeded in 24-well plates (Greiner Bio-one, the Netherlands) at 10,000 cells/well in 
1 ml medium. Medium was changed twice a week. Cell cultures were observed 
using an inverted light microscopy during the culture period. Measurements for all 
assays were performed in triplicate (n=3). 
2.3.2. Cell metabolic activity 
Cell metabolic activity was measured using AlamarBlue assay (Invitrogen; Breda, 
the Netherlands) according to the instructions of the manufacturer. Briefly, 
AlamarBlue solution was prepared by mixing AlamarBlue with culture medium in a 
ratio of 1:9 (v/v). After selected culture periods, cell metabolic activity was 
measured as described hereafter. Medium was removed and 1 ml of AlamarBlue 
solution was added to each well, then the plates were incubated (37 °C, 5% CO2) 
for 4 h. Medium only group served as blank control. After incubation, 200 µl of the 
AlamarBlue solution of each well was transferred to 96-well plates (Greiner Bio-one, 
the Netherlands). Fluorescence was measured using a microplate reader (FL 600, 
Bio-Tek, Abcoude, the Netherlands) at 570 nm. The final values of each group 
were determined by subtracting the values of the blank control. 
2.3.3. Cellular DNA content 
Cellular DNA content was measured using Quant-iTTM Picogreen Kit (Invitrogen; 
Breda, the Netherlands) according to the instructions of the manufacturer. Samples 
were prepared by washing the cells layers twice with PBS and adding 1 ml of MilliQ 
to each well, after which repetitive freezing (-80 °C) and thawing (37 °C) cycles 
were performed. For the standard curve, serial dilutions of dsDNA stock were 
prepared to final concentrations of 0-2000 ng/ml. Next, 100 μl of either sample or 
standard was added to the wells, followed by 100 μl of working solution. Then the 
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plates were incubated in the dark for 5 min at room temperature. The absorbance 
of the samples was read using a microplate reader at 450 nm. 
2.3.4. ALP activity 
ALP activity was measured using the same samples as described for the cellular 
DNA content measurement. For the assay, 80 µl of sample and 20 µl of buffer 
solution (0.5 M 2-amino-2-methyl-1-propanol) were added in 96-well plates. Then, 
100 µl of substrate solution (5 nM p-nitrophenyl phosphate) was added in all the 
wells and the plates were incubated (37 °C, 5% CO2) for 1 h. The reaction was 
stopped by adding 100 μl of stop solution (0.3 M NaOH). For the standard curve, 
serial dilutions of 4-nitrophenol (4-NP) were added to final amount of 0-25 nmol. 
The absorbance of the samples was read using an ELISA microplate reader (EL 
800, Bio-Tek, Abcoude, the Netherlands) at 405 nm. ALP activity was normalized 
for DNA content. 
2.3.5. Mineralization 
Mineralization was measured using a calcium assay (orthocresolphtalein 
complexone, OCPC; Sigma). For sampling, cell layers were washed twice with 
PBS, after which 1 ml of 0.5 N acetic acid was added to each well and the plates 
were incubated on a shaking table overnight at room temperature. Subsequently, 
the samples were stored at -20 °C until measurement. For the biochemical assay, 
10 µl of sample or standard was pipetted in a 96-well plate, followed by the addition 
of 300 µl working solution. Working solution consisted: 5 ml of OCPC solution, 5 ml 
of 14.8 M ethanolamine/boric acid buffer (PH=11), 2 ml of 8-hydroxyquinoline (1 g 
in 20 ml 95% ethanol), and 88 ml of MilliQ. For the standard curve, serial dilutions 
of calcium stock (CaCl2) were prepared to final concentrations of 0-100 µg/ml. The 
plates were incubated at room temperature for 10 min and the absorbance was 
afterwards read using an ELISA microplate reader at 570 nm. 
2.4. 3D culture experiments 
2.4.1. Generation of cell pellets 
Different cell ratios of BM-MSCs and HUVECs were pooled to a total of 500,000 
cells in 15 ml tubes (Greiner Bio-one, Frichenhausen, Germany) (n=3). The cells 
were centrifuged at relative centrifugal force (RCF) of 400 g for 4 min. Then, the 
supernatant was removed and the cells were resuspended in 4 ml of OM. The cells 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2.3. 2D culture experiments 
2.3.1. Groups and cell seeding 
BM-MSCs and HUVECs were cultured at different cell ratios (BM-MSCs:HUVECs 
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controls. Cell suspensions were prepared at appropriate ratio and cells were 
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assays were performed in triplicate (n=3). 
2.3.2. Cell metabolic activity 
Cell metabolic activity was measured using AlamarBlue assay (Invitrogen; Breda, 
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to each well, after which repetitive freezing (-80 °C) and thawing (37 °C) cycles 
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plates were incubated in the dark for 5 min at room temperatur . The absorbance 
of the samples was re d using a microplate read r at 450 nm. 
2.3.4. ALP activity 
ALP activity was measured using the same samples as described for the cellular 
DNA content measur ment. For the ssay, 80 µl of sample and 20 µl of buffer 
soluti n (0.5 M 2-amino-2-methyl-1-propanol) were added in 96-well plates. Then, 
100 µ  of substrate solution (5 nM p-nitroph nyl phosphate) was added in all the 
w lls and the plates wer  incubated (37 °C, 5% CO2) for 1 h. The react on was 
stopped by adding 100 μl of stop solution (0.3 M NaOH). For the standard curve, 
serial dilutions of 4-nitrophenol (4-NP) were added to final amount of 0-25 nmol. 
The absorbance of the samples was r ad using an ELISA microplate r ader (EL 
800, Bio-Tek, Abcoude, the Ne herlands) at 405 nm. ALP activity was norm lized 
for DNA content. 
2.3.5. Mineralization 
Mineralization was measured using a calcium assay (orthocresolphtalein 
complexone, OCPC; Sigma). For sampling, cell layers were washed twice with 
PBS, after which 1 ml of 0.5 N acetic acid was added to each well and the plates 
were incubated on a shaking table overnight at room temperature. Subsequently, 
the samples were stored at -20 °C until measurement. For the biochemical assay, 
10 µl of sample or standard was pipetted in a 96-well plate, followed by the addition 
of 300 µl working solution. Working solution consisted: 5 ml of OCPC solution, 5 ml 
of 14.8 M ethanolamine/boric acid buffer (PH=11), 2 ml of 8-hydroxyquinoline (1 g 
in 20 ml 95% ethanol), and 88 ml of MilliQ. For the standard curve, serial dilutions 
of calcium stock (CaCl2) were prepared to final concentrations of 0-100 µg/ml. The 
plates were incubated at room temperature for 10 min and the absorbance was 
afterwards read using an ELISA microplate reader at 570 nm. 
2.4. 3D culture experiments 
2.4.1. Generation of cell pellets 
Different cell ratios of BM-MSCs and HUVECs were pooled to a total of 500,000 
cells in 15 ml tubes (Greiner Bio-one, Frichenhausen, Germany) (n=3). The c lls 
were ce trifuged a  r lative ce trifugal force (RCF) of 400 g for 4 min. Then, the 
supernatant was removed and the c lls wer  resuspended in 4 ml of OM. Th  cells 
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were centrifuged again at RCF of 700g for 5 min, after which the tubes were 
incubated (37 °C, 5% CO2). The cell pellets were cultured for 10 days, during which 
medium was changed on days 4 and 8. 
2.4.2. Immunohistochemical staining 
In order to observe ECs distribution within the cell pellets, platelet/endothelial cell 
adhesion molecule-1 (PECAM-1; CD31) staining was applied on cryo-sections from 
the cell pellets which were embedded in Oct Embedding Matrix (CellPath Ltd, UK). 
Sections (6 μm thickness) were cut with a cryotome (Microm HM 560, the 
Netherlands) and fixed in cold acetone for 10 min before air-drying for 30 min. 
Sections were incubated with 1:40 diluted monoclonal mouse anti-human CD31 
primary antibody (clone JC70A, Dako, Germany) for 1 h at room temperature. 
Subsequently, sections were washed with PBS for 10 min and incubated with the 
secondary antibody (Powervision, Poly-horse radish peroxidase-anti mouse 
immunoglobulin, ImmunoLogic, Duiven, the Netherlands) for 30 min. After washing 
with PBS, slides were developed with the substrate diaminobenzidine (DAB, 
Powervision DAB Substrate Kit, ImmunoLogic, Duiven, the Netherlands) and 
weakly counterstained with hematoxylin (Mayer). Finally, the sections were 
dehydrated and mounted. Images were taken using an automatic microscope 
(Zeiss; Göttingen, Germany). CD31+ areas were pseudo-colored and Leica Qwin 
Imaging System (Leica BV; Clifton Road, Cambridge, England) was used to count 
the area percentage CD31-staining in the cross-sections. 
2.5. Statistical analysis 
The data are presented as mean ± standard deviation. Statistical analysis was 
performed with GraphPad Instat 3 software (GraphPad Software Inc., San Diego, 
CA, USA) using analysis of variance (ANOVA) combined with a posthoc Tukey 
Multiple Comparisons Test or a Dunnett Multiple Comparisons Test. Results were 
considered significant at p<0.05. 
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3. Results 
3.1. BM-MSCs isolation, expansion, and characterization 
A total number of 10 biopsies were obtained from human donors for the isolation 
and expansion of BM-MSCs. Characterization of the BM-MSCs from these isolates 
showed consistent expression of CD29, CD44, CD90 and CD105, while CD31 was 
not expressed (data not shown). Further, seven BM-MSCs isolates showed 
mineralizing capacity by optical evaluation and von-Kossa staining (data not 
shown). 
For reasons of insufficient cell numbers, three isolates were excluded from 
experiments. The remaining 4 isolates showed similar results in the (co)culture 
experiments performed. Consequently, the results obtained with BM-MSCs from 
one representative donor are presented below. 
3.2. Optimization of culture medium 
Cocultures of BM-MSCs and HUVECs and monocultures of BM-MSCs or HUVECs 
were carried out using different culture media (Table 2) in 2D-culture systems. 
Cocultures and monocultures were qualitatively evaluated using light microscopic 
analysis. Cell metabolic activity and mineralization were used as output parameters 
to quantitatively evaluate cellular performance in these different culture media. 
Light microscopic observation of all cocultures (98:2 - 50:50) and the BM-MSCs 
monoculture showed normal cell morphology and an increase of cell numbers 
during culture time. In contrast, HUVECs monoculture demonstrated culture 
medium dependent characteristics. HUVECs monoculture showed altered 
morphology in PM and OM, associated with a decline in cell numbers during time. 
In EM and MIX, HUVECs monoculture showed normal cell morphology and 
increasing cell numbers during cell culture. 
Cell metabolic activity was assessed on days 15 and 21 after cell seeding. In 
general, cocultures showed a higher cell metabolic activity compared to both BM-
MSCs and HUVECs monocultures (Figure 1A). 
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In order to observe ECs distribution within the cell pellets, platelet/endothelial cell 
adhesion molecule-1 (PECAM-1; CD31) staining was applied on cryo-sections from 
the cell pellets which were embedded in Oct Embedding Matrix (CellPath Ltd, UK). 
Sections (6 μm thickness) were cut with a cryotome (Microm HM 560, the 
Netherlands) and fixed in cold acetone for 10 min before air-drying for 30 min. 
Sections were incubated with 1:40 diluted monoclonal mouse anti-human CD31 
primary antibody (clone JC70A, Dako, Germany) for 1 h at room temperature. 
Subsequently, sections were washed with PBS for 10 min and incubated with the 
secondary antibody (Powervision, Poly-horse radish peroxidase-anti mouse 
immunoglobulin, ImmunoLogic, Duiven, the Netherlands) for 30 min. After washing 
with PBS, slides were developed with the substrate diaminobenzidine (DAB, 
Powervision DAB Substrate Kit, ImmunoLogic, Duiven, the Netherlands) and 
weakly counterstained with hematoxylin (Mayer). Finally, the sections were 
dehydrated and mounted. Images were taken using an automatic microscope 
(Zeiss; Göttingen, Germany). CD31+ areas were pseudo-colored and Leica Qwin 
Imaging System (Leica BV; Clifton Road, Cambridge, England) was used to count 
the area percentage CD31-staining in the cross-sections. 
2.5. Statistical analysis 
The data are presented as mean ± standard deviation. Statistical analysis was 
performed with GraphPad Instat 3 software (GraphPad Software Inc., San Diego, 
CA, USA) using analysis of variance (ANOVA) combined with a posthoc Tukey 
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3. Results 
3.1. BM-MSCs isolation, expansio , and c aracteriz tion 
A total number of 10 biopsies were obtained from human donors for the isolation 
and expansion of BM-MSCs. Characterization of the BM-MSCs from these isolates 
showed consistent expression of CD29, CD44, CD90 and CD105, while CD31 was 
not expressed (data not shown). Further, seven BM-MSCs isolates showed 
mineralizing capacity by optical evaluation and von-Kossa staining (data not 
shown). 
For reasons of insufficient cell numbers, three isolates were excluded from 
experiments. The remaining 4 isolates showed similar results in the (co)culture 
experiments performed. Consequently, the results obtained with BM-MSCs from 
one representative donor are presented below. 
3.2. Opt mization of culture medium 
Cocultures of BM-MSCs and HUVECs and monocultures of BM-MSCs or HUVECs 
were carried out using different culture media (Table 2) in 2D-culture systems. 
Cocultures and monocultures were qualitatively evaluated using light microscopic 
analysis. Cell metabolic activity and mineralization were used as output parameters 
to quantitatively evaluate cellular performance in these different culture media. 
Light microscopic observation of all cocultures (98:2 - 50:50) and the BM-MSCs 
monoculture showed normal cell morphology and an increase of cell numbers 
during culture time. In contrast, HUVECs monoculture demonstrated culture 
medium dependent characteristics. HUVECs monoculture showed altered 
morphology in PM and OM, associated with a decline in cell numbers during time. 
In EM and MIX, HUVECs monoculture showed normal cell morphology and 
increasing cell numbers during cell culture. 
Cell metabolic activity was assessed on days 15 and 21 after cell seeding. In 
general, cocultures showed a higher cell metabolic activity compared to both BM-
MSCs and HUVECs monocultures (Figure 1A). 
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Figure 1. Cell metabolic activity and calcium content in different culture media (n=3). (A) Cell metabolic 
activity in different culture media on day 21. (B) Calcium content in different culture media on day 24. 
PM-proliferation medium for MSCs or OBs, OM-osteogenic medium, EM-ECs medium, MIX-1:1 mixture 
of OM/EM. *, p<0.05; **, p<0.01, indicate significant difference with those in OM in each group. 
 
Cell metabolic activity results for the various cocultures showed similarly high 
values for OM and EM, whereas lower values were obtained when cell culture was 
performed with PM or MIX. For BM-MSCs monoculture, equally high cell metabolic 
activity values were measured in OM, EM, and MIX, whereas significantly lower 
values (p<0.01) were obtained in PM. On the other hand, HUVECs monoculture 
showed the highest cell metabolic activity in EM and MIX, whereas OM and PM 
displayed low metabolic activity. 
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Mineralization was assessed by measuring calcium deposition in the extracellular 
matrix after 24 days of culture in the different media. The results showed that 
mineralization only occurred in the cocultures in OM (Figure 1B). Cocultures 
showed substantial mineralization, especially those at a ratio of 50:50. BM-MSCs 
monocultures showed only limited mineralization, whereas mineralization was 
absent in HUVECs monocultures. 
3.3. Optimization of cell ratio 
To determine the optimal ratio of BM-MSCs and HUVECs in coculture, cells were 
cocultured at different ratios (98:2 - 10:90) in both 2D- and 3D-culture systems. 
The culture medium used in these experiments was OM, as only this medium was 
capable of inducing mineralization (see above). Cell morphology demonstrated to 
be normal for (co)cultures with high BM-MSCs percentage (100% - 50%), whereas 
abnormal cell morphology and even cell death was observed for (co)cultures with 
high HUVECs percentage (60% - 100%; Figure 2A-B). The results of cell metabolic 
activity confirmed these results, showing relatively high metabolic activity in 
(co)cultures with high BM-MSCs percentage and substantially decreased metabolic 
activity in (co)cultures with high HUVECs percentage (Figure 2C). Moreover, cell 
pellets could hardly be formed for (co)cultures containing high HUVECs 
percentages due to the non-viability of the cells. Consequently, (co)cultures with 
high HUVECs percentages (> 50%) were excluded from the experiments. 
3.3.1. 2D-cultures 
In the 2D-culture system, osteogenic output parameters were cell metabolic activity, 
proliferation, differentiation and mineralization. 
Cell metabolic activity showed a significant increase in BM-MSCs monoculture as 
well as in the 50:50 and 80:20 cocultures from day 4 to 7, after which it remained 
stable over time. For the other ratios (98:2, 95:5 and 90:10), there was no 
significant difference between the later and previous time point (Figure 2C). Cell 
proliferation was assessed by measuring cellular DNA content at selective time 
points. An increase in cellular DNA content was observed for all cocultures over 
time, whereas a plateau phase was reached for BM-MSCs monoculture from day 
24 on. The DNA contents were lower in the cocultures compared to BM-MSCs 
monocultures at the earlier time points (day 14 and 18), but this trend was opposite 
on day 28, on which the 80:20 coculture showed significantly increased DNA 
content (Figure 3). 
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contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Figure 1. Cell metabolic activity and calcium content in different culture media (n=3). (A) Cell metabolic 
activity in different culture media on day 21. (B) Calcium content in different culture media on day 24. 
PM-proliferation medium for MSCs or OBs, OM-osteogenic medium, EM-ECs medium, MIX-1:1 mixture 
of OM/EM. *, p<0.05; **, p<0.01, indicate significant difference with those in OM in each group. 
 
Cell metabolic activity results for the various cocultures showed similarly high 
values for OM and EM, whereas lower values were obtained when cell culture was 
performed with PM or MIX. For BM-MSCs monoculture, equally high cell metabolic 
activity values were measured in OM, EM, and MIX, whereas significantly lower 
values (p<0.01) were obtained in PM. On the other hand, HUVECs monoculture 
showed the highest cell metabolic activity in EM and MIX, whereas OM and PM 
displayed low metabolic activity. 
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Mi eralization was assessed by m asuring calcium deposition in the extracellular 
matrix after 24 days of culture in the different media. The results showed that 
mineralization only occu red in he cocultures in OM (Figure 1B). Cocultures 
showed substantial mineralization, especially those at a ratio of 50:50. BM-MSCs 
monocultures showed only limited mineralization, whereas mineralization was 
absent in HUVECs monocultures. 
3.3. Optimization of cell ratio 
To determine th  optimal rat o of BM-MSCs and HUVECs in cocultur , cell  were 
cocultured at different ratios (98:2 - 10:90) i  both 2D- and 3D-culture systems. 
The culture medium used in these experiments was OM, s only this medium was 
capable of indu ing mineralization (se  above). Cell morphology demonstrated to 
be norm l for (co)cultures with high BM-MSCs pe centage (100% - 50%), wherea  
abnormal cell morphology and even cell death was observed for (co)cultures ith 
high HUVEC  percentage (60% - 100%; Figure 2A-B). The results f cell metabolic 
activity confirmed these resu ts, showing relatively high metabolic activity in 
(co)cultures with high BM-MSCs percentage and substantially d creased metabolic 
activity in (co)cultures with high HUVECs percentag  (Figure 2C). Mor over, cell 
pellets could hardly be formed for (co)cultures containing high HUVECs 
percentages due to the non-viability of the cells. Cons quently, (co)cultur  with 
high HUVECs percentag s (> 50%) were excluded fr m the experiments. 
3.3.1. 2D-cultures 
In the 2D-culture system, osteogenic output parameters were cell metabolic activity, 
proliferation, differentiation and mineralization. 
Cell metabolic activity showed a significant increase in BM-MSCs monoculture as 
well as in the 50:50 and 80:20 cocultures from day 4 to 7, after which it remained 
stable over time. For the other ratios (98:2, 95:5 and 90:10), there was no 
significant difference between the later and previous time point (Figure 2C). Cell 
proliferation was assessed by measuring cellular DNA content at selective time 
points. An increase in cellular DNA content was observed for all cocultures over 
time, whereas a plateau phase was reached for BM-MSCs monoculture from day 
24 on. The DNA contents were lower in the cocultures compared to BM-MSCs 
monocultures at the earlier time points (day 14 and 18), but this trend was opposite 
on day 28, on which the 80:20 coculture showed significantly increased DNA 
content (Figure 3). 
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Figure 2. Cell morphology and metabolic activity of BM-MSCs and HUVECs monocultures and BM-
MSCs/HUVECs cocultures in OM (n=3). (A) Cell morphology showed cells proliferated in the cultures 
with more BM-MSCs in OM (representative picture from 50:50 group on day 7). (B) Cell morphology 
showed cells could not survive in the cultures with more HUVECs in OM (representative picture from 
40:60 group on day 7). (C) Cell metabolic activity in different cultures (100:0 - 0:100) in OM. *, p<0.05; **, 
p<0.01; ***, p<0.001, indicate significant difference between the later and previous time point in each 
group. 
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Figure 3. Cellular DNA content of BM-MSCs monoculture and BM-MSCs/HUVECs cocultures in OM 
(n=3). *, p<0.05; **, p<0.01, indicate significant difference compared to BM-MSCs monoculture on day 
14; #, p<0.05, indicates significant difference compared to BM-MSCs monoculture on day 18; @, 
p<0.05, indicates significant difference compared to BM-MSCs monoculture on day 28. 
 
Cocultures showed obviously higher ALP-activity compared to BM-MSCs 
monoculture, especially for 50:50 cocultures, which showed highest ALP-activity on 
day 14 and 18. Significantly higher ALP-activity was found in 50:50 coculture on 
day 14 and in 50:50, 80:20, 90:10 and 98:2 cocultures on day 18 when compared 
to BM-MSCs monoculture (Figure 4). Mineralization was visualized using light 
microscopy and quantified using a calcium assay. Microscopic observation showed 
the onset of mineralization on day 14 and became more apparent from day 18 on 
for both 50:50 and 80:20 cocultures, although it was more evident in the 50:50 
coculture. No or minor signs of mineralization could be observed for other 
cocultures or the BM-MSCs monoculture. Quantification of the amount of calcium 
deposited in the extracellular matrix (Figure 5) showed substantial mineralization 
for 50:50 coculture, followed by 80:20, and increased over time. Mineralization was 
always significantly higher in the 50:50 coculture compared to the BM-MSCs group 
at each time point. All other cocultures and the BM-MSCs monoculture 
demonstrated only basal calcium levels during the entire cell culture. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Figure 3. Cellular DNA content of BM-MSCs monoculture and BM-MSCs/HUVECs cocultures in OM 
(n=3). *, p<0.05; **, p<0.01, indicate significant difference compared to BM-MSCs monoculture on day 
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Cocultures showed obviously higher ALP-activity compared to BM-MSCs 
monoculture, especially for 50:50 cocultures, which showed highest ALP-activity on 
day 14 and 18. Significantly higher ALP-activity was found in 50:50 coculture on 
day 14 and in 50:50, 80:20, 90:10 and 98:2 cocultures on day 18 when compared 
to BM-MSCs monoculture (Figure 4). Mineralization was visualized using light 
microscopy and quantified using a calcium assay. Microscopic observation showed 
the onset of mineralization on day 14 and became more apparent from day 18 on 
for both 50:50 and 80:20 cocultures, although it was more evident in the 50:50 
coculture. No or minor signs of mineralization could be observed for other 
cocultures or the BM-MSCs monoculture. Quantification of the amount of calcium 
deposited in the extracellular matrix (Figure 5) showed substantial mineralization 
for 50:50 coculture, followed by 80:20, and increased over time. Mineralization was 
always significantly higher in the 50:50 coculture compared to the BM-MSCs group 
at each time point. All other cocultures and the BM-MSCs monoculture 
demonstrated only basal calcium levels during the entire cell culture. 
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Figure 4. Osteogenic differentiation for BM-MSCs monoculture and BM-MSCs/HUVECs cocultures in 
OM (n=3). **, p<0.01, indicates significantly higher ALP-activity compared to the BM-MSCs group on 
day 14. #, p<0.05; ##, p<0.01, indicate significantly higher ALP-activity compared the BM-MSCs group 
on day 18. 
 
 
Figure 5.  Mineralization of BM-MSCs monoculture and BM-MSCs/HUVECs cocultures in OM (n=3). *, 
p<0.05; **, p<0.01, indicate significantly higher mineralization compared to the BM-MSCs group at each 
time point. 
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3.3.2. 3D-cultures 
In the 3D-culture system, cell pellets consisting of BM-MSCs and HUVECs at the 
same cell ratios as in the 2D system were cultured in OM to evaluate the effect of 
cell ratio on the angiogenic output parameter CD31 expression. After a culture 
period of 10 days in OM, cryo-sections were prepared for CD31 staining. The 
negative control (without anti-CD31 antibody) demonstrated the absence of non-
specific staining of the peroxidase-labeled secondary antibody. Histological 
evaluation (Figure 6A) showed an apparent increase of CD31-staining with 
increasing number of HUVECs in the pellet coculture. BM-MSCs monoculture 
pellets also showed marginal CD31 staining after cultured in OM. Quantification of 
CD31-staining (Figure 6B) showed substantial CD31 area percentage for all the 
cocultures, with a significant decrease when lower numbers of HUVECs used in 
the cocultures (50:50 > 80:20 > 90:10 > 95:5 > 98:2). Marginal CD31 area 
percentage was observed for BM-MSCs monoculture pellets. Normalization for the 
percentage of HUVECs seeded in the coculture pellets showed a significant 
increase with decreasing numbers of HUVECs in the coculture pellets (Figure 6C). 
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Figure 4. Osteogenic differentiation for BM-MSCs monoculture and BM-MSCs/HUVECs cocultures in 
OM (n=3). **, p<0.01, indicates significantly higher ALP-activity compared to the BM-MSCs group on 
day 14. #, p<0.05; ##, p<0.01, indicate significantly higher ALP-activity compared the BM-MSCs group 
on day 18. 
 
 
Figure 5.  Mineralization of BM-MSCs monoculture and BM-MSCs/HUVECs cocultures in OM (n=3). *, 
p<0.05; **, p<0.01, indicate significantly higher mineralization compared to the BM-MSCs group at each 
time point. 
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3.3.2. 3D-cul ures 
In the 3D-culture system, cell pellets consisting of BM-MSCs and HUVECs at the 
same cell ratios as in the 2D system were cultured in OM to evaluate the effect of 
cell ratio on the angiogenic output parameter CD31 expression. After a culture 
period of 10 days in OM, cryo-sections were prepared for CD31 staining. The 
negative control (without anti-CD31 antibody) demonstrated the absence of non-
specific staining of the peroxidase-labeled secondary antibody. Histological 
evaluation (Figure 6A) showed an apparent increase of CD31-staining with 
increasing number of HUVECs in the pellet coculture. BM-MSCs monoculture 
pellets also showed marginal CD31 staining after cultured in OM. Quantification of 
CD31-staining (Figure 6B) showed substantial CD31 area percentage for all the 
cocultures, with a significant decrease when lower numbers of HUVECs used in 
the cocultures (50:50 > 80:20 > 90:10 > 95:5 > 98:2). Marginal CD31 area 
percentage was observed for BM-MSCs monoculture pellets. Normalization for the 
percentage of HUVECs seeded in the coculture pellets showed a significant 
increase with decreasing numbers of HUVECs in the coculture pellets (Figure 6C). 
Chapter 3 
 
60 
 
 
Figure 6.  CD31 immunohistochemical staining of cell pellets (n=3) (day 10). (A) Images of cross-
sections (brown, CD31; blue, hematoxylin; scale bars, 100 μm). The apparent differences in the size of 
the pellets are due to the plane of section. (B) CD31 percentage in different groups. *, p<0.05; ***, 
p<0.001, indicate the difference between 50:50 and the other groups. (C) Normalized CD31 percentage 
in different groups. *, p<0.05; **, p<0.01; ***, p<0.001, indicate the difference between 95:5 and the 
other ratios. ###, p<0.001, indicates the difference between 98:2 and the other ratios. 
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4. Discussion 
Coculture of OBs with ECs has been proposed as a useful prevascularization 
strategy in bone tissue engineering. Although attempts have shown encouraging 
results both in vitro6,8,10-11 and in vivo7,16-21, hardly any consistency exists in the 
experimental set-ups for those studies. It is straightforward to hypothesize that 
(co)culture conditions determine both the osteogenic and angiogenic outcome 
parameters. Consequently, it is crucial to determine optimal (co)culture conditions, 
such as culture medium and cell ratio22. In view of this, the present study sought to 
explore the optimal cell ratio and culture medium for both osteogenic and 
angiogenic outcome parameters in BM-MSCs/HUVECs cocultures. It was 
demonstrated that only osteogenic medium was capable of inducing mineralization, 
whereas proliferation medium, endothelial medium and a mixture of osteogenic 
medium and endothelial medium were not. Extended experiments with osteogenic 
medium subsequently showed that mineralization occurred only in cocultures with 
50:50 or 80:20 ratios of BM-MSCs and HUVECs, respectively. Although 
normalized angiogenic outcome was highest for low numbers of HUVECs in 
cocultures, substantial numbers of HUVECs demonstrated to be required to obtain 
mineralization as well as CD31 staining. 
4.1. Cocultures in OM induced mineralization with preservation of angiogenic 
marker expression 
In this study, we evaluated how the different culture media affected mineralization 
in cocultures and monoculture. In 2D-cultures using different cell culture media, the 
primary focus was on mineralization, as the ultimate aim for bone tissue 
engineering is the formation of (mineralized) bone tissue. Mineralization was 
observed only for cocultures in OM, while PM, EM and MIX demonstrated to be 
incapable of inducing osteogenic differentiation. Consequently, these results show 
that osteogenic differentiation of BM-MSCs depends on (i) osteogenic constituents 
(dexamethasone and β-glycerophosphate) above a certain threshold level, and (ii) 
interaction with ECs. Regarding the requirement of osteogenic constituents, 
several reports describe cocultures in either PM or EM to induce either higher ALP 
activity or more bone formation for cocultures than monocultures6,8,10,16. It needs to 
be emphasized, however, that in none of these reports mineralization was 
assessed using a quantitative mineralization assay. 
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Figure 6.  CD31 immunohistochemical staining of cell pellets (n=3) (day 10). (A) Images of cross-
sections (brown, CD31; blue, hematoxylin; scale bars, 100 μm). The apparent differences in the size of 
the pellets are due to the plane of section. (B) CD31 percentage in different groups. *, p<0.05; ***, 
p<0.001, indicate the difference between 50:50 and the other groups. (C) Normalized CD31 percentage 
in different groups. *, p<0.05; **, p<0.01; ***, p<0.001, indicate the difference between 95:5 and the 
other ratios. ###, p<0.001, indicates the difference between 98:2 and the other ratios. 
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It is known that the osteogenic capacity of expanded BM-MSCs decreases with 
serial passaging23-24. The results in this experiment showed that mineralization 
occurred in all cocultures during the quest for the optimal culture medium using 
BM-MSCs of passage 3, albeit to a varying extent with highest values for 50:50 
cocultures. In the subsequent experiments to optimize cell ratio, BM-MSCs of 
passage 4 were used, showing obvious mineralization for only coculture ratios of 
50:50 and 80:20 (BM-MSCs:HUVECs). Additionally, long time BM-MSCs 
expansion (i.e. time, not passaging) may lead to senescence, which is 
characterized by a lack of proliferation and differentiation of BM-MSCs25-26. In view 
of this, ECs appear capable of inducing mineralization of OBs. Reported data from 
coculture experiments7,15,27 suggest that ECs drive OBs into an osteoblastic 
phenotype and therefore ECs were proposed as “osteoinductive” mediators in a 
coculture model22. For the interaction of the two cell types, two pathways exist: (i) 
direct cell-cell direct (such as gap junction6 and cellular bridge28), and (ii) diffusible 
mediators which are secreted by one cell type and influence the other cell type via 
specific receptors22. Direct contact has been suggested necessary for inducing 
osteogenic differentiation because increased ALP-activity could only be found in 
direct contact when it failed in indirect contact or conditioned medium5-6. For the 
diffusible mediators, although not determined in the present experiment, many 
studies have shown bi-lateral secretion of stimulatory factors between the two cell 
types. ECs can secrete bone morphogenetic protein-229 and insulin-like growth 
factor30 which modulate the proliferation and differentiation of OBs7,31. On the other 
hand, OBs can secrete vascular endothelial growth factor to enhance the growth 
and differentiation of ECs6,29,32-33. Recently, it was reported that ALP expression in 
coculture in PM was even higher than that of monoculture of BM-MSCs in OM28, 
which also demonstrated the strong interactions between the two cell types. 
Due to these types of communication, ECs can survive and preserve angiogenic 
marker expression in cocultures and similar results were also reported previously, 
in which 50:50 of OBs/ECs were cocultured in PM on polyurethane scaffolds10. 
Apparently, ECs need specific growth factors in the culture medium to support 
proliferation and survival, and it appears that coculture-conditioned medium meets 
this requirement. However, it seems that this is a cell ratio-dependent process, 
since ECs can only survive in the cultures with high OBs-percentage (100% - 50%) 
in OM. Meanwhile, the life-span of ECs was reported to be prolonged in 
cocultures34, which might be caused by the cell interactions as well. Herein, CD31-
staining was used to evaluate angiogenic marker expression, but this parameter is 
not comparable with functional blood vessels and it needs further in vivo research. 
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4.2. Osteogenic and angiogenic potential increases with decreasing BM-
MSCs/HUVECs ratio in cocultures 
ALP-activity and calcium deposition represent frequently-used early and late 
markers for osteogenic differentiation, respectively35-36. In the present study, ALP-
activity was highest for 50:50 cocultures on day 14 and 18. Two previous reports 
also observed higher ALP-activity for this ratio, but using culture medium consisting 
of either 1:1 mixture of PM/EM, or PM6-7. Therefore, we assume that cell ratio has a 
more important role than culture medium does in affecting the ALP-activity. 
Mineralization was also highest for the 50:50 cocultures, followed by 80:20 
cocultures. This observation shows that a decreasing BM-MSCs/HUVECs ratio (up 
to 50:50) at the time of coculture initiation resulted in higher osteogenic 
differentiation. In view of the complicated interactions between the two cell types 
during culture period, the ratio at sample collection might be quite different from the 
initial one. Although not determined in the present study, Fuchs et al. cocultured 
OBs with ECs in a ratio of 3:2 onto silk fibroin scaffolds for up to 4 weeks, showing 
that the cell proliferation rate for these two cell types is different, where OBs were 
increasing from 60% to 89% while ECs were decreasing from 40% to 11.5% over 
time9. 
In the present study, BM-MSCs did not express CD31 at the time of (co)culture 
initiation, but the exclusivity of CD31-expression for ECs appears questionable, as 
rat BM-MSCs were recently reported to express concurrently both osteogenic and 
angiogenic markers in OM37. Meanwhile, another study also showed that 
immunostaining can magnify the signal (while CD31 was negative using flow 
cytometry test, it was weakly positive using immunohistochemical staining)3. 
Nevertheless, we speculate that the majority of CD31-expression in BM-
MSCs/HUVECs cocultures results from HUVECs and potential contribution of BM-
MSCs CD31-expression is only marginal. Consequently, the observation that 
CD31+ staining increased with decreasing BM-MSCs/HUVECs ratio in the cell 
pellets seems straightforward. Nevertheless, after normalized by the percentage of 
ECs seeded, the relative CD31+ staining showed the opposite result. This 
observation corroborates the results from Rouwkema et al.11, although it needs to 
be emphasized that less than 20% of HUVECs in the initial cell pellets appeared 
not to be capable of inducing mineralization. 
The results from this experiment pave the way for future coculture studies. For 
clinical application using coculture techniques for cell-based bone tissue 
engineering, however, the present results only indicate that culture medium and 
ratio are important parameters for the in vitro part of the entire procedure. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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It is known that the osteogenic capacity of expanded BM-MSCs decreases with 
serial passaging23-24. The results in this experiment showed that mineralization 
occurred in all cocultures during the quest for the optimal culture medium using 
BM-MSCs of passage 3, albeit to a varying extent with highest values for 50:50 
cocultures. In the subsequent experiments to optimize cell ratio, BM-MSCs of 
passage 4 were used, showing obvious mineralization for only coculture ratios of 
50:50 and 80:20 (BM-MSCs:HUVECs). Additionally, long time BM-MSCs 
expansion (i.e. time, not passaging) may lead to senescence, which is 
characterized by a lack of proliferation and differentiation of BM-MSCs25-26. In view 
of this, ECs appear capable of inducing mineralization of OBs. Reported data from 
coculture experiments7,15,27 suggest that ECs drive OBs into an osteoblastic 
phenotype and therefore ECs were proposed as “osteoinductive” mediators in a 
coculture model22. For the interaction of the two cell types, two pathways exist: (i) 
direct cell-cell direct (such as gap junction6 and cellular bridge28), and (ii) diffusible 
mediators which are secreted by one cell type and influence the other cell type via 
specific receptors22. Direct contact has been suggested necessary for inducing 
osteogenic differentiation because increased ALP-activity could only be found in 
direct contact when it failed in indirect contact or conditioned medium5-6. For the 
diffusible mediators, although not determined in the present experiment, many 
studies have shown bi-lateral secretion of stimulatory factors between the two cell 
types. ECs can secrete bone morphogenetic protein-229 and insulin-like growth 
factor30 which modulate the proliferation and differentiation of OBs7,31. On the other 
hand, OBs can secrete vascular endothelial growth factor to enhance the growth 
and differentiation of ECs6,29,32-33. Recently, it was reported that ALP expression in 
coculture in PM was even higher than that of monoculture of BM-MSCs in OM28, 
which also demonstrated the strong interactions between the two cell types. 
Due to these types of communication, ECs can survive and preserve angiogenic 
marker expression in cocultures and similar results were also reported previously, 
in which 50:50 of OBs/ECs were cocultured in PM on polyurethane scaffolds10. 
Apparently, ECs need specific growth factors in the culture medium to support 
proliferation and survival, and it appears that coculture-conditioned medium meets 
this requirement. However, it seems that this is a cell ratio-dependent process, 
since ECs can only survive in the cultures with high OBs-percentage (100% - 50%) 
in OM. Meanwhile, the life-span of ECs was reported to be prolonged in 
cocultures34, which might be caused by the cell interactions as well. Herein, CD31-
staining was used to evaluate angiogenic marker expression, but this parameter is 
not comparable with functional blood vessels and it needs further in vivo research. 
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4.2. Osteogenic and angiogenic potential increases with decreasing BM-
MSCs/HUVECs ratio in cocultures 
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angiogenic markers in OM37. Meanwhile, another study also showed that 
immunostaining can magnify the signal (while CD31 was negative using flow 
cytometry test, it was weakly positive using immunohistochemical staining)3. 
Nevertheless, we speculate that the majority of CD31-expression in BM-
MSCs/HUVECs cocultures results from HUVECs and potential contribution of BM-
MSCs CD31-expression is only marginal. Consequently, the observation that 
CD31+ staining increased with decreasing BM-MSCs/HUVECs ratio in the cell 
pellets seems straightforward. Nevertheless, after normalized by the percentage of 
ECs seeded, the relative CD31+ staining showed the opposite result. This 
observation corroborates the results from Rouwkema et al.11, although it needs to 
be emphasized that less than 20% of HUVECs in the initial cell pellets appeared 
not to be capable of inducing mineralization. 
The results from this experiment pave the way for future coculture studies. For 
clinical application using coculture techniques for cell-based bone tissue 
engineering, however, the present results only indicate that culture medium and 
ratio are important parameters for the in vitro part of the entire procedure. The 
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entire procedure involves many more steps, including cell isolation, cell expansion, 
cell seeding onto a scaffold, and finally implantation of the cell-loaded scaffold into 
a bone defect. Additionally, it needs to be emphasized that still huge donor 
variation exists in the in vitro and in vivo performance of BM-MSCs, demonstrating 
the need for more standardization in the isolation and expansion procedures for 
these cells in combination with pre-usage screening. From the present results, the 
50:50 ratio of BM-MSCs/HUVECs cocultured in OM as appears to be the optimal 
condition for coculture in vitro. Nevertheless, future studies need to be done to 
verify the feasibility of in vivo bone formation in such coculture system and optimize 
the cell-scaffold culture conditions (e.g. cell ratio, culture medium, and culture time) 
to enhance clinical efficacy. 
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5. Conclusion 
The results from the present study showed that both cell culture medium and cell 
ratio are important parameters for cocultures of BM-MSCs and HUVECs. Only 
osteogenic medium demonstrated to be capable of inducing mineralization. It was 
also shown that mineralization and angiogenic potential of the cocultures increased 
with decreasing BM-MSCs/HUVECs ratio till 50:50. Therefore, we conclude that a 
BM-MSCs/HUVECs coculture ratio of 50:50 in osteogenic medium is optimal for 
both osteogenic and angiogenic potential. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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1. Introduction 
The multipotential differentiation capacity of mesenchymal stem cells (MSCs), 
including osteogenic and chondrogenic differentiation1-2 enables their widespread 
use in a variety of regenerative medicine applications. However, clinical application 
of MSCs normally requires stem cell isolation, expansion, seeding on a scaffold 
and pre-culture in vitro. The conditions during this in vitro period need to be optimal 
to warrant stem cell potency in tissue regenerative treatments. 
For MSCs, the in vitro period between isolation and implantation involves cell 
culture under standardized conditions, in which MSCs come in contact with artificial 
surfaces, such as tissue culture polystyrene and/or scaffold material, and liquids, 
being cell culture medium. The latter consist mainly of basic culture medium 
supplemented with a nutritional source (in most cases serum), antibiotics, 
cytokines/growth factors, and/or components that either promote cell proliferation 
or induce cells to differentiate into a specific lineage. A basic culture medium (such 
as alpha Minimum Essential Medium, α-MEM) is suitable for a broad spectrum of 
mammalian cells and contains the basic essentials for cell cultures, including 
amino acids, salts, and glucose. Occasionally, the amino acids in a basic culture 
medium are insufficient for some cell types, for which glutamine is provided as an 
amino acid source. In bone tissue engineering, dexamethasone, L-ascorbic acid (-
2-phosphate) and β-glycerophosphate are the common supplements for inducing 
osteogenic differentiation of MSCs3. Major importance, however, should be 
devoted to the choice for a suitable nutritional source, as this is the critical 
component for cell culture medium that can maintain MSCs survival, as well as 
their proliferation and differentiation capacity. 
Fetal bovine serum (FBS) or fetal calf serum has been the most frequently utilized 
nutritional source for cell culture since decades. However, it represents the 
concern of bringing xenogeneic antigens to patients and baring the risk of 
transmitting zoonose contaminations4-5. Additionally, cultured cells in FBS may 
incorporate bovine proteins that can elicit allergic reactions6. The ideal situation 
would be to avoid the use of FBS in human cell cultures. In order to achieve this, 
either chemically defined culture medium or cell culture supplements from human 
origin7-8 have been explored. Unfortunately, it appeared difficult to apply chemically 
defined media for clinical use because recombinant human growth factors are 
expensive and only a few growth factors are licensed for clinics9. To date, several 
possibilities have been reported as a human-derived nutritional source, such as 
serum, platelet-rich-plasma (PRP) and platelet lysate (PL). However, human serum 
does not fully support growth of MSCs in vitro and it may induce MSCs to display 
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genetic alterations10, while obtaining human PRP involves a complicated, non-
standardized procedure8. Recently, platelet-derived products have gained clinical 
interest due to their efficacy regarding enhancement of bone regeneration11. PL 
contains a plethora of growth factors that are secreted by platelets and has been 
proposed as a safe substitute for animal serum for MSCs expansion12. Beside 
enhancing proliferation of MSCs13, PL has been reported to maintain their 
phenotype, multi-differentiation capacity and immune-modulation capacity, 
indicating that MSCs cultured in PL-supplemented medium can function normally 
and reduce potential graft-versus-host reactions14-15. Nevertheless, inconsistency 
exists on the effects of PL on osteogenic capacity of MSCs. While some authors 
found that PL enhanced osteogenic marker expression of MSCs11,16, others did 
not17-18. 
Human bone marrow-derived MSCs (BM-MSCs) and human adipose tissue-
derived MSCs (AT-MSCs) are the most frequently used MSCs in the field of tissue 
engineering and regenerative medicine. Although their bone formation capacity has 
been tested in animal studies19-20, limited clinical studies for either BM-MSCs21-22 or 
AT-MSCs23-24 can be found and difficulties exist in evaluating their bone forming 
capacity in clinics, which is due to the restricted chance of including accellular 
control groups. Moreover, big success in clinic studies has not been achieved yet25, 
which is generally attributed to insufficient blood supply inside the tissue-
engineered constructs26. Cocultures with angiogenic cells, which relates to 
introducing angiogenic cells into osteoblastic cell cultures, is hypothesized to 
mitigate this problem, since these cells can form vessels to enhance bone 
formation27. Most of the cocultures reported so far have used BM-MSCs and were 
cultured in FBS-supplemented medium28-29. As AT-MSCs represent a relatively 
new cell type explored in the recent decade, only limited data are available on 
cocultures using AT-MSCs. The effects of PL-supplemented medium on such 
cocultures have not been reported yet. 
The aim of this study was to evaluate the effects of medium supplementation with 
FBS or PL on in vitro cell behavior (mainly osteogenic differentiation) of (i) 
monocultures of BM-MSCs or AT-MSCs, and (ii) cocultures of BM-MSCs or AT-
MSCs with human umbilical vein endothelial cells (HUVECs). 
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2. Materials and methods 
2.1. Preparation of platelet lysate 
PL was prepared as described previously30. Briefly, pooled platelet products 
(containing approximately 1×109 thrombocytes/ml) were provided by Transfusion 
department (VU University Medical Center, Amsterdam, the Netherlands). This 
product was divided into 5 ml aliquots in 15 ml tubes (Greiner Bio-one), subjected 
to one freeze/thaw (-80°C/37°C) cycle, and stored at -80°C until use. Before 
supplementation to the medium, PL was thawed and centrifuged (2000g, 10 min) 
to remove remaining platelet fragments. 
2.2. Medium preparation and cell cultures 
The composition of the cell culture media used in this study is listed in Table 1. 
Cells were cultured at 37°C in a humid atmosphere with 5% CO2 and medium 
refreshing twice a week. Cells of passage 3 from three donors of either BM-MSCs 
(donor 1, 2 and 3) or AT-MSCs (donor A, B and C) were used in the experiments. 
Human iliac bone chips were obtained from the residual tissue after oral and 
maxillofacial reconstruction surgery upon informed consent from patients in 
Radboud University Nijmegen Medical Center, the Netherlands. BM-MSCs were 
isolated and expanded as described previously31. Briefly, iliac bone chips were 
chopped into small pieces and put into 50 ml tubes. The tubes with minced bone 
chips and α-MEM were shaken vigorously and medium with cells was collected 
and plated in culture flasks (T175; Greiner Bio-one). Cells were expanded in FBS-
supplemented proliferation medium (PMFBS, Table 1) and passaged at a density of 
5,000 cells/cm2. Cells from two female donors and one male donor with age 30, 52 
and 38 years were used in this study. 
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contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2. Materials and methods 
2.1. Preparation of platelet lysate 
PL was prepared as described previously30. Briefly, pooled platelet products 
(containing approximately 1×109 thrombocytes/ml) were provided by Transfusion 
department (VU University Medical Center, Amsterdam, the Netherlands). This 
product was divided into 5 ml aliquots in 15 ml tubes (Greiner Bio-one), subjected 
to one freeze/thaw (-80°C/37°C) cycle, and stored at -80°C until use. Before 
supplementation to the medium, PL was thawed and centrifuged (2000g, 10 min) 
to remove remaining platelet fragments. 
2.2. Medium preparation and cell cultures 
The composition of the cell culture media used in this study is listed in Table 1. 
Cells were cultured at 37°C in a humid atmosphere with 5% CO2 and medium 
refreshing twice a week. Cells of passage 3 from three donors of either BM-MSCs 
(donor 1, 2 and 3) or AT-MSCs (donor A, B and C) were used in the experiments. 
Human iliac bone chips were obtained from the residual tissue after oral and 
maxillofacial reconstruction surgery upon informed consent from patients in 
Radboud University Nijmegen Medical Center, the Netherlands. BM-MSCs were 
isolated and expanded as described previously31. Briefly, iliac bone chips were 
chopped into small pieces and put into 50 ml tubes. The tubes with minced bone 
chips and α-MEM were shaken vigorously and medium with cells was collected 
and plated in culture flasks (T175; Greiner Bio-one). Cells were expanded in FBS-
supplemented proliferation medium (PMFBS, Table 1) and passaged at a density of 
5,000 cells/cm2. Cells from two female donors and one male donor with age 30, 52 
and 38 years were used in this study. 
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Human subcutaneous adipose tissue samples from elective plastic surgery were 
obtained from the department of Plastic Surgery (Tergooi Hospital in Hilversum, 
the Netherlands) after written informed consent. Adipose tissue was harvested 
from the abdomen after resection. This study complied with the principles of the 
Declaration of Helsinki. After surgery, adipose tissue was stored in sterile 
phosphate-buffered saline (PBS; B. Braun, Melsungen, Germany) at 4ºC overnight 
and processed within 24 h as described previously32. In brief, adipose tissue was 
minced using a surgical scalpel and washed with PBS. The tissue was then 
digested with 0.1% collagenase A (Roche Diagnostics, Mannheim, Germany) in 
PBS containing 1% bovine serum albumin (Roche Diagnostics) under continuous 
shaking conditions at 37ºC for 45 min. After Ficoll density centrifugation 
(Lymphoprep, 1000g, 20min; Axis-Shield, Oslo, Norway), the cell containing 
interface was harvested, counted and plated at a density of 100,000 cells/cm2 in 
PL-supplemented proliferation medium (PMPL, Table 1). In this study, three female 
donors with age 38, 43 and 40 years were included. 
HUVECs were obtained from a commercial source (Becton Dickinson Biosciences, 
BD; Breda, the Netherlands) and cultured in endothelial cell culture medium (EM, 
Table 1). Cells from passage 4 were used in the experiments. 
2.3. Comparison of cell behavior in FBS or PL supplemented medium 
Before the experiment was performed, multipotential differentiation capacity 
including osteogenic, chondrogenic and endothelial differentiation for both BM-
MSCs and AT-MSCs was examined as previously described31,33. BM-MSCs and 
AT-MSCs were cultured and expanded in PMFBS and PMPL respectively before the 
multipotential differentiation test.  
For osteogenic differentiation study, BM-MSCs and AT-MSCs were monocultured 
or cocultured with HUVECs (1:1) at a density of 5,000 cells/cm2 in 24-well plates in 
osteogenic medium supplemented with FBS or PL (OMFBS or OMPL), which means 
that culture media were similar except for FBS (15% in OMFBS) or PL (5% in OMPL). 
For stainings, Thermanox (NuncTM, New York, USA) was used. Samplings 
described below were performed in duplicate (n=2) for the qualitative assessments 
and in quadruplicate (n=4) for all quantitative assessments. 
2.3.1. Cell morphology 
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BM-MSCs and AT-MSCs were monocultured at a density of 5,000 cells/cm2 in 24-
well plates in either proliferation medium (PMFBS or PMPL) or osteogenic medium 
(OMFBS or OMPL) and observed with an inverted microscope (Leica) on day 3. 
2.3.2. Platelet/endothelial cell adhesion molecule-1 (CD31) staining 
In order to assess the ECs phenotype (CD31) changes over time in cocultures, 
CD31 immunohistochemical staining was performed as previously described31 for 
the samples from day 3 and 7. Observational analysis was processed with the 
Zeiss Imager Z1 microscope equipped with the AxioCam MRc5 camera using 
AxioVision 4.8 software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). 
2.3.3. Proliferative capacity 
Cell metabolic activity and DNA content were used to analyze the cell proliferative 
capacity in OMFBS or OMPL. AlamarBlue assay (Invitrogen) was used as an 
indicative index for cell metabolic activity specifically in the early phase of culture. 
Cell metabolic activity on day 3 and 7 was measured according to the instructions 
of the manufacturer. Briefly, AlamarBlue solution was prepared by mixing 
AlamarBlue with medium in a ratio of 1:9 (v/v). The cells were incubated with the 
AlamarBlue medium solution for 4 h. Fluorescence was measured using a 
microplate reader (FL 600; Bio-Tek, Belgium) at 570 nm. DNA content was 
measured using Quant-iTTM Picogreen Kit (Invitrogen). Samples were washed 
twice with PBS and 1 ml of MilliQ was added to each well, after which repetitive 
freezing (-80°C) and thawing (37°C) cycles were performed. For the standard 
curve, serial dilutions of dsDNA stock were prepared to final concentrations of 0–
2000 ng/ml. The samples were diluted appropriately to become measurable within 
the range of the standard curve (range: 0–2000 ng/ml). Next, 100 µl of either 
sample or standard was added to the wells, followed by 100 µl of working solution. 
The absorbance of the samples was read at 450 nm. 
2.3.4. Osteogenic differentiation capacity 
ALP-activity, calcium content as well as Von-Kossa staining were used to analyze 
the osteogenic capacity. The ALP-activity was measured using the same samples 
as the cellular DNA content measurement and it was determined using 5 nM p-
nitrophenyl phosphate (4-NP). The reaction was stopped by adding stop solution 
(0.3M NaOH). The amount of 4-NP released was determined by measuring the 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2.3.3. Proliferative capacity 
Cell metabolic activity and DNA content were used to analyze the cell proliferative 
capacity in OMFBS or OMPL. AlamarBlue assay (Invitrogen) was used as an 
indicative index for cell metabolic activity specifically in the early phase of culture. 
Cell metabolic activity on day 3 and 7 was measured according to the instructions 
of the manufacturer. Briefly, AlamarBlue solution was prepared by mixing 
AlamarBlue with medium in a ratio of 1:9 (v/v). The cells were incubated with the 
AlamarBlue medium solution for 4 h. Fluorescence was measured using a 
microplate reader (FL 600; Bio-Tek, Belgium) at 570 nm. DNA content was 
measured using Quant-iTTM Picogreen Kit (Invitrogen). Samples were washed 
twice with PBS and 1 ml of MilliQ was added to each well, after which repetitive 
freezing (-80°C) and thawing (37°C) cycles were performed. For the standard 
curve, serial dilutions of dsDNA stock were prepared to final concentrations of 0–
2000 ng/ml. The samples were diluted appropriately to become measurable within 
the range of the standard curve (range: 0–2000 ng/ml). Next, 100 µl of either 
sample or standard was added to the wells, followed by 100 µl of working solution. 
The absorbance of the samples was read at 450 nm. 
2.3.4. Osteogenic differentiation capacity 
ALP-activity, calcium content as well as Von-Kossa staining were used to analyze 
the osteogenic capacity. The ALP-activity was measured using the same samples 
as the cellular DNA content measurement and it was determined using 5 nM p-
nitrophenyl phosphate (4-NP). The reaction was stopped by adding stop solution 
(0.3M NaOH). The amount of 4-NP released was determined by measuring the 
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absorbance at 405 nm using an ELISA microplate reader (EL 800; Bio-Tek, 
Canada). The ALP-activities were normalized to the cellular DNA content. 
For qualitative assessment of mineralization, Von-Kossa staining was performed 
after 24 days culture to detect mineralization. Samples were washed twice with 
PBS and fixed in 10% formalin for 15 min. Then, 5% silver nitrate (Sigma) was 
added and samples were placed under ultraviolet light for 30 min. After rinsing in 
MilliQ for ten times, 2% sodium thiosulfate (Merck, Germany) was added to remove 
the un-reacted silver. Next, the samples were washed with running tap water for 10 
min and counterstained with nuclear fast red (Polysciences, Inc, Warrington PA, 
USA) for 10 min. Samples were then dehydrated through a graded series of 
ethanol and mounted. Mineralization was measured quantitatively using a calcium 
assay (orthocresolphtalein complexone; Sigma) according to previously 
described31. Samples were washed twice with PBS and added with 1 ml of 0.5N 
acetic acid into each well, after which the plates were incubated on a shaking table 
overnight at room temperature. For the standard curve, serial dilutions of calcium 
stock (CaCl2) were prepared to final concentrations of 0–100 µg/ml. Then, 10 µl of 
sample or standard was added in a 96-well plate, followed by 300 µl working 
solution. The plates were read at 570 nm using an ELISA microplate reader. 
2.4. Statistical analysis 
Data are presented as mean ± standard deviation. Statistical analysis was 
performed with GraphPad Instat 3 software (Instat® 3.05, Graphpad Software Inc., 
La Jolla, USA) using unpaired t-tests. Results were considered significant at 
p<0.05. 
Chapter 4 
 
77 
 
3. Results 
Both BM-MSCs and AT-MSCs showed multipotential differentiation into osteogenic, 
chondrogenic and endothelial lineages (data not shown). 
BM-MSCs and AT-MSCs cultures that were established from each of the three 
donors presented similar morphological characteristics. In non-osteogenic 
conditions (i.e. either PMFBS or PMPL), both cell types maintained an 
undifferentiated phenotype with a spindle-shaped morphology (Figure 1A-D). After 
3 days of osteogenic induction in OMFBS or OMPL, BM-MSCs and AT-MSCs cells 
exhibited morphological changes typical of the osteoblastic phenotype (Figure 1E-
H), and cells had acquired a complete polygonal osteoblast-like morphology after 7 
days (data not shown). 
 
Figure 1. Morphology of BM-MSCs and AT-MSCs in PMFBS, PMPL, OMFBS and OMPL on day 3. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3.1. CD31 expression in BM-MSCs/HUVECs and AT-MSCs/HUVECs 
The endothelial differentiation marker CD31 expression was increasing and 
becoming better organized in both BM-MSCs/HUVECs and AT-MSCs/HUVECs 
cocultures in OMFBS or OMPL over time. On day 3, CD31 expression in OMFBS 
(Figure 2A-B) was less than that in OMPL (Figure 2E-F), although the two cell types 
did not demonstrate obvious differences. On day 7, CD31 expression exhibited 
more pronounced organization compared to that on day 3, and the two cell types 
showed different patterns in OMFBS and OMPL. In OMFBS culture, CD31 distribution 
was agglomerated, no matter in BM-MSCs/HUVECs and AT-MSCs/HUVECs 
(Figure 2C-D). However, in OMPL culture, CD31 expression indicated the initiation 
of re-organization of endothelial cells for BM-MSCs/HUVECs (Figure 2G) and even 
pre-mature vessel-like structures were formed for AT-MSCs/HUVECs (Figure 2H). 
 
Figure 2. CD31 staining of BM-MSCs/HUVECs and AT-MSCs/HUVECs cultured in either OMFBS or 
OMPL on day 3 and 7. Brown color indicates CD31 positive. 
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3.2. Effects of FBS or PL supplemented medium on proliferative capacity 
Both BM-MSCs and AT-MSCs monocultures showed higher cell metabolic activity 
and proliferative capacity in OMPL compared to OMFBS. Cell metabolic activity 
increased over time and was higher in OMPL compared to OMFBS, and this trend 
became more obvious on day 7 (Figure 3A). DNA content was increased in OMPL 
compared to OMFBS at almost all time points (Figure 4A). Similar observations were 
made for cocultures regarding cell metabolic activity (Figure 3B) and proliferation 
(Figure 4B), irrespective of BM-MSCs/HUVECs or AT-MSCs/HUVECs. 
Figure 3. Cell metabolic 
activity in OMFBS or 
OMPL on day 3 and 7. 
(A) BM-MSCs and AT-
MSCs monocultures; 
(B) BM-MSCs/HUVECs 
and AT-MSCs/HUVECs 
cocultures. 
**, p<0.01; ***, p<0.001, 
indicate significant 
differences compared to 
OMFBS. 
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constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3.1. CD31 expression in BM-MSCs/HUVECs and AT-MSCs/HUVECs 
The endothelial differentiation marker CD31 expression was increasing and 
becoming better organized in both BM-MSCs/HUVECs and AT-MSCs/HUVECs 
cocultures in OMFBS or OMPL over time. On day 3, CD31 expression in OMFBS 
(Figure 2A-B) was less than that in OMPL (Figure 2E-F), although the two cell types 
did not demonstrate obvious differences. On day 7, CD31 expression exhibited 
more pronounced organization compared to that on day 3, and the two cell types 
showed different patterns in OMFBS and OMPL. In OMFBS culture, CD31 distribution 
was agglomerated, no matter in BM-MSCs/HUVECs and AT-MSCs/HUVECs 
(Figure 2C-D). However, in OMPL culture, CD31 expression indicated the initiation 
of re-organization of endothelial cells for BM-MSCs/HUVECs (Figure 2G) and even 
pre-mature vessel-like structures were formed for AT-MSCs/HUVECs (Figure 2H). 
 
Figure 2. CD31 staining of BM-MSCs/HUVECs and AT-MSCs/HUVECs cultured in either OMFBS or 
OMPL on day 3 and 7. Brown color indicates CD31 positive. 
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3.2. Effects of FBS or PL supplemented medium on proliferative capacity 
Both BM-MSCs and AT-MSCs monocultures showed higher cell metabolic activity 
and proliferative capacity in OMPL compared to OMFBS. Cell metabolic activity 
increased over time and was higher in OMPL compared to OMFBS, and this trend 
became more obvious on day 7 (Figure 3A). DNA content was increased in OMPL 
compared to OMFBS at almost all time points (Figure 4A). Similar observations were 
made for cocultures regarding cell metabolic activity (Figure 3B) and proliferation 
(Figure 4B), irrespective of BM-MSCs/HUVECs or AT-MSCs/HUVECs. 
Figure 3. Cell metabolic 
activity in OMFBS or 
OMPL on day 3 and 7. 
(A) BM-MSCs and AT-
MSCs monocultures; 
(B) BM-MSCs/HUVECs 
and AT-MSCs/HUVECs 
cocultures. 
**, p<0.01; ***, p<0.001, 
indicate significant 
differences compared to 
OMFBS. 
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Figure 4. Cellular DNA content in OMFBS or OMPL on day 7, 14 and 21. (A) BM-MSCs and AT-MSCs 
monocultures; (B) BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures. *, p<0.05; **, p<0.01; ***, 
p<0.001, indicate significant differences compared to OMFBS. 
3.3. Effects of FBS or PL supplemented medium on osteogenic differentiation 
capacity 
Cell-type dependent effects of OMFBS and OMPL on osteogenic differentiation 
capacity of BM-MSCs and AT-MSCs were found. For BM-MSCs, similar trend was 
demonstrated in two out of three donors (Donor 1 and Donor 2). ALP-activity 
increased over time and was significantly increased in OMFBS compared to OMPL at 
all time points (Figure 5A, p<0.001). In view of mineralization, Von-Kossa staining 
and calcium content showed apparently more mineralized nodules (Figures 6A) 
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and higher calcium content (Figure 7A, Table 2, p<0.001; Donor 1: 12.4-fold; Donor 
2: 6.0-fold) in OMFBS compared to OMPL. For another donor (Donor 3), ALP-activity 
increased over time and was significantly increased in OMPL compared to OMFBS at 
all time points (Figure 5A, p<0.001). However, Von-Kossa staining did not show 
apparently differences (data not shown) and there was no significant difference in 
calcium content as well (Figure 7A, Table 2) between OMFBS and OMPL group. 
 
Figure 5. ALP-activity in OMFBS or OMPL on day 7, 14 and 21. (A) BM-MSCs and AT-MSCs 
monocultures; (B) BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures. *, p<0.05; **, p<0.01; ***, 
p<0.001, indicate significant differences compared to OMFBS. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Figure 4. Cellular DNA content in OMFBS or OMPL on day 7, 14 and 21. (A) BM-MSCs and AT-MSCs 
monocultures; (B) BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures. *, p<0.05; **, p<0.01; ***, 
p<0.001, indicate significant differences compared to OMFBS. 
3.3. Effects of FBS or PL supplemented medium on osteogenic differentiation 
capacity 
Cell-type dependent effects of OMFBS and OMPL on osteogenic differentiation 
capacity of BM-MSCs and AT-MSCs were found. For BM-MSCs, similar trend was 
demonstrated in two out of three donors (Donor 1 and Donor 2). ALP-activity 
increased over time and was significantly increased in OMFBS compared to OMPL at 
all time points (Figure 5A, p<0.001). In view of mineralization, Von-Kossa staining 
and calcium content showed apparently more mineralized nodules (Figures 6A) 
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and higher calcium content (Figure 7A, Table 2, p<0.001; Don r 1: 12.4-fold; Donor 
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increased over time and was signific ntly increased i  OMPL compared to OMFBS at 
all time points (Figure 5A, p<0.001). However, Von-Kossa staining did not show 
apparently differences (data not shown) and there was no significant difference in 
calcium content as well (Figure 7A, Table 2) between OMFBS and OMPL group. 
 
Figure 5. ALP-activity in OMFBS or OMPL on day 7, 14 and 21. (A) BM-MSCs and AT-MSCs 
monocultures; (B) BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures. *, p<0.05; **, p<0.01; ***, 
p<0.001, indicate significant differences compared to OMFBS. 
Chapter 4 
 
82 
 
In contrast, ALP-activity of AT-MSCs increased over time and was significantly 
increased in OMPL compared to OMFBS at almost all time points (Figure 5A, p<0.01). 
Additionally, more mineralized nodules were observed and significantly higher 
calcium content was measured in OMPL compared to OMFBS (Figure 6B & 7A, 
p<0.001; Donor A: 33.8-fold; Donor B: 10.9-fold; Donor C: 36.1-fold). All three 
donors showed the same trend. 
 
Figure 6. Von-Kossa staining of BM-MSCs and AT-MSCs on day 24. Top panel (A) and bottom panel (B) 
indicate BM-MSCs and AT-MSCs, respectively. Mo, Monoculture; Co, Coculture (Scale bar, 500 μm). 
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For BM-MSCs/HUVECs cocultures, similar observations were made as for BM-
MSCs monocultures: ALP-activity was significantly higher (Donor 1 and Donor 2, 
Figure 5B, p<0.01), Von-Kossa staining was apparently more pronounced (Figures 
6A), and calcium content was significantly higher (Figure 7B, p<0.05; Donor 1: 
12.7-fold; Donor 2: 2.4-fold; Donor 3: 1.1-fold) in OMFBS compared to OMPL. AT-
MSCs/HUVECs cocultures showed similar osteogenic differentiation characteristics 
compared to AT-MSCs monocultures: significantly higher ALP-activity (Figure 5B, 
p<0.01), apparently more pronounced Von-Kossa staining (Figures 6B), and 
significantly higher calcium content (Figure 7B, p<0.001; Donor A: 37.8-fold; Donor 
B: 9.5-fold; Donor C: 14.6-fold) in OMPL compared to OMFBS. 
 
Figure 7. Calcium content in OMFBS or OMPL on day 24. (A) BM-MSCs and AT-MSCs monocultures; (B) 
BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures. *, p<0.05; ***, p<0.001, indicate significant 
differences compared to OMFBS. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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In contrast, ALP-activity of AT-MSCs increased over time and was significantly 
increased in OMPL compared to OMFBS at almost all time points (Figure 5A, p<0.01). 
Additionally, more mineralized nodules were observed and significantly higher 
calcium content was measured in OMPL compared to OMFBS (Figure 6B & 7A, 
p<0.001; Donor A: 33.8-fold; Donor B: 10.9-fold; Donor C: 36.1-fold). All three 
donors showed the same trend. 
 
Figure 6. Von-Kossa staining of BM-MSCs and AT-MSCs on day 24. Top panel (A) and bottom panel (B) 
indicate BM-MSCs and AT-MSCs, respectively. Mo, Monoculture; Co, Coculture (Scale bar, 500 μm). 
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For BM-MSCs/HUVECs cocultures, imilar observations were made as for BM-
MSCs monocultures: ALP-activity was ignificantly higher (Donor 1 and Donor 2, 
Figure 5B, p<0.01), Von-K ssa stai ing was apparently o e pronounced (Figures 
6A), and calcium content was significantly higher (Figure 7B, p<0.05; Donor 1: 
12.7-fold; Donor 2: 2.4-fold; Donor 3: 1.1-fold) in OMFBS compared to OMPL. AT-
MSCs/HUVECs cocultures showed similar osteogenic differentiation characteristics 
compared to AT-MSCs monocultures: significantly higher ALP-activity (Figure 5B, 
p<0.01), apparently more pronounced Von-Kossa staining (Figures 6B), and 
significantly higher calcium content (Figure 7B, p<0.001; Donor A: 37.8-fold; Donor 
B: 9.5-fold; Donor C: 14.6-fold) in OMPL compared to OMFBS. 
 
Figure 7. Calcium content in OMFBS or OMPL on day 24. (A) BM-MSCs and AT-MSCs monocultures; (B) 
BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures. *, p<0.05; ***, p<0.001, indicate significant 
differences compared to OMFBS. 
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3.4. Comparison of calcium content in cocultures versus monocultures 
Calcium content comparison between mono- and cocultures showed MSCs cell-
type dependent differences (Table 2). For BM-MSCs, cocultures in OMFBS showed 
significantly higher calcium content values compared to monocultures (Donor 1: 
p<0.05; Donor 2: p<0.01; Donor 3: p<0.001). On the other hand, BM-MSCs 
cultures in OMPL showed similar calcium content values for mono- and cocultures 
for both Donor 1 and Donor 3 and increased values for cocultures compared to 
monocultures for Donor 2 (p<0.01). For AT-MSCs, similar calcium content values 
were observed for mono- and cocultures (p>0.05), irrespective of culture medium 
(i.e. OMFBS and OMPL). 
Ta
bl
e 
2.
 C
om
pa
ris
on
 o
f c
al
ci
um
 c
on
te
nt
 in
 F
B
S
 o
r P
L 
su
pp
le
m
en
te
d 
os
te
og
en
ic
 m
ed
iu
m
 o
n 
da
y 
24
 
C
on
di
tio
ns
D
on
or
s
M
on
oc
ul
tu
re
C
oc
ul
tu
re
M
on
o-
vs
. C
oc
ul
tu
re
FB
S
(μ
g
/m
l)
PL (μ
g
/m
l)
FB
S 
vs
. P
L
(P
 v
al
ue
s)
FB
S
(μ
g
/m
l)
PL (μ
g
/m
l)
FB
S 
vs
. P
L
(P
 v
al
ue
s)
FB
S
(P
 v
al
ue
s)
PL (P
 v
al
ue
s)
B
M
-M
S
C
s
D
on
or
 1
12
3.
6±
13
.4
10
.0
±3
.7
<0
.0
01
16
0.
9±
16
.0
12
.7
±6
.5
<0
.0
01
<0
.0
5
n.
s.
(*
)
D
on
or
 2
14
3.
6±
12
.0
24
.1
±7
.3
<0
.0
01
18
1.
4±
7.
2
76
.6
±1
6.
4
<0
.0
01
<0
.0
1
<0
.0
1
D
on
or
 3
92
.1
±1
1.
4
12
2.
0±
24
.1
n.
s.
15
8.
4±
9.
5
14
2.
3±
3.
9
<0
.0
5
<0
.0
01
n.
s.
A
T-
M
S
C
s
D
on
or
 A
2.
7±
0.
3
91
.3
±2
4.
4
<0
.0
01
1.
9±
0.
1
71
.8
±4
.5
<0
.0
01
n.
s.
(*
)
n.
s.
D
on
or
 B
16
.9
±5
.6
18
3.
9±
15
.4
<0
.0
01
18
.1
±4
.8
17
2.
7±
19
.1
<0
.0
01
n.
s.
(*
)
n.
s.
D
on
or
 C
5.
4±
2.
0
19
5.
0±
6.
0
<0
.0
01
13
.3
±1
.6
19
3.
8±
6.
9
<0
.0
01
<0
.0
01
(*
)
n.
s.
N
ot
e:
 n
.s
., 
in
di
ca
te
s 
no
t s
ig
ni
fic
an
t; 
*,
 in
di
ca
te
s 
no
 o
bv
io
us
 m
in
er
al
iz
at
io
n.
 
Chapter 2 
 
28 
 
contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3.4. Comparison of calcium content in cocultures versus monocultures 
Calcium content comparison between mono- and cocultures showed MSCs cell-
type dependent differences (Table 2). For BM-MSCs, cocultures in OMFBS showed 
significantly higher calcium content values compared to monocultures (Donor 1: 
p<0.05; Donor 2: p<0.01; Donor 3: p<0.001). On the other hand, BM-MSCs 
cultures in OMPL showed similar calcium content values for mono- and cocultures 
for both Donor 1 and Donor 3 and increased values for cocultures compared to 
monocultures for Donor 2 (p<0.01). For AT-MSCs, similar calcium content values 
were observed for mono- and cocultures (p>0.05), irrespective of culture medium 
(i.e. OMFBS and OMPL). 
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4. Discussion 
The objective of this study was to comparatively evaluate the effects of either FBS- 
or PL-supplemented culture medium on cell behavior and osteogenic differentiation 
capacity of BM-MSCs and AT-MSCs in both monocultures and cocultures with 
HUVECs. The results demonstrated that the osteogenic differentiation capacity of 
BM-MSCs was significantly enhanced in FBS-supplemented medium. In contrast, 
AT-MSCs showed significantly enhanced osteogenic differentiation capacity in PL-
supplemented medium. Comparing monocultures versus cocultures, both FBS- 
and PL-supplemented osteogenic media significantly enhanced osteogenic 
differentiation of BM-MSCs/HUVECs cocultures, whereas no differences were 
observed between AT-MSCs monocultures and AT-MSCs/HUVECs cocultures. 
The multilineage differentiation capacity of BM-MSCs and AT-MSCs was confirmed 
in this study (data not shown). This is in consistent with previous reports, in which 
multipotency of BM-MSCs and AT-MSCs in either FBS-31,34 or PL-supplemented 
medium13,30 was demonstrated. 
PL contains various growth factors, including platelet-derived growth factor (PDGF), 
basic fibroblast growth factor (bFGF), vascular endothelial growth factor, insulin-
like growth factor-1 (IGF-1), transforming growth factor-β (TGF-β) and epidermal 
growth factor13,16,35. The concentrations of growth factors in PL are much higher 
compared to those in FBS35-36, and for that reason, lower concentrations of PL 
compared to FBS are normally used for supplementing culture medium. PL at a 
concentration of 5% have been used in this study, because this concentration 
previously showed advantages in promoting MSCs proliferation in terms of 
economic as well as practical culture (cell expansion rates and time to confluence) 
considerations35 and most researchers use this concentration11,30. The FBS 
concentration was set at 15%, as this concentration has been demonstrated to 
enhance proliferation of stem cells compared to 10%37. 
The present study showed significantly increased cell proliferation for PL- 
compared to FBS-supplemented osteogenic medium for both BM-MSCs and AT-
MSCs, which corroborates previous data on proliferation in medium without 
osteogenic supplements4,38-39. Beside the higher concentrations of growth factors in 
PL (compared to FBS), several growth factors in PL act as mitogens for stem 
cells40-41, which likely explains the increased proliferation in PL- compared to FBS-
supplemented medium. Moreover, stem cells cultured in PL were smaller12,30, 
leading to a higher cell number at identical surface areas and hence leads to the 
enhancement of proliferation compared to FBS group. 
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In contrast to the consistency regarding proliferative effects, PL-supplementation 
affected the osteogenic capacity of BM-MSCs and AT-MSCs in a cell type-
dependent manner, i.e. limited osteogenic differentiation of BM-MSCs but 
substantial osteogenic differentiation of AT-MSCs. The inhibition effects for BM-
MSCs is in line with previous reports that utilized human- and rat-derived BM-
MSCs17-18,42 while there has been no report yet for AT-MSCs cultured in PL 
supplemented medium. Related to the growth factors in PL, Bieback et al. 
previously showed that they can evoke stimulatory activities as well as inhibitory 
activities on cell behavior13. For instance, TGF-β is a potent promoter of osteogenic 
differentiation in BM-MSCs43, while PDGF can decrease osteogenic differentiation 
of stem cells under in vitro conditions42,44. However, the effects of combined 
administration of growth factors are difficult to predict. For instance, when IGF-I 
was combined with TGF-β, PDGF or bFGF, it failed in increasing the ALP-activity 
of bovine osteoblastic cells45. The balance between these factors as well as the 
different responses of stem cells to (combinations of) growth factors likely 
determines the fate of osteogenesis. Moreover, the gene expression profile for 
osteogenesis in BM-MSCs and AT-MSCs are different46, which can have some 
inherent effects on different reactions of the two stem cell types. In addition, effects 
of PL- or FBS-supplementation on gene expression might partially explain the 
observed cell-dependency, as previous studies revealed that the expression of 
genes for osteogenic differentiation and TGF-β signaling was decreased when BM-
MSCs were cultured in PL- instead of FBS-supplemented medium4. A final aspect 
is related to concentration effects of FBS and PL. Previous reports have shown a 
dose-dependent effect of PL-supplementation on osteogenesis of rat BM-MSCs, 
inducing a decreased osteogenic differentiation with higher concentrations of PL17-
18,42. 
Data describing effects of PL- versus FBS-supplemented medium on osteogenesis 
are limited for BM-MSCs and even lacking for AT-MSCs. In contrast to our findings, 
a few previous reports described that osteogenesis of BM-MSCs was increased in 
PL-supplemented medium compared to FBS-supplemented medium, irrespective 
of PL concentrations, e.g. 5% PL11,30 or 10% PL47 in comparison to 10% FBS, and 
similar results were found for in vivo bone formation11,30. In view of this, it needs to 
be emphasized that the composition of PL can vary depending on the preparation 
method, including separation methods (apheresis versus multi-step centrifugation 
separation of the whole blood), storage conditions, and freeze/thaw cycles35. On 
the other hand, PL has been reported to induce stem cell migration32,48, which is 
likely to enhance bone formation in vivo. Finally, donor variability which is 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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4. Discussion 
The objective of this study was to comparatively evaluate the effects of either FBS- 
or PL-supplemented culture medium on cell behavior and osteogenic differentiation 
capacity of BM-MSCs and AT-MSCs in both monocultures and cocultures with 
HUVECs. The results demonstrated that the osteogenic differentiation capacity of 
BM-MSCs was significantly enhanced in FBS-supplemented medium. In contrast, 
AT-MSCs showed significantly enhanced osteogenic differentiation capacity in PL-
supplemented medium. Comparing monocultures versus cocultures, both FBS- 
and PL-supplemented osteogenic media significantly enhanced osteogenic 
differentiation of BM-MSCs/HUVECs cocultures, whereas no differences were 
observed between AT-MSCs monocultures and AT-MSCs/HUVECs cocultures. 
The multilineage differentiation capacity of BM-MSCs and AT-MSCs was confirmed 
in this study (data not shown). This is in consistent with previous reports, in which 
multipotency of BM-MSCs and AT-MSCs in either FBS-31,34 or PL-supplemented 
medium13,30 was demonstrated. 
PL contains various growth factors, including platelet-derived growth factor (PDGF), 
basic fibroblast growth factor (bFGF), vascular endothelial growth factor, insulin-
like growth factor-1 (IGF-1), transforming growth factor-β (TGF-β) and epidermal 
growth factor13,16,35. The concentrations of growth factors in PL are much higher 
compared to those in FBS35-36, and for that reason, lower concentrations of PL 
compared to FBS are normally used for supplementing culture medium. PL at a 
concentration of 5% have been used in this study, because this concentration 
previously showed advantages in promoting MSCs proliferation in terms of 
economic as well as practical culture (cell expansion rates and time to confluence) 
considerations35 and most researchers use this concentration11,30. The FBS 
concentration was set at 15%, as this concentration has been demonstrated to 
enhance proliferation of stem cells compared to 10%37. 
The present study showed significantly increased cell proliferation for PL- 
compared to FBS-supplemented osteogenic medium for both BM-MSCs and AT-
MSCs, which corroborates previous data on proliferation in medium without 
osteogenic supplements4,38-39. Beside the higher concentrations of growth factors in 
PL (compared to FBS), several growth factors in PL act as mitogens for stem 
cells40-41, which likely explains the increased proliferation in PL- compared to FBS-
supplemented medium. Moreover, stem cells cultured in PL were smaller12,30, 
leading to a higher cell number at identical surface areas and hence leads to the 
enhancement of proliferation compared to FBS group. 
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separation of the whole blood), storage conditions, and freeze/thaw cycles35. On 
the other hand, PL has been reported to induce stem cell migration32,48, which is 
likely to enhance bone formation in vivo. Finally, donor variability which is 
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inevitable should be emphasized since it also plays vital role in affecting 
osteogenesis49. 
Comparison of osteogenic capacity in FBS- versus PL-supplemented medium in 
cocultures showed the same trend as observed for monocultures. This 
demonstrates that the coculturing of these stem cells with HUVECs does not 
change the stem cells response to the culture medium. However, when 
osteogenesis in cocultures was compared to that in monocultures, effects of 
coculturing with HUVECs became obvious. Consistent with previously reported 
data, osteogenesis was enhanced in BM-MSCs/HUVECs compared to BM-MSCs 
monocultures, in which cellular interactions between BM-MSCs and endothelial 
cells were mentioned to play an important role28,50. In contrast, a similar osteogenic 
differentiation was observed for AT-MSCs/HUVECs compared to AT-MSCs 
monocultures. A likely reason for this observation is that osteogenic differentiation 
of AT-MSCs is marginally affected by bone morphogenetic protein-251-52, the 
growth factor that can be secreted by endothelial cells53 in cocultures. Remarkably, 
it needs to be emphasized that for cocultures, half the amount of stem cells (i.e. 
50:50 ratio with HUVECs) achieved similar or higher amounts of calcium content in 
cocultures compared to the full amount in monocultures. This indicates that the 
interaction between stem cells and HUVECs in cocultures, including both direct 
contact and bioactive soluble growth factors, can increase the osteogenic capacity 
of stem cells compared to stem cell monocultures. 
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5. Conclusions 
The outcome of this study revealed that increased proliferation of stem cells (i.e. 
both BM-MSCs and AT-MSCs) was found in PL- compared to FBS-supplemented 
medium. However, osteogenic differentiation capacity in FBS- or PL-supplemented 
medium showed to be cell-type dependent, i.e., FBS-supplemented medium 
enhanced osteogenesis of BM-MSCs, whereas PL-supplemented medium 
accelerated osteogenesis of AT-MSCs, irrespective of using monocultures or 
cocultures with HUVECs. Cocultures of BM-MSCs/HUVECs promoted 
osteogenesis when compared to BM-MSCs monocultures, whereas cocultures of 
AT-MSCs/HUVECs did not when compared to AT-MSCs monocultures. 
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3), which emphasizes the need for randomized control trials and systematic clinical 
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still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
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Chapter 4 
 
90 
 
6. References 
1. Pachon-Pena G, Yu G, Tucker A, Wu X, Vendrell J, Bunnell BA, Gimble JM. Stromal stem cells 
from adipose tissue and bone marrow of age-matched female donors display distinct 
immunophenotypic profiles. J Cell Physiol 2011;226(3):843-851. 
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti 
DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 
1999;284(5411):143-7. 
3. Peter SJ, Liang CR, Kim DJ, Widmer MS, Mikos AG. Osteoblastic phenotype of rat marrow stromal 
cells cultured in the presence of dexamethasone, beta-glycerolphosphate, and L-ascorbic acid. J 
Cell Biochem 1998;71(1):55-62. 
4. Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR. Accelerated 
and safe expansion of human mesenchymal stromal cells in animal serum-free medium for 
transplantation and regenerative medicine. J Cell Physiol 2007;213(1):18-26. 
5. Aldahmash A, Haack-Sorensen M, Al-Nbaheen M, Harkness L, Abdallah BM, Kassem M. Human 
serum is as efficient as fetal bovine serum in supporting proliferation and differentiation of human 
multipotent stromal (mesenchymal) stem cells In vitro and In vivo. Stem Cell Rev 2011;7(4):860-8. 
6. Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic 
nonhuman sialic acid. Nat Med 2005;11(2):228-32. 
7. Agata H, Watanabe N, Ishii Y, Kubo N, Ohshima S, Yamazaki M, Tojo A, Kagami H. Feasibility and 
efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-
free conditions. Biochem Biophys Res Commun 2009;382(2):353-8. 
8. Kocaoemer A, Kern S, Kluter H, Bieback K. Human AB serum and thrombin-activated platelet-rich 
plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells 
from adipose tissue. Stem Cells 2007;25(5):1270-8. 
9. Shih DT, Chen JC, Chen WY, Kuo YP, Su CY, Burnouf T. Expansion of adipose tissue 
mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated 
allogeneic human platelet lysate. Transfusion 2011;51(4):770-8. 
10. Rodrigues M, Griffith LG, Wells A. Growth factor regulation of proliferation and survival of 
multipotential stromal cells. Stem Cell Res Ther 2010;1(4):32. 
11. Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, Bierling P, Hernigou P, 
Layrolle P, Rouard H. Osteoblastic differentiation of human mesenchymal stem cells with platelet 
lysate. Biomaterials 2010;31(2):270-8. 
12. Blande IS, Bassaneze V, Lavini-Ramos C, Fae KC, Kalil J, Miyakawa AA, Schettert IT, Krieger JE. 
Adipose tissue mesenchymal stem cell expansion in animal serum-free medium supplemented with 
autologous human platelet lysate. Transfusion 2009;49(12):2680-5. 
13. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, Kluter H. Human 
alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone 
marrow. Stem Cells 2009;27(9):2331-41. 
14. Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvade A, Capelli C, Belotti 
D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi 
A, Biondi A, D'Amico G, Biagi E. Platelet-lysate-expanded mesenchymal stromal cells as a salvage 
therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow 
Transplant 2010;16(9):1293-301. 
15. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, 
Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M. Treatment 
of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. 
Bone Marrow Transplant 2009;43(3):245-51. 
16. Salvade A, Della Mina P, Gaddi D, Gatto F, Villa A, Bigoni M, Perseghin P, Serafini M, Zatti G, 
Biondi A, Biagi E. Characterization of platelet lysate cultured mesenchymal stromal cells and their 
Chapter 4 
 
91 
 
potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue 
Eng Part C Methods 2010;16(2):201-14. 
17. Soffer E, Ouhayoun JP, Dosquet C, Meunier A, Anagnostou F. Effects of platelet lysates on select 
bone cell functions. Clin Oral Implants Res 2004;15(5):581-8. 
18. Song H, Wang Z, Zhao Y, Chen X, Zhang Y, Li B. Interventional effect of platelet lysate on 
osteogenic differentiation of BMSCs in rats. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 
2008;22(6):737-41. 
19. Mankani MH, Kuznetsov SA, Wolfe RM, Marshall GW, Robey PG. In vivo bone formation by 
human bone marrow stromal cells: rec nstruction of the mouse calvarium and mandible. Stem 
Cells 2006;24(9):2140-9. 
20. de Girolamo L, Arrigoni E, Stanco D, Lopa S, Di Giancamillo A, Addis A, Borgonovo S, Dellavia C, 
Domeneghini C, Brini AT. Role of autologous rabbit adipose-derived stem cells in the early phases 
of the repairing process of critical bone defects. J Orthop Res 2011;29(1):100-8. 
21. Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, Mastrogiacomo M, 
Cancedda R. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-
year outcome of a pilot clinical study. Tissue Eng 2007;13(5):947-55. 
22. Morishita T, Honoki K, Ohgushi H, Kotobuki N, Matsushima A, Takakura Y. Tissue engineering 
approach to the treatment of bone tumors: three cases of cultured bone grafts derived from 
patients' mesenchymal stem cells. Artif Organs 2006;30(2):115-8. 
23. Lendeckel S, Jodicke A, Christophis P, Heidinger K, Wolff J, Fraser JK, Hedrick MH, Berthold L, 
Howaldt HP. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic 
calvarial defects: case report. J Craniomaxillofac Surg 2004;32(6):370-3. 
24. Thesleff T, Lehtimaki K, Niskakangas T, Mannerstrom B, Miettinen S, Suuronen R, Ohman J. 
Cranioplasty with adipose-derived stem cells and biomaterial: a novel method for cranial 
reconstruction. Neurosurgery 2011;68(6):1535-40. 
25. Meijer GJ, de Bruijn JD, Koole R, van Blitt rswijk CA. Cell based bone tissue engi eering in jaw 
defects. Biomaterials 2008;29(21):3053-61. 
26. Santos MI, Reis RL. Vascularization in bone tissue engineering: physiology, current strategies, 
major hurdles and future challenges. Macromol Biosci 2010;10(1):12-27. 
27. Zhou J, Lin H, Fang TL, Li X, Dai WD, Uemura T, Dong J. The repair of large segmental bone 
defects in the rabbit with vascularized tissue engineered bone. Biomaterials 2010;31(6):1171-9. 
28. Kaigler D, Krebsbach PH, Wang Z, West ER, Horger K, Mooney DJ. Transplanted endothelial cells 
enhance orthotopic b n  regeneration. J Dent Res 2006;85(7):633-7. 
29. Seebach C, Henrich D, Kahling C, Wilhelm K, Tami AE, Alini M, Marzi I. Endothelial progenitor 
cells and mesenchymal stem cells seeded onto beta-TCP granules enhance early vascularization 
and bone healing in a critical-sized bone d fect in rats. Tissu  Eng Part A 2010;16(6):1961-70. 
30. Prins HJ, Rozemuller H, Vonk-Griffioen S, Verweij VG, Dhert WJ, Slaper-Cortenbach IC, Martens 
AC. Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human 
platelet lysate as substitute for fetal bovine serum. Tissue Eng Part A 2009;15(12):3741-51. 
31. Ma J, van den Beucken JJ, Yang F, Both SK, Cui FZ, Pan J, Jansen JA. Coculture of osteoblasts 
and endothelial cells: optimization of culture medium and cell ratio. Tissue Eng Part C Methods 
2010;17(3):349-57. 
32. Na ijkens BA, Ni ssen HW, Prins HJ, Krijnen PA, Kokhuis TJ, de Jong N, van Hi sbergh VW, 
Kamp O, Helder MN, Musters RJ, van Dijk A, Juffermans LJ. Human platelet lysate as a fetal 
bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac 
repair applications. Cell Tissue Res 2012;348(1):119-30. 
33. Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine 
umbilical cord blood. BMC Biotechnol 2007;7:26. 
34. Varma MJ, Breuls RG, Schouten TE, Jurgens WJ, Bontkes HJ, Schuurhuis GJ, van Ham SM, van 
Milligen FJ. Phenotypical and functional characterization of freshly isolated a ipose tissue-derived 
stem cells. Stem Cells Dev 2007;16(1):91-104. 
Chapter 4 
 
92 
 
35. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. Platelet lysates promote 
mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy 
applications. J Cell Physiol 2005;205(2):228-36. 
36. Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer 
G, Linkesch W, Strunk D. Human platelet lysate can replace fetal bovine serum for clinical-scale 
expansion of functional mesenchymal stromal cells. Transfusion 2007;47(8):1436-46. 
37. Baghaban Eslaminejad M, Nazarian H, Falahi F, Taghiyar L, Taghi Daneshzadeh M. Ex vivo 
expansion and differentiation of mesenchymal stem cells from goat bone marrow. Iranian Journal 
of Basic Medical Sciences 2009;12(2):70-79. 
38. Schallmoser K, Rohde E, Reinisch A, Bartmann C, Thaler D, Drexler C, Obenauf AC, Lanzer G, 
Linkesch W, Strunk D. Rapid large-scale expansion of functional mesenchymal stem cells from 
unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 2008;14(3):185-96. 
39. Muller AM, Davenport M, Verrier S, Droeser R, Alini M, Bocelli-Tyndall C, Schaefer DJ, Martin I, 
Scherberich A. Platelet lysate as a serum substitute for 2D static and 3D perfusion culture of 
stromal vascular fraction cells from human adipose tissue. Tissue Eng Part A 2009;15(4):869-75. 
40. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 
2000;28(8):875-84. 
41. Huang Z, Ren PG, Ma T, Smith RL, Goodman SB. Modulating osteogenesis of mesenchymal stem 
cells by modifying growth factor availability. Cytokine 2010;51(3):305-10. 
42. Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G. Platelet-released 
supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone 
marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets 2004;15(1):29-35. 
43. Friedman MS, Long MW, Hankenson KD. Osteogenic differentiation of human mesenchymal stem 
cells is regulated by bone morphogenetic protein-6. J Cell Biochem 2006;98(3):538-54. 
44. Cho HS, Song IH, Park SY, Sung MC, Ahn MW, Song KE. Individual variation in growth factor 
concentrations in platelet-rich plasma and its influence on human mesenchymal stem cells. Korean 
J Lab Med 2011;31(3):212-8. 
45. Giannobile WV, Whitson SW, Lynch SE. Non-coordinate control of bone formation displayed by 
growth factor combinations with IGF-I. J Dent Res 1997;76(9):1569-78. 
46. Liu TM, Martina M, Hutmacher DW, Hui JH, Lee EH, Lim B. Identification of common pathways 
mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem 
cells into three mesenchymal lineages. Stem Cells 2007;25(3):750-60. 
47. Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, Koch C, Drescher W, Hutschenreuther G, 
Zenke M, Ho AD, Wagner W. Impact of individual platelet lysates on isolation and growth of human 
mesenchymal stromal cells. Cytotherapy 2010;12(7):888-98. 
48. Massberg S, Konrad I, Schurzinger K, Lorenz M, Schneider S, Zohlnhoefer D, Hoppe K, 
Schiemann M, Kennerknecht E, Sauer S, Schulz C, Kerstan S, Rudelius M, Seidl S, Sorge F, 
Langer H, Peluso M, Goyal P, Vestweber D, Emambokus NR, Busch DH, Frampton J, Gawaz M. 
Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor 
cells to arterial thrombi in vivo. J Exp Med 2006;203(5):1221-33. 
49. Janicki P, Boeuf S, Steck E, Egermann M, Kasten P, Richter W. Prediction of in vivo bone forming 
potency of bone marrow-derived human mesenchymal stem cells. Eur Cell Mater 2011;21:488-507. 
50. Kim JY, Jin GZ, Park IS, Kim JN, Chun SY, Park EK, Kim SY, Yoo J, Kim SH, Rhie JW, Cho DW. 
Evaluation of solid free-form fabrication-based scaffolds seeded with osteoblasts and human 
umbilical vein endothelial cells for use in vivo osteogenesis. Tissue Eng Part A 2010;16(7):2229-36. 
51. Grewal NS, Gabbay JS, Ashley RK, Wasson KL, Bradley JP, Zuk PA. BMP-2 does not influence 
the osteogenic fate of human adipose-derived stem cells. Plast Reconstr Surg 2009;123(2 
Suppl):158S-65S. 
52. Zuk P, Chou YF, Mussano F, Benhaim P, Wu BM. Adipose-derived stem cells and BMP2: part 2. 
BMP2 may not influence the osteogenic fate of human adipose-derived stem cells. Connect Tissue 
Res 2011;52(2):119-32. 
53. Grellier M, Bordenave L, Amedee J. Cell-to-cell communication between osteogenic and 
endothelial lineages: implications for tissue engineering. Trends Biotechnol 2009;27(10):562-71.
 
 
93 
 
Chapter 2 
 
28 
 
contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
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These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
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1. Introduction 
Bone defects can be caused by trauma, tumor resection and congenital disorder, 
and bone lesions above a critical size often lead to nonunion, for which bone 
regeneration still represents a great clinical challenge nowadays1. Bone 
regenerative medicine, the approach that includes, but is not limited to, the use of 
scaffolds, cells and biomolecules, has remarkable potential for bone regeneration2. 
As the success of using only scaffolds to repair large bone defects is limited, it has 
been postulated that greater regeneration can be obtained by supplementing 
scaffolds with cells and/or biomolecules1. 
In bone regenerative approaches, scaffolds play a role as cell delivery vehicles in 
which cells and/or biomolecules are incorporated and delivered to the hosts3,4. 
Various types of scaffolds with variation in composition and forms (e.g. polymers, 
bioceramics and metals) have been used for bone regeneration5. The 
characteristics of an ideal scaffold include biocompatibility, bioresorbability, 
appropriate pore size and mechanical properties6. Moreover, the increasing 
demand for minimally invasive surgical procedures necessitates the injectability of 
scaffolds7, for which hydrogels have attracted huge interests. Precisely, engineered 
injectable hydrogels could enable minimally invasive surgical implantation for 
improved control in the delivery of cells and/or molecules within bioactive, 
degradable scaffolds. 
Hydrogels, which consist of networks of polymer chains that can approximate the 
viscoelastic properties of native tissue8, are appealing for clinical applications 
because of their high water content, biocompatibility and injectability9. Hydrogels 
can be made from natural polymers (e.g. collagen, fibrin, or hyaluronic acid) or 
synthetic polymers (e.g. poly(ethylene glycol) (PEG), poly(vinyl alcohol) or poly(2-
hydroxy ethyl methacrylate)10. Amongst these, collagen hydrogel and 
oligo(poly(ethylene glycol)fumarate) (OPF), a PEG-based hydrogel, have been 
widely used for bone regenerative medicine11-13. Collagen hydrogels can support 
the survival and expression of osteogenic and chondrogenic phenotypes of 
mesenchymal stem cells (MSCs) in vivo14. Additionally, collagen hydrogels 
combined with osteoblastic cells successfully restored the rabbit segmental bone 
defects while the cell-free collagen group showed no evidence of gap bridging13, 
indicating the necessity of incorporation of cells in bone regeneration. OPF can 
induce the osteo-/osteochondral differentiation of MSCs both in vitro15 and in 
vivo11,12,16, though the effect of cell-loaded OPF hydrogels on bone/cartilage 
formation in comparison to that of the cell-free hydrogels is controversial and 
needs further investigation16. 
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The effects of cell-loaded hydrogels on bone formation depend on both cell-cell 
and cell-scaffold interactions. First, cell-cell contact regulates stem cell 
differentiation both in two-dimensional17 and three-dimensional culture18. Often, 
single cells are encapsulated homogeneously within hydrogels (i.e. dispersed 
loading)19,20, which leads to inadequate or delayed cell-cell contact and potentially 
impairs cell survival21. Recently, it has been reported that cells cultured in the 
format of spheroids within hydrogels (i.e. spheroid loading) showed much higher 
viability due to the increased cell-cell contact compared to those cultured as single 
cells21. Nevertheless, no data are available on the comparison of these two 
possible cell-loading approaches on osteogenesis for injectable regenerative 
medicine. Meanwhile, another approach, although not clinically applicable, can be 
used to enhance cell-cell contact by culturing single cells in between two hydrogels 
layers (i.e. sandwich loading). This method was initially used in hepatocytes culture 
to maintain the function of cells22. Systematic studies on the optimal cell loading 
methods in hydrogels are lacking. Besides, cell-scaffold interaction influences the 
function of osteoblastic cells and subsequently bone formation23. OPF hydrogels 
do not allow cell adhesion, whereas collagen hydrogels do24. 
Bone marrow- and adipose tissue-derived MSCs (BM- and AT-MSCs) are the most 
frequently used types of stem cells25. Under their optimal cell culture conditions, 
AT-MSCs have greater osteogenic differentiation than BM-MSCs26. The aim of this 
study was to compare the osteogenic capacity of these cells loaded using three 
methods (i.e. dispersed-, sandwich- and spheroid-loading) in two hydrogel systems 
(i.e. collagen and OPF). It was hypothesized that (i) collagen hydrogels would 
induce enhanced osteogenesis compared to OPF hydrogels due to the better cell-
scaffold interaction, (ii) sandwich- and spheroid-loading can induce higher 
osteogenic differentiation than dispersed-loading because of the increased cell-cell 
contact, and (iii) AT-MSCs have higher osteogenic capacity compared to BM-
MSCs. BM-MSCs and AT-MSCs were loaded in both collagen and OPF hydrogels 
using the three cell loading methods after which cell behavior was evaluated in 
vitro. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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1. Introduction 
Bone defects can be caused by trauma, tumor resection and congenital disorder, 
and bone lesions above a critical size often lead to nonunion, for which bone 
regeneration still represents a great clinical challenge nowadays1. Bone 
regenerative medicine, the approach that includes, but is not limited to, the use of 
scaffolds, cells and biomolecules, has remarkable potential for bone regeneration2. 
As the success of using only scaffolds to repair large bone defects is limited, it has 
been postulated that greater regeneration can be obtained by supplementing 
scaffolds with cells and/or biomolecules1. 
In bone regenerative approaches, scaffolds play a role as cell delivery vehicles in 
which cells and/or biomolecules are incorporated and delivered to the hosts3,4. 
Various types of scaffolds with variation in composition and forms (e.g. polymers, 
bioceramics and metals) have been used for bone regeneration5. The 
characteristics of an ideal scaffold include biocompatibility, bioresorbability, 
appropriate pore size and mechanical properties6. Moreover, the increasing 
demand for minimally invasive surgical procedures necessitates the injectability of 
scaffolds7, for which hydrogels have attracted huge interests. Precisely, engineered 
injectable hydrogels could enable minimally invasive surgical implantation for 
improved control in the delivery of cells and/or molecules within bioactive, 
degradable scaffolds. 
Hydrogels, which consist of networks of polymer chains that can approximate the 
viscoelastic properties of native tissue8, are appealing for clinical applications 
because of their high water content, biocompatibility and injectability9. Hydrogels 
can be made from natural polymers (e.g. collagen, fibrin, or hyaluronic acid) or 
synthetic polymers (e.g. poly(ethylene glycol) (PEG), poly(vinyl alcohol) or poly(2-
hydroxy ethyl methacrylate)10. Amongst these, collagen hydrogel and 
oligo(poly(ethylene glycol)fumarate) (OPF), a PEG-based hydrogel, have been 
widely used for bone regenerative medicine11-13. Collagen hydrogels can support 
the survival and expression of osteogenic and chondrogenic phenotypes of 
mesenchymal stem cells (MSCs) in vivo14. Additionally, collagen hydrogels 
combined with osteoblastic cells successfully restored the rabbit segmental bone 
defects while the cell-free collagen group showed no evidence of gap bridging13, 
indicating the necessity of incorporation of cells in bone regeneration. OPF can 
induce the osteo-/osteochondral differentiation of MSCs both in vitro15 and in 
vivo11,12,16, though the effect of cell-loaded OPF hydrogels on bone/cartilage 
formation in comparison to that of the cell-free hydrogels is controversial and 
needs further investigation16. 
Chapter 5 
 
97 
 
The effects of cell-loaded hydr gel  on bon  formation depend n both cell-cell 
and cell-scaffold interactions. First, cell-cell c ntact regulates stem cell 
differentiation both in two-dimensional17 and three-dimensional culture18. Often, 
single cells are encapsulated homogeneously within hydrogels (i.e. dispersed 
loading)19,20, which leads to inadequate or delayed cell-cell contact and potentially 
impairs cell survival21. Recently, it has been reported that cells cultured in the 
format of spheroids within hydrogels (i.e. spheroid loading) showed much higher 
viability due to the increased cell-cell contact compared to those cultured as single 
cells21. Nevertheless, no data are available on the comparison of these two 
possible cell-loading approaches on osteogenesis for injectable regenerative 
medicine. Meanwhile, another approach, although not clinically applicable, can be 
used to enhance cell-cell contact by culturing single cells in between two hydrogels 
layers (i.e. sandwich loading). This method was initially used in hepatocytes culture 
to maintain the function of cells22. Systematic studies on the optimal cell loading 
methods in hydrogels are lacking. Besides, cell-scaffold interaction influences the 
function of osteoblastic cells and subsequently bone formation23. OPF hydrogels 
do not allow cell adhesion, whereas collagen hydrogels do24. 
Bone marrow- and adipose tissue-derived MSCs (BM- and AT-MSCs) are the most 
frequently used types of stem cells25. Under their optimal cell culture conditions, 
AT-MSCs have greater osteogenic differentiation than BM-MSCs26. The aim of this 
study was to compare the osteogenic capacity of these cells loaded using three 
methods (i.e. dispersed-, sandwich- and spheroid-loading) in two hydrogel systems 
(i.e. collagen and OPF). It was hypothesized that (i) collagen hydrogels would 
induce enhanced osteogenesis compared to OPF hydrogels due to the better cell-
scaffold interaction, (ii) sandwich- and spheroid-loading can induce higher 
osteogenic differentiation than dispersed-loading because of the increased cell-cell 
contact, and (iii) AT-MSCs have higher osteogenic capacity compared to BM-
MSCs. BM-MSCs and AT-MSCs were loaded in both collagen and OPF hydrogels 
using the three cell loading methods after which cell behavior was evaluated in 
vitro. 
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2. Materials and methods 
2.1. Reagents for preparing hydrogels 
Rat tail type I collagen was purchased from Becton Dickinson Biosciences (BD; 
Breda, the Netherlands). Fumaryl chloride was obtained from Acros (Pittsburgh, PA, 
USA). PEG was purchased from Aldrich (Milwaukee, WI, USA). Poly(ethylene 
glycol) diacrylate (PEGDA, MW 4000 Da) was purchased by Glycosan Biosystems 
(Salt Lake City, UT, USA). N,N,N΄,N΄-tetramethylethylenediamine (TEMED) was 
obtained from Fluka (Buchs, Switzerland). Ammonium persulfate (APS) and 
phosphate-buffered saline (PBS, pH 7.4) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). 
2.2. Mesenchymal stem cell isolation and culture 
BM-MSCs and AT-MSCs were isolated according to a previously described 
method26, with written consent from the involved human donors. This study 
complied with the principles of the Declaration of Helsinki. The study was 
performed in three separate runs (i.e. cells from three donors for each cell type 
were used). BM-MSCs (male donors; 37, 38 and 69 years old) and AT-MSCs 
(female donors; 38, 40 and 43 years old) from passage 3 were used in this study. 
The detailed information of the medium components is listed in Table 1. Fetal 
bovine serum (FBS) and human platelet lysate (PL) were used as supplements for 
BM-MSCs and AT-MSCs culture, respectively. Proliferation medium was used for 
cell expansion and osteogenic medium (OM) was used after the cells were loaded 
in the hydrogels. 
2.3. Preparation of hydrogels 
The components for preparation of the hydrogels were listed in Table 2. For 
collagen hydrogels, a final concentration of 3 mg/ml was used according to the 
instructions from the manufacturer. For OPF hydrogels, OPF macromer was 
synthesized by the reaction of PEG with a molecular weight of 3,400 g/mol and 
fumaryl chloride according to a previously described protocol27. OPF macromer 
and PEGDA were mixed and sterilized by exposing the mixed powder to ultraviolet 
light (254 nm) for 3 h and then stored at -20 °C until use. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2. Materials and methods 
2.1. Reagents for preparing hydrogels 
Rat tail type I collagen was purchased from Becton Dickinson Biosciences (BD; 
Breda, the Netherlands). Fumaryl chloride was obtained from Acros (Pittsburgh, PA, 
USA). PEG was purchased from Aldrich (Milwaukee, WI, USA). Poly(ethylene 
glycol) diacrylate (PEGDA, MW 4000 Da) was purchased by Glycosan Biosystems 
(Salt Lake City, UT, USA). N,N,N΄,N΄-tetramethylethylenediamine (TEMED) was 
obtained from Fluka (Buchs, Switzerland). Ammonium persulfate (APS) and 
phosphate-buffered saline (PBS, pH 7.4) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). 
2.2. Mesenchymal stem cell isolation and culture 
BM-MSCs and AT-MSCs were isolated according to a previously described 
method26, with written consent from the involved human donors. This study 
complied with the principles of the Declaration of Helsinki. The study was 
performed in three separate runs (i.e. cells from three donors for each cell type 
were used). BM-MSCs (male donors; 37, 38 and 69 years old) and AT-MSCs 
(female donors; 38, 40 and 43 years old) from passage 3 were used in this study. 
The detailed information of the medium components is listed in Table 1. Fetal 
bovine serum (FBS) and human platelet lysate (PL) were used as supplements for 
BM-MSCs and AT-MSCs culture, respectively. Proliferation medium was used for 
cell expansion and osteogenic medium (OM) was used after the cells were loaded 
in the hydrogels. 
2.3. Preparation of hydrogels 
The components for preparation of the hydrogels were listed in Table 2. For 
collagen hydrogels, a final concentration of 3 mg/ml was used according to the 
instructions from the manufacturer. For OPF hydrogels, OPF macromer was 
synthesized by the reaction of PEG with a molecular weight of 3,400 g/mol and 
fumaryl chloride according to a previously described protocol27. OPF macromer 
and PEGDA were mixed and sterilized by exposing the mixed powder to ultraviolet 
light (254 nm) for 3 h and then stored at -20 °C until use. 
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2.4. Cell loading methods in hydrogels 
Three loading methods were carried out with different initial cell distribution within 
each hydrogel system (i.e. collagen and OPF) using BM-MSCs and AT-MSCs. The 
experiment was performed in triplicate for quantitative analysis and in duplicate for 
qualitative analysis. Cell-free scaffolds were included as a control. The detailed 
information for cell-loaded groups is displayed below: 
 Dispersed (D) loading: single cells were encapsulated in the hydrogels. 
BM-MSCs and AT-MSCs that were loaded using this method were 
named D-BM and D-AT. 
 Sandwich (S) loading: single cells were encapsulated in between two 
hydrogel layers. BM-MSCs and AT-MSCs that were loaded using this 
method were named S-BM and S-AT. 
 Spheroid (Sp) loading: spheroids were encapsulated in the hydrogels. BM-
MSCs and AT-MSCs that were loaded using this method were named 
Sp-BM and Sp-AT. 
Cells were trypsinized, counted and divided into three portions for the three loading 
groups. Cells were loaded on the same day with cell trypsinization for D- and S-
loading, while for Sp-loading, cells were firstly seeded on the prepared chitosan 
coated (see below for the detailed information) cell culture flasks (Greiner bio-one, 
Alphen aan den Rijn, the Netherlands) and incubated overnight (37 °C, 5% CO2) to 
form spheroids. Cells cultured in the format of spheroids do not proliferate28, for 
which the cell number in Sp-loading is still comparable with the cells in D- and S-
loading. The three cell loading methods are described below and the schematic 
diagram is demonstrated in Figure 1. The preparation of the hydrogels was 
performed according to Table 2. The formed hydrogels were cultured in OM in a 
humid atmosphere (37 °C, 5% CO2) and medium was changed twice a week. 
Figure 1. Schematic 
representation of the three 
cell loading methods. 
Single cells were either 
encapsulated in the 
hydrogels (D) or loaded in 
between two hydrogel 
layers (S); alternatively, cell 
spheroids were 
encapsulated in the 
hydrogels (Sp). D, 
dispersed; S, sandwich; Sp, 
spheroids. 
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2.4.1. Dispersed (D) loading 
One hundred microliter of cell suspension containing 0.5×106 cells were added up 
to 1 ml of the hydrogel solution and mixed gently (without creating air bubbles) to 
prepare cell-loaded hydrogel. Then, 300 μl of the hydrogel solution (containing 
0.15×106 cells) was quickly injected in the non-adhesive 48-well plates (Greiner 
bio-one), followed by incubation (37 °C, 5% CO2) for 30 min for gelation. 
Afterwards, 1 ml OM was directly added to each collagen hydrogel while the OPF 
hydrogels were firstly transferred to non-adhesive 24-well plates (Greiner bio-one) 
due to the swelling after gelation before 1 ml OM was added to each sample. 
2.4.2. Sandwich (S) loading 
The first hydrogel layer was formed by pipetting 150 µl of hydrogel solution (cell-
free) in the non-adhesive 48-well plates and incubated (37 °C, 5% CO2) for 30 min. 
Before cell loading, OPF hydrogel layer was transferred to non-adhesive 24-well 
plates as a result of swelling while the collagen hydrogels remained in the non-
adhesive 48-well plates. Then, 150 µl cell suspension (containing 0.15×106 cells) 
was dripped on the surface of the first hydrogel layer and incubated (37 °C, 5% 
CO2) for 3 h. Next, another 150 µl of hydrogel solution (cell-free) was added to form 
the second hydrogel layer without removing supernatant of the cell suspension. 
After 30 min incubation (37 °C, 5% CO2) for gelation, 1 ml OM was added to each 
well. 
2.4.3. Spheroid (Sp) loading 
Spheroids were formed on chitosan surface according to a previously described 
protocol28. In brief, chitosan (medium molecular weight, Sigma, St. Louis, MO) was 
dissolved in 1% (v/v) acetic acid to obtain 1% (w/v) chitosan solution. The solution 
(20 ml) was coated on the T75 cell culture flask (Greiner bio-one) and dried in an 
oven at 60 °C for 24 h to form a thin membrane, after which it was neutralized 
using 0.5 N NaOH aqueous solution (Sigma) for 2 h and washed thoroughly with 
double-distilled water (MilliQ). Before cell culture, the prepared chitosan-coated 
flasks were sterilized in 70% alcohol overnight and rinsed extensively with PBS, 
followed by treatment under ultraviolet light overnight. BM-MSCs or AT-MSCs were 
seeded on the chitosan-coated flasks at a density of 3×104 cells/cm2 and incubated 
(37 °C, 5% CO2) overnight. The next day, the formed spheroids were retrieved and 
processed for encapsulation in hydrogels. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2.4. Cell loading methods in hydrogels 
Three loading methods were carried out with different initial cell distribution within 
each hydrogel system (i.e. collagen and OPF) using BM-MSCs and AT-MSCs. The 
experiment was performed in triplicate for quantitative analysis and in duplicate for 
qualitative analysis. Cell-free scaffolds were included as a control. The detailed 
information for cell-loaded groups is displayed below: 
 Dispersed (D) loading: single cells were encapsulated in the hydrogels. 
BM-MSCs and AT-MSCs that were loaded using this method were 
named D-BM and D-AT. 
 Sandwich (S) loading: single cells were encapsulated in between two 
hydrogel layers. BM-MSCs and AT-MSCs that were loaded using this 
method were named S-BM and S-AT. 
 Spheroid (Sp) loading: spheroids were encapsulated in the hydrogels. BM-
MSCs and AT-MSCs that were loaded using this method were named 
Sp-BM and Sp-AT. 
Cells were trypsinized, counted and divided into three portions for the three loading 
groups. Cells were loaded on the same day with cell trypsinization for D- and S-
loading, while for Sp-loading, cells were firstly seeded on the prepared chitosan 
coated (see below for the detailed information) cell culture flasks (Greiner bio-one, 
Alphen aan den Rijn, the Netherlands) and incubated overnight (37 °C, 5% CO2) to 
form spheroids. Cells cultured in the format of spheroids do not proliferate28, for 
which the cell number in Sp-loading is still comparable with the cells in D- and S-
loading. The three cell loading methods are described below and the schematic 
diagram is demonstrated in Figure 1. The preparation of the hydrogels was 
performed according to Table 2. The formed hydrogels were cultured in OM in a 
humid atmosphere (37 °C, 5% CO2) and medium was changed twice a week. 
Figure 1. Schematic 
representation of the three 
cell loading methods. 
Single cells were either 
encapsulated in the 
hydrogels (D) or loaded in 
between two hydrogel 
layers (S); alternatively, cell 
spheroids were 
encapsulated in the 
hydrogels (Sp). D, 
dispersed; S, sandwich; Sp, 
spheroids. 
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2.4.1. Dispersed (D) loading 
One hundred microliter of cell suspension containing 0.5×106 cells were added up 
to 1 ml of the hydrogel solution and mixed gently (without creating air bubbles) to 
prepare cell-loaded hydrogel. Then, 300 μl of the hydrogel olution (containing 
0.15×106 cells) was quickly injected in the non-adhesive 48-well plates (Greiner 
bio-one), followed by incubation (37 °C, 5% CO2) for 30 min for gelation. 
Afterwards, 1 ml OM was directly added to each collagen hydrogel while the OPF 
hydrogels were firstly transferred to non-adhesive 24-well plates (Greiner bio-one) 
due to the swelling after gelation before 1 ml OM was added to each sample. 
2.4.2. Sandwich (S) loadi g 
The first hydrogel layer was formed by pipetting 150 µl of hydrogel solution (cell-
free) in the non-adhesive 48-well plates and incubated (37 °C, 5% CO2) for 30 min. 
Before cell loading, OPF hydrogel layer was transferred to non-adhesive 24-well 
plates as a result of swelling while the collagen hydrogels remained in the non-
adhesive 48-well plates. Then, 150 µl cell suspension (containing 0.15×106 cells) 
was dripped on the surface of the first hydrogel layer and incubated (37 °C, 5% 
CO2) for 3 h. Next, another 150 µl of hydrogel solution (cell-free) was added to form 
the second hydrogel layer without removing supernatant of the cell suspension. 
After 30 min incubation (37 °C, 5% CO2) for gelation, 1 ml OM was added to each 
well. 
2.4.3. Spheroid (Sp) loading 
Spheroids were formed on chitosan surface according to a previously described 
protocol28. In brief, chitosan (medium molecular weight, Sigma, St. Louis, MO) was 
dissolved in 1% (v/v) acetic acid to obtain 1% (w/v) chitosan solution. The solution 
(20 ml) was coated on the T75 cell culture flask (Greiner bio-one) and dried in an 
oven at 60 °C for 24 h to form a thin membrane, after which it was neutralized 
using 0.5 N NaOH aqueous solution (Sigma) for 2 h and washed thoroughly with 
double-distilled water (MilliQ). Before cell culture, the prepared chitosan-coated 
flasks were sterilized in 70% alcohol overnight and rinsed extensively with PBS, 
followed by treatment under ultraviolet light overnight. BM-MSCs or AT-MSCs were 
seeded on the chitosan-coated flasks at a density of 3×104 cells/cm2 and incubated 
(37 °C, 5% CO2) overnight. The next day, the formed spheroids were retrieved and 
processed for encapsulation in hydrogels. 
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The morphology of the formed spheroids was firstly observed and photographed 
using an inverted microscope (Leica, Rijswijk, the Netherlands) equipped with a 
camera (Leica) using Leica Application Suite V 3.3.0 software, and further followed 
by DAPI staining. Cell survival in the spheroids was evaluated using a LIVE/DEAD 
Viability/Cytotoxicity Kit (Molecular Probes, Invitrogen, Eugene, OR, USA), which is 
based on the simultaneous determination of live and dead cells with two probes 
that measure the parameters of cell viability: intercellular esterase activity and the 
plasma membrane integrity. Briefly, the spheroids were gently collected in 15 ml 
centrifugation tube (Greiner bio-one), centrifuged at 200g for 10 min, resuspended 
and washed in PBS. After another time centrifugation, PBS was removed and the 
spheroids were resuspended in 2 mM calcein-AM and 4 mM ethidium homodimer 
in PBS solution and incubated in dark at room temperature for 45 min. The 
spheroids were washed and resuspended in PBS. Thereafter, a small volume of 
spheroids-containing PBS was dripped on glass slides (Thermo, Gerhard Menzel 
GmbH, Germany), covered by coverslips (Thermo) and imaged with the Zeiss 
Imager Z1 microscope equipped with the AxioCam MRc5 camera using AxioVision 
4.8 software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). 
In general, the cell loading steps were similar in Sp-loading with that in D-loading. 
The total cell number in the spheroids was determined at the moment cells were 
seeded on the chitosan film to form spheroids. The spheroids-containing medium 
was firstly collected from the culture flasks and centrifuged at 200g for 10 min. The 
spheroids containing a total number of 0.5×106 cells were suspended in 100 μl of 
medium and thereafter mixed gently with 1 ml of the hydrogel solution. Afterwards, 
the same steps were followed as presented in D-loading. 
2.5. Evaluation of mesenchymal stem cell behavior in hydrogels 
The size of the hydrogels was observed over time during culture and the cell-free 
scaffolds (collagen or OPF hydrogels) were used as a reference to evaluate the 
size changes in each hydrogel type. 
2.5.1. Cell morphology 
The morphology of the cells inside the hydrogels were observed daily and imaged 
with an inverted microscope (Leica) using Leica Application Suite V 3.3.0 software 
at the indicated time points (day 1 and 3). 
2.5.2. Cell metabolic activity 
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The metabolic activity of the cells inside the hydrogels was analyzed using 
alamarBlue® assay (Invitrogen) as previously described29,30. Before measurement 
at the appointed time points (day 3, 7 and 10), the hydrogels were transferred into 
new wells to avoid the influence of the unattached cells. One milliliter of 
alamarBlue solution, which was prepared by mixing alamarBlue® with OM in a ratio 
of 1:9 (v/v), was added into each well and incubated (37 °C, 5% CO2) for 4 h. 
Fluorescence was measured using a microplate reader (FL 600; Bio-Tek, Belgium) 
at 570 nm. The final values of each group were determined by subtracting the 
values of the cell-free scaffold. 
2.5.3. DNA content and alkaline phosphatase (ALP) activity 
DNA content was measured to evaluate cell proliferation, while ALP activity was 
used as an indicator of osteogenic differentiation. For each time point (day 7, 13 
and 21), the same samples were used for DNA content and ALP activity assay. 
The selection of such time points was based on our previous study26. Due to the 
differences in the hydrogel properties, two methods were used respectively for 
extracting cells from the hydrogels for further analysis according to previously 
described, which are papain digestion method for collagen hydrogel31,32 and 
homogenizer method for OPF hydrogel33. For papain digestion, each collagen 
hydrogel was washed with PBS and digested with 250 μl of digestion buffer (200 
mM sodium chloride, 100 mM sodium acetate trihydrate, 10 mM cysteine 
hydrochloride, 50 mM ethylenediaminetetraacetic acid [EDTA], pH 6.0; all reagents 
were purchased from Sigma) and 25 μl of papain solution (10 mg/ml) at 60°C for 1 
h until complete digestion was achieved. For homogenizer method, the OPF 
hydrogels were washed with PBS and homogenized with a pellet grinder (Kontes 
Pellet Pestle, Daigger, Vernon Hills, IL, USA) in 1 ml MilliQ. The samples from both 
hydrogel groups were stored at -20 °C until measurement. Before biological 
analysis, the collagen hydrogels were thawed and left standing, while the OPF 
hydrogels were subjected to twice freeze-thaw cycles and sedimentation. The 
biological analysis for DNA content and ALP activity was performed according to 
previously described methods29,33. The values of ALP activity were normalized to 
the DNA amount. The final values of the cell-loaded hydrogels were presented by 
subtracting the values from the cell-free hydrogels and the values that were less 
than zero after subtraction were regarded as zero. 
2.5.4. Calcium content 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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The morphology of the formed spheroids was firstly observed and photographed 
using an inverted microscope (Leica, Rijswijk, the Netherlands) equipped with a 
camera (Leica) using Leica Application Suite V 3.3.0 software, and further followed 
by DAPI staining. Cell survival in the spheroids was evaluated using a LIVE/DEAD 
Viability/Cytotoxicity Kit (Molecular Probes, Invitrogen, Eugene, OR, USA), which is 
based on the simultaneous determination of live and dead cells with two probes 
that measure the parameters of cell viability: intercellular esterase activity and the 
plasma membrane integrity. Briefly, the spheroids were gently collected in 15 ml 
centrifugation tube (Greiner bio-one), centrifuged at 200g for 10 min, resuspended 
and washed in PBS. After another time centrifugation, PBS was removed and the 
spheroids were resuspended in 2 mM calcein-AM and 4 mM ethidium homodimer 
in PBS solution and incubated in dark at room temperature for 45 min. The 
spheroids were washed and resuspended in PBS. Thereafter, a small volume of 
spheroids-containing PBS was dripped on glass slides (Thermo, Gerhard Menzel 
GmbH, Germany), covered by coverslips (Thermo) and imaged with the Zeiss 
Imager Z1 microscope equipped with the AxioCam MRc5 camera using AxioVision 
4.8 software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). 
In general, the cell loading steps were similar in Sp-loading with that in D-loading. 
The total cell number in the spheroids was determined at the moment cells were 
seeded on the chitosan film to form spheroids. The spheroids-containing medium 
was firstly collected from the culture flasks and centrifuged at 200g for 10 min. The 
spheroids containing a total number of 0.5×106 cells were suspended in 100 μl of 
medium and thereafter mixed gently with 1 ml of the hydrogel solution. Afterwards, 
the same steps were followed as presented in D-loading. 
2.5. Evaluation of mesenchymal stem cell behavior in hydrogels 
The size of the hydrogels was observed over time during culture and the cell-free 
scaffolds (collagen or OPF hydrogels) were used as a reference to evaluate the 
size changes in each hydrogel type. 
2.5.1. Cell morphology 
The morphology of the cells inside the hydrogels were observed daily and imaged 
with an inverted microscope (Leica) using Leica Application Suite V 3.3.0 software 
at the indicated time points (day 1 and 3). 
2.5.2. Cell metabolic activity 
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The metabolic activity of the cell  inside the hydrogels was analyzed usi g 
alamarBlue® assay (Invitrogen) as previously d scribed29,30. Before me sur ment 
at the appointed time points (day 3, 7 and 10), the hydrog ls ere transferred into 
new wells to avoid the influence of the unattached cells. One milliliter of 
alamarBlue solution, which was prepared by mixing alamarBlue® with OM in a ratio 
of 1:9 (v/v), was added into each well and incubated (37 °C, 5% CO2) for 4 h. 
Fluorescence was measured using a microplate reader (FL 600; Bio-Tek, Belgium) 
at 570 nm. The final values of each group were determined by subtracting the 
values of the cell-free scaffold. 
2.5.3. DNA content and alkaline phosphatase (ALP) activity 
DNA content was measured to evaluate cell proliferation, whil  ALP activity was 
us d a  an indicator of osteogenic diff rentiation. For e ch time point (day 7, 13 
and 21), the same samples were used for DNA content and ALP activity assay. 
The sel ction of such time points was based on our previous study26. Due to the 
differences in the hydrogel properties, two methods w re us d respect vely for 
extracting cells from the hydrogels for further analysi  a cording to previously 
described, which are papain digestio  method for collagen hydrogel31,32 and 
homogenizer method for OPF hydrogel33. For papain digestion, each collagen 
hydrogel was washed with PBS and digested with 250 μl of digestion buff r (200 
mM sodium chloride, 100 mM sodium cetate rihydrate, 10 mM cysteine 
hydrochloride, 50 mM ethylenediaminetetraacetic acid [EDTA], pH 6.0; all reagent  
w re purchas d from Sigma) and 25 μl of papain solution (10 mg/ml) at 60°C for 1 
h until compl te digestion was achieved. For homo enizer method, the OPF 
hydrogels were washed wi h PBS and homogenized with  p llet grinder (Kontes 
Pellet Pestle, Daigger, Vernon Hills, IL, USA) in 1 ml MilliQ. The samples from both 
hydrogel groups were stored t -20 °C until measurement. Before biological 
analysis, th  collagen hydrogels were thaw d and left standing, while the OPF 
hydrogels w re subject d t twice fr eze-thaw cycles and sedimentation. The 
biological analysis for DNA content and ALP activity w s performed according to 
previously described methods29,33. The valu s of ALP activity were normalized t  
the DNA amount. The final values of the cell-loaded hydrog ls w re presen e  by 
subtracting the values from the cell-free hydrogels and the values that w re less 
than zero after subtraction were regarded as zero. 
2.5.4. Calcium content 
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Mineralization was evaluated by measuring the calcium content (day 7, 13, 21 and 
28) in the hydrogels. A later time point (d28) was included in calcium assay 
because BM-MSCs (cultured in 2-D condition) initiate mineralization from ~day 20 
on29, for which these cells need a longer period for mineralization to become 
apparent. For sample preparation, after PBS wash, 1 ml of 0.5 N acetic acid was 
added to each sample and the plates were placed on an orbital shaker overnight to 
dissolve mineral deposits. The samples were then stored at -20 °C until the 
measurement, according to previously described protocols29,33. The readout values 
of the cell-loaded hydrogels were compensated for the values from the cell-free 
group to avoid the influence of the possible calcium uptake of the hydrogels from 
the culture medium33,34. The values that were less than zero were regarded as zero. 
2.5.5. Cytological evaluation 
Hematoxylin-eosin (HE) staining was used to analyze the cell distribution. Von 
Kossa staining, in which silver ions react with phosphate, was performed to 
visualize the mineralized matrix inside the hydrogels. Briefly, two samples (n=2) of 
each group from day 28 were washed with PBS, fixed in 10% neutral-buffered 
formalin for 6 h, dehydrated in serial ethanol and embedded in paraffin. Cross-
sections with a thickness of 5 μm were cut using a microtome (Leica). After the 
sections were mounted on glass slides, HE and Von Kossa staining26 were 
followed. The staining was imaged with the Zeiss Imager Z1 microscope equipped 
with the AxioCam MRc5 camera using AxioVision 4.8 software. 
2.6. Statistical analysis 
Data are presented as mean ± standard deviation. Graphpad Instat software 
(Instat® 3.05, Graphpad Software Inc., La Jolla, USA) was used for the statistical 
analysis. For the comparison of either D- vs. S-loading or D- vs. Sp-loading, one-
way analysis of variance (ANOVA) followed by posthoc Dunnett test was applied 
(using D-loading as a control at each time period). To analyze the differences 
between the two cell types (BM-MSCs or AT-MSCs) within the same cell loading 
method, an unpaired t-test was performed. 
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3. Results 
3.1. Observation of the spheroids 
The morphology and the cell viability of the spheroids are shown in Figure 2. 
Spheroids were formed one day after the cells were seeded on the chitosan 
membrane, for both BM-MSCs and AT-MSCs. The spheroids consisted of a cluster 
of cells, with an average dimension of 44 ± 12 μm, with the spheroids maintaining 
similar size (Figure 2A). DAPI staining further confirmed the formation of spheroids, 
showing multiple cell nuclei within individual spheroids (Figure 2B). The viability 
examination demonstrated that most of the cells within the spheroids were alive 
(Figure 2C). 
 
Figure 2. Morphology and LIVE/DEAD assay for the formed spheroids. (A) Image of inverted contrast 
microscope, indicating spheroids formation on chitosan membrane on day 1 (arrow indicates spheroid). 
(B) DAPI staining confirmed spheroid formation (blue, cell nuclei; dashed line indicates the profile of the 
spheroid). (C) LIVE/DEAD assay showed that most of the cells within a spheroid were viable (green). 
3.2. Evaluation of mesenchymal stem cell behavior in hydrogels 
Cells from all three donors for each cell type demonstrated a similar trend and 
therefore representative data are shown. Hydrogel shrinkage was exclusively 
observed for cell-loaded collagen hydrogels, which started from day 1 on and 
continued over time, whereas the cell-free collagen hydrogels maintained the initial 
size. OPF hydrogels, which swelled upon immersion in culture medium, maintained 
the same size until day 28, irrespective of the cell-loaded and cell-free scaffolds. 
3.2.1. Cell morphology 
The morphology of the cells incorporated within collagen and OPF hydrogels 
following the three cell loading methods is presented in Figure 3. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Mineralization was evaluated by measuring the calcium content (day 7, 13, 21 and 
28) in the hydrogels. A later time point (d28) was included in calcium assay 
because BM-MSCs (cultured in 2-D condition) initiate mineralization from ~day 20 
on29, for which these cells need a longer period for mineralization to become 
apparent. For sample preparation, after PBS wash, 1 ml of 0.5 N acetic acid was 
added to each sample and the plates were placed on an orbital shaker overnight to 
dissolve mineral deposits. The samples were then stored at -20 °C until the 
measurement, according to previously described protocols29,33. The readout values 
of the cell-loaded hydrogels were compensated for the values from the cell-free 
group to avoid the influence of the possible calcium uptake of the hydrogels from 
the culture medium33,34. The values that were less than zero were regarded as zero. 
2.5.5. Cytological evaluation 
Hematoxylin-eosin (HE) staining was used to analyze the cell distribution. Von 
Kossa staining, in which silver ions react with phosphate, was performed to 
visualize the mineralized matrix inside the hydrogels. Briefly, two samples (n=2) of 
each group from day 28 were washed with PBS, fixed in 10% neutral-buffered 
formalin for 6 h, dehydrated in serial ethanol and embedded in paraffin. Cross-
sections with a thickness of 5 μm were cut using a microtome (Leica). After the 
sections were mounted on glass slides, HE and Von Kossa staining26 were 
followed. The staining was imaged with the Zeiss Imager Z1 microscope equipped 
with the AxioCam MRc5 camera using AxioVision 4.8 software. 
2.6. Statistical analysis 
Data are presented as mean ± standard deviation. Graphpad Instat software 
(Instat® 3.05, Graphpad Software Inc., La Jolla, USA) was used for the statistical 
analysis. For the comparison of either D- vs. S-loading or D- vs. Sp-loading, one-
way analysis of variance (ANOVA) followed by posthoc Dunnett test was applied 
(using D-loading as a control at each time period). To analyze the differences 
between the two cell types (BM-MSCs or AT-MSCs) within the same cell loading 
method, an unpaired t-test was performed. 
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3. Results 
3.1. Observation of the spheroids 
The morphology and the cell viability of the spheroids are shown in Figure 2. 
Spheroids were formed one day after the cells were seeded on th  c itosan 
membrane, for both BM-MSCs and AT-MSCs. The pheroids c nsisted of a cluster 
of cells, with a  average imension f 44 ± 12 μm, with the spheroids maintaining 
simil r size (Figure 2A). DAPI staining further con irmed the formation of spheroids, 
show ng multiple cell nuclei wi hin individual spheroids (Figur  2B). Th  v ability 
examination demonstrat d that most of the cells within the spheroids were alive 
(Figure 2C). 
 
Figure 2. Morphology and LIVE/DEAD assay for the formed spheroids. (A) Image of inverted contrast 
microscope, indicating spheroids formation on chitosan membrane on day 1 (arrow indicates spheroid). 
(B) DAPI staining confirmed spheroid formation (blue, cell nuclei; dashed line indicates the profile of the 
spheroid). (C) LIVE/DEAD assay showed that most of the cells within a spheroid were viable (green). 
3.2. Evaluation of mesenchymal stem cell behavior in hydrogels 
Cells from all three donors for each cell type demonstrated a similar trend and 
therefore representative data are shown. Hydrogel shrinkage was exclusively 
observed for cell-loaded collagen hydrogels, which started from day 1 on and 
continued over time, whereas the cell-free collagen hydrogels maintained the initial 
size. OPF hydrogels, which swelled upon immersion in culture medium, maintained 
the same size until day 28, irrespective of the cell-loaded and cell-free scaffolds. 
3.2.1. Cell morphology 
The morphology of the cells incorporated within collagen and OPF hydrogels 
following the three cell loading methods is presented in Figure 3. 
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Figure 3. Morphological appearance of cells/spheroids in the hydrogels loaded using the three loading 
methods. Similar trends were observed for BM-MSCs and AT-MSCs and representative images from 
BM-MSCs are displayed. (A) and (B), representative images showing cell/spheroid morphology of D-, S- 
and Sp-loading in collagen hydrogels on day 1 and 3. (C) Cell/spheroid morphology (at higher 
magnification) of both BM-MSCs and AT-MSCs in Sp-loading in collagen hydrogels on day 1 and 3. (D) 
Representative images showing cell/spheroid morphology of D-, S- and Sp-loading in OPF hydrogels on 
day 3. →, cell clusters; *, spheroids. 
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In both of the hydrogels, BM-MSCs and AT-MSCs showed the same trend, 
regardless of the cell loading groups. In collagen hydrogels, cells exhibited a high 
degree of cell spreading. Cells distributed evenly in D-loading, or formed clusters in 
S-loading, or started to migrate out of the spheroids in Sp-loading on day 1 (Figure 
3A), and this trend was more obvious on day 3 (Figure 3B). However, the patterns 
of BM-MSCs and AT-MSCs migration out of the spheroids were not exactly the 
same. On day 1, the spheroids were more condensed for Sp-BM, while those in 
Sp-AT began to sprout and merge into the collagen hydrogels (Figure 3C). On day 
3, cell-cell interaction in the neighboring spheroids was initiated in Sp-BM while 
cell-cell contact has been clearly established in Sp-AT (Figure 3C). Further, the 
spheroids encapsulated in collagen gels tended to become bigger (~100 µm, 
Figure 3A-C) than those directly formed from the chitosan film (44±12 µm, Figure 
2A). That is because cells in the spheroids started to spread and migrate out due 
to the pronounced cell-scaffold contact, which already obviously occurred even 
after 1 day encapsulation in collagen hydrogels. In contrast, cells in OPF hydrogels 
remained round and did not spread at all during the entire culture period. Cells 
neither spread in D- and S-loading nor migrated out of the spheroids in Sp-loading 
(Figure 3D). 
3.2.2. Proliferative capacity in collagen hydrogels 
Cell metabolic activity of the collagen hydrogels is shown in Figure 4A. According 
to the instructions from the company (alamarBlue®, Invitrogen), certain threshold 
exists for the cell number measured, meaning with high cell numbers or extended 
incubation time (days), the values of cell metabolic activity will stop increasing and 
begin to decline. The cell metabolic activity until day 14 was measured and the 
threshold appeared on day 10. Therefore, only the cell metabolic activity up to 10 
days was measured. The values are presented by subtracting the values from cell-
free scaffolds. For BM-MSCs, cell metabolic activity on day 3 was significantly 
higher in S-loading and lower in Sp-loading compared to D-loading. Nevertheless, 
significantly higher metabolic activity was observed in both S- and Sp-loading than 
that in D-loading on day 10. For AT-MSCs, S-loading only induced significantly 
higher metabolic activity than D-loading on day 3 while this occurred in Sp-loading 
at all the time points. For the comparison of the two cell types in each loading 
method, cell metabolic activity was significantly higher in Sp-AT than in Sp-BM at 
all the time points, and lower in S-AT than in S-BM on day 10. 
The results of cell proliferation, measured by DNA content, are displayed in Figure 
4B. For BM-MSCs cultured in collagen hydrogels, significantly lower DNA content 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Figure 3. Morphological appearance of cells/spheroids in the hydrogels loaded using the three loading 
methods. Similar trends were observed for BM-MSCs and AT-MSCs and representative images from 
BM-MSCs are displayed. (A) and (B), representative images showing cell/spheroid morphology of D-, S- 
and Sp-loading in collagen hydrogels on day 1 and 3. (C) Cell/spheroid morphology (at higher 
magnification) of both BM-MSCs and AT-MSCs in Sp-loading in collagen hydrogels on day 1 and 3. (D) 
Representative images showing cell/spheroid morphology of D-, S- and Sp-loading in OPF hydrogels on 
day 3. →, cell clusters; *, spheroids. 
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In both f the hydrogels, BM-MSCs and AT-MSCs showed the same trend, 
regardless of th  cell loading groups. In collagen hydrogels, ells exhibited a high 
degree of cell spreading. Cells distributed evenly in D-loading, or formed cluster  in 
S-loading, or started to migrate out of the spheroids in Sp-loading on day 1 (Figure 
3A), and this trend was more obvious on day 3 (Figure 3B). However, the patterns 
of BM-MSCs and AT-MSCs migration out of the spheroids were not exactly the 
same. On day 1, the spheroids were more condensed for Sp-BM, while those in 
Sp-AT began to sprout and merge into the collagen hydrogels (Figure 3C). On day 
3, cell-cell interaction in the neighboring spheroids was initiated in Sp-BM while 
cell-cell contact has been clearly established in Sp-AT (Figure 3C). Further, the 
spheroids encapsulated in collagen gels tended to become bigger (~100 µm, 
Figure 3A-C) than those directly formed from the chitosan film (44±12 µm, Figure 
2A). That is because cells in the spheroids started to spread and migrate out due 
to the pronounced cell-scaffold contact, which already obviously occurred even 
after 1 day encapsulation in collagen hydrogels. In contrast, cells in OPF hydrogels 
remained round and did not spread at all during the entire culture period. Cells 
neither spread in D- and S-loading nor migrated out of the spheroids in Sp-loading 
(Figure 3D). 
3.2.2. Proliferative capacity in collagen hydrogels 
Cell metabolic activity of the collagen hydrog ls is shown in Figure 4A. According 
to the instructions from the company (alamarBlue®, Invi rogen), certain threshold 
exists for the cell number measured, meaning with high cell umbers or ext nded 
incubatio  ti  (day ), the values of cell metabolic ctivity will stop increasing and 
begin to decline. Th  cell metabolic activity until day 14 was mea ured and the 
thr shold app ared on day 10. Therefore, only the cell metaboli  activity up to 10 
days was measured. The values are presented by subtracting the values from cell-
free sca f ld . For BM-MSCs, cell metabolic activity on day 3 was significan ly 
higher in S-loading and lower i  Sp-loading compared to D-lo ding. Nevertheless, 
sign ficantly higher metabolic activity was observed in both S- and Sp-loading than 
that in D-loading on day 10. For AT-MSCs, S-loading only ind ced significantly 
higher metabol c activity than D-loadi g on day 3 while this occurred in Sp-loa ing 
at all the time points. For th  comparison of the two cell types in each lo ding 
method, cell metabolic activity was significantly higher n Sp-AT than in Sp-B  at 
all the time points, and lower in S-AT than in S-BM on day 10. 
The results of cell proliferation, measured by DNA c nt t, are displayed in F gure 
4B. For BM-MSC cultured in collagen hy rogel , s gnificantly lowe  DNA content 
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was observed in S-loading on day 13 and in Sp-loading on both day 7 and 13 
compared to D-loading, though no difference was observed among the three 
loading groups on day 21. For AT-MSCs cultured in collagen hydrogels, DNA 
content was significantly lower in both S- and Sp-loading in comparison to D-
loading on day 13 but no difference was found on day 7 and 21. The comparison of 
the two cell types in collagen hydrogels displayed significantly higher DNA content 
for AT-MSCs than BM-MSCs in all the three loading methods on both day 7 and 13, 
and in Sp-loading on day 21. The difference of DNA content between BM-MSCs 
and AT-MSCs on day 7 is due to the faster proliferation capacity of AT-MSCs 
compared to BM-MSCs rather than cell death in BM-MSCs, since cell morphology 
(stained from HE) can be clearly observed on day 7 (data not shown). 
3.2.3. Osteogenic differentiation capacity in collagen hydrogels 
ALP activity in collagen hydrogels, which was normalized by the DNA content, is 
shown in Figure 4C. Except for the significantly higher ALP activity when Sp-
loading was compared with D-loading in AT-MSCs culture on day 13, no difference 
was observed in the other comparisons (i.e. D- vs. S-loading or D- vs. Sp-loading) 
at the other time points (i.e. d7 or d21). The ALP activity in AT-MSCs was much 
higher in S- and Sp-loading on day 7, D- and Sp-loading on day 13 and D-, S- and 
Sp-loading on day 21 compared to BM-MSCs. However, due to the relatively 
higher standard deviation in S-AT on day 21, less significance was observed in S-
AT vs. S-BM (p<0.01) compared to Sp-AT vs. Sp-BM (p<0.001). 
The calcium contents for collagen hydrogels are represented in Figure 4D. 
Mineralization only occurred in AT-MSCs and initiated on day 21. Nevertheless, no 
significant difference was observed in D- vs. S-loading or D- vs. Sp-loading on both 
day 21 and 28. 
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Figure 4. Cell proliferative and osteogenic differentiation capacity in collagen hydrogels. (A) Cell 
metabolic activity; (B) DNA content; (C) ALP activity and (D) calcium content (n=3 for each 
measurement). The values of both cell metabolic activity and calcium content are presented by 
subtracting the values from cell-free hydrogels. *, p<0.05; **, p<0.01, indicate the differences when S- or 
Sp-loading was compared to D-loading. #, p<0.05; ##, p<0.01; ###, p<0.001, indicate the differences 
between BM-MSCs and AT-MSCs for each cell loading method. 
3.2.4. Proliferative and osteogenic capacity in OPF hydrogels 
For cell metabolic activity, it is not possible to measure the values in OPF 
hydrogels because they show a strong influence on the fluorescence reaction. For 
proliferation (i.e. DNA content) and osteogenic differentiation (i.e. ALP activity and 
calcium content), the values in OPF hydrogels were much more decreased and 
even undetectable (data not shown) compared to those in collagen hydrogels. 
3.2.5. HE staining 
HE staining (day 28), in which cell nuclei is stained as blue and cytoplasm is 
stained as pink, depicts the cell distribution and alignment in the hydrogels (Figure 
5). 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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was observed in S-loading on day 13 and in Sp-loading on both day 7 and 13 
compared to D-loading, though no difference was observed among the three 
loading groups on day 21. For AT-MSCs cultured in collagen hydrogels, DNA 
content was significantly lower in both S- and Sp-loading in comparison to D-
loading on day 13 but no difference was found on day 7 and 21. The comparison of 
the two cell types in collagen hydrogels displayed significantly higher DNA content 
for AT-MSCs than BM-MSCs in all the three loading methods on both day 7 and 13, 
and in Sp-loading on day 21. The difference of DNA content between BM-MSCs 
and AT-MSCs on day 7 is due to the faster proliferation capacity of AT-MSCs 
compared to BM-MSCs rather than cell death in BM-MSCs, since cell morphology 
(stained from HE) can be clearly observed on day 7 (data not shown). 
3.2.3. Osteogenic differentiation capacity in collagen hydrogels 
ALP activity in collagen hydrogels, which was normalized by the DNA content, is 
shown in Figure 4C. Except for the significantly higher ALP activity when Sp-
loading was compared with D-loading in AT-MSCs culture on day 13, no difference 
was observed in the other comparisons (i.e. D- vs. S-loading or D- vs. Sp-loading) 
at the other time points (i.e. d7 or d21). The ALP activity in AT-MSCs was much 
higher in S- and Sp-loading on day 7, D- and Sp-loading on day 13 and D-, S- and 
Sp-loading on day 21 compared to BM-MSCs. However, due to the relatively 
higher standard deviation in S-AT on day 21, less significance was observed in S-
AT vs. S-BM (p<0.01) compared to Sp-AT vs. Sp-BM (p<0.001). 
The calcium contents for collagen hydrogels are represented in Figure 4D. 
Mineralization only occurred in AT-MSCs and initiated on day 21. Nevertheless, no 
significant difference was observed in D- vs. S-loading or D- vs. Sp-loading on both 
day 21 and 28. 
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Figure 4. Cell proliferative and osteogenic differentiation capacity in collagen hydrogels. (A) Cell 
metabolic activity; (B) DNA content; (C) ALP activity and (D) calcium content (n=3 for each 
measurement). The values of both cell metabolic activity and calcium content are pres nted by 
subtracting the values from cell-free hydrogels. *, p<0.05; **, p<0.01, indicate the differences when S- or 
Sp-loading was compared to D-loading. #, p<0.05; ##, p<0.01; ###, p<0.001, indicate the differences 
between BM-MSCs and AT-MSCs for each cell loading method. 
3.2.4. Proliferative and osteogenic capacity in OPF hydrogels 
For cell metabolic activity, it is not possible to measure the values in OPF 
hydrogels because they show a strong influence on the fluorescence reaction. For 
proliferation (i.e. DNA content) and osteogenic differentiation (i.e. ALP activity and 
calcium content), the values in OPF hydrogels were much more decreased and 
even undetectable (data not shown) compared to those in collagen hydrogels. 
3.2.5. HE staining 
HE staining (day 28), in which cell nuclei is stained as blue and cytoplasm is 
stained as pink, depicts the cell distribution and alignment in the hydrogels (Figure 
5). 
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Figure 5. HE staining (n=2) on day 28. In collagen hydrogels, BM-MSCs and AT-MSCs displayed the 
same trend and images from BM-MSCs are shown. In OPF hydrogels, representative image from D-AT 
is shown. *, indicates cells in OPF hydrogels; blue, indicates cell nuclei; pink, indicates cytoplasm. 
 
In collagen hydrogels, cells distributed evenly inside the hydrogels for both D- and 
Sp-loading, while cells in S-loading dispersed into the hydrogels and mainly 
arranged on the interface of the two hydrogel layers. These trends were observed 
for both BM-MSCs and AT-MSCs, with cells located closer with each other in AT-
MSCs than in BM-MSCs. For OPF hydrogels, it is difficult to analyze the cell 
distribution due to the tearing and folding of the samples during sample processing 
as previously described35, as well as the strong background out of the staining. 
3.2.6. Von Kossa staining 
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Von Kossa staining was used to assess the mineralization inside the hydrogels on 
day 28 (Figure 6). Only the images from collagen hydrogels are displayed since 
OPF hydrogels did not induce 
calcium deposition based on 
results from the calcium assay. 
Calcium deposition was observed 
in all the groups on day 28, 
including cell-free collagen 
hydrogels, in which the calcium 
was passively deposited mainly 
on the edges of the hydrogels. 
 
Figure 6. Von Kossa staining (n=2) in 
collagen hydrogels on day 28. Images for 
the cell-free collagen hydrogel and all 
three groups of cell-loaded hydrogels 
from both BM-MSCs and AT-MSCs are      
presented. Brown color indicates 
mineralized nodules. 
For BM-MSCs, slight 
mineralization was observed on 
both the edge and inner side of 
the scaffold in D-loading. 
Mineralized nodules mainly 
occurred on the interface 
between the two hydrogel layers 
in S-loading and no 
mineralization was discovered in 
Sp-loading. For AT-MSCs, 
mineralized nodules distributed 
evenly in both D- and Sp-loading, 
while they were mostly observed 
on the interface between the two hydrogel layers in S-loading. AT-MSCs exhibited 
more obvious mineralization compared to BM-MSCs. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Figure 5. HE staining (n=2) on day 28. In collagen hydrogels, BM-MSCs and AT-MSCs displayed the 
same trend and images from BM-MSCs are shown. In OPF hydrogels, representative image from D-AT 
is shown. *, indicates cells in OPF hydrogels; blue, indicates cell nuclei; pink, indicates cytoplasm. 
 
In collagen hydrogels, cells distributed evenly inside the hydrogels for both D- and 
Sp-loading, while cells in S-loading dispersed into the hydrogels and mainly 
arranged on the interface of the two hydrogel layers. These trends were observed 
for both BM-MSCs and AT-MSCs, with cells located closer with each other in AT-
MSCs than in BM-MSCs. For OPF hydrogels, it is difficult to analyze the cell 
distribution due to the tearing and folding of the samples during sample processing 
as previously described35, as well as the strong background out of the staining. 
3.2.6. Von Kossa staining 
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day 28 (Figure 6). Only th  images from collagen hydr gels are displ yed since 
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calcium deposition based on 
results from the calcium assay. 
Calcium deposition was observed 
in all the groups on day 28, 
including cell-free collagen 
hydrogels, in which the calcium 
was passively deposited mainly 
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Figure 6. Von Kossa staining (n=2) in 
collagen hydrogels n day 28. Images for 
the cell-free collagen hydrogel and all 
three groups of cell-loaded hydrogels 
from both BM-MSCs and AT-MSCs are      
presented. Brown color indicates 
mineralized nodules. 
For BM-MSCs, slight 
mineralization was observed on 
both the edge and inner side of 
the scaffold in D-loading. 
Mineralized nodules mainly 
occurred on the interface 
between the two hydrogel layers 
in S-loading and no 
mineralization was discovered in 
Sp-loading. For AT-MSCs, 
mineralized nodules distributed 
evenly in both D- and Sp-loading, 
while they were mostly observed 
on the interface between the two hydrogel layers in S-loading. AT-MSCs exhibited 
more obvious mineralization compared to BM-MSCs. 
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4. Discussion 
This study aimed to evaluate the effects of hydrogel type on cell behavior (i.e. BM-
MSCs and AT-MSCs) and compare the osteogenic capacity of these cells loaded 
using three methods (i.e. dispersed-, sandwich- and spheroid-loading). We 
hypothesized that (i) collagen enhances osteogenesis in comparison to OPF 
hydrogels as a result of the improved cell-scaffold interaction, (ii) sandwich and 
spheroids loading can increase osteogenic differentiation compared to dispersed 
loading due to the greater cell-cell contact, and (iii) AT-MSCs have higher 
osteogenic capacity compared to BM-MSCs. The parameters for evaluation were 
cell proliferative capacity (i.e. cell metabolic activity and DNA content) and 
osteogenic differentiation (i.e. ALP activity and mineralization). The results 
suggested that cell behavior was influenced by the hydrogel type, meaning cells 
cultured in collagen hydrogels had greater proliferation and osteogenic 
differentiation capacity than those in OPF hydrogels, because collagen hydrogels 
allow cells to attach and function while OPF hydrogels do not. Nevertheless, 
regarding the osteogenic capacity of the three loading methods in collagen 
hydrogels, no obvious difference was observed. 
Hydrogels are materials that contain a high amount of water, and their nature and 
properties affect the (cell-loaded) hydrogel behavior (e.g. shrinkage and swelling) 
and cell behavior (e.g. adhesion, proliferation and differentiation). OPF hydrogels 
have higher mechanical properties (storage modulus: 500 Pa)33 compared to 
collagen hydrogels (storage modulus: 290 Pa)36 and the substrate stiffness can 
affect the cell fate37. The two cell-loaded hydrogel systems behaved differently, 
meaning collagen hydrogels contracted over time whereas OPF hydrogels swelled 
in the process of gelification and remained stable without any observable changes 
in matrix shape or volume. Moreover, cells behaved distinctly and superior capacity 
of osteogenic differentiation was found in collagen compared to OPF hydrogels. 
Firstly, it has been reported that the molecular characteristics of the hydrogels, 
especially their cross-linking mechanisms (e.g. physical cross-linking for collagen 
hydrogels and covalent cross-linking for OPF hydrogels) and the resulting 
viscoelastic behaviors may influence the ability of the cells to contract the gels38. 
Secondly, collagen hydrogels shrink because of the traction forces exerted by the 
cells, while in OPF hydrogels, the cells remain spherical and do not exert traction 
forces. It has been proved that osteogenic differentiation capacity is largely 
determined by the traction forces among the cells and osteogenesis was 
associated with spread cells, rather than round ones39. The shrinkage/swelling 
properties make the distance between the adjacent cells in collagen hydrogels 
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relatively small while that in OPF hydrogels relatively big, which thereafter 
increases the cell-cell contact in collagen hydrogels but decreases that in OPF 
hydrogels. The increased cell-cell contact in the compacted collagen hydrogels 
allows the cells to establish numerous intercellular contacts and to form a three-
dimensional network (i.e. extracellular matrix). Last, material surface characteristics, 
like topography and chemical composition can affect the cell-scaffold interaction23. 
Cell adhesion and migration is dependent on the recognition of specific receptors 
on the surface of scaffolds. Natural-based (e.g. collagen) hydrogels promote 
cellular functions due to the myriad of endogenous factors, which can be 
advantageous for the cell viability, proliferation and differentiation. Synthetic-based 
(e.g. OPF) hydrogels lack the endogenous factors that promote cell behavior and 
they act mainly as a passive template to permit cell function40. Although cells 
cannot attach to OPF hydrogels, evaluation of the Sp-loading method was 
especially interesting in such conditions, as it was hypothesized that the enhanced 
cell-cell contact in this loading method could overcome lack of interaction between 
(individual) cells and the hydrogel material. These differences can also explain why 
while loading the same number of cells, mineralization was observed only for 
collagen hydrogels and not for OPF hydrogels. Because of the swollen state of 
OPF hydrogels, relatively higher cell loading density may be required for cell 
behavior compared to collagen hydrogels. 
Based on the fact that cell-cell contact regulates osteogenesis17,41, our hypothesis 
was made, which is by restricting the cells in between two hydrogel layers (i.e. S-
loading) or culturing the cells in the format of spheroids (i.e. Sp-loading), cell-cell 
contact can be increased and hence osteogenesis is enhanced. Yet, no differences 
on osteogenesis were examined when S- or Sp-loading was compared with D-
loading. On one hand, there is no consistency in cell loading density in hydrogels. 
According to the literature, in which D-loading was normally used, the loading 
density from a range of 105 ~108 cells/ml for collagen hydrogels32,42 and a scale of 
107 cells/ml for OPF hydrogels33,35 were used. Comparing to this, the cell loading 
density in this study was within the range for collagen hydrogels and lower for OPF 
hydrogels. Lower cell loading density was chosen in order to make the three 
loading groups comparable, which may be insufficient for Sp-loading and hence 
Sp-loading did not show advantages for osteogenesis in comparison to the other 
two loading methods. On the other hand, cell-scaffold interaction influences cell 
behavior. For collagen hydrogels, the cell dispersion/migration in the hydrogels at 
the very early stage (day 1) in both S- and Sp-loading made their culture conditions 
more or less equal with D-loading within several days of culture. For OPF 
hydrogels, because the components do not possess biospecific adhesion sites, 
Chapter 2 
 
28 
 
contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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4. Discussion 
This study aimed to evaluate the effects of hydrogel type on cell behavior (i.e. BM-
MSCs and AT-MSCs) and compare the osteogenic capacity of these cells loaded 
using three methods (i.e. dispersed-, sandwich- and spheroid-loading). We 
hypothesized that (i) collagen enhances osteogenesis in comparison to OPF 
hydrogels as a result of the improved cell-scaffold interaction, (ii) sandwich and 
spheroids loading can increase osteogenic differentiation compared to dispersed 
loading due to the greater cell-cell contact, and (iii) AT-MSCs have higher 
osteogenic capacity compared to BM-MSCs. The parameters for evaluation were 
cell proliferative capacity (i.e. cell metabolic activity and DNA content) and 
osteogenic differentiation (i.e. ALP activity and mineralization). The results 
suggested that cell behavior was influenced by the hydrogel type, meaning cells 
cultured in collagen hydrogels had greater proliferation and osteogenic 
differentiation capacity than those in OPF hydrogels, because collagen hydrogels 
allow cells to attach and function while OPF hydrogels do not. Nevertheless, 
regarding the osteogenic capacity of the three loading methods in collagen 
hydrogels, no obvious difference was observed. 
Hydrogels are materials that contain a high amount of water, and their nature and 
properties affect the (cell-loaded) hydrogel behavior (e.g. shrinkage and swelling) 
and cell behavior (e.g. adhesion, proliferation and differentiation). OPF hydrogels 
have higher mechanical properties (storage modulus: 500 Pa)33 compared to 
collagen hydrogels (storage modulus: 290 Pa)36 and the substrate stiffness can 
affect the cell fate37. The two cell-loaded hydrogel systems behaved differently, 
meaning collagen hydrogels contracted over time whereas OPF hydrogels swelled 
in the process of gelification and remained stable without any observable changes 
in matrix shape or volume. Moreover, cells behaved distinctly and superior capacity 
of osteogenic differentiation was found in collagen compared to OPF hydrogels. 
Firstly, it has been reported that the molecular characteristics of the hydrogels, 
especially their cross-linking mechanisms (e.g. physical cross-linking for collagen 
hydrogels and covalent cross-linking for OPF hydrogels) and the resulting 
viscoelastic behaviors may influence the ability of the cells to contract the gels38. 
Secondly, collagen hydrogels shrink because of the traction forces exerted by the 
cells, while in OPF hydrogels, the cells remain spherical and do not exert traction 
forces. It has been proved that osteogenic differentiation capacity is largely 
determined by the traction forces among the cells and osteogenesis was 
associated with spread cells, rather than round ones39. The shrinkage/swelling 
properties make the distance between the adjacent cells in collagen hydrogels 
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relatively small while that in OPF hydrog ls relatively big, which thereafter 
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allows the cells to establish numerous intercellular contacts and to form a three-
dimensional network (i.e. extracellular matrix). Last, material surface characteristics, 
like topography and chemical composition can affect the cell-scaffold interaction23. 
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on the surface of scaffolds. Natural-based (e.g. collagen) hydrogels promote 
cellular functions due to the myriad of endogenous factors, which can be 
advantageous for the cell viability, proliferation and differentiation. Synthetic-based 
(e.g. OPF) hydrogels lack the endogenous factors that promote cell behavior and 
they act mainly as a passive template to permit cell function40. Although cells 
cannot attach to OPF hydrogels, evaluation of the Sp-loading method was 
especially interesting in such conditions, as it was hypothesized that the enhanced 
cell-cell contact in this loading method could overcome lack of interaction between 
(individual) cells and the hydrogel material. These differences can also explain why 
while loading the same number of cells, mineralization was observed only for 
collagen hydrogels and not for OPF hydrogels. Because of the swollen state of 
OPF hydrogels, relatively higher cell loading density may be required for cell 
behavior compared to collagen hydrogels. 
Based on the fact that cell-cell contact regulates osteogenesis17,41, our hypothesis 
was made, which is by restricting the cells in between two hydrogel layers (i.e. S-
loading) or culturing the cells in the format of spheroids (i.e. Sp-loading), cell-cell 
contact can be increased and hence osteogenesis is enhanced. Yet, no differences 
on osteogenesis were examined when S- or Sp-loading was compared with D-
loading. On one hand, there is no consistency in cell loading density in hydrogels. 
According to the literature, in which D-loading was normally used, the loading 
density from a range of 105 ~108 cells/ml for collagen hydrogels32,42 and a scale of 
107 cells/ml for OPF hydrogels33,35 were used. Comparing to this, the cell loading 
density in this study was within the range for collagen hydrogels and lower for OPF 
hydrogels. Lower cell loading density was chosen in order to make the three 
loading groups comparable, which may be insufficient for Sp-loading and hence 
Sp-loading did not show advantages for osteogenesis in comparison to the other 
two loading methods. On the other hand, cell-scaffold interaction influences cell 
behavior. For collagen hydrogels, the cell dispersion/migration in the hydrogels at 
the very early stage (day 1) in both S- and Sp-loading made their culture conditions 
more or less equal with D-loading within several days of culture. For OPF 
hydrogels, because the components do not possess biospecific adhesion sites, 
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cells could not adhere and cell proliferation was rather poor, which corroborates 
with previous findings33. This leads to the lack of the differences among the three 
methods. Nevertheless, the highest cell metabolic activity was found in Sp-loading 
among the three methods in collagen hydrogels. Although the cells within the 
spheroids obtained pronounced contact, the cell-cell contact between the adjacent 
spheroids, was slower compared to D-BM and S-BM at the earlier time points (i.e. 
< day 7), which lead to slower cell growth and proliferation (i.e. lower DNA content) 
in Sp-BM compared to D-BM and S-BM on day 7. However, as it was much faster 
for the cell migration out of the spheroids in Sp-AT, there was no significant 
difference in DNA content among the three loading methods using AT-MSCs on 
day 7. Additionally, no significant difference was observed in the three loading 
methods on day 21, irrespective of BM-MSCs and AT-MSCs. Spheroids cell 
loading was found to more closely resemble the physiological tissue environment 
than conventional tissue culture plates (TCPS) monolayer cultures43. Additionally, 
spheroids-derived cells after re-seeded on TCPS had higher cell metabolic activity 
compared to the initially monolayer cultured cells28. The current study further 
confirmed that this is also applicable when spheroids were loaded in hydrogels 
instead of on TCPS. 
In view of the cell behavior in collagen hydrogels, AT-MSCs induced higher 
proliferation and osteogenic differentiation compared to BM-MSCs. First of all, BM-
MSCs and AT-MSCs were cultured in FBS- and PL- supplemented osteogenic 
medium respectively, since this was demonstrated as the optimal culture condition 
for each cell type26. The advantage of using PL instead of FBS supplementation in 
the culture medium is that it can avoid the transmission of animal (bovine) 
pathogens. Furthermore, it was discovered that AT-MSCs cultured in PL-
supplemented medium can enhance cell proliferation compared to BM-MSCs 
cultured in FBS-supplemented medium in TCPS cultures26. Consistently, when 
cells were cultured in hydrogels, AT-MSCs can easily obtain cell-cell contact due to 
their faster proliferation and hence higher mineralization was achieved. Conversely, 
obvious mineralization was only observed for AT-MSCs but not for BM-MSCs in 
hydrogels, although mineralization was found for both of the cell types in TCPS 
culture26. This indicates that cells cultured in hydrogels may behave differently with 
those in monolayer cultures, and higher loading density should be considered 
when BM-MSCs are loaded in hydrogels. 
This study aimed to compare the behavior of both BM-MSCs and AT-MSCs in 
three loading methods (i.e. D-, S- and Sp-loading) in two types of hydrogels (i.e. 
collagen and OPF). The results indicated that cell behavior differed between the 
two hydrogel systems. Cells mineralized in collagen hydrogels, but not in OPF 
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hydrogels. However, there was no difference for mineralization among the three 
loading methods, regardless of the hydrogel systems. Moreover, AT-MSCs 
exhibited higher proliferation and osteogenic capacity compared to BM-MSCs. 
Chapter 2 
 
28 
 
contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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cells could not adhere and cell proliferation was rather poor, which corroborates 
with previous findings33. This leads to the lack of the differences among the three 
methods. Nevertheless, the highest cell metabolic activity was found in Sp-loading 
among the three methods in collagen hydrogels. Although the cells within the 
spheroids obtained pronounced contact, the cell-cell contact between the adjacent 
spheroids, was slower compared to D-BM and S-BM at the earlier time points (i.e. 
< day 7), which lead to slower cell growth and proliferation (i.e. lower DNA content) 
in Sp-BM compared to D-BM and S-BM on day 7. However, as it was much faster 
for the cell migration out of the spheroids in Sp-AT, there was no significant 
difference in DNA content among the three loading methods using AT-MSCs on 
day 7. Additionally, no significant difference was observed in the three loading 
methods on day 21, irrespective of BM-MSCs and AT-MSCs. Spheroids cell 
loading was found to more closely resemble the physiological tissue environment 
than conventional tissue culture plates (TCPS) monolayer cultures43. Additionally, 
spheroids-derived cells after re-seeded on TCPS had higher cell metabolic activity 
compared to the initially monolayer cultured cells28. The current study further 
confirmed that this is also applicable when spheroids were loaded in hydrogels 
instead of on TCPS. 
In view of the cell behavior in collagen hydrogels, AT-MSCs induced higher 
proliferation and osteogenic differentiation compared to BM-MSCs. First of all, BM-
MSCs and AT-MSCs were cultured in FBS- and PL- supplemented osteogenic 
medium respectively, since this was demonstrated as the optimal culture condition 
for each cell type26. The advantage of using PL instead of FBS supplementation in 
the culture medium is that it can avoid the transmission of animal (bovine) 
pathogens. Furthermore, it was discovered that AT-MSCs cultured in PL-
supplemented medium can enhance cell proliferation compared to BM-MSCs 
cultured in FBS-supplemented medium in TCPS cultures26. Consistently, when 
cells were cultured in hydrogels, AT-MSCs can easily obtain cell-cell contact due to 
their faster proliferation and hence higher mineralization was achieved. Conversely, 
obvious mineralization was only observed for AT-MSCs but not for BM-MSCs in 
hydrogels, although mineralization was found for both of the cell types in TCPS 
culture26. This indicates that cells cultured in hydrogels may behave differently with 
those in monolayer cultures, and higher loading density should be considered 
when BM-MSCs are loaded in hydrogels. 
This study aimed to compare the behavior of both BM-MSCs and AT-MSCs in 
three loading methods (i.e. D-, S- and Sp-loading) in two types of hydrogels (i.e. 
collagen and OPF). The results indicated that cell behavior differed between the 
two hydrogel systems. Cells mineralized in collagen hydrogels, but not in OPF 
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hydrogels. However, there was no difference for mineralization among the three 
loading methods, regardl ss of the hy rogel sys ems. Moreover, AT-MSCs 
exhibited higher proliferation and osteogenic capacity compared to BM-MSCs. 
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5. Conclusions 
In conclusion, D- and Sp-loading represent two promising cell loading methods for 
injectable bone substitute materials that allow application of minimally invasive 
surgery. Further studies with higher cell loading density are necessary to better 
compare these two cell loading methods in the hydrogels. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
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using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
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 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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1. Introduction 
Repair of critical size bone defects is often problematic and poses a serious 
challenge for orthopedic surgeons1. Bone regenerative medicine, based on 
autologous cells combined with a biomaterial, offers a possibility of regenerating 
damaged bone tissue2. Mesenchymal stem cells (MSCs) represent a potential cell 
source for bone regeneration3, of which bone marrow-derived MSCs (BM-MSCs) 
are most commonly used. In view of disadvantages related to the use of BM-MSCs, 
including patient discomfort during isolation and low cell yield4-5, adipose tissue (AT) 
is an alternative source for MSCs that is easily accessible and yields more MSCs 
compared to the BM6-7. 
Although differences in gene expression profiles are reported for these two 
different anatomical harvesting sites8, and the in vitro osteogenic differentiation 
capacity of AT-MSCs is well established9-11 and optimized by using platelet lysate 
(PL) as a culture medium supplement rather than fetal bovine serum (FBS)12, the in 
vivo bone forming capacity has not been irrefutably proven. Few studies have 
demonstrated in vivo bone formation by AT-MSCs, either ectopically or 
orthotopically. For instance, a 30% higher bone formation was demonstrated for 
human AT-MSCs seeded on demineralized bone matrix (DBM) implanted in 
abdominal muscles of rats compared to empty scaffolds13. Similarly, others showed 
enhanced bone regeneration (compared to empty scaffolds) upon implantation of 
human AT-MSCs seeded on DBM14 or hydroxyapatite (HA) coated poly(lactic-co-
glycolic acid)15 in rat or mouse cranial defects. In contrast, when human AT-MSCs 
seeded HA scaffolds were ectopically implanted in mice16 or rats17, only small 
amounts of bone or even no bone at all was observed. In an orthotopic study, no 
additive value of AT-MSCs on bone formation was observed when ovine AT-MSCs 
were seeded on mineralized collagen sponges in comparison to empty scaffolds 
after implantation into sheep tibia18. These controversies make it necessary to 
further investigate bone regeneration using AT-MSCs. 
In view of cell survival within a cell/scaffold construct, vascularization within the 
constructs has been suggested as a key factor19. The slow rate (<1 mm/day) of 
blood vessel infiltration into scaffolds hampers cell survival and the integration of 
the graft with the host20. Coculture of osteoblastic cells with endothelial (progenitor) 
cells (ECs) has attracted huge interest with the anticipation of stimulating 
vascularization21. Moreover, such cocultures were demonstrated to induce at least 
equal levels of mineralization in vitro22 and bone formation in vivo23 compared to 
MSCs monocultures. Interestingly, these cocultures require lower numbers of 
MSCs to achieve similar levels of mineralization compared to MSCs monocultures, 
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which is related to the cellular cross-talk between the two cell types24. So far, 
limited data are available on cocultures using AT-MSCs in combination with ECs. 
Consequently, it is important to find out the optimal (co)culture conditions and 
compare the osteogenic capacity between mono- and cocultures using AT-MSCs 
for bone regeneration. 
The aim of this study was to compare the in vitro osteogenic capacity as well as 
the in vivo bone forming capacity between human AT-MSCs and human AT-MSCs 
cocultured with human umbilical vein ECs (HUVECs). We hypothesized that the 
AT-MSCs/HUVECs cocultures enhance osteogenesis and induce more bone 
formation in comparison to AT-MSCs monocultures. In vitro, AT-MSCs and AT-
MSCs/HUVECs were seeded on tissue-culture plates (TCPS) and porous titanium 
fiber mesh scaffolds (Ti) to analyze the optimal cell ratio in cocultures and 
associated in vitro osteogenic capacity. In vivo, Ti were implanted in 5-mm 
diameter bilateral cranial defects in athymic nude rats for 8 weeks and bone 
formation was evaluated histologically and histomorphometrically. Ti scaffolds were 
used to provide mechanical support and served as a substrate for cell adhesion, 
proliferation and osteogenic differentiation25, as it has been widely used in animal 
studies26-27 and even for clinical applications28. This is the first study demonstrating 
the in vivo bone forming capacity of Ti scaffolds combined with either AT-MSCs 
monocultures or AT-MSCs/HUVECs cocultures in a rat cranial defect model. 
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2. Materials and methods 
2.1. Cell isolation and culture 
AT-MSCs from two donors (donor 1: 52 years old, female; donor 2: 38 years old, 
male) from passage 4 were used in the experiment. Human subcutaneous adipose 
tissue from the abdomen was obtained from waste material from the Department of 
Plastic Surgery (Tergooi Hospital, Hilversum, the Netherlands) after written 
informed consent. This study complied with the principles of the Declaration of 
Helsinki. 
AT-MSCs isolation was performed as described previously29. Briefly, resected 
tissue was minced using surgical scalpel and scissor and digested with 0.1% 
collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) in phosphate-
buffered saline (PBS; B. Braun, Melsungen, Germany) containing 1% bovine 
serum albumin (BSA; Roche Diagnostics) at 37 °C for 45 min with shaking. The 
digested tissue was centrifuged (600 g) for 10 min and the cell pellet was 
resuspended in 5 ml of PBS/1% BSA and filtered with a 200 µm mesh (Roche 
Diagnostics). Cells were then subjected to a Ficoll density centrifugation step to 
remove erythrocytes and were plated at a density of 100,000 cells/cm2. 
Proliferation medium was used for cell expansion, in which PL was supplemented 
(PMPL, see Table 1). 
HUVECs were obtained from a commercial source (Becton Dickinson Biosciences, 
BD; Breda, the Netherlands) and cultured in endothelial cell culture medium (EM, 
see Table 1) according to instructions from BD. Cells from passage 4 were used for 
cell seeding in the experiment. 
2.2. Optimization of cell ratio in cocultures for osteogenic differentiation 
The experimental procedure of this study is shown schematically in Figure 1. To 
determine the effects of cell ratio on osteogenesis, AT-MSCs and HUVECs were 
(co)cultured on tissue culture 24-well TCPS (Greiner Bio-one, Alphen aan den Rijn, 
the Netherlands) in different ratios varying from 100:0 to 0:100 (n=4) at a seeding 
density of 5,000 cells/cm2 in FBS or PL supplemented osteogenic medium (OMFBS 
or OMPL, see Table 1). Cells were incubated at 37 °C in a humid atmosphere and 
medium was changed twice a week. On day 28, samples were collected for 
calcium content assay (see detailed method below). 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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2. Materials and methods 
2.1. Cell isolation and culture 
AT-MSCs from two donors (donor 1: 52 years old, female; donor 2: 38 years old, 
male) from passage 4 were used in the experiment. Human subcutaneous adipose 
tissue from the abdomen was obtained from waste material from the Department of 
Plastic Surgery (Tergooi Hospital, Hilversum, the Netherlands) after written 
informed consent. This study complied with the principles of the Declaration of 
Helsinki. 
AT-MSCs isolation was performed as described previously29. Briefly, resected 
tissue was minced using surgical scalpel and scissor and digested with 0.1% 
collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) in phosphate-
buffered saline (PBS; B. Braun, Melsungen, Germany) containing 1% bovine 
serum albumin (BSA; Roche Diagnostics) at 37 °C for 45 min with shaking. The 
digested tissue was centrifuged (600 g) for 10 min and the cell pellet was 
resuspended in 5 ml of PBS/1% BSA and filtered with a 200 µm mesh (Roche 
Diagnostics). Cells were then subjected to a Ficoll density centrifugation step to 
remove erythrocytes and were plated at a density of 100,000 cells/cm2. 
Proliferation medium was used for cell expansion, in which PL was supplemented 
(PMPL, see Table 1). 
HUVECs were obtained from a commercial source (Becton Dickinson Biosciences, 
BD; Breda, the Netherlands) and cultured in endothelial cell culture medium (EM, 
see Table 1) according to instructions from BD. Cells from passage 4 were used for 
cell seeding in the experiment. 
2.2. Optimization of cell ratio in cocultures for osteogenic differentiation 
The experimental procedure of this study is shown schematically in Figure 1. To 
determine the effects of cell ratio on osteogenesis, AT-MSCs and HUVECs were 
(co)cultured on tissue culture 24-well TCPS (Greiner Bio-one, Alphen aan den Rijn, 
the Netherlands) in different ratios varying from 100:0 to 0:100 (n=4) at a seeding 
density of 5,000 cells/cm2 in FBS or PL supplemented osteogenic medium (OMFBS 
or OMPL, see Table 1). Cells were incubated at 37 °C in a humid atmosphere and 
medium was changed twice a week. On day 28, samples were collected for 
calcium content assay (see detailed method below). 
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Figure 1. Schematic structure of the experimental design. OMFBS and OMPL, indicate FBS- and PL-
supplemented osteogenic medium, respectively. 
2.3. Scaffold preparation and cell seeding 
Sintered Ti scaffolds (Bekaert N.V. Zwevegem, Belgium) with a volumetric porosity 
of 86%, density of 600 g/m2, fiber diameter of 50 µm and thickness of 0.8 mm30 
were punched into discs with a diameter of 5 mm. All the discs were sterilized by 
autoclaving and pre-wetted in PMPL overnight before cell seeding. Cells from donor 
2 were used for the below mentioned study. A total of 24 scaffolds were put into a 
5 ml syringe (BD Plastipak), in which 4 ml of OMPL containing a total number of 
24x106 cells of either AT-MSCs or AT-MSCs/HUVECs (50:50) was included. The 
ratio of 50:50 was chosen for the cell seeding on the Ti scaffolds in cocultures for 
both in vitro and in vivo study since it was optimal for osteogenesis based on the 
results from TCPS culture. Cells were seeded by rotating at a speed of 12 rpm/min 
at 37 °C in a humid atmosphere for 3 h. Next, the scaffolds were transferred from 
the syringe into non-adhesive 25-well square plates (Greiner Bio-one). The 
unattached cells from the syringe were resuspended into OMPL, divided and 
dripped onto each scaffold (100 µl) and the scaffolds were incubated for another 2 
h. Subsequently, 1 ml of OMPL was added to each well and medium was changed 
twice a week until sample collection or in vivo implantation. Bare Ti scaffolds that 
were incubated in OMPL were included as a control. 
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2.4. In vitro performance of cultures on Ti scaffolds 
To analyze the cell proliferation and osteogenic differentiation of the seeded cells, 
an in vitro study was performed, in which three groups were included: 
1. Ti (Ti scaffolds without cells); 
2. Ti+Mo (Ti scaffolds seeded with AT-MSCs - monoculture); 
3. Ti+Co (Ti scaffolds seeded with AT-MSCs/HUVECs - coculture). 
Samples (n=2) were analyzed with scanning electron microscopy (SEM) and with 
all other tests (n=4) in vitro. 
2.4.1. Cell metabolic activity 
Cell metabolic activity (day 1, 3 and 7) was measured using AlamarBlue assay 
(Invitrogen; Breda, the Netherlands) as previously described22. In brief, samples 
(n=4) were transferred to new well plates before sample collection. AlamarBlue 
solution was prepared by mixing AlamarBlue with culture medium in a ratio of 1:9 
(v/v). Medium was removed and 1 ml of AlamarBlue solution was added to each 
well, then the plates were incubated (37 °C, 5% CO2) for 4 h. After incubation, 200 
µl of the AlamarBlue solution of each well was transferred to 96-well plates 
(Greiner Bio-one). Fluorescence was measured using a microplate reader (FL 600, 
Bio-Tek, Abcoude, the Netherlands) at 570 nm. The final values for the metabolic 
activity from cell-seeded groups (Ti+Mo, Ti+Co) were calculated by subtracting the 
values from the Ti group. 
2.4.2. Alkaline phosphatase activity and calcium content assay 
ALP-activity and calcium content were assessed for evaluation of the osteogenic 
differentiation. The extracellular ALP-activity was measured in the conditioned 
medium from the cultured scaffolds using an ALP assay kit (p-nitrophenyl 
phosphate, pNPP; Sigma-Aldrich, the Netherlands). For the medium preparation, 
the samples (n=4) were cultured in a precise volume of medium (1.0 ml) and 
medium was collected at indicated time points (day 7, 14 and 21) during medium 
refreshment. The medium was stored at -80°C until the measurement. For the 
calcium content, which was measured using a calcium assay (orthocresolphtalein 
complexone, OCPC; Sigma-Aldrich), scaffolds (n=4) from day 28 were washed 
with PBS, transferred into new wells, followed by adding 1 ml 0.5 N acetic acid into 
each well. The plates were placed on an orbital shaker overnight and stored at -
80°C until the measurement. Both of the assays were performed as previously 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Figure 1. Schematic structure of the experimental design. OMFBS and OMPL, indicate FBS- and PL-
supplemented osteogenic medium, respectively. 
2.3. Scaffold preparation and cell seeding 
Sintered Ti scaffolds (Bekaert N.V. Zwevegem, Belgium) with a volumetric porosity 
of 86%, density of 600 g/m2, fiber diameter of 50 µm and thickness of 0.8 mm30 
were punched into discs with a diameter of 5 mm. All the discs were sterilized by 
autoclaving and pre-wetted in PMPL overnight before cell seeding. Cells from donor 
2 were used for the below mentioned study. A total of 24 scaffolds were put into a 
5 ml syringe (BD Plastipak), in which 4 ml of OMPL containing a total number of 
24x106 cells of either AT-MSCs or AT-MSCs/HUVECs (50:50) was included. The 
ratio of 50:50 was chosen for the cell seeding on the Ti scaffolds in cocultures for 
both in vitro and in vivo study since it was optimal for osteogenesis based on the 
results from TCPS culture. Cells were seeded by rotating at a speed of 12 rpm/min 
at 37 °C in a humid atmosphere for 3 h. Next, the scaffolds were transferred from 
the syringe into non-adhesive 25-well square plates (Greiner Bio-one). The 
unattached cells from the syringe were resuspended into OMPL, divided and 
dripped onto each scaffold (100 µl) and the scaffolds were incubated for another 2 
h. Subsequently, 1 ml of OMPL was added to each well and medium was changed 
twice a week until sample collection or in vivo implantation. Bare Ti scaffolds that 
were incubated in OMPL were included as a control. 
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2.4. In vitro performance of culture  on Ti scaffolds 
To analyze the cell proliferation and osteogenic differentiation of the seeded cells, 
an in vitro study was performed, in which three groups were included: 
1. Ti (Ti scaffolds without cells); 
2. Ti+Mo (Ti scaffolds seeded with AT-MSCs - monoculture); 
3. Ti+Co (Ti scaffolds seeded with AT-MSCs/HUVECs - coculture). 
Samples (n=2) were analyzed with scanning electron microscopy (SEM) and with 
all other tests (n=4) in vitro. 
2.4.1. Cell metabolic activity 
Cell metabolic activity (day 1, 3 and 7) was measured using AlamarBlue assay 
(Invitrogen; Breda, the Netherlands) as previously described22. In brief, samples 
(n=4) were transferred to new well plates before sample collection. AlamarBlue 
solution was prepared by mixing AlamarBlue with culture medium in a ratio of 1:9 
(v/v). Medium was removed and 1 ml of AlamarBlue solution was added to each 
well, then the plates were incubated (37 °C, 5% CO2) for 4 h. After incubation, 200 
µl of the AlamarBlue solution of each well was transferred to 96-well plates 
(Greiner Bio-one). Fluorescence was measured using a microplate reader (FL 600, 
Bio-Tek, Abcoude, the Netherlands) at 570 nm. The final values for the metabolic 
activity from cell-seeded groups (Ti+Mo, Ti+Co) were calculated by subtracting the 
values from the Ti group. 
2.4.2. Alkaline phosphatase activity and calcium content assay 
ALP-activity and calcium content were assessed for evaluation of the osteogenic 
differentiation. The extracellular ALP-activity was measured in the conditioned 
medium from the cultured scaffolds using an ALP assay kit (p-nitrophenyl 
phosphate, pNPP; Sigma-Aldrich, the Netherlands). For the medium preparation, 
the samples (n=4) were cultured in a precise volume of medium (1.0 ml) and 
medium was collected at indicated time points (day 7, 14 and 21) during medium 
refreshment. The medium was stored at -80°C until the measurement. For the 
calcium content, which was measured using a calcium assay (orthocresolphtalein 
complexone, OCPC; Sigma-Aldrich), scaffolds (n=4) from day 28 were washed 
with PBS, transferred into new wells, followed by adding 1 ml 0.5 N acetic acid into 
each well. The plates were placed on an orbital shaker overnight and stored at -
80°C until the measurement. Both of the assays were performed as previously 
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described22. Values of the ALP-activity in cell-seeded groups were corrected by 
subtracting the values from Ti only group. 
2.4.3. SEM 
SEM was used to evaluate morphological aspects during cell culture. Cells were 
cultured on the scaffolds for 7 days in OMPL (i.e. the day of implantation in vivo), 
rinsed with filtered PBS, and fixed in 2% glutaraldehyde for 10 min. Then, the 
samples (n=2) were washed with 0.1 M sodium-cacodylate for 10 min, dehydrated 
in a graded series of ethanol, and dried with tetramethylsilane (Merck, Frankfurt, 
Germany). Examinations from both overview and cross-sections of the samples 
were performed using a SEM (JEOL 6340F, Peabody, USA) after deposition of a 
sputter-coated gold layer. 
2.5. In vivo experiment design 
Ten healthy 9-week old male athymic nude rats (Crl:NIH-Foxn1rnu, Charles River), 
weighing between 250 g and 300 g, were used for the in vivo study. The 
experiment was performed according to national guidelines and after ethical 
approval by the Animal Ethical Committee (RU-DEC 2011-140). 
Cells were seeded onto Ti scaffolds as described above and cultured for 7 days in 
vitro, after which the constructs were randomly distributed over and implanted in 
the cranial defects in the animals. Four groups (n=5) were defined: 
1. Ti (Ti scaffold without cells); 
2. Ti+Mo (Ti scaffold seeded with AT-MSCs - monoculture); 
3. Ti+Co (Ti scaffold seeded with AT-MSCs/HUVECs - coculture); 
4. Empty (no scaffold, no cells). 
To prevent soft tissue ingrowth into the defect area, a custom-made electrospun 
polycaprolactone/gelatin membrane31 with a diameter of 8 mm was placed on top 
of the cranial defects. These membranes were sterilized by ethylene oxide gas 
(Synergy health, Venlo, the Netherlands) before use. 
2.5.1. Surgical procedure 
For surgery, the animals were pre-medicated by subcutaneous injection of 
carprofen (5 mg/kg; Rimadyl®, Pfizer Animal Health B.V., Capelle aan de IJssel, 
Netherlands) to reduce operative pain. Surgery was performed under general 
anesthesia with nitrous oxide, oxygen, and isoflurane. The animals were placed in 
a ventral position and the dorsal part of the rat cranium was shaved and disinfected 
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with povidone-iodine. A median sagittal incision was made in the soft tissue 
including the periosteum, lidocaine HCl 1% (B. Braun, Melsungen, Germany) was 
sprayed onto the periosteum to minimize pain, and the parietal bone was exposed. 
Bilateral full-thickness cranial defects with a diameter of 5 mm were made using a 
hollow trephine bur (Hager & Meisinger GmbH, Neuss, Germany) at low rotational 
speed, with saline irrigation. The defects were either treated with a construct and 
covered with an electrospun membrane, or left empty. Afterwards, the soft tissues 
were closed in two layers with 5-0 and 4-0 Vicryl® resorbable sutures. After surgery, 
subcutaneous injections of buprenorphine (150 mg/kg; Temgesic®, Schering-
Plough, Amstelveen, the Netherlands) were given for 2 days to reduce 
postoperative pain. 
2.5.2. Explantation and microcomputed tomography (micro-CT) 
Eight weeks after implantation, the animals were euthanized using CO2 suffocation. 
The craniums with the surrounding tissue were retrieved. Next, the specimens 
were fixed in 10% neutral formalin for 48 h and transferred into 70% ethanol for 
micro-CT scanning. Three samples (n=3) randomly selected from each group were 
used for micro-CT imaging to qualitatively visualize implant location and bone 
formation. The harvested cranial bone defects were imaged using a high resolution 
SkyScan-1172 micro-CT imaging system (SkyScan, Aartselaar, Belgium). For each 
sample, a total of 1023 micro-tomographic slices were obtained using a slice 
increment of 20 μm in order to scan the whole defect (5 mm) area. Then, a cone 
beam reconstruction was performed on the projected files using Nrecon V1.5 
(SkyScan, Kontich, Belgium). Finally, a 3D-reconstruction of the defect was 
obtained by using 3D creator software as previously described32. 
2.5.3. Histological and histomorphometrical evaluation 
After fixation, the specimens were dehydrated in a graded series of ethanol and 
embedded in methylmethacrylate. Thin sections (10 µm; 3 per specimen) were 
prepared perpendicularly to the plane of the defect31 using a histological diamond 
saw (Leica Microsystems SP 1600, Nussloch, Germany) and stained with 
methylene blue/basic fuchsin. 
All histological sections (n = 3 per implant) were photographed with the Zeiss 
Imager Z1 microscope equipped with the AxioCam MRc5 camera using AxioVision 
4.8 software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). The bone 
forming capacity of animals in each group was analyzed. Furthermore, 
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addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
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 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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histomorphometrical evaluation was performed to quantify bone formation within 
the three experimental groups (Ti, Ti+Mo, and Ti+Co) according to previously 
described31. Empty defects were included as biological control and used to confirm 
that the defects were critical-sized, and hence excluded from histomorphometrical 
evaluation. In brief, the sections were scored using computer-based image 
analysis techniques (Leica® Qwin Proimage analysis system, Wetzlar, Germany), 
which recognize bone tissue from the titanium fiber mesh based on different RGB 
values from highly magnified digitalized images. Manual corrections were applied 
to ensure the precise selection of newly formed bone tissue within the defect area. 
The bone amount was normalized by dividing the bone volume (µm2) inside the 
scaffold by the defect length (µm) measured from the cross-section, and three 
sections per specimen were measured and averaged. 
2.6. Statistical analysis 
Data were expressed as mean ± standard deviation. SPSS 18.0 (SPSS, Chicago, 
USA) and Graphpad Instat software (Instat® 3.05, Graphpad Software Inc., La Jolla, 
USA) were used for statistical analysis. For in vitro data, an independent t-test was 
performed to compare Ti+Mo and Ti+Co. A one-way ANOVA with posthoc (Tukey 
HSD or Dunnett) test was used for the other comparisons. For in vivo bone 
formation analysis, a Chi-square test was applied to assess bone forming capacity. 
A one-way ANOVA with posthoc Tukey HSD test was applied to compare bone 
formation. Further, an independent t-test was performed to investigate the 
differences between Ti+Mo and Ti+Co. 
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3. Results 
3.1. Optimization of cell ratio in cocultures for osteogenic differentiation 
Cells from both donors showed a similar trend regarding the calcium content on 
day 28 in TCPS (Figure 2). Significantly higher mineralization was observed in 
OMPL compared to that in OMFBS for both two donors. 
 
Figure 2. Effects of cell ratio on osteogenesis in vitro. Calcium content (day 28, n=4) of cells cultured on 
tissue culture plates from two donors (donor 1 and donor 2, indicated as A and B, respectively) are 
shown. *, p<0.05; **, p<0.01; ***, p<0.001. 
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still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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shown. *, p<0.05; **, p<0.01; ***, p<0.001. 
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For donor 1 (Figure 2A), cells only mineralized in OMPL with significant differences 
(p<0.01) between AT-MSCs and HUVECs monocultures. For donor 2 (Figure 2B), 
mineralization was observed for cells cultured in both OMFBS and OMPL, with 
significantly higher mineralization for OMPL equivalents (p<0.001), except for 
HUVECs monocultures. Moreover, irrespective of culture medium, the coculture 
ratios with less than 50% AT-MSCs demonstrated significantly decreased 
mineralization compared to AT-MSCs monocultures. 
3.2. In vitro performance of cultures on Ti scaffolds 
A significant increase of cell metabolic activity (Figure 3) was found from day 1 to 7 
for Ti+Mo, but not for Ti+Co. Comparison of metabolic activity between Ti+Mo and 
Ti+Co at individual time points showed significantly lower (p<0.05) values on day 1, 
but significantly higher values on days 3 (p<0.05) and 7 (p<0.001) for Ti+Mo. 
 
Figure 3. Cell metabolic activity (n=4) of AT-MSCs monocultures (Ti+Mo) and AT-MSCs/HUVECs 
cocultures (Ti+Co) on porous titanium fiber mesh in vitro. Cells from donor 2 were used. *, p<0.05; ***, 
p<0.001. 
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For both Ti+Mo and Ti+Co, the ALP-activity reached a peak around culture day 14, 
after which ALP-activity decreased. The ALP-activity for Ti+Mo was significantly 
higher on both day 7 (p<0.05) and 14 (p<0.01) compared to Ti+Co (Figure 4A). 
The calcium content on day 28 was significantly higher for Ti+Mo compared to 
Ti+Co (p<0.01, Figure 4B). 
 
Figure 4. Osteogenic differentiation (n=4) of AT-MSCs monocultures (Ti+Mo) and AT-MSCs/HUVECs 
cocultures (Ti+Co) on porous titanium fiber mesh in vitro. Cells from donor 2 were used. (A) ALP-activity; 
(B) calcium content on day 28. *, p<0.05; **, p<0.01. 
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mineralization was observed for cells cultured in both OMFBS and OMPL, with 
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3.2. In vitro performance of cultures on Ti scaffolds 
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for Ti+Mo, but not for Ti+Co. Comparison of metabolic activity between Ti+Mo and 
Ti+Co at individual time points showed significantly lower (p<0.05) values on day 1, 
but significantly higher values on days 3 (p<0.05) and 7 (p<0.001) for Ti+Mo. 
 
Figure 3. Cell metabolic activity (n=4) of AT-MSCs monocultures (Ti+Mo) and AT-MSCs/HUVECs 
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Figure 4. Osteogenic differentiation (n=4) of AT-MSCs monocultures (Ti+Mo) and AT-MSCs/HUVECs 
cocultures (Ti+Co) on porous titanium fiber mesh in vitro. Cells from donor 2 were used. (A) ALP-activity; 
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SEM images demonstrated the structure of the bare Ti scaffolds as well as 
homogenous cell distribution on the surface and cell ingrowth into the scaffolds for 
both Ti+Mo and Ti+Co (Figure 5). Cells clearly covered the surface of the Ti 
scaffolds, whereas cross-sections displayed the presence of cells throughout the 
porous structure of the Ti scaffolds. 
 
Figure 5. Representative scanning electron microscopy (SEM) images (n=2) of Ti, AT-MSCs 
monocultures (Ti+Mo) and AT-MSCs/HUVECs cocultures (Ti+Co) on porous titanium fiber mesh in vitro 
on day 7. Cells from donor 2 were used. Arrows indicate cell layer. 
3.3. In vivo experiment 
3.3.1. General observations 
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All animals recovered uneventfully from the surgery and no infections or 
complications occurred during the implantation period. All samples (n=5 per group) 
were retrieved and at retrieval, no macroscopic signs of inflammation or adverse 
tissue response in the defect area were observed. Further, all Ti scaffolds were still 
covered with the membrane and had remained in situ inside the defects. 
3.3.2. Micro-CT 
The implant location and bone formation in the skull defects (n = 3, randomly 
selected) was imaged with micro-CT. The micro-CT images (Figure 6) showed no 
bone formation for empty controls after 8 weeks implantation. Due to scattering of 
the titanium fiber mesh, reliable quantification of bone formation within the cranial 
defect was not possible. 
3.3.3. Descriptive histology 
Histological sections for each experimental group are presented in Figure 6. In 
general, none of the specimens showed the presence of an inflammatory response. 
The Ti scaffolds remained inside the defects and the membrane still covered the 
defect area from the cranial side and stayed intact in the defect area. For Ti, Ti+Mo 
and Ti+Co, the porous structure of the Ti scaffold was filled with fibrous as well as 
bone tissue (Figure 6). Instead, for those defects in which bone formation was not 
shown, only fibrous tissue was observed in the porous structure (data not shown). 
In contrast, in empty defects, except that a small amount of bone was found in only 
one defect (data not shown), no bone formation was observed in the other defects 
(Figure 6). At higher magnification (Figure 7), osteocyte-like cells were clearly 
visible within the newly formed bone tissue. Additionally, blood vessels containing 
erythrocytes were frequently observed inside the Ti scaffold for Ti, Ti+Mo, and 
Ti+Co. 
3.3.4. Bone forming capacity 
The bone forming capacity for each experimental group is presented in Table 2. 
Bone formation was observed in 3 out of 5 samples for Ti, 2 out of 5 samples for 
Ti+Mo, and 2 out of 5 samples for Ti+Co group. In empty defects, 1 out of 5 
samples demonstrated bone formation. Statistical analysis using a Chi-square test 
demonstrated no significant differences (p>0.05) for bone forming capacity. 
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scaffolds, whereas cross-sections displayed the presence of cells throughout the 
porous structure of the Ti scaffolds. 
 
Figure 5. Representative scanning electron microscopy (SEM) images (n=2) of Ti, AT-MSCs 
monocultures (Ti+Mo) and AT-MSCs/HUVECs cocultures (Ti+Co) on porous titanium fiber mesh in vitro 
on day 7. Cells from donor 2 were used. Arrows indicate cell layer. 
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complications occurred during the implantation period. All samples ( =5 per group) 
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covered with the membrane and had remained in situ inside the defects. 
3.3.2. Micro-CT 
The impla t location and bone forma ion in the sku l def cts (n = 3, randomly 
s lected) was imaged with micro-CT. The micro-CT images (Figure 6) showed no 
bone formation for empty controls after 8 weeks implantation. Due to scattering of 
the titanium fiber mesh, reliable quantification of bone formation within the cranial 
defect was not possible. 
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Histological sections for each experimental group are presented in Figure 6. In 
general, none of the specimens showed the presence of an inflammatory response. 
The Ti scaffolds remained inside the defects and the membrane still covered the 
defect area from the cranial side and stayed intact in the defect area. For Ti, Ti+Mo 
and Ti+Co, the porous structure of the Ti scaffold was filled with fibrous as well as 
bone tissue (Figure 6). Instead, for those defects in which bone formation was not 
shown, only fibrous tissue was observed in the porous structure (data not shown). 
In contrast, in empty defects, except that a small amount of bone was found in only 
one defect (data not shown), no bone formation was observed in the other defects 
(Figure 6). At higher magnification (Figure 7), osteocyte-like cells were clearly 
visible within the newly formed bone tissue. Additionally, blood vessels containing 
erythrocytes were frequently observed inside the Ti scaffold for Ti, Ti+Mo, and 
Ti+Co. 
3.3.4. Bone forming capacity 
The bone forming capacity for each experimental group is presented in Table 2. 
Bone formation was observed in 3 out of 5 samples for Ti, 2 out of 5 samples for 
Ti+Mo, and 2 out of 5 samples for Ti+Co group. In empty defects, 1 out of 5 
samples demonstrated bone formation. Statistical analysis using a Chi-square test 
demonstrated no significant differences (p>0.05) for bone forming capacity. 
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Figure 6. Micro-CT (n=3) and histology images (n=5) from methylene blue/basic fuchsin staining after 8 
weeks in vivo implantation of constructs without (Ti) or with AT-MSCs monocultures (Ti+Mo) or with AT-
MSCs/HUVECs cocultures (Ti+Co) as well as empty controls (Empty). Cells from donor 2 were used. 
Dashed lines indicate the original defect area. m, membrane; b, new bone; f, fibrous tissue. 
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Figure 7. Magnified images (n=5) for bone and blood vessel formation from methylene blue/basic 
fuchsin staining after 8 weeks in vivo implantation of constructs without (Ti) or with AT-MSCs 
monocultures (Ti+Mo) or with AT-MSCs/HUVECs cocultures (Ti+Co). Cells from donor 2 were used. ↑, 
indicates osteocyte-like cells; *, indicates erythrocytes. 
 
Table 2. Bone forming capacity after 8 weeks in vivo implantation 
Groups Ability of animals showing bone formationa 
Ti 3/5 
Ti+Mo 2/5 
Ti+Co 2/5 
Empty 1/5 
a Chi-square analysis indicated no statistical difference (p>0.05) among all the groups regarding 
the capacity of animals showing bone formation. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3.3.5. Histomorphometry 
After the bone forming capacity was evaluated, histomorphometrical evaluation for 
only the samples with bone formation for Ti, Ti+Mo, and Ti+Co were performed 
(Figure 8). The total amount of bone formation in Ti, Ti+Mo and Ti+Co group was 
57 ± 39 µm2 (bone area)/µm (defect length), 151 ± 21 µm2/µm and 44 ± 11 µm2/µm, 
respectively. The 95% confidence interval for the comparison of Ti+Mo vs. Ti+Co, 
Ti+Mo vs. Ti, and Ti+Co vs. Ti was (8; 206) µm2/µm, (-6; 194) µm2/µm and (-108; 
82) µm2/µm, respectively. Statistical analysis indicated a difference (p<0.05) 
between Ti+Mo and Ti+Co. 
 
Figure 8. Histomorphometrical analysis of bone formation in the cranial defects after 8 weeks in vivo 
implantation of constructs without (Ti, n=3) or with AT-MSCs monocultures (Ti+Mo, n=2) or with AT-
MSCs/HUVECs cocultures (Ti+Co, n=2). Cells from donor 2 were used. ■, ◆ and ▲ represent the actual 
values of bone amount from the samples with bone formation in each group. *, p<0.05. 
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4. Discussion 
The aim of this study was to compare the in vitro osteogenic capacity as well as 
the in vivo bone forming capacity between AT-MSCs monocultures and AT-
MSCs/HUVECs cocultures on porous titanium fiber mesh scaffolds. It was 
hypothesized that AT-MSCs/HUVECs cocultures enhance osteogenesis and 
induce more bone formation in comparison to AT-MSCs monocultures. First, the 
optimal cell ratio in coculture was determined by seeding AT-MSCs and HUVECs 
in different ratios (100:0-0:100) on tissue culture plates and measuring the calcium 
deposition after 28 days. Then, porous titanium fiber mesh scaffolds were seeded 
with monocultures and cocultures and cultured in vitro for 7 days, after which the 
constructs were implanted in rat bilateral cranial defects for a period of 8 weeks. 
Although donor variability existed, a coculture ratio of 50:50 was considered as 
lowest ratio at which a similar level of mineralization was retained compared to AT-
MSCs monocultures. Further, constructs containing AT-MSCs induced higher 
osteogenic differentiation in vitro and more bone formation in vivo compared to 
equivalents with AT-MSCs/HUVECs cocultures. No difference of the bone forming 
capacity was observed among all the groups, but in case of bone formation, AT-
MSCs formed more bone than AT-MSCs/HUVECs cocultures. 
Irrespective of the cell ratio or the medium supplement (FBS or PL), AT-MSCs in 
the monoculture displayed equal or superior osteogenesis compared to the cells in 
coculture. Nevertheless, the 50:50 ratio was chosen for further (in vitro and in vivo) 
studies since equal levels of mineralization as for AT-MSCs monocultures was 
observed while only half the number of AT-MSCs were used for these cocultures. 
This is consistent with previous results, which demonstrated equal osteogenic 
capacity of 50:50 ratio cocultures of rat AT-MSCs with rat cord blood ECs (in 
proliferation medium) in vitro compared to monocultures33. Further, these results 
corroborate with those of monocultures and cocultures of human BM-MSCs with 
HUVECs22. PL was included as a safe and alternative substitute of FBS34 and to 
avoid the risk of transmitting animal pathogens35-36. PL supplementation to the 
medium corroborated previous results37, showing superior in vitro mineralization 
compared to FBS supplementation for both AT-MSCs monocultures and all studied 
ratios of AT-MSCs/HUVECs cocultures. 
Osteogenic capacity in vitro and bone formation in vivo were consistently 
decreased for AT-MSCs/HUVECs cocultures compared to AT-MSCs monocultures. 
The reason for this lack of enhancement of osteogenesis remains unclear, 
although it can be speculated that several issues apply. Firstly, although equal total 
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host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
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such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
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 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3.3.5. Histomorphometry 
After the bone forming capacity was evaluated, histomorphometrical evaluation for 
only the samples with bone formation for Ti, Ti+Mo, and Ti+Co were performed 
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in different ratios (100:0-0:100) on tissue culture plates and measuring the calcium 
deposition after 28 days. Then, porous titanium fiber mesh scaffolds were seeded 
with monocultures and cocultures and cultured in vitro for 7 days, after which the 
constructs were implanted in rat bilateral cranial defects for a period of 8 weeks. 
Although donor variability existed, a coculture ratio of 50:50 was considered as 
lowest ratio at which a similar level of mineralization was retained compared to AT-
MSCs monocultures. Further, constructs containing AT-MSCs induced higher 
osteogenic differentiation in vitro and more bone formation in vivo compared to 
equivalents with AT-MSCs/HUVECs cocultures. No difference of the bone forming 
capacity was observed among all the groups, but in case of bone formation, AT-
MSCs formed more bone than AT-MSCs/HUVECs cocultures. 
Irrespective of the cell ratio or the medium supplement (FBS or PL), AT-MSCs in 
the monoculture displayed equal or superior osteogenesis compared to the cells in 
coculture. Nevertheless, the 50:50 ratio was chosen for further (in vitro and in vivo) 
studies since equal levels of mineralization as for AT-MSCs monocultures was 
observed while only half the number of AT-MSCs were used for these cocultures. 
This is consistent with previous results, which demonstrated equal osteogenic 
capacity of 50:50 ratio cocultures of rat AT-MSCs with rat cord blood ECs (in 
proliferation medium) in vitro compared to monocultures33. Further, these results 
corroborate with those of monocultures and cocultures of human BM-MSCs with 
HUVECs22. PL was included as a safe and alternative substitute of FBS34 and to 
avoid the risk of transmitting animal pathogens35-36. PL supplementation to the 
medium corroborated previous results37, showing superior in vitro mineralization 
compared to FBS supplementation for both AT-MSCs monocultures and all studied 
ratios of AT-MSCs/HUVECs cocultures. 
Osteogenic capacity in vitro and bone formation in vivo were consistently 
decreased for AT-MSCs/HUVECs cocultures compared to AT-MSCs monocultures. 
The reason for this lack of enhancement of osteogenesis remains unclear, 
although it can be speculated that several issues apply. Firstly, although equal total 
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cell numbers were used in AT-MSCs monocultures and AT-MSCs/HUVECs 
cocultures, less AT-MSCs were used in cocultures compared to monocultures, 
which could explain the lower osteogenic capacity. In addition, previous coculture 
studies with AT-MSCs used different media and showed large outcome variation. 
Consequently, culture medium may also affect osteogenesis. For instance, when 
using proliferation medium as (co)culture medium, Wang et al. observed improved 
osteogenic differentiation in AT-MSCs/HUVECs cocultures over AT-MSCs in 
TCPS38. In a recent study, two culture media were used for two culture groups, i.e. 
osteogenic medium for AT-MSCs and a 50:50 mixture of osteogenic medium with 
endothelial culture medium for rat AT-MSCs/ECs (50:50 ratio). Consistent with our 
results, those cocultures did not increase bone formation in comparison to 
monocultures after 8 weeks in vivo implantation into 8-mm rat cranial defects39, 
indicating that such a mixed culture medium also does not increase the bone 
formation for cocultures. Osteogenic medium was used in the present study 
because it was previously shown to be beneficial for both osteogenic differentiation 
of AT-MSCs40 and ECs growth and maturation41. Finally, the response of AT-MSCs 
to bone morphogenetic protein-2 (BMP-2), one of the main growth factors that are 
secreted by ECs42, is unclear. While some researchers observed enhanced 
osteogenic differentiation of AT-MSCs by short (15 min) stimulation with BMP-243-44, 
others found that the osteogenic fate of AT-MSCs might not be influenced by BMP-
245-46, for which the cellular cross-talk with angiogenic cells in cocultures can be 
decreased compared to equivalents with BM-MSCs. Nevertheless, it is necessary 
to address that varying the scaffold material and properties might increase 
mineralization and bone formation of such constructs while the system used in this 
study did not yield efficacious results, demonstrating possible effects of research 
systems on the cocultures using AT-MSCs. 
Constructs containing cells (i.e. either monocultures or cocultures) did not show 
significantly more bone formation than bare titanium scaffolds, which is probably 
related to the relatively low capacity and high variation in bone formation. The 
empty defect did not heal within the implantation time, confirming the previous 
studies that a 5-mm diameter defect is of critical-size for a period of 8 weeks31,47. In 
view of bone and vessel formation in cell containing constructs, it is interesting to 
address specifically the source of newly formed bone (i.e. donor or host origin) as 
well as the contribution of the seeded endothelial cells. Nevertheless, due to the 
embedding method necessary for the hard titanium scaffolds and the relative thick 
sections (10 μm) that are thereby produced, it is not possible to do staining to 
further distinguish the origin of the newly formed bone and vessels. Nevertheless, it 
has been reported that AT-MSCs/ECs cocultures can induce vascular network 
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formation in vitro48 and maintain the specific endothelial markers expression in 
vivo23. 
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5. Conclusions 
The results of this study demonstrate that the ratio of 50:50 for AT-MSCs/HUVECs 
cocultures was the threshold to obtain equal levels of mineralization compared to 
AT-MSCs monocultures in vitro. Further, osteogenic medium supplemented with 
PL displayed higher mineralization in comparison to FBS supplementation, for both 
AT-MSCs monocultures and all ratios of AT-MSCs/HUVECs cocultures. When 
seeded on porous titanium fiber mesh scaffolds, AT-MSCs showed higher 
osteogenic differentiation in vitro and more bone formation in vivo compared to AT-
MSCs/HUVECs cocultures. However, the present study cannot ascertain the 
contribution of the seeded cells to the newly formed bone, for which future 
research is needed. The outcome of the current study suggests that the use of 
cocultures of AT-MSCs/HUVECs in clinical applications would not prove beneficial 
since it has not been demonstrated in the animal study to improve bone formation 
in comparison to AT-MSCs monocultures. 
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 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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5. Conclusions 
The results of this study demonstrate that the ratio of 50:50 for AT-MSCs/HUVECs 
cocultures was the threshold to obtain equal levels of mineralization compared to 
AT-MSCs monocultures in vitro. Further, osteogenic medium supplemented with 
PL displayed higher mineralization in comparison to FBS supplementation, for both 
AT-MSCs monocultures and all ratios of AT-MSCs/HUVECs cocultures. When 
seeded on porous titanium fiber mesh scaffolds, AT-MSCs showed higher 
osteogenic differentiation in vitro and more bone formation in vivo compared to AT-
MSCs/HUVECs cocultures. However, the present study cannot ascertain the 
contribution of the seeded cells to the newly formed bone, for which future 
research is needed. The outcome of the current study suggests that the use of 
cocultures of AT-MSCs/HUVECs in clinical applications would not prove beneficial 
since it has not been demonstrated in the animal study to improve bone formation 
in comparison to AT-MSCs monocultures. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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1. Introduction 
The worldwide incidence (i.e. 2.2 million annually1) of bone disorders and bone 
defects has increased substantially and is expected to double by 20202. The 
potential of bone regeneration strategies becomes especially challenging under 
compromised conditions, such as patients with medically compromised conditions 
(e.g. osteoporosis, diabetes and cancer), or in case of critical size bone defects 
and bone defects cannot heal spontaneously2. The gold standard of current 
therapeutic strategies is autologous bone grafts. However, the limitation in bone 
amount to be harvested and donor site morbidity (e.g. pain and infection) are 
disadvantageous for the clinical use of autologous bone grafts. The use of 
allografts can avoid these disadvantages, but is associated with risks of disease 
transmission or immunogenic rejection3. Bone tissue engineering and regenerative 
medicine (BTE/RM), using constructs based on combinations of scaffolds, cells, 
and growth factors are considered as a promising alternative approach to repair 
bone defects. 
Bone morphogenetic protein 2 (BMP-2) is the most extensively studied 
osteoinductive factor4 and is currently available via recombinant technology-based 
production methods. Recombinant human (rh)BMP-2 has been widely used as a 
component in several commercially available bone regenerative products (e.g. 
Infuse® and Amplify™ Matrix), which have received FDA-approval for several 
clinical applications, such as spinal fusion5, treatments of cleft lip and palate6, and 
maxillofacial bone defects7-8. 
Mesenchymal stem cells (MSCs) represent the high potential cell type for bone 
regeneration9 as a result of the multipotential differentiation capacity including 
differentiation into the osteogenic lineage10. Despite of the exciting outcomes in 
animal studies, in which bone regeneration was demonstrated using human 
MSCs11-12, the application of human MSCs in a clinical setting is far behind. Since 
mid 2012, there is only one approved stem cell product on the market in the United 
States (Hemacord®, i.e. hematopoietic progenitor cells from cord blood for patients 
with disorders affecting the hematopoietic system) and only one approved stem 
cell drug in Canada (Prochymal®, i.e. a stem cell therapy based on allogenic MSCs 
to treat acute graft-vs-host disease)13. To date, no stem cell-based product is 
available for bone regeneration, although both clinical trials and few unlicensed 
human MSCs treatments have been carried out14. For bone regeneration in clinical 
applications, beyond the safety and efficacy aspects, vascularization plays an 
essential role. Insufficient vascularization caused by the slow rate (<1 mm/day) of 
blood vessel infiltration into the tissue-engineered constructs hampers cell survival 
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and successful integration of the graft15. Coculture of MSCs with endothelial 
(progenitor) cells (ECs) has attracted most attention in strategies that seek rapid 
vascularization16. Surprisingly, such cocultures were demonstrated to induce 
higher in vitro mineralization17 and more in vivo bone formation18-19 compared to 
MSCs monocultures, but no clinical data are available yet. Adipose tissue-derived 
MSCs (AT-MSCs) were explored within the last decade20 due to the easy handling 
in cell harvesting and high cell yields reviewed previously21-22. Limited data are 
available on cocultures using AT-MSCs in combination with ECs. 
The apparent unsatisfactory bone regenerative capacity of human MSCs in clinics 
leads to an interest in analyzing the potential causative mechanisms. The earlier 
mentioned lack of vascular supply and related cell death after implantation23, is 
suggested to be a major cause of failure of BTE/RM in patients24. From this, it is 
straightforward to assume that different implantation sites, which differ in blood flow 
and thereby oxygen, nutrition supply and waste products removal25, influence the 
bone forming capacity of BTE/RM constructs. Experimentally, ectopic implantation 
models have been used tremendously for the evaluation of osteoinductive 
scaffolds, bone-forming stem cells, and growth factors. Subcutaneous (SQ) and 
intramuscular (IM) implantation are the two mainly used ectopic models, for which 
vascularization (IM>SQ) has been regarded as the predominant difference25. 
The aim of this study was to compare the effect of implantation site (i.e. SQ vs. IM) 
on the bone forming capacity of cell- and growth factor-based constructs in athymic 
nude rats after 8 weeks implantation. We hypothesized that IM implantation would 
induce higher amounts of bone formation compared to SQ implantation, 
irrespective of the scaffolds used, owing to an increased vascularization in muscle 
tissue compared to SQ connective tissue. Porous hydroxyapatite/tricalcium 
phosphate (HA/TCP) was used as a scaffold, with either pre-cultured (7 days in 
osteogenic medium) AT-MSCs or AT-MSCs/HUVECs to generate cell-based 
constructs or pre-adsorbed BMP-2 (20 µg/scaffold) to generate growth factor-
based constructs. Histological and histomorphometrical analysis were used to 
assess bone formation. A differentiation experiment was performed in parallel in 
vitro to compare the osteogenic capacity of cell-based constructs. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
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2. Materials and methods 
2.1. Experimental set-up 
The experimental set-up is schematically represented in Figure 1. An in vitro 
parallel study was used to compare the osteogenic capacity of AT-MSCs and AT-
MSCs/HUVECs cultured on HA/TCP scaffolds. To further compare the bone 
forming capacity in the two implantation sites (SQ and IM), HA/TCP scaffolds 
combined with either cells (AT-MSCs or AT-MSCs/HUVECs) or growth factor 
(BMP-2) were implanted in athymic nude rats for 8 weeks and bone formation was 
assessed histologically and histomorphometrically. 
Figure 1. Schematic representation of the experimental design. SQ, subcutaneous; IM, intramuscular.  
2.2. Cell isolation and culture 
Human subcutaneous adipose tissue from the abdomen was obtained from waste 
material from the Department of Plastic Surgery (Tergooi Hospital, Hilversum, the 
Netherlands) after written informed consent. This study complied with the principles 
of the Declaration of Helsinki. 
AT-MSCs isolation was performed according to a previously described protocol26. 
Briefly, resected tissue was minced using surgical scalpel and scissor and digested 
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with 0.1% collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) in 
phosphate-buffered saline (PBS; B. Braun, Melsungen, Germany) containing 1% 
bovine serum albumin (BSA; Roche Diagnostics) at 37 °C for 45 min with shaking. 
The digested tissue was centrifuged (600 g) for 10 min and the cell pellet was 
resuspended in 5 ml of PBS/1% BSA and filtered with a 200 µm mesh (Roche 
Diagnostics). Cells were then subjected to a Ficoll density centrifugation step to 
remove erythrocytes and were plated at a density of 100,000 cells/cm2. 
Proliferation medium was used for cell expansion, in which human platelet lysate 
(PL) was supplemented (PM, see Table 1) because PL-supplementation in 
medium has been proved to be optimal for AT-MSCs culture27. AT-MSCs from 1 
donor (female, 38 years old) from passage 4 were used in the experiment. These 
cells have been confirmed to mineralize in vitro according to our previous study27. 
HUVECs were obtained from a commercial source (Becton Dickinson Biosciences, 
BD; Breda, the Netherlands) and cultured in endothelial cell culture medium (EM, 
see Table 1) according to instructions from BD. Cells from passage 7 were used in 
the experiment. 
2.3. Scaffold preparation and cell seeding 
Porous cubic biphasic 75% HA/ 25 % β-TCP ceramic scaffolds (Camceram®; 3 x 3 
x 3 mm; CAM Bioceramics BV, Leiden, the Netherlands) with a volumetric porosity 
of ~75%, and a pore diameter ranging from 100 to 500 mm were used in this study. 
The scaffolds were sterilized by autoclaving and pre-wetted in 50% fetal bovine 
serum (in alpha minimum essential medium) overnight before cell seeding. A total 
of 30 scaffolds were put into a 20 ml syringe (BD Plastipak), in which 10 ml of 
osteogenic medium (OM, see Table 1) containing a total number of 30x106 cells 
(AT-MSCs or AT-MSCs/HUVECs (50:50)) was included. AT-MSCs and HUVECs 
were seeded at a ratio of 50:50 (previously demonstrated optimal for 
osteogenesis28). Cells were seeded by rotating at a speed of 12 rpm/min at 37 °C 
in a humid atmosphere for 3 h. Next, the cell-based scaffolds were transferred from 
the syringe into non-adhesive 25-well square plates (Greiner Bio-one). The 
unattached cells from the syringe were resuspended into OM, divided and dripped 
onto each scaffold (50 µl) and the scaffolds were incubated for another 1 h. 
Subsequently, 1.5 ml of OM was added to each well and the cell-based scaffolds 
were cultured at 37 °C in a humid atmosphere in OM for 7 days, with medium 
refreshment twice. Thereafter, the cell-based scaffolds were randomly assigned to 
enrollment in in vitro and in vivo experiments. 
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For in vitro experiments, scaffolds were collected on different time points (day 7, 14 
and 21) for evaluation of cell morphology, proliferation and differentiation. For in 
vivo experiments, both cell-based and growth factor-based scaffolds were used. 
For preparation of growth factor-based scaffolds, 30 µl of BMP-2 (InductOs®, 
London, UK) solution (containing 20 μg BMP-2 in 30 μl of PBS) was dripped onto 
each scaffold in sterilized non-adhesive 25-well plates and allowed to adsorb for 2 
h. 
2.4. In vitro performance of cell-based scaffolds 
To analyze cell proliferation and osteogenic differentiation of the seeded cells, an 
in vitro study was performed (n=3), including the following three groups: 
 HA/TCP (no cells); 
 Mo (HA/TCP scaffolds seeded with AT-MSCs - monoculture); 
 Co (HA/TCP scaffolds seeded with AT-MSCs/HUVECs - coculture). 
2.4.1. Methylene blue staining 
On day 1, scaffolds were stained with methylene blue (MB) to observe cell 
distribution. The staining method used was slightly modified according to the web 
protocol29. Briefly, scaffolds were washed with PBS for 3 times and then 1% MB 
(Merck, Darmstadt, Germany) solution was added to each scaffold at room 
temperature for 5 min. Afterwards, the scaffolds were washed thoroughly with PBS 
until no residual color could be washed out. The scaffolds were maintained in PBS 
and imaged using a stereomicroscope (Leica MZ12, Rijswijk, the Netherlands) 
equipped with a Leica camera (Leica DC200, Rijswijk, the Netherlands). 
2.4.2. Methylene blue/basic fuchsin staining and scanning electron microscopy 
In order to observe cell morphology on day 7 (time point of parallel in vivo 
implantation), methylene blue/basic fuchsin (MB/BF) staining as well as scanning 
electron microscopy (SEM) analysis were performed. For MB/BF staining, scaffolds 
(n=3) were washed with PBS and fixed in 10% neutral formalin for 2 h. After 
fixation, the scaffolds were dehydrated in a graded series of ethanol and 
embedded in methylmethacrylate. Thin sections (10 µm; 3 per scaffold) were 
prepared using a histological diamond saw (Leica Microsystems SP 1600, 
Nussloch, Germany) and stained with 1% MB and 0.3% BF. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 st dies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicat d to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far hav  demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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For in vitro experi ents, scaffolds were collected on different tim  poin s (day 7, 14 
and 21) for evaluation of cell morphology, proliferation and differe tiation. For in 
vivo experiments, both ell-based and growth factor-based scaffolds were used. 
For preparation of growth factor-based scaffolds, 30 µl of BMP-2 (InductOs®, 
London, UK) solution (containing 20 μg BMP-2 in 30 μl of PBS) was dripped onto 
each scaffold in sterilized non-adhesive 25-well plates and allowed to adsorb for 2 
h. 
2.4. In vitro performance of cell-based scaffolds 
To a alyze cell proliferation and osteogenic differentiation of the eeded cells, an 
in vitro study was performed (n=3), including the f llowing three groups: 
 HA/TCP ( cells); 
 Mo (HA/TCP scaffolds seeded with AT-MSCs - monoculture); 
 Co (HA/TCP scaffolds seeded with AT-MSCs/HUVECs - coculture). 
2.4.1. Methylene blue staining 
On day 1, caffolds were stai d with methylene blue (MB) to observe cell 
distribution. The staining method sed was slightly modified according to the web 
protocol29. Briefly, scaffolds were washed with PBS for 3 tim s and then 1% MB 
(Merck, Darmstadt, Germany) solution was added to each scaffold at r om 
temperature for 5 min. Afterwards, the scaffolds were washed thorou hly with PBS 
until no residual color could be washed out. he scaffolds wer  maintained in PBS 
and imaged using a stereomicroscope (Leica MZ12, Rijswijk, the Netherlands) 
equipped with a Leic  amera (Leica DC200, Rijswijk, the Netherla ds). 
2.4.2. Methylene blue/basic fuchsin staining and scanning electron microscopy 
In order to observe cell morphology on day 7 (time point of parallel in vivo 
implantation), methylene blue/basic fuchsin (MB/BF) staining as well as scanning 
electron microscopy (SEM) analysis were performed. For MB/BF staining, scaffolds 
(n=3) were washed with PBS and fixed in 10% neutral formalin for 2 h. After 
fixation, the scaffolds were dehydrated in a graded series of ethanol and 
embedded in methylmethacrylate. Thin sections (10 µm; 3 per scaffold) were 
prepared using a histological diamond saw (Leica Microsystems SP 1600, 
Nussloch, Germany) and stained with 1% MB and 0.3% BF. 
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For SEM analysis, scaffolds were rinsed with filtered PBS, and fixed in 2% 
glutaraldehyde for 2 h. Then, the scaffolds (n=3) were washed with 0.1 M sodium-
cacodylate for 30 min, dehydrated in a graded series of ethanol, and dried with 
tetramethylsilane (Merck, Frankfurt, Germany). Examinations from both peripheral 
and cross-sections of the scaffolds were performed using a SEM (JEOL 6340F, 
Peabody, USA) after deposition of a sputter-coated gold layer. 
2.4.3. DNA content and alkaline phosphatase activity 
DNA content and alkaline phosphatase (ALP)-activity (extra- and intracellular ALP-
activity separately) were assessed for evaluation of cell proliferation and 
osteogenic differentiation, respectively, at multiple time points (day 7, 14 and 21). 
Firstly, medium from each scaffold (bare HA/TCP and cell-based scaffolds) was 
collected for extracellular ALP-activity measurements. For sampling, scaffolds (n=3) 
were cultured in a precise volume of medium (1.5 ml) and collected at indicated 
time points during medium refreshment. The medium was stored at -80°C until the 
measurement. After medium collection, the same scaffolds were used for sampling 
of DNA content and intracellular ALP-activity samples via rinsing with PBS, 
addition of 1 ml of MilliQ per scaffold, and two freeze-thaw cycles (-80°C ~ 37°C) 
before biochemical analysis. 
Both DNA content and ALP-activity assays were carried out according to 
previously described methods17. DNA content was measured using Quant-iTTM 
Picogreen Kit (Invitrogen; Breda, the Netherlands) and ALP-activity was 
determined using an ALP assay kit (p-nitrophenyl phosphate, pNPP; Sigma-Aldrich, 
the Netherlands). Values of the ALP-activity in cell-seeded scaffolds were 
corrected by subtracting the values from HA/TCP scaffolds without cells. 
2.5. In vivo experiment design 
Nine healthy 6-weeks old male athymic nude rats (weight 150-200 g; Crl:NIH-
Foxn1rnu, Charles River) were used according to national guidelines for the use and 
care of laboratory animals and after ethical approval by the Animal Ethical 
Committee (RU-DEC 2012-013). 
After in vitro pre-culture for 7 days, cell-based constructs were randomly distributed 
for implantation either at SQ or IM sites. Three groups were defined for each 
implantation site, with 6 scaffolds for each group (n=6): 
 Mo (HA/TCP scaffold seeded with AT-MSCs - monoculture); 
 Co (HA/TCP scaffold seeded with AT-MSCs/HUVECs - coculture); 
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 BMP-2 (HA/TCP scaffold loaded with BMP-2). 
2.5.1. Surgical procedure 
For surgery, the animals were pre-medicated by subcutaneous injection of 
carprofen (5 mg/kg; Rimadyl®, Pfizer Animal Health B.V., Capelle aan de IJssel, 
Netherlands) to reduce operative pain. Surgery was performed under general 
anesthesia with nitrous oxide, oxygen, and isoflurane. 
For SQ implantation, the animals were immobilized and placed in a ventral 
position. The back of the animals was shaved and disinfected with povidone-
iodine. A longitudinal incision was made on each side of the vertebral column. A 
subcutaneous pocket was created using blunt dissection. After placement of the 
scaffolds, the skin was closed using 4-0 Vicryl® resorbable sutures. 
For IM implantation in the adductor thigh muscle, the animals were placed in a 
dorsal position. The groin and leg area were shaved, disinfected with povidone-
iodine, and a longitudinal incision was made in the thigh. The incision was through 
the fascia and a pocket was made in the adductor thigh muscle. After the scaffolds 
were placed into the pockets, the soft tissues were closed in two layers with 5-0 
and 4-0 Vicryl® resorbable sutures. 
Each animal received four constructs in total (1 construct/pocket, either SQ or IM), 
with two for each lateral side (i.e. SQ and IM implantation), respectively. After 
surgery, subcutaneous injections of carprofen (5 mg/kg; Rimadyl®) were given for 2 
days to reduce postoperative pain. 
2.5.2. Explantation and micro-computed tomography (micro-CT) 
Eight weeks after implantation, animals were euthanized using CO2 suffocation. 
The specimens with the surrounding tissue were retrieved. Next, the specimens 
were fixed in 10% neutral formalin for 24 h and transferred into 70% ethanol for 
micro-CT scanning. Two specimens (n=2) randomly selected from each group 
were used for micro-CT imaging. The specimens were imaged using a high 
resolution SkyScan-1172 micro-CT imaging system (SkyScan, Aartselaar, 
Belgium). Next, cone beam reconstruction was performed on the projected files 
using Nrecon V1.5 (SkyScan, Kontich, Belgium). Finally, a 3D-reconstruction of the 
specimens was obtained by using 3D creator software as previously described30. 
The porosity of each specimen was analyzed using Bruker-CT-Ananalyzer 
software (Coventry, UK). In brief, a volume of interest (VOI) with a cubic volume of 
interest of 8 mm3 was selected from the center of each specimen from the 3D-
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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For SEM analysis, scaffolds were rinsed with filtered PBS, and fixed in 2% 
glutaraldehyde for 2 h. Then, the scaffolds (n=3) were washed with 0.1 M sodium-
cacodylate for 30 min, dehydrated in a graded series of ethanol, and dried with 
tetramethylsilane (Merck, Frankfurt, Germany). Examinations from both peripheral 
and cross-sections of the scaffolds were performed using a SEM (JEOL 6340F, 
Peabody, USA) after deposition of a sputter-coated gold layer. 
2.4.3. DNA content and alkaline phosphatase activity 
DNA content and alkaline phosphatase (ALP)-activity (extra- and intracellular ALP-
activity separately) were assessed for evaluation of cell proliferation and 
osteogenic differentiation, respectively, at multiple time points (day 7, 14 and 21). 
Firstly, medium from each scaffold (bare HA/TCP and cell-based scaffolds) was 
collected for extracellular ALP-activity measurements. For sampling, scaffolds (n=3) 
were cultured in a precise volume of medium (1.5 ml) and collected at indicated 
time points during medium refreshment. The medium was stored at -80°C until the 
measurement. After medium collection, the same scaffolds were used for sampling 
of DNA content and intracellular ALP-activity samples via rinsing with PBS, 
addition of 1 ml of MilliQ per scaffold, and two freeze-thaw cycles (-80°C ~ 37°C) 
before biochemical analysis. 
Both DNA content and ALP-activity assays were carried out according to 
previously described methods17. DNA content was measured using Quant-iTTM 
Picogreen Kit (Invitrogen; Breda, the Netherlands) and ALP-activity was 
determined using an ALP assay kit (p-nitrophenyl phosphate, pNPP; Sigma-Aldrich, 
the Netherlands). Values of the ALP-activity in cell-seeded scaffolds were 
corrected by subtracting the values from HA/TCP scaffolds without cells. 
2.5. In vivo experiment design 
Nine healthy 6-weeks old male athymic nude rats (weight 150-200 g; Crl:NIH-
Foxn1rnu, Charles River) were used according to national guidelines for the use and 
care of laboratory animals and after ethical approval by the Animal Ethical 
Committee (RU-DEC 2012-013). 
After in vitro pre-culture for 7 days, cell-based constructs were randomly distributed 
for implantation either at SQ or IM sites. Three groups were defined for each 
implantation site, with 6 scaffolds for each group (n=6): 
 Mo (HA/TCP scaffold seeded with AT-MSCs - monoculture); 
 Co (HA/TCP scaffold seeded with AT-MSCs/HUVECs - coculture); 
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days to reduce postoperative pain. 
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Eight weeks after implantation, animals were euthanized using CO2 suffocation. 
The specimens with the surrounding tissue were retrieved. Next, the specimens 
were fixed in 10% neutral formalin for 24 h and transferred into 70% ethanol for 
micro-CT scanning. Two specimens (n=2) randomly selected from each group 
were used for micro-CT imaging. The specimens were imaged using a high 
resolution SkyScan-1172 micro-CT imaging system (SkyScan, Aartselaar, 
Belgium). Next, cone beam reconstruction was performed on the projected files 
using Nrecon V1.5 (SkyScan, Kontich, Belgium). Finally, a 3D-reconstruction of the 
specimens was obtained by using 3D creator software as previously described30. 
The porosity of each specimen was analyzed using Bruker-CT-Ananalyzer 
software (Coventry, UK). In brief, a volume of interest (VOI) with a cubic volume of 
interest of 8 mm3 was selected from the center of each specimen from the 3D-
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reconstructed image. A threshold of grey values was selected and the values 
above and below this value were regarded separately as: material and mineralized 
tissue; void and soft tissue. The pore volume was determined by subtracting the 
volume of the former part (i.e. material and mineralized tissue) from the total VOI. 
Thereafter, the porosity volume percentage (PV%) for each specimen was 
calculated by dividing the porosity volume (mm3) by the total VOI (mm3). 
2.5.3. Histological and histomorphometrical evaluation 
After fixation, the specimens were dehydrated in a graded series of ethanol and 
embedded in methylmethacrylate. Thin sections (10 µm; 3 per specimen) were 
prepared using a histological diamond saw (Leica) and stained with MB/BF. 
All histological sections (3 per construct) were photographed with the Zeiss Imager 
Z1 microscope equipped with the AxioCam MRc5 camera using AxioVision 4.8 
software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). The incidence of 
bone formation for each group was analyzed. Furthermore, histomorphometrical 
evaluation was performed to quantify bone formation within the three experimental 
groups (Mo, Co, and BMP-2) in both SQ and IM sites according as described 
previously31. In brief, histological sections were scored using computer-based 
image analysis techniques (Leica® Qwin Proimage analysis system, Wetzlar, 
Germany), which recognize bone tissue from the others (e.g. HA/TCP scaffolds, 
pores and soft tissues) based on different RGB values from magnified digitalized 
images (100x). Manual corrections based on morphological appearance were 
applied to ensure adequate selection of newly formed bone tissue within the 
selected area. A region of interest (ROI) was defined by selecting the area within 
fibrous tissue capsule. The parameters for evaluating bone amount as listed below 
were measured: 
 BA/PA (%): bone area (mm2)/pore area (mm2); 
 BA/ROI (%): bone area (mm2)/region of interest (mm2, i.e. the scaffold 
area). 
2.6. Statistical analysis 
Data were expressed as mean ± standard deviation. Graphpad Instat software 
(Instat® 3.05, Graphpad Software Inc., La Jolla, USA) was used for statistical 
analysis. For the statistical analysis for DNA content and ALP-activity in vitro, an 
independent t-test was performed to compare between Mo and Co and a one-way 
ANOVA with posthoc Tukey HSD test was applied for the comparison among 
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different time points (day 7, 14 and 21). For the comparison of bone formation in 
SQ and IM sites in vivo, a paired t-test was performed. 
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reconstructed image. A threshold of grey values was selected and the values 
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analysis. For the statistical analysis for DNA content and ALP-activity in vitro, an 
independent t-test was performed to compare between Mo and Co and a one-way 
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different time points (day 7, 14 and 21). For the comparison of b ne formation in 
SQ and IM sites i  vivo, a paired t-test was performed. 
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3. Results 
3.1. Microscopic observation for cell-based scaffolds in vitro 
MB staining (Figure 2) on day 1 showed an apparent difference between bare 
HA/TCP scaffolds (Figure 2A) and the cell-based constructs (Figure 2B, 
representative image from Mo), for which the latter clearly demonstrated positively 
stained cell nuclei. On day 7, microscopic observation including both MB/BF 
staining and SEM was performed to observe the cell morphology for the cell-based 
constructs. MB/BF staining showed that cells penetrated inside the pores (Figure 
3A), and at higher magnification, cell nuclei were clearly observed (Figure 3B). The 
structure of the bare HA/TCP scaffolds was shown from both peripheral (Figure 3C) 
and cross-sections (Figure 3D) using SEM analysis. SEM images demonstrated a 
homologous cell distribution on the surface (Figure 3E, G) as well as cell ingrowth 
into the center of the constructs (Figure 3F, H) for both Mo (Figure 3E-F) and Co 
(Figure 3G-H). Cells clearly covered the surface of the constructs, whereas cross-
sections displayed the presence of cells throughout the porous structure of the 
constructs. 
 
Figure 2. Microscopic observation using methylene blue staining on HA/TCP on day 1 in vitro (n=3). (A) 
bare HA/TCP scaffold and (B) cell-seeded scaffold (from AT-MSCs seeded HA/TCP, Mo). Arrow 
indicates cells. 
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Figure 3. Microscopic observation of cell morphology on HA/TCP on day 7 in vitro (n=3). (A) 
Representative image of methylene blue/basic fuchsin staining for cell-seeded scaffolds (from AT-
MSCs/HUVECs seeded HA/TCP, Co). (B) magnified image of the insert in (A). (C-H) represent 
scanning microscopy (SEM) images of both peripheral (C, E, G) and cross-sections (D, F, H) for bare 
HA/TCP, Mo, and Co, respectively. Arrows indicate cell layer. 
3.2. In vitro performance of cell-based scaffolds 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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DNA content, as an index for cell proliferation, is displayed in Figure 4A. No 
significant difference was observed between Mo and Co at any time point. 
Additionally, Mo and Co constructs showed a rather constant DNA content over 
time. 
Both the extra- and intracellular ALP-activity were analyzed and the results are 
shown in Figures 4B-C. For extracellular ALP-activity (Figure 4B), no significant 
differences were found between Mo and Co at individual time points or over time 
(p>0.05), although a tendency toward higher ALP-activity for Mo constructs was 
apparent. For intracellular ALP-activity (Figure 4C), significantly higher values were 
found for Mo constructs compared to Co constructs on day 7 (p<0.01), while similar 
values were observed for Mo and Co on days 14 and 21. Analogous to 
extracellular ALP-activity results, intracellular ALP-activity showed a tendency 
toward higher ALP-activity for Mo constructs. Comparison among different time 
points demonstrated that intracellular ALP-activity increased over time for both Mo 
and Co constructs, showing significantly higher values on day 21 than on day 7 
and day 14. 
3.3. In vivo experiment 
3.3.1. General observations 
All animals recovered uneventfully from the surgery and no infections or 
complications were observed during the 8 week implantation period. All specimens 
(n=6 per group) were retrieved and during retrieval, no macroscopic signs of 
inflammation or adverse tissue response were observed at the implantation sites. 
Obvious soft tissue encapsulation was observed for all constructs at all 
implantation sites. 
3.3.2. Micro-CT 
A 3D reconstruction was generated using micro-CT and the porosity of the 
constructs was determined (Figure 5). The 3D reconstructions were all derived 
from the central part of the constructs and showed porous structures of the 
constructs, with large similarity for constructs from both implantation sites. The 
dimension and the number of the pores showed an apparent decrease for growth 
factor-based constructs compared to both original bare scaffolds and cell-based 
constructs. 
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Figure 4. Cell proliferation and osteogenic differentiation on HA/TCP in vitro (n=3). (A) DNA content; (B) 
extracellular ALP-activity (from cell culture medium); (C) intracellular ALP-activity (from cell lysis). **, 
p<0.01, indicates significant difference between Mo and Co; #, p<0.05, ##, p<0.01, indicate significant 
difference on day 7 vs. day 21 or day 14 vs. day 21. Mo, AT-MSCs seeded HA/TCP; Co, AT-
MSCs/HUVECs seeded HA/TCP. 
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Figure 4. Cell proliferatio  nd ost ogenic differentiation on HA/TCP in vitro (n=3). (A) DNA content; (B) 
extracellular ALP-activity (from cell culture medium); (C) intracellular ALP-activity (from cell lysis). **, 
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Figure 5. Micro-CT 3D reconstructions for Mo, Co and BMP-2 scaffolds after 8 weeks in vivo 
implantation (n=2). Mo, AT-MSCs seeded HA/TCP; Co, AT-MSCs/HUVECs seeded HA/TCP; BMP-2, 
BMP-2 loaded HA/TCP; SQ, subcutaneous; IM, intramuscular. 
 
The porosity of the bare scaffolds (n=2) was 67.0±11.0%. The average values of 
porosity for the two randomly selected specimens in each group showed a 
decrease in the BMP-2 group (33.4±3.9% in SQ and 37.4±3.4% in IM) compared to 
Mo (49.0±19.0% in SQ and 56.5±26.1% in IM) and Co constructs (58.2±0.1% in 
SQ and 66.5±6.6% in IM), which showed a comparable porosity. 
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3.3.3. Descriptive histology 
Histological images for sections of SQ and IM implantation are presented in 
Figures 6 and 7, respectively. 
 
Figure 6. Representative histological images from methylene blue/basic fuchsin stained sections after 8 
weeks subcutaneous (SQ) implantation in vivo. Bone marrow structures are only observed in the BMP-2 
group, which is also the only group with bone formation. Black arrows indicate vessel-like structures and 
white arrows indicate osteocyte-like cells. Mo, AT-MSCs seeded HA/TCP; Co, AT-MSCs/HUVECs 
seeded HA/TCP; BMP-2, BMP-2 loaded HA/TCP. 
 
Similar results were observed for SQ and IM implantation sites. In general, none of 
the specimens showed the presence of an inflammatory response and soft tissues 
(i.e. layers of fibrous cells) firmly encapsulated the implanted scaffolds. For Mo and 
Co constructs, the porous structure of the scaffolds was filled with fibrous tissues. 
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porosity for the two randomly selected specimens in each group showed a 
decrease in the BMP-2 group (33.4±3.9% in SQ and 37.4±3.4% in IM) compared to 
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SQ and 66.5±6.6% in IM), which showed a comparable porosity. 
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3.3.3. Descriptive histology 
Histological images for sections of SQ and IM implantation are presented in 
Figures 6 and 7, respectively. 
 
Figure 6. Representative histological images from met ylene blue/basic fuchsin stained sections after 8 
weeks subcutaneous (SQ) implantation in vivo. Bone marrow structures are only observed in the BMP-2 
group, which is also the only group with bone formation. Black arrows indicate vessel-like structures and 
white arrows indicate osteocyte-like cells. Mo, AT-MSCs seeded HA/TCP; Co, AT-MSCs/HUVECs 
seeded HA/TCP; BMP-2, BMP-2 loaded HA/TCP. 
 
Similar results were observed for SQ and IM implantation sites. In general, none of 
the specimens showed the presence of an inflammatory response and soft tissues 
(i.e. layers of fibrous cells) firmly encapsulated the implanted scaffolds. For Mo and 
Co constructs, the porous structure of the scaffolds was filled with fibrous tissues. 
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In contrast, growth factor-based constructs showed large amounts of bone tissue 
present, predominantly at the concave areas of the pores. For growth factor-based 
constructs, bone formation was observed both on the periphery and in the center of 
the constructs and bone marrow-like tissue was observed inside the pores of the 
scaffold. At higher magnification (Figure 6 & 7), osteocyte-like cells were clearly 
visible within the newly formed bone tissue. Additionally, vessel-like structures 
were frequently observed for all the groups. 
 
Figure 7. Histological images from methylene blue/basic fuchsin staining after 8 weeks intramuscular 
(IM) implantation in vivo (n=6). Bone marrow structures are only observed in the BMP-2 group, which is 
also the only group with bone formation. Black arrows indicate vessel-like structures and white arrows 
indicate osteocyte-like cells. Mo, AT-MSCs seeded HA/TCP; Co, AT-MSCs/HUVECs seeded HA/TCP; 
BMP-2, BMP-2 loaded HA/TCP. 
3.3.4. Bone forming incidence 
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Bone formation was observed in none of the specimens (0/6) for both Mo and Co 
constructs, while all of the specimens (6/6) of the growth factor-based constructs 
showed the presence of bone tissue, irrespective of implantation site. 
3.3.5. Histomorphometry 
Histomorphometrical evaluation of bone formation for growth factor-based 
constructs at both SQ and IM sites was performed, for which the results are 
displayed in Figure 8. The percentage of BA/PA at SQ and IM sites was similar 
(35±8% and 33±4%, respectively). Similarly, the percentage of BA/ROI at SQ and 
IM sites was comparable (20±5% and 19±3%, respectively). 
 
Figure 8. Histomorphometrical analysis of bone formation in BMP-2 scaffolds after 8 weeks in vivo 
implantation (n=6). SQ, subcutaneous; IM, intramuscular. BA, bone area; PA, pore area; ROI, region of 
interest. 
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4. Discussion 
The aim of this study was to compare the effect of implantation site on the bone 
forming capacity of cell-based or growth factor-based constructs in athymic nude 
rats after an implantation period of 8 weeks. It was hypothesized that IM 
implantation would induce more bone formation in comparison to SQ implantation 
due to more pronounced vascularization in IM site. Porous HA/TCP scaffolds were 
either seeded with AT-MSC monocultures or AT-MSC/HUVEC cocultures and pre-
cultured in vitro for 7 days or pre-loaded with BMP-2, after which the constructs 
were implanted. Histological and histomorphometrical analyses were used to 
assess bone formation. An in vitro parallel experiment was performed to 
comparatively evaluate the proliferation and osteogenic differentiation capacity of 
cell-based constructs. In general, cells from in vitro cultures showed osteogenic 
differentiation with a slightly increased ALP-activity for monocultures compared to 
cocultures. In vivo experiments demonstrated that only growth factor-based 
constructs induced bone formation without significant implantation site dependent 
differences in the amount of formed bone. 
So far, MSCs derived from either mouse32 or rat33-34 have been combined with 
various scaffolds and no difference in bone formation was observed in SQ and IM 
sites. Nevertheless, research is missing on such comparison using human MSCs, 
which behave differently with those from other animal species35. Besides, growth 
factor-based (i.e. BMP-2) bone formation in SQ and IM sites was compared as well 
since BMP-2 induce bone formation through the recruitment and stimulation of 
stem cells (either from donor or host) to differentiate into osteoblasts36-37, for which 
vascularization also acts as a key factor for cell survival. Moreover, although 
HA/TCP favors MSCs differentiation into osteogenic lineages38, it has been 
reported previously that bare HA/TCP scaffolds failed in inducing bone formation in 
both SQ and IM implantation in rats39. Therefore, the bare scaffold group was not 
included in this experimental design. 
Yet, bone formation was observed in growth factor- rather than cell-based 
constructs. In theory, BMP-2 induces osteogenic differentiation of resident stem 
cells and hence bone formation, but AT-MSCs (either mono- or cocultures) were 
expected to improve bone formation, based on their osteogenic differentiation 
capacities in vivo. No BMP-2 induced bone formation by resident stem cells is to 
be expected for cell-based constructs since either osteogenically induced AT-
MSCs do not produce BMP-240 or the osteogenic fate of AT-MSCs is not 
influenced by BMP-2 both in vitro and in vivo41-42. However, bone formation using 
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human bone marrow MSCs (BM-MSCs) was more frequently observed because 
osteogenically differentiated BM-MSCs can secrete much higher amount of BMP-2 
compared to AT-MSCs40. 
Our study further showed that IM implantation did not enhance bone formation 
compared to SQ implantation for growth factor-based scaffolds. The hypothesis 
that IM implantation can induce more bone formation was based on the fact that 
more pronounced vascularization in IM tissue43-44 can provide more oxygen and 
nutrition supply for osteoblastic cells as well as recruitment of more stem cells from 
the circulation, and hence enhance bone formation45. Up to now, bone forming 
capacity of only rat BM-MSCs seeded constructs were compared in SQ and IM 
implantation, and equal bone formation was observed33-34. Nevertheless, it is still 
unclear for the bone formation in SQ vs. IM when human AT-MSCs are used since 
no bone formation was observed in either of the implantation sites. Moreover, our 
study showed that BMP-2 induced similar bone formation at the two different 
ectopic implantation sites. Although only one dose of BMP-2 (i.e. 20 μg/construct) 
was used in this study, it cannot be excluded that different dosages of BMP-2 may 
influence bone formation of the two implantation sites. 
Strong arguments exist for the in vivo bone forming capacity of AT-MSCs, even 
though their in vitro osteogenic differentiation capacity has been well 
established40,46-47. Using human AT-MSCs, few studies have demonstrated (effects 
on) in vivo bone formation, either ectopically48 or orthotopically49-50, while others 
found no bone formation ectopically51-52 or orthotopically28. But it is hard to tell the 
contribution of the implanted cells to bone formation, especially at orthotopic 
implantation sites because the origin of the formed bone was not identified. In 
terms of the failure in ectopic bone formation using human AT-MSCs, this study is 
in accordance with the research from Martin‟s group
51-52, in which the tissue-
engineered constructs were SQ implanted for a period of 8 weeks. In one of these 
two studies, human AT-MSCs were statically seeded on HA ceramic scaffolds and 
implanted in athymic nude mice, without in vitro pre-culture in OM52. In the other, 
human AT-MSCs were dynamically (perfusion) seeded and cultured on HA in OM 
for 5 days in vitro and subsequently implanted in athymic nude rats51. These 
authors emphasized in a review paper that two parameters were critically required 
for induction of osteogenic potential by AT-MSCs, which are the osteogenic 
commitment of AT-MSCs and the presence of a mineral component in the 
scaffold47. Although our experimental design met these two requirements, no bone 
formation was found. This suggests that more or other requirements are needed to 
obtain in vivo bone formation at ectopic implantation sites. Nevertheless, it is not 
possible to dispose the potential for stem cells by ignoring the carrier selected, 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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4. Discussion 
The aim of this study was to compare the effect of implantation site on the bone 
forming capacity of cell-based or growth factor-based constructs in athymic nude 
rats after an implantation period of 8 weeks. It was hypothesized that IM 
implantation would induce more bone formation in comparison to SQ implantation 
due to more pronounced vascularization in IM site. Porous HA/TCP scaffolds were 
either seeded with AT-MSC monocultures or AT-MSC/HUVEC cocultures and pre-
cultured in vitro for 7 days or pre-loaded with BMP-2, after which the constructs 
were implanted. Histological and histomorphometrical analyses were used to 
assess bone formation. An in vitro parallel experiment was performed to 
comparatively evaluate the proliferation and osteogenic differentiation capacity of 
cell-based constructs. In general, cells from in vitro cultures showed osteogenic 
differentiation with a slightly increased ALP-activity for monocultures compared to 
cocultures. In vivo experiments demonstrated that only growth factor-based 
constructs induced bone formation without significant implantation site dependent 
differences in the amount of formed bone. 
So far, MSCs derived from either mouse32 or rat33-34 have been combined with 
various scaffolds and no difference in bone formation was observed in SQ and IM 
sites. Nevertheless, research is missing on such comparison using human MSCs, 
which behave differently with those from other animal species35. Besides, growth 
factor-based (i.e. BMP-2) bone formation in SQ and IM sites was compared as well 
since BMP-2 induce bone formation through the recruitment and stimulation of 
stem cells (either from donor or host) to differentiate into osteoblasts36-37, for which 
vascularization also acts as a key factor for cell survival. Moreover, although 
HA/TCP favors MSCs differentiation into osteogenic lineages38, it has been 
reported previously that bare HA/TCP scaffolds failed in inducing bone formation in 
both SQ and IM implantation in rats39. Therefore, the bare scaffold group was not 
included in this experimental design. 
Yet, bone formation was observed in growth factor- rather than cell-based 
constructs. In theory, BMP-2 induces osteogenic differentiation of resident stem 
cells and hence bone formation, but AT-MSCs (either mono- or cocultures) were 
expected to improve bone formation, based on their osteogenic differentiation 
capacities in vivo. No BMP-2 induced bone formation by resident stem cells is to 
be expected for cell-based constructs since either osteogenically induced AT-
MSCs do not produce BMP-240 or the osteogenic fate of AT-MSCs is not 
influenced by BMP-2 both in vitro and in vivo41-42. However, bone formation using 
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engineered constructs were SQ implanted for a period of 8 weeks. In one of these 
two studies, human AT-MSCs were statically seeded on HA ceramic scaffolds and 
implanted in athymic nude mice, without in vitro pre-culture in OM52. In the other, 
human AT-MSCs were dynamically (perfusion) seeded and cultured on HA in OM 
for 5 days in vitro and subsequently implanted in athymic nude rats51. These 
authors emphasized in a review paper that two parameters were critically required 
for induction of osteogenic potential by AT-MSCs, which are the osteogenic 
commitment of AT-MSCs and the presence of a mineral component in the 
scaffold47. Although our experimental design met these two requirements, no bone 
formation was found. This suggests that more or other requirements are needed to 
obtain in vivo bone formation at ectopic implantation sites. Nevertheless, it is not 
possible to dispose the potential for stem cells by ignoring the carrier selected, 
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indicating perhaps the performance of the cells compared to the growth factor 
suffers from an inherent prejudice in choice of a scaffold. Additionally, although no 
statistical analysis was performed, the porosity from micro-CT analysis 
demonstrated a decrease for both Mo and Co constructs after 8 weeks in vivo 
implantation compared to the original bare HA/TCP scaffolds, suggesting the 
formation of radiopaque tissue in cell-based constructs. 
The lack of bone formation in both culture conditions (Mo and Co) was in contrast 
with cocultures using BM-MSCs, in which half of the MSCs in cocultures formed 
even more bone compared to monocultures18. Consistently, the in vitro results also 
showed the same trend, since ALP-activity was not enhanced in Co compared to 
Mo. Despite the observation of vessel-like structures for both Mo and Co, the 
technical challenge to histologically process ceramic-containing constructs via 
paraffin embedding which is necessary for immunohistochemical staining, makes it 
hard to do quantitative analysis of blood vessel formation and determine the origin 
(either donor or host). 
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5. Conclusions 
The results of this study demonstrate that different ectopic implantation sites did 
not affect the bone forming capacity of either cell- or growth factor-based HA/TCP 
constructs. Further, bone formation was only observed for growth factor-based 
constructs. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
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as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
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1. Introduction 
Regeneration of bone defects caused by trauma, injury or tumor resection remains 
a major challenge in the current orthopedic and dental clinic1. Bone tissue 
engineering and regenerative medicine, when based on autologous cells combined 
with tissue-engineered scaffolds, have demonstrated exciting potential of 
regenerating bone defects2. However, as these successes have been limited to 
animal studies3-5, their translation to clinics is not satisfactory yet. A hurdle in bone 
regenerative medicine is the difficulty in vascularizing the tissue-engineered 
constructs6-7. Bone is an active tissue supplied with an intraosseous vasculature 
with osteocytes at a distance of maximum 100 µm from an intact capillary7. After 
the in vivo implantation of cell-loaded constructs, only the cells within a distance of 
100~200 µm to the nearest capillaries can obtain sufficient blood and nutrient 
supply to maintain their metabolism and function while the cells in the core of the 
constructs may die6,8. 
To overcome or minimize this problem, two approaches have been explored, i.e. in 
vivo microsurgery and in vitro prevascularization9. In the former approach, a 
scaffold needs to be firstly implanted in a region of the recipient with an abundant 
vascular supply to obtain a microvascular network within the construct before the 
construct is harvested and implanted in the bone defect. This approach requires 
two surgeries with potential for donor site morbidity9. Thus, in vitro 
prevascularization is often explored nowadays, which consists of both scaffold- 
(e.g. microfabrication of scaffolds either or not combined with angiogenic growth 
factors) and cell-based strategies (i.e. cocultures of osteoblastic cells with 
angiogenic cells)6-8. 
From a cellular point of view, cocultures have attracted increasing attention as 
these cell-based systems have shown the potential to achieve vessel-like 
structures (VLS) both in vitro10-11 and in vivo12-13. In such a coculture system, 
angiogenic cells are the basic components to form the VLS. The use of the 
osteoblastic cells in cocultures could, on one side, directly contribute to bone 
formation, and on the other side, play a pericyte-like role to line along the vessels 
formed by angiogenic cells through the production of extracellular matrix and the 
secretion of pro-angiogenic signaling molecules12,14. 
Mesenchymal stem cells (MSCs) represent a potential osteoblastic precursor cell 
type for bone regeneration15, of which bone marrow-derived MSCs (BM-MSCs) are 
most frequently used. In view of disadvantages related to the use of BM-MSCs, 
including patient discomfort during isolation and low cell yield16-17, adipose tissue-
derived MSCs (AT-MSCs) have been explored as an alternative within the recent 
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decades because they are easily accessible with higher cell yield18-19. AT-MSCs 
can secrete a broad range of paracrine factors that are known to be angiogenic, 
similar to BM-MSCs20. Human umbilical vein endothelial cells (HUVECs) are the 
most commonly used type of human endothelial cells (ECs) for both in vitro and in 
vivo studies for bone regenerative medicine21-22. 
Although BM-MSCs and AT-MSCs are phenotypically similar, they promote 
angiogenesis through distinct mechanisms by modulating ECs proteolysis using a 
different repertoire of proteases23. It has been reported that both BM-MSCs and 
AT-MSCs can play an active role in the formation, stabilization and maturation of 
newly formed VLS14,24, but no systematic knowledge is available about the 
comparison of angiogenic capacity between BM-MSCs/HUVECs and AT-
MSCs/HUVECs cocultures. Hydrogels (e.g. fibrin gels, collagen gels and Matrigel®) 
can act as versatile and accessible material platforms that are required in the 
process of angiogenesis and cell delivery25. So far, most studies on the angiogenic 
capacity of cocultures in hydrogel-based culture systems have been related to BM-
MSCs, either in collagen/fibrin26 and Matrigel®27 in vitro, or in Matrigel®28 and 
collagen/fibronectin/fibrinogen gels29 in vivo, while to date only two studies reported 
the use of AT-MSCs for this purpose. In one of these, AT-MSCs/ECs (1:1 cell ratio) 
induced higher (human origin) vessel density compared to BM-MSCs/ECs on day 7 
and 14 and VLS density decreased over time after the subcutaneous injection of 
fibrin gels in athymic nude mice30. In another study, both BM-MSCs and AT-MSCs 
were cocultured with ECs (MSCs:ECs=3:2) in Matrigel® and followed by 
subcutaneous injection in athymic nude mice. After 7 days, a similar vessel density 
was observed for both types of cocultures31. However, both of the studies 
evaluated the angiogenic capacity of cocultures after 7 days. From the cell survival 
point of view, it is essential to analyze the angiogenic capacity at earlier time points 
(i.e. < 7 days) and no data is available so far. Based on aforementioned, we 
hypothesized that AT-MSCs/HUVECs have at least equal angiogenic capacity in 
comparison to BM-MSCs/HUVECs at early time points (day 3 and 7). 
In view of this, the aim of this study was to compare the angiogenic capacity 
between BM-MSCs/HUVECs and AT-MSCs/HUVECs at early time points (day 3 
and 7) both in vitro and in vivo. Collagen gels have been widely used in 
angiogenesis assays and provide a suitable model for physiological and 
developmental angiogenesis in comparison to fibrin gel and Matrigel®25. For in vitro 
experiments, monocultures (i.e. BM-MSCs, AT-MSCs and HUVECs) and 
cocultures (i.e. BM-MSCs/HUVECs and AT-MSCs/HUVECs) were cultured either 
on Thermanox® or in collagen gels. For in vivo experiments, cocultures of cells (i.e. 
BM-MSCs/HUVECs and AT-MSCs/HUVECs) were embedded in collagen gels and 
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host cells, among which most of the studies demonstrated that bone14,71 and blood 
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addressing cell-based constructs for bone repair are limited to case reports (Table 
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alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
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constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
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structures (VLS) both in vitro10-11 and in vivo12-13. In such a coculture system, 
angiogenic cells are the basic components to form the VLS. The use of the 
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formation, and on the other side, play a pericyte-like role to line along the vessels 
formed by angiogenic cells through the production of extracellular matrix and the 
secretion of pro-angiogenic signaling molecules12,14. 
Mesenchymal stem cells (MSCs) represent a potential osteoblastic precursor cell 
type for bone regeneration15, of which bone marrow-derived MSCs (BM-MSCs) are 
most frequently used. In view of disadvantages related to the use of BM-MSCs, 
including patient discomfort during isolation and low cell yield16-17, adipose tissue-
derived MSCs (AT-MSCs) have been explored as an alternative within the recent 
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dec des because they are easily acc ssib e with higher cell yield18-19. AT-MSCs 
can secrete a broad range of paracrine factors t at are known to be angiogenic, 
similar to BM-MSCs20. Human umbilical v in endothelial cells (HUVECs) are th  
most commonly used type of human endothelial cells (ECs) for both in vitro and in 
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newly formed VLS14,24, but no systematic knowledge is available about the 
comparison of angiogenic capacity between BM-MSCs/HUVECs and AT-
MSCs/HUVECs cocultures. Hydrogels (e.g. fibrin gels, collagen gels and Matrigel®) 
can act as versatile and accessible material platforms that are required in the 
process of angiogenesis and cell delivery25. So far, most studies on the angiogenic 
capacity of cocultures in hydrogel-based culture systems have been related to BM-
MSCs, either in collagen/fibrin26 and Matrigel®27 in vitro, or in Matrigel®28 and 
collagen/fibronectin/fibrinogen gels29 in vivo, while to date only two studies reported 
the use of AT-MSCs for this purpose. In one of these, AT-MSCs/ECs (1:1 cell ratio) 
induced higher (human origin) vessel density compared to BM-MSCs/ECs on day 7 
and 14 and VLS density decreased over time after the subcutaneous injection of 
fibrin gels in athymic nude mice30. In another study, both BM-MSCs and AT-MSCs 
were cocultured with ECs (MSCs:ECs=3:2) in Matrigel® and followed by 
subcutaneous injection in athymic nude mice. After 7 days, a similar vessel density 
was observed for both types of cocultures31. However, both of the studies 
evaluated the angiogenic capacity of cocultures after 7 days. From the cell survival 
point of view, it is essential to analyze the angiogenic capacity at earlier time points 
(i.e. < 7 days) and no data is available so far. Based on aforementioned, we 
hypothesized that AT-MSCs/HUVECs have at least equal angiogenic capacity in 
comparison to BM-MSCs/HUVECs at early time points (day 3 and 7). 
In view of this, the aim of this study was to compare the angiogenic capacity 
between BM-MSCs/HUVECs and AT-MSCs/HUVECs at early time points (day 3 
and 7) both in vitro and in vivo. Collagen gels have been widely used in 
angiogenesis assays and provide a suitable model for physiological and 
developmental angiogenesis in comparison to fibrin gel and Matrigel®25. For in vitro 
experiments, monocultures (i.e. BM-MSCs, AT-MSCs and HUVECs) and 
cocultures (i.e. BM-MSCs/HUVECs and AT-MSCs/HUVECs) were cultured either 
on Thermanox® or in collagen gels. For in vivo experiments, cocultures of cells (i.e. 
BM-MSCs/HUVECs and AT-MSCs/HUVECs) were embedded in collagen gels and 
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implanted subcutaneously in athymic nude mice. For both in vitro and in vivo study, 
samples were collected on day 3 and 7 and followed by hematoxylin-eosin (HE) 
and platelet endothelial cell adhesion molecule (PECAM-1; CD31) staining. The 
quantitative parameters for evaluating angiogenesis for the in vivo samples were 
CD31-positive staining percentage, total VLS area percentage, VLS density and 
average VLS area (i.e. the size of per VLS). 
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2. Materials and methods 
2.1. Cell isolation and culture 
For each type of MSCs, cells from two donors (BM-MSC; donor 1: 52 years old, 
female; donor 2: 38 years old, male, AT-MSCs; donor A: 38 years old, female; 
donor B: 43 years old, female) from passage 4 were used for both in vitro and in 
vivo study. The biopsies of human bone chips were the discarded tissues during 
standard surgical procedures at Radboud University Nijmegen Medical Center 
(Nijmegen, the Netherlands). Human subcutaneous adipose tissue was obtained 
from waste material of the abdomen from the Department of Plastic Surgery 
(Tergooi Hospital, Hilversum, the Netherlands). This study was performed after 
written informed consent and complied with the principles of the Declaration of 
Helsinki. The detailed information for isolation and culture of BM-MSCs and AT-
MSCs can be found in previous protocols32-33. The multipotential differentiation 
capacity of both BM-MSCs and AT-MSCs has been tested (data not shown) 
according to the protocols in our previous studies32-33. The components for culture 
medium are listed in Table 1. 
Table 1. Main cell culture media used in the experiment 
Medium name Constituents Origin of constituents 
Proliferation medium 
for BM-MSCs 
α-MEM 
15% FBS 
0.2 mM L-ascorbic acid-2-phosphate 
2mM L-glutamine 
100 U/ml penicillin 
10 μg/ml streptomycin 
10-3 μg/ml bFGF 
Gibco-BRL 
Lonza 
Sigma 
Gibco-BRL 
Gibco-BRL 
Gibco-BRL 
Invitrogen 
Proliferation medium 
for AT-MSCs 
α-MEM 
5% PL 
100 U/ml penicillin 
10 μg/ml streptomycin 
10 U/ml heparin 
Gibco-BRL 
VU University Medical Centre 
Gibco-BRL 
Gibco-BRL 
LEO Pharma 
Endothelial cell 
culture medium (EM) 
basal Medium 200 + low serum 
growth supplements containing 2% 
FBS, 10 ng/ml epidermal growth 
factor, 3 ng/ml bFGF, 10 µg/ml 
heparin, 0.2 μg /ml bovine serum 
albumin, 1 µg/ml hydrocortisone, and 
0.2% gentamicin/amphotericin B 
Invitrogen 
α-MEM, Minimal Essential Medium; bFGF, basic fibroblast growth factor; FBS, fetal bovine serum; 
PL, platelet lysate. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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HUVECs were obtained from a commercial source (Becton Dickinson Biosciences, 
BD; Breda, the Netherlands) and cultured in endothelial cell culture medium (EM, 
see Table 1) according to the instructions from BD. Cells from passage 5 were 
used in the experiment. The experimental set-up is schematically represented in 
Figure 1. 
2.2. In vitro evaluation 
Five groups, including both monocultures (Mo) and cocultures (Co, with the cell 
ratio of 1:1), were used for in vitro evaluation, and the experiment was conducted 
in triplicate (n=3): 
 Monocultures of BM-MSCs (BM-Mo); 
 Monocultures of AT-MSCs (AT-Mo); 
 Monocultures of HUVECs (HUVECs); 
 Cocultures of BM-MSCs/HUVECs (BM-Co); 
 Cocultures of AT-MSCs/HUVECs (AT-Co). 
 
 
Figure 1. Schematic structure of the experimental design (in vitro, n=3 and in vivo, n=5). Cells from two 
donors from each cell type (BM-MSCs or AT-MSCs) were used. 
2.2.1. Cell (co)culture on Thermanox® (2-dimensional, 2D culture) 
One milliliter of cell suspension containing a total number of 0.2x106 cells from 
either monoculture or cocultures was seeded on Thermanox® cover slips (NuncTM, 
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New York, USA) in non-adhesive 24-well plates (Greiner Bio-one, Alphen aan den 
Rijn, the Netherlands). Cells were cultured in EM and incubated at 37 °C in a 
humid atmosphere, with medium refreshment twice a week. After 3 and 7 days 
culture, the samples were collected for further analysis (i.e. CD31 staining, see 
below the detailed information for samples treatment in “Sample collection and 
analysis” section). 
2.2.2. Cell (co)culture in collagen gels (3-dimensional, 3D culture) 
Collagen gels (3 mg/ml) were used according to the instructions from the 
manufacturer. Briefly, 100 µl PBS (10x), 532 µl Milli-Q H2O and 6 µl NaOH were 
mixed with 262 µl collagen stock solution (collagen I, bovine, 11.43 mg/ml; BD) by 
gentle pipetting. The prepared collagen solution was kept on ice until mixing with 
cells. Cells (either monoculture or coculture) were prepared at a concentration of 
5x107 cells/ml and 100 µl of cell suspension were pipetted into the prepared 
collagen solution (i.e. 5x106 cells/ml gels) and mixed carefully. Afterwards, a 
volume of 300 µl of the collagen solution (containing 1.5x106 cells) was aliquoted 
into non-adhesive 48 well plates (Greiner Bio-one) and incubated at 37°C in a 
humid atmosphere for 30 min to allow the solution to gel. After gelation, 0.5 ml of 
EM was added into each well and the samples were randomly allocated for in vitro 
and in vivo assessments. For in vitro experiments, samples were cultured in 1 ml of 
EM at 37 °C in a humid atmosphere, with medium refreshment twice a week. For in 
vivo experiments, samples were implanted within 2 h after gelation. After 3 and 7 
days in vitro culture or in vivo implantation, the samples were collected for further 
analysis (i.e. HE and CD31 staining, see below the detailed information for 
samples treatment in “Sample collection and analysis” section). 
2.3. In vivo implantation 
Ten healthy 9-week old male athymic nude mice (HsdCpb:NMRI-nu, Harlan), 
weighing 30-40 g, were used for in vivo study. The experiment was performed 
according to national guidelines for the use and care of laboratory animals, after 
ethical approval by the Animal Ethical Committee (RU-DEC 2011-269). 
Due to the lack of VLS forming capacity in monocultures (i.e. BM-Mo, AT-Mo and 
HUVECs) from in vitro evaluation, only coculture groups were included in the 
animal study (n=5): BM-Co and AT-Co (cells from two donors of each cell type 
were used). Cells were seeded in collagen gels as described above and the cell-
containing scaffolds were implanted within 2 h after gelation in athymic nude mice. 
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2.3. In vivo implantation 
Ten healthy 9-week old male athymic nude mice (HsdCpb:NMRI-nu, Harlan), 
weighing 30-40 g, were used for in vivo study. The experiment was performed 
according to national guidelines for the use and care of laboratory animals, after 
ethical approval by the Animal Ethical Committee (RU-DEC 2011-269). 
Due to the lack of VLS forming capacity in monocultures (i.e. BM-Mo, AT-Mo and 
HUVECs) from in vitro evaluation, only coculture groups were included in the 
animal study (n=5): BM-Co and AT-Co (cells from two donors of each cell type 
were used). Cells were seeded in collagen gels as described above and the cell-
containing scaffolds were implanted within 2 h after gelation in athymic nude mice. 
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Four subcutaneous pockets were created in each animal, with implants from the 
four donors (two donors each cell type) located randomly inside the pockets. 
Before surgery, animals were pre-medicated by subcutaneous injection of 
carprofen (5 mg/kg; Rimadyl®, Pfizer Animal Health B.V., Capelle aan de IJssel, 
Netherlands) to reduce operative pain. Surgery was performed under general 
anesthesia with nitrous oxide, oxygen, and isoflurane. The animals were placed in 
a ventral position and the dorsal flank of each mouse was shaved and disinfected 
with povidone-iodine. Four incisions were made on the dorsal flank of each mouse 
(two left and two right of the vertebral column) and the scaffolds were randomly 
implanted. Afterwards, the soft tissues were closed with staples (Agraven, Instruvet 
Boxmeer, the Netherlands). After surgery, subcutaneous injections of carprofen (5 
mg/kg; Rimadyl®) were given for 2 days to reduce postoperative pain. At 3 and 7 
days after implantation, the animals were euthanized using CO2 suffocation. The 
specimens with the surrounding tissue were retrieved and histologically processed. 
2.4. Gross examination of collagen gels (in vitro and in vivo) 
Collagen gels from both in vitro and in vivo study were macroscopically observed 
during samples collection/harvesting on both day 3 and 7. Images were taken 
using a digital camera (Canon). 
2.5. Sample collection and analysis (in vitro and in vivo) 
After 3 and 7 days in vitro culture (including both Thermanox® and collagen gels) or 
in vivo implantation (i.e. collagen gels), samples were washed in phosphate-
buffered saline (PBS) for three times, fixed in 10% neutral formalin and transferred 
into 70% ethanol. The samples were then dehydrated in a graded series of ethanol 
and processed as described below. 
2.6. Histology and immunohistochemistry 
For the Thermanox® samples, CD31 staining was performed after fixation. For the 
collagen gels both in vitro and in vivo, the samples were embedded in paraffin and 
cross-sections (5 µm) were made using a microtome (Leica). Consecutive sections 
were mounted on glass slides (3 sections per sample) and stained histologically 
(HE) and immunohistochemically (CD31). 
HE staining was performed according to a standard protocol from Merck Millipore. 
For CD31 staining, paraffin sections were rehydrated in serials of ethanol and 
antigen was retrieved by heating the slides in sodium citrate buffer (PH 6.0) at 
Chapter 8 
 
183 
 
70°C for 10 min. Subsequently, blocking was carried out using 10% normal donkey 
serum (NDS), and the primary antibody (rabbit anti-human CD31, clone EP3095, 
Millipore 04-1074, Billerica, USA) was diluted 1:150 in 2% NDS and incubated at 
4°C overnight. Slides were then treated with a biotin-conjugated secondary 
antibody (donkey anti-rabbit, Jackson ImmunoResearch, West Grove, PA, USA) at 
1:500 for 1 h at room temperature, followed by counterstaining with hematoxylin 
(Mayer). Negative controls using 2% NDS instead of the primary antibody were 
generated in parallel to ensure that the staining was specific. Finally, the sections 
were dehydrated and mounted. Stained sections were photographed with a Zeiss 
Imager Z1 microscope equipped with the AxioCam MRc5 camera using AxioVision 
4.8 software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). 
2.7. Histomorphometrical evaluation 
For in vivo samples, histomorphometrical analysis was performed to evaluate the 
angiogenic capacity of the two coculture systems (i.e. BM-Co and AT-Co) based 
on CD31 staining (n = 3 per sample). In brief, the sections were scored using 
computer-based image analysis techniques (Leica® Qwin Proimage analysis 
system, Wetzlar, Germany), which recognize human endothelial marker (CD31, 
stained as brown) within the collagen gels based on different RGB values from 
highly magnified (200x) digitalized images. Manual corrections were applied to 
ensure the precise selection of human CD31 staining positive parts within the 
region of interest (ROI, i.e. the total scaffold area). For the evaluation, VLS (from 
human origin) were defined by the presence of CD31 positive (evidenced by CD31 
positive staining; brownish) structures with lumens. The parameters for assessing 
the angiogenic capacity are listed below: 
 CD31%:   CD31-positive stained area (mm2)/ROI (mm2) 
 VLS area%:   CD31-positive stained area + lumen area 
(mm2)/ROI (mm2) 
 VLS density:   VLS number/ROI (mm2) 
 Average VLS area:  VLS area%/VLS density (mm2) 
2.8. Statistical analysis 
Data are expressed as mean ± standard deviation. Graphpad Instat software 
(Instat® 3.05, Graphpad Software Inc., La Jolla, USA) was used for statistical 
analysis. For comparison of the samples between day 3 and day 7 in each group, 
an independent t-test was performed. For the comparisons between the two 
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Four subcutaneous pockets were created in each animal, with implants from the 
four donors (two donors each cell type) located randomly inside the pockets. 
Before surgery, animals were pre-medicated by subcutaneous injection of 
carprofen (5 mg/kg; Rimadyl®, Pfizer Animal Health B.V., Capelle aan de IJssel, 
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buffered saline (PBS) for three times, fixed in 10% neutral formalin and transferred 
into 70% ethanol. The samples were then dehydrated in a graded series of ethanol 
and processed as described below. 
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For the Thermanox® samples, CD31 staining was performed after fixation. For the 
collagen gels both in vitro and in vivo, the samples were embedded in paraffin and 
cross-sections (5 µm) were made using a microtome (Leica). Consecutive sections 
were mounted on glass slides (3 sections per sample) and stained histologically 
(HE) and immunohistochemically (CD31). 
HE staining was performed according to a standard protocol from Merck Millipore. 
For CD31 staining, paraffin sections were rehydrated in serials of ethanol and 
antigen was retrieved by heating the slides in sodium citrate buffer (PH 6.0) at 
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70°C f r 10 min. Subsequently, blocking w s carried out using 10% normal donkey 
serum (NDS), and the primary antibo y (rabbit anti-human CD31, clone EP3095, 
Millipore 04-1074, Bi erica, USA) w s d luted 1:150 n 2% NDS and incubated at 
4°C overnight. Slides were then treated with a biotin-conjugated secondary 
antibody (donkey anti-rabbit, Jackson ImmunoResearch, West Grove, PA, USA) at 
1:500 for 1 h at room temperature, followed by counterstaining with hematoxylin 
(Mayer). Negative controls using 2% NDS instead of the primary antibody were 
generated in parallel to ensure that the staining was specific. Finally, the sections 
were dehydrated and mounted. Stained sections were photographed with a Zeiss 
Imager Z1 microscope equipped with the AxioCam MRc5 camera using AxioVision 
4.8 software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). 
2.7. Histomorphometrical evaluation 
For in vivo samples, histomorphometrical analysis was performed to evaluate th  
angiogenic capacity of the two coculture systems (i. . BM-Co and AT-Co) ased 
on CD31 staining (n = 3 per sampl ). In brief, th  sections were scored using 
computer-based image analysis techniqu s (Leica® Qwin Proimage analysis 
system, Wetzlar, Germany), which recognize human endothe i l mark r (CD31, 
stained as brown) within the colla n gels based on different RGB valu s from 
highly magnified (200x) digital zed images. Manual corrections wer  applied to 
ens re the precise selection of human CD31 staining positive p rts wi hin the 
region of interest (ROI, i.e. the total caffold area). For the evaluation, VLS (from 
human origin) w re defined b  th  presence of CD31 positive (evidenced by CD31 
positive st ining; brownish) structures with lume s. The parameter  for assessing 
the angiogeni  capacity are listed below: 
 CD31%:   CD31-po itive stai d area (mm2)/ROI (mm2) 
 VLS ar a%:   CD31-positiv  stained are  + lum n area 
(mm2)/ROI (mm2) 
 VLS density:   VLS number/ROI (mm2) 
 Average VLS area:  VLS area%/VLS density (mm2) 
2.8. Statistical analysis 
Data are expressed as mean ± standard deviation. Graphpad Instat software 
(Instat® 3.05, Graphpad Software Inc., La Jolla, USA) was used for statistical 
analysis. For comparison of the samples between day 3 and day 7 in each group, 
an independent t-test was performed. For the comparisons between the two 
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cocultures, data from the two donors of each cell type were pooled and a paired t-
test was carried out. 
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3. Results 
3.1. Vessel-like structures formation in vitro 
3.1.1. 2D culture (Thermanox®) 
For 2D culture, angiogenic capacity was evaluated on day 3 and 7 and 
representative images from day 3 are displayed (Figure 2), as observations were 
similar to those on day 7 for all experimental groups (i.e. BM-Mo, AT-Mo, HUVECs, 
BM-Co, and AT-Co). For both BM-Mo and AT-Mo, cells showed a spindle-like 
shape, without expressing CD31 marker. Monoculture of HUVECs demonstrated 
that the cells, which stained positively for CD31, distributed separately in a 
cobblestone-like morphology without VLS formation. Nevertheless, VLS, in which 
ECs re-oriented and elongated and were positively stained with CD31, were 
observed for both BM-Co and AT-Co. Moreover, VLS were more organized in AT-
Co compared to that in BM-Co. 
 
Figure 2. Vessel-like structure formation on Thermanox (n=3) on day 3 in vitro. CD31 staining (brown) 
demonstrated that obvious VLS were only observed in cocultures of BM-MSCs/HUVECs (BM-Co) or 
AT-MSCs/HUVECs (AT-Co) but not in monocultures of BM-MSCs (BM-Mo) or AT-MSCs (AT-Mo) or 
HUVECs. Samples on day 7 showed the same trend. VLS, vessel-like structures. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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cocultures, data from the two donors of each cell type were pooled and a paired t-
test was carried out. 
Chapter 8 
 
185 
 
3. Results 
3.1. Vessel-like structures formation in vitro 
3.1.1. 2D culture (Thermanox®) 
For 2D culture, angiogenic capacity was evaluated on day 3 and 7 and 
representative images from day 3 are displayed (Figure 2), as observations were 
similar to those on day 7 for all experimental groups (i.e. BM-Mo, AT-Mo, HUVECs, 
BM-Co, and AT-Co). For both BM-Mo and AT-Mo, cells showed a spindle-like 
shape, without expressing CD31 marker. Monoculture of HUVECs demonstrated 
that the cells, which stained positively for CD31, distributed separately in a 
cobblestone-like morphology without VLS formation. Nevertheless, VLS, in which 
ECs re-oriented and elongated and were positively stained with CD31, were 
observed for both BM-Co and AT-Co. Moreover, VLS were more organized in AT-
Co compared to that in BM-Co. 
 
Figure 2. Vessel-like structure formation on Thermanox (n=3) on day 3 in vitro. CD31 staining (brown) 
demon trated that obvious VLS were only observed in cocultures of BM-MSCs/HUVECs (BM-Co) or 
AT-MSCs/HUVECs (AT-Co) but not in monocultures of BM-MSCs (BM-Mo) or AT-MSCs (AT-Mo) or 
HUVECs. Samples on day 7 showed the same trend. VLS, vessel-like structures. 
Chapter 8 
 
186 
 
3.1.2. 3D culture (collagen gels) 
Macroscopic observation of the collagen gels from in vitro culture indicated gel 
shrinking over time in all the groups, except for HUVECs monoculture. 
Representative images of sections of both HE and CD31 stained collagen gels 
cultured in vitro are shown in Figure 3 (day 3) and Figure 4 (day 7). 
 
Figure 3. Vessel-like structure formation in collagen gels (n=3) on day 3 in vitro. HE staining showed 
homogeneous cell distribution (blue indicates cell nuclei) in BM-MSCs (BM-Mo), AT-MSCs (AT-Mo), 
BM-MSCs/HUVECs (BM-Co) and AT-MSCs/HUVECs (AT-Co) while cell number decreased and cells 
tended to cluster in monocultures of HUVECs. CD31 staining (brown) demonstrated that obvious VLS 
(indicated by arrows) were only observed in BM-Co and AT-Co rather than in BM-Mo, AT-Mo and 
HUVECs (*, clustered HUVECs). VLS, vessel-like structures. 
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For both BM-Mo and AT-Mo, cells spread randomly and dispersed evenly inside 
the scaffolds without CD31 expression on either day 3 or 7. In HUVECs culture, 
apparently lower number of CD31-positively stained cells was observed on both 
day 3 and 7. Additionally, cells tended to cluster and single cells could hardly be 
observed on day 3, with this became more distinct on day 7. In contrast, for both 
BM-Co and AT-Co culture, VLS formation initiated and mainly located at the 
margin of the scaffolds on day 3. VLS were found abundantly and became 
elongated and more organized on day 7. 
 
Figure 4. Vessel-like structure formation in collagen gels (n=3) on day 7 in vitro. HE staining showed 
homogeneous cell distribution (blue indicates cell nuclei) in BM-MSCs (BM-Mo) and AT-MSCs (AT-Mo), 
cell re-organization in BM-MSCs/HUVECs (BM-Co) and AT-MSCs/HUVECs (AT-Co) while hardly can 
cells be seen in monocultures of HUVECs. CD31 staining (brown) demonstrated that obvious VLS 
(indicated by arrows) could be observed only in BM-Co and AT-Co. VLS, vessel-like structures. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
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 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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3.2. In vivo experiment 
3.2.1. Gross examination 
All animals recovered uneventfully from the surgery and no infections or 
complications occurred during the implantation period. All samples (n=5 per group) 
were retrieved and at retrieval, no macroscopic signs of inflammation or adverse 
tissue response in the implantation area were observed. The scaffolds were in an 
oval shape, with a dimension of ~3 mm (Figure 5). Blood vessels from the host 
were found surrounding the scaffolds on both day 3 (Figure 5a) and day 7 (Figure 
5b) and even penetrating into the scaffolds on day 7. 
 
Figure 5. Explantation after 3 and 7 days in vivo implantation. (a) harvesting on day 3; (b) harvesting on 
day 7. Arrows indicate vessels surrounding or penetrating inside the scaffolds. 
3.2.2. Descriptive histology 
Both HE and CD31 stained sections of collagen gels retrieved in vivo are shown in 
Figure 6 (day 3) and Figure 7 (day 7). Cell nuclei were stained as blue in both HE 
and CD31 staining, while cytoplasm was stained as pink in HE and human 
endothelial cell marker was stained as brown in CD31 staining. Images from HE 
and CD31 staining were from consecutive sections, with a distance of 5 µm. In 
general, none of the specimens showed the presence of an inflammatory response. 
No obvious fibrous encapsulation was observed surrounding the scaffolds on day 3 
while the encapsulation was more distinct on day 7. All samples were condensed 
and there was no visible degradation. Cells were found inside the entire collagen 
gels on both day 3 and day 7, irrespective of BM-Co and AT-Co. On day 3 (Figure 
6), VLS were observed from co-localized images out of both HE and CD31 staining 
for both BM-Co and AT-Co. At higher magnification, human endothelial cell marker 
CD31 staining indicated that VLS were from human origin. No erythrocytes were 
observed in the newly formed VLS. On day 7 (Figure 7), VLS were observed 
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throughout the entire scaffold, with a pronounced increase in the size of VLS 
compared to those on day 3, especially for those at the margin of the scaffolds. At 
higher magnification, some of the blood vessels clearly contained erythrocytes and 
were mostly found in the periphery of the scaffolds. In addition, these blood vessels 
were closely associated with cells staining positively for human specific CD31 
marker. 
 
Figure 6. Representative image of vessel-like structures formation after 3 days in vivo implantation (n=5). 
Images of HE and CD31 staining for each sample were from consecutive sections, with a distance of 5 
um. VLS can be observed in both BM-MSCs/HUVECs (BM-Co) and AT-MSCs/HUVECs (AT-Co) from 
CD31 staining (arrows), though no erythrocytes were found inside the VLS. VLS, vessel-like structures. 
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Figure 7. Representative image of vessel-like structures formation after 7 days in vivo implantation (n=5). 
Images of HE and CD31 staining for each sample were from consecutive sections, with a distance of 5 
um. VLS can be observed in both BM-MSCs/HUVECs (BM-Co) and AT-MSCs/HUVECs (AT-Co) from 
CD31 staining (arrows), and they anastomosed with host vasculature, with erythrocytes inside the VLS. 
VLS, vessel-like structures. 
3.2.3. Histomorphometry 
Quantification of the angiogenic capacity of BM-Co and AT-Co is presented in 
Figure 8. Both the comparison between the two cocultures (i.e. BM-Co vs. AT-Co, 
two donors each) as well as the differences in angiogenesis over time (i.e. day 3 vs. 
day 7) were evaluated. For CD31-positive stained area (Figure 8b), no significant 
difference was found for AT-Co compared to BM-Co, neither on day 3 nor on day 7. 
Regarding the differences in angiogenesis over time in both cocultures, a 
significant decrease in CD31-positive stained area (p<0.05) was only observed in 
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BM-Co (donor 1) from day 3 to 7. For VLS area (i.e. (CD31-positive stained area + 
lumen area) /ROI, Figure 8c), no difference was found in the comparison of either 
between the two types of cocultures or between the two time points. For VLS 
density (Figure 8d), AT-Co induced equal VLS density compared to BM-Co at both 
day 3 and day 7. In addition, a significant decrease in VLS density was observed 
over time for both BM-Co and AT-Co (two donors for each cell type). Although the 
average VLS area tended to increase over time, the increase was not significant 
(Figure 8e). 
 
Figure 8. Quantification of vessel-like structures after 3 and 7 days in vivo implantation (n=5). (a) 
Schematic picture showing the parameters in VLS. (b) CD31 percentage [CD31-positive area 
(mm2)/ROI (mm2)]. (c) Percentage of VLS area [VLS area (CD31-positive area + lumen area, mm2)/ROI 
(mm2)]. (d) VLS density [VLS number/ROI (mm2)]. (e) Average VLS area [percentage of VLS area/VLS 
density (/mm2)]. *, p<0.05; **, p<0.01, indicate significant difference between day 3 and day 7. VLS, 
vessel-like structures. ROI, total scaffold area. BM-Co, BM-MSCs/HUVECs; AT-Co, AT-MSCs/HUVECs. 
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BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
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Figure 7. Representative image of vessel-like structures formation after 7 days in vivo implantation (n=5). 
Images of HE and CD31 staining for each sample were from consecutive sections, with a distance of 5 
um. VLS can be observed in both BM-MSCs/HUVECs (BM-Co) and AT-MSCs/HUVECs (AT-Co) from 
CD31 staining (arrows), and they anastomosed with host vasculature, with erythrocytes inside the VLS. 
VLS, vessel-like structures. 
3.2.3. Histomorphometry 
Quantification of the angiogenic capacity of BM-Co and AT-Co is presented in 
Figure 8. Both the comparison between the two cocultures (i.e. BM-Co vs. AT-Co, 
two donors each) as well as the differences in angiogenesis over time (i.e. day 3 vs. 
day 7) were evaluated. For CD31-positive stained area (Figure 8b), no significant 
difference was found for AT-Co compared to BM-Co, neither on day 3 nor on day 7. 
Regarding the differences in angiogenesis over time in both cocultures, a 
significant decrease in CD31-positive stained area (p<0.05) was only observed in 
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BM-Co (donor 1) fr m day 3 to 7. For VLS area (i.e. (CD31-p sitive stained area + 
lumen are ) /ROI, Figure 8c), no diff rence was found in the comparison of ither 
between the two types of c cultures or between the two time points. F r VLS 
density (Figure 8d), AT-Co induced equal VLS density compared to BM-Co at both 
day 3 and day 7. In addition, a significant decrease in VLS density was observed 
over time for both BM-Co and AT-Co (two donors for each cell type). Although the 
average VLS area tended to increase over time, the increase was not significant 
(Figure 8e). 
 
Figure 8. Quantification of vessel-like structures after 3 and 7 days in vivo implantation (n=5). (a) 
Schematic picture showing the parameters in VLS. (b) CD31 percentage [CD31-positive area 
(mm2)/ROI (mm2)]. (c) Percentage of VLS area [VLS area (CD31-positive area + lumen area, mm2)/ROI 
(mm2)]. (d) VLS density [VLS number/ROI (mm2)]. (e) Average VLS area [percentage of VLS area/VLS 
density (/mm2)]. *, p<0.05; **, p<0.01, indicate significant difference between day 3 and day 7. VLS, 
vessel-like structures. ROI, total scaffold area. BM-Co, BM-MSCs/HUVECs; AT-Co, AT-MSCs/HUVECs. 
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4. Discussion 
The aim of this study was to compare the angiogenic capacity between BM-
MSCs/HUVECs and AT-MSCs/HUVECs cocultures at early time points (i.e. day 3 
and 7) both in vitro and in vivo. It was hypothesized that AT-MSCs/HUVECs can 
form similar numbers of vessel-like structures compared to BM-MSCs/HUVECs. In 
vitro, cells from both monocultures (i.e. BM-MSCs, AT-MSCs and HUVECs) and 
cocultures (i.e. BM-MSCs/HUVECs and AT-MSCs/HUVECs) were evaluated in 2D 
(Thermanox®) and 3D (collagen gels) conditions. In vivo, cocultures (i.e. BM-
MSCs/HUVECs and AT-MSCs/HUVECs) were embedded in collagen gels and 
implanted subcutaneously in athymic nude mice. Samples were collected on day 3 
and 7 and followed by HE and CD31 staining for both in vitro and in vivo 
experiments. The angiogenic capacity of cocultures from in vivo experiment was 
evaluated quantitatively. The in vitro study showed that VLS formed in cocultures 
but not in monocultures. VLS were more organized in 2D cultures and similar in 3D 
cultures when AT-MSCs/HUVECs were compared to BM-MSCs/HUVECs. 
Moreover, no change was observed in angiogenesis over time. AT-MSCs/HUVECs 
showed equal in vivo angiogenic capacity as BM-MSCs/HUVECs. Similarly, in both 
of the cocultures, anastomosis with the host vessels was observed while the 
density of VLS decreased over time. 
A number of studies have proven that direct contact and communication between 
ECs and pericyte-like cells are essential for vascularization26,34. In this study, cells 
were cultured in direct contact and a 1:1 cell ratio was chosen because firstly it was 
proven to be optimal for VLS formation for BM-Co in vitro27, though no research on 
the optimal cell ratio for AT-Co is available; and secondly, a 1:1 cell ratio was 
considered to be the most appropriate for osteogenesis for the cocultures using 
both BM-MSCs33 and AT-MSCs32,35. Endothelial cell culture medium was selected 
as it favored growth factors involved in vessel stabilization by pericytes in 
cocultures36. Furthermore, it has been reported that both BM-MSCs37 and AT-
MSCs38 can function as pericyte-like cells by directly contacting ECs to firstly 
induce vessel-like structure formation and subsequent stabilization24. In contrast, 
ECs monocultures were not able to form stable VLS, meaning either VLS cannot 
be formed or even if they are formed, they cannot remain stable and normally 
undergo regression13,39. Previous work has demonstrated that monocultures of 
HUVECs cannot survive prolonged culture periods in 3D culture (i.e. >6 weeks)13. 
Our study has further confirmed this by observing an apparent decrease in cell 
number, indicating low cell viability and probably cell death within short period (i.e. 
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3 and 7 days) in 3D HUVECs monocultures. By monoculturing BM-MSCs or AT-
MSCs in endothelial cell culture medium, no VLS were formed in vitro (neither on 
2D Thermanox® nor in 3D collagen gels). Therefore, only cocultures were chosen 
for in vivo study for the further comparison of the angiogenic capacity between the 
two cocultures over time. 
In general, the outcome of this study demonstrated that AT-Co had similar 
angiogenic capacity as BM-Co both in vitro and in vivo, using two donors for each 
cell type, without obvious donor-dependency. Conversely, in a recent study, AT-Co 
showed higher VLS density compared to BM-Co on both day 7 and 14 when cells 
were cultured in fibrin gel and injected subcutaneously in athymic nude mice30. It 
has been reported that matrix composition can regulate VLS formation, which 
might explain the difference between those results using fibrin and our results 
using collagen gels26. Nevertheless, collagen gels represent a more suitable model 
for physiological and developmental angiogenesis and hence were used in this 
study, which aimed to comparatively evaluate VLS forming capacity in two types of 
cocultures. 
Regarding VLS formation over time, VLS density decreased and anastomosed in 
both the cocultures. Partially consistent with 2-D in vitro culture using AT-MSCs, in 
which ECs number percentage as well as CD31 intensity decreased over 6 days 
culture40, CD31 percentage declined in one donor (donor 1, BM-Co) and 
maintained stable in the other three donors in this study. Although from both 
microscopic observation and the quantitative analysis the size of VLS tended to 
increase over time, no statistically difference was found for both BM-Co and AT-Co 
culture. This is in contrast with previous work41, in which the diameter of VLS 
significantly increased when BM-Co was cultured in fibrin gel and injected 
subcutaneously into athymic nude mice. Nonetheless, it needs to be emphasized 
that in that study the size of only the perfused human blood vessels was analyzed 
while in our study the size of all human origin VLS (including both perfused and 
non-perfused ones) were determined. Previous work reported that VLS density 
decreased from day 7 to 1430, and our study further displayed that VLS density 
also dropped dramatically at the earlier time points (from day 3 to 7). Besides, it 
has been reported that the total VLS density, which included both human and 
murine origin VLS, was also identical in the two cocultures in Matrigel® after 7 days 
culture31. Although the authors are aware that the cell and scaffold type may also 
influence angiogenic capacity, it is necessary to stress that anastomosis with the 
host vessels took place without in vitro (pre)vasculature formation, in contrast to 
reports in which the cell-scaffold constructs were (pre)cultured in vitro for at least 7 
days to form vascularization before in vivo implantation12,39. Further, perfused 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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4. Discussion 
The aim of this study was to compare the angiogenic capacity between BM-
MSCs/HUVECs and AT-MSCs/HUVECs cocultures at early time points (i.e. day 3 
and 7) both in vitro and in vivo. It was hypothesized that AT-MSCs/HUVECs can 
form similar numbers of vessel-like structures compared to BM-MSCs/HUVECs. In 
vitro, cells from both monocultures (i.e. BM-MSCs, AT-MSCs and HUVECs) and 
cocultures (i.e. BM-MSCs/HUVECs and AT-MSCs/HUVECs) were evaluated in 2D 
(Thermanox®) and 3D (collagen gels) conditions. In vivo, cocultures (i.e. BM-
MSCs/HUVECs and AT-MSCs/HUVECs) were embedded in collagen gels and 
implanted subcutaneously in athymic nude mice. Samples were collected on day 3 
and 7 and followed by HE and CD31 staining for both in vitro and in vivo 
experiments. The angiogenic capacity of cocultures from in vivo experiment was 
evaluated quantitatively. The in vitro study showed that VLS formed in cocultures 
but not in monocultures. VLS were more organized in 2D cultures and similar in 3D 
cultures when AT-MSCs/HUVECs were compared to BM-MSCs/HUVECs. 
Moreover, no change was observed in angiogenesis over time. AT-MSCs/HUVECs 
showed equal in vivo angiogenic capacity as BM-MSCs/HUVECs. Similarly, in both 
of the cocultures, anastomosis with the host vessels was observed while the 
density of VLS decreased over time. 
A number of studies have proven that direct contact and communication between 
ECs and pericyte-like cells are essential for vascularization26,34. In this study, cells 
were cultured in direct contact and a 1:1 cell ratio was chosen because firstly it was 
proven to be optimal for VLS formation for BM-Co in vitro27, though no research on 
the optimal cell ratio for AT-Co is available; and secondly, a 1:1 cell ratio was 
considered to be the most appropriate for osteogenesis for the cocultures using 
both BM-MSCs33 and AT-MSCs32,35. Endothelial cell culture medium was selected 
as it favored growth factors involved in vessel stabilization by pericytes in 
cocultures36. Furthermore, it has been reported that both BM-MSCs37 and AT-
MSCs38 can function as pericyte-like cells by directly contacting ECs to firstly 
induce vessel-like structure formation and subsequent stabilization24. In contrast, 
ECs monocultures were not able to form stable VLS, meaning either VLS cannot 
be formed or even if they are formed, they cannot remain stable and normally 
undergo regression13,39. Previous work has demonstrated that monocultures of 
HUVECs cannot survive prolonged culture periods in 3D culture (i.e. >6 weeks)13. 
Our study has further confirmed this by observing an apparent decrease in cell 
number, indicating low cell viability and probably cell death within short period (i.e. 
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3 and 7 days) in 3D HUVECs monocultures. By monoculturing BM-MSCs or AT-
MSCs in endothelial cell culture medium, no VLS were formed in vitro (neither on 
2D Thermanox® nor in 3D collag n gels). T erefore, only cocultures were cho en 
for in vivo study for the further comparison of the angiogenic capacity between the 
two cocultures over time. 
In general, the outcome of this study demonstrated that AT-Co had similar 
angiogenic capacity as BM-Co both in vitro and in vivo, using two donors for each 
cell type, without obvious donor-dependency. Conversely, in a recent study, AT-Co 
showed higher VLS density compared to BM-Co on both day 7 and 14 when cells 
were cultured in fibrin gel and injected subcutaneously in athymic nude mice30. It 
has been reported that matrix composition can regulate VLS formation, which 
might explain the difference between those results using fibrin and our results 
using collagen gels26. Nevertheless, collagen gels represent a more suitable model 
for physiological and developmental angiogenesis and hence were used in this 
study, which aimed to comparatively evaluate VLS forming capacity in two types of 
cocultures. 
Regarding VLS formation over time, VLS density decreased and anastomosed in 
both the cocultures. Partially consistent with 2-D in vitro culture using AT-MSCs, in 
which ECs number percentage as well as CD31 intensity decreased over 6 days 
culture40, CD31 percentage declined in one donor (donor 1, BM-Co) and 
maintained stable in the other three donors in this study. Although from both 
microscopic observation and the quantitative analysis the size of VLS tended to 
increase over time, no statistically difference was found for both BM-Co and AT-Co 
culture. This is in contrast with previous work41, in which the diameter of VLS 
significantly increased when BM-Co was cultured in fibrin gel and injected 
subcutaneously into athymic nude mice. Nonetheless, it needs to be emphasized 
that in that study the size of only the perfused human blood vessels was analyzed 
while in our study the size of all human origin VLS (including both perfused and 
non-perfused ones) were determined. Previous work reported that VLS density 
decreased from day 7 to 1430, and our study further displayed that VLS density 
also dropped dramatically at the earlier time points (from day 3 to 7). Besides, it 
has been reported that the total VLS density, which included both human and 
murine origin VLS, was also identical in the two cocultures in Matrigel® after 7 days 
culture31. Although the authors are aware that the cell and scaffold type may also 
influence angiogenic capacity, it is necessary to stress that anastomosis with the 
host vessels took place without in vitro (pre)vasculature formation, in contrast to 
reports in which the cell-scaffold constructs were (pre)cultured in vitro for at least 7 
days to form vascularization before in vivo implantation12,39. Further, perfused 
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vessels stained positively for human specific CD31, meaning that the newly formed 
human vasculature had formed functional anastomoses with host blood vessels. 
However, quantification of perfused vessels (i.e. blood vessels with erythrocytes) 
was not performed because of the possibility of erythrocytes leakage during 
sample treatment for histology. Besides, the presence of the human CD31 marker 
in both BM-Co and AT-Co after in vivo implantation suggests that the implanted 
human endothelial cells survived until (at least) 7 days, demonstrating the 
contribution and feasibility of cocultured angiogenic cells in cell-based bone 
regenerative strategies. 
In summary, the results of this study indicate that VLS can form in both BM-Co and 
AT-Co cocultures, but not in any of the monocultures (i.e. BM-MSCs, AT-MSCs 
and HUVECs), irrespective of 2D and 3D culture in vitro. Moreover, VLS formed in 
AT-Co were more organized in 2D culture and similar in 3D culture when compared 
to that of BM-Co. After in vivo implantation, AT-Co showed equal VLS forming 
capacity compared to BM-Co, with the VLS anastomosed with host vasculature 
over time. The outcomes of this study indicate that AT-Co had comparable 
angiogenic capacity to BM-Co. 
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5. Conclusions 
This study demonstrated that cocultures of AT-MSCs with ECs have a similar 
angiogenic capacity compared to cocultures of BM-MSCs with ECs in collagen gels 
both in vitro and in vivo. Vessel-like structures were observed in both cocultures, 
which showed anastomosis with host vasculature within 7 days of implantation. 
Chapter 2 
 
28 
 
contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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vessels stained positively for human specific CD31, meaning that the newly formed 
human vasculature had formed functional anastomoses with host blood vessels. 
However, quantification of perfused vessels (i.e. blood vessels with erythrocytes) 
was not performed because of the possibility of erythrocytes leakage during 
sample treatment for histology. Besides, the presence of the human CD31 marker 
in both BM-Co and AT-Co after in vivo implantation suggests that the implanted 
human endothelial cells survived until (at least) 7 days, demonstrating the 
contribution and feasibility of cocultured angiogenic cells in cell-based bone 
regenerative strategies. 
In summary, the results of this study indicate that VLS can form in both BM-Co and 
AT-Co cocultures, but not in any of the monocultures (i.e. BM-MSCs, AT-MSCs 
and HUVECs), irrespective of 2D and 3D culture in vitro. Moreover, VLS formed in 
AT-Co were more organized in 2D culture and similar in 3D culture when compared 
to that of BM-Co. After in vivo implantation, AT-Co showed equal VLS forming 
capacity compared to BM-Co, with the VLS anastomosed with host vasculature 
over time. The outcomes of this study indicate that AT-Co had comparable 
angiogenic capacity to BM-Co. 
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5. Conclusions 
This study demonstrated that cocultures of AT-MSCs with ECs have a similar 
angiogenic capacity compared to cocultures of BM-MSCs with ECs in collagen gels 
both in vitro and in vivo. Vessel-like structures were observed in both cocultures, 
which showed anastomosis with host vasculature within 7 days of implantation. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
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Summary 
Bone tissue engineering (BTE) represents a promising approach for bone 
regeneration, even though great challenges remain. The use of mesenchymal stem 
cells (MSCs) in BTE approaches has been proven to be valuable for increasing the 
bone regeneration capacity in animal studies1. Among the different types of MSCs, 
those derived from bone marrow (BM) are the most commonly used and have 
been extensively studied in BTE. Nevertheless, a major challenge for MSCs 
transplantation is to obtain a large number of cells from an easily accessible 
location2. Since BM-MSCs cannot fully meet these requirements, MSCs derived 
from adipose tissue (AT) have attracted increased research attention to act as an 
alternative cell source in cell-based BTE. 
Beside cell source, it is well-recognized that vascularization inside engineered 
constructs is pre-requisite for BTE strategies. Insufficient vascularization results in 
poor cell survival within the construct3-4 and hampers the success of bone 
regeneration especially for large bone defects5-6. To address this problem, 
research efforts have been dedicated to possible strategies to improve bone tissue 
regeneration by improving vascularization in engineered constructs. Several 
techniques have been utilized, for instance biofabrication of scaffolds with 
angiogenesis properties, growth factor delivery to direct blood vessel formation, 
and coculturing MSCs with endothelial cells (ECs). The underlying principle of 
using a coculture system of MSCs and ECs in BTE is based on the intricate 
connection between osteogenesis and angiogenesis during bone formation. This 
connection is evidenced by the fact that bone is a highly vascularized tissue, in 
which close spatial and temporal association occurs between blood vessels and 
bone cells7. Recent ﬁndings have shown that cocultures of BM-MSCs and ECs can 
enhance vascular network formation8-9 as well as bone formation10-11 compared to 
BM-MSC monocultures. However, few studies have focused on the use of AT-
MSCs for this application. 
The aim of this thesis was to evaluate the effects of MSC origin (i.e. BM or AT) on 
osteogenesis and angiogenesis for both MSCs monocultures and cocultures with 
ECs. To this end, the (co)culture conditions (e.g. culture medium, cell ratio) were 
firstly optimized. In Chapter 1, a brief introduction has been given on BTE and the 
relative cellular strategies, as well as cocultures for BTE applications. This 
summary addresses the aims as described in the first chapter in a successive 
order. 
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1. What is the current state of the art for the use of BM-MSCs and AT-MSCs, and 
their cocultures with ECs in BTE? 
Cells represent a basic component in BTE. The current status of the in vitro culture 
conditions and in vivo bone forming efficacy of BM-MSCs and AT-MSCs, and their 
cocultures with ECs has been reviewed in Chapter 2, in which the inconsistency in 
scientific literature regarding the effects of both preparation of cell-based 
constructs and MSC origin on osteogenesis and angiogenesis was summarized. 
Firstly, the variability in the in vitro pre-culture conditions (e.g. culture medium, pre-
culture time) was reviewed as these influence the experimental outcomes. 
Secondly, the bone forming efficacy of cell-based constructs was compared to 
acellular constructs, including discrimination for monoculture and coculture 
approaches. Most of the published results are related to BM-MSCs and little 
information was found regarding the use of AT-MSCs. In conclusion, cell-based 
strategies appear promising since they are beneficial for in vivo bone formation, 
albeit that in vitro cell (co)culture conditions urgently need standardization and 
optimization to allow inter-experiment comparisons and further increase the 
potential of cell-based BTE/RM. 
2. What is the optimal cell culture medium and cell ratio in cocultures of BM-
MSCs/ECs, in terms of osteogenesis and angiogenesis? 
Based on the fact that various culture media and cell ratios have been used 
previously in BM-MSCs/ECs cocultures and no consensus has been reached, the 
optimal culture medium and cell ratio for both osteogenesis and angiogenesis was 
explored in Chapter 3. Cell (co)cultures were performed in four different media: 
MSCs proliferation medium, osteogenic medium (OM), endothelial medium, and a 
1:1 mixture of the latter two media. Mineralization within the cocultures was 
observed only in OM. Subsequent experiments for cells cultured in OM showed 
that alkaline phosphatase (ALP) activity, mineralization, and CD31 (platelet 
endothelial cell adhesion molecule, PECAM-1) positive staining percentage were 
highest for cocultures at a 50:50 BM-MSCs/ECs ratio. The results from this study 
demonstrated that a BM-MSCs/ECs coculture ratio of 50:50 in OM is the optimal 
condition to obtain both osteogenic and angiogenic differentiation. 
3. Is human platelet lysate an ideal alternative to fetal bovine serum to be used as 
a supplement in culture medium for both BM-MSCs and AT-MSCs, and their 
cocultures with ECs? 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Summary 
Bone tissue engineering (BTE) represents a promising approach for bone 
regeneration, even though great challenges remain. The use of mesenchymal stem 
cells (MSCs) in BTE approaches has been proven to be valuable for increasing the 
bone regeneration capacity in animal studies1. Among the different types of MSCs, 
those derived from bone marrow (BM) are the most commonly used and have 
been extensively studied in BTE. Nevertheless, a major challenge for MSCs 
transplantation is to obtain a large number of cells from an easily accessible 
location2. Since BM-MSCs cannot fully meet these requirements, MSCs derived 
from adipose tissue (AT) have attracted increased research attention to act as an 
alternative cell source in cell-based BTE. 
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MSCs for this application. 
The aim of this thesis was to evaluate the effects of MSC origin (i.e. BM or AT) on 
osteogenesis and angiogenesis for both MSCs monocultures and cocultures with 
ECs. To this end, the (co)culture conditions (e.g. culture medium, cell ratio) were 
firstly optimized. In Chapter 1, a brief introduction has been given on BTE and the 
relative cellular strategies, as well as cocultures for BTE applications. This 
summary addresses the aims as described in the first chapter in a successive 
order. 
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1. What is the current state of the art for the use of BM-MSCs and AT-MSCs, a d 
their cocultures with ECs in BTE? 
Cells represent a basic component in BTE. The current status of the in vitro culture 
conditions and in vivo bone forming efficacy of BM-MSCs and AT-MSCs, a d their 
cocultures with ECs has been reviewed in Chapter 2, in which the inconsistency in 
scientific literature regarding the effects of both preparation of cell-based 
constructs and MSC origin on osteogenesis and angiogenesis was summarized. 
Firstly, the variability in the in vitro pre-culture conditions (e.g. culture medium, pre-
culture time) was reviewed as these influence the experimental outcomes. 
Secondly, the bone forming efficacy of cell-based constructs was compared to 
acellular constructs, including discrimination for monoculture and coculture 
approaches. Most of the published results are related to BM-MSCs and little 
information was found regarding the use of AT-MSCs. In conclusion, cell-based 
strategies appear promising since they are beneficial for in vivo bone formation, 
albeit that in vitro cell (co)culture conditions urgently need standardization and 
optimization to allow inter-experiment comparisons and further increase the 
potential of cell-based BTE/RM. 
2. What is th  optimal cell culture medium and cell r tio in coculture  of BM-
MSCs/ECs, in terms of osteogenesi and a giog sis? 
Based on the fact that various culture media and cell ratios have been used 
previously in BM-MSCs/ECs cocultures and no consensus has been reached, the 
optimal culture medium and cell ratio for both osteogenesis and angiogenesis was 
explored in Chapter 3. Cell (co)cultures were performed in four different media: 
MSCs proliferation medium, osteogenic medium (OM), endothelial medium, and a 
1:1 mixture of the latter two media. Mineralization within the cocultures was 
observed only in OM. Subsequent experiments for cells cultured in OM showed 
that alkaline phosphatase (ALP) activity, mineralization, and CD31 (platelet 
endothelial cell adhesion molecule, PECAM-1) positive staining percentage were 
highest for cocultures at a 50:50 BM-MSCs/ECs ratio. The results from this study 
demonstrated that a BM-MSCs/ECs coculture ratio of 50:50 in OM is the optimal 
condition to obtain both osteogenic and angiogenic differentiation. 
3. Is human platelet lysate an ideal alternative to fetal bovine serum to be used as 
a supplement in culture medium for both BM-MSCs and AT-MSCs, and their 
cocultures with ECs? 
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As mentioned earlier, BM-MSCs and AT-MSCs represent the most frequently used 
stem cells in BTE/RM. Considering the clinical demands, it is necessary to find an 
optimally safe and efficient way for the large-scale expansion of these cells. Until 
now, fetal bovine serum (FBS) has been used as the nutritional supplement in cell 
cultures. However, due to the risks of transmission of animal pathogens into 
human beings in future clinical application, alternatives for FBS have been 
explored, e.g. human platelet lysate (PL). In Chapter 4, we aimed to analyze the 
effects of FBS- and PL-supplemented medium on osteogenesis in MSCs 
monocultures or cocultures with ECs. Cells from three donors of each type (i.e. 
BM-MSCs and AT-MSCs) were used and cell proliferation and osteogenic 
differentiation were evaluated. The results showed that cell metabolic activity and 
proliferation increased in PL- compared to FBS-supplemented medium in 
monocultures and cocultures for both BM-MSCs and AT-MSCs. On the other hand, 
calcium deposition was cell type-dependent and decreased for BM-MSCs, but 
increased for AT-MSCs in PL-supplemented medium in both mono- and cocultures. 
In view of the effects of cocultures, BM-MSCs/ECs enhanced osteogenesis 
compared to BM-MSCs monocultures in both FBS- and PL-supplemented media, 
whereas AT-MSCs/ECs showed similar results compared to AT-MSCs 
monocultures. From these data, it can be concluded that FBS-supplemented 
medium is more suitable for inducing BM-MSCs to mineralize, while PL-
supplemented medium favors AT-MSCs osteogenic differentiation, irrespective of 
monoculture or coculture conditions. 
4. What is the optimal cell loading method for osteogenesis of BM-MSCs, AT-
MSCs, and their cocultures with ECs in hydrogels? 
After the optimal culture medium for both BM-MSCs and AT-MSCs was determined 
in two-dimensional (2D) culture conditions in Chapter 4, a subsequent study was 
performed using three-dimensional (3D) culture conditions, in which cells were 
incorporated within hydrogels (Chapter 5). Hydrogels have attracted huge interests 
for minimally invasive surgical applications because of their injectability, among 
which collagen and oligo(poly(ethylene glycol)fumarate) (OPF) hydrogels are 
representatives of two main categories, i.e. natural and synthetic based hydrogels, 
respectively. Regarding cell loading methods (i.e. cell distribution) in hydrogels, 
single cells were often encapsulated and dispersed homogenously throughout the 
hydrogels, which is called dispersed- (D-) loading. However, due to the spatial 
distribution of the cells in this seeding method, cell-cell contact can be 
compromised and hamper cell performance. Therefore, both sandwich- (S-, cells 
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were loaded in between two hydrogel layers) and spheroid- (Sp-, spheroids were 
encapsulated in hydrogels, rather than single cells) loading were hypothesized to 
induce higher osteogenesis because of the improved cell-cell contact. The cell 
behavior of both BM-MSCs and AT-MSCs in three loading methods, which are D-, 
S- and Sp-loading in two hydrogel systems (i.e. collagen and OPF), was compared. 
The results suggested that the cell behavior was influenced by the hydrogel type, 
meaning cells cultured in collagen hydrogels had higher proliferation and 
osteogenic differentiation capacity than in OPF hydrogels. In addition, AT-MSCs 
exhibited higher proliferation and osteogenic properties compared to BM-MSCs. 
However, no difference was observed for mineralization among the three loading 
methods, which did not confirm the hypothesis that S- and Sp-loading increases 
osteogenic capacity compared to D-loading. In conclusion, D- and Sp-loading 
represents two promising cell loading methods for injectable bone substitute 
materials that allow application of minimally invasive surgery for cell-based 
regenerative treatment. 
5. Will cocultures of AT-MSCs/ECs form more bone in comparison to AT-MSCs 
monocultures in an orthotopic implantation model? 
While the bone forming capacity of BM-MSCs has been proved by a number of 
studies12-13, the feasibility of bone formation using AT-MSCs remains 
controversial14-16. In Chapter 6, the osteogenic capacity between AT-MSCs and 
AT-MSCs/ECs was compared both in vitro and in vivo (i.e. rat cranial defects). 
Firstly, the optimal cell ratio in cocultures for osteogenic differentiation was 
determined by seeding AT-MSCs and ECs in ratios varying from 100:0 to 0:100 on 
tissue culture plates. Afterwards, AT-MSCs and AT-MSCs/ECs were seeded on 
porous titanium fiber mesh scaffolds (Ti) for both in vitro and in vivo osteogenic 
evaluation. For in vitro evaluation, osteogenic differentiation was assessed by ALP-
activity and calcium assay. For in vivo evaluation, the scaffolds were implanted 
bilaterally into rat cranial defects (5 mm diameter) and bone formation was 
assessed histologically and histomorphometrically after 8 weeks. The ratio of 50:50 
was chosen in the cocultures since this coculture condition retained similar amount 
of calcium deposition while using the least number of AT-MSCs. Moreover, AT-
MSCs showed higher osteogenic differentiation in comparison to AT-MSCs/ECs on 
Ti in vitro. Further, superior bone formation was observed in AT-MSCs compared 
to AT-MSCs/ECs in rat cranial defects. In conclusion, AT-MSCs showed 
significantly higher osteogenic potential compared to AT-MSCs/ECs both in vitro 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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As mentioned earlier, BM-MSCs and AT-MSCs represent the most frequently used 
stem cells in BTE/RM. Considering the clinical demands, it is necessary to find an 
optimally safe and efficient way for the large-scale expansion of these cells. Until 
now, fetal bovine serum (FBS) has been used as the nutritional supplement in cell 
cultures. However, due to the risks of transmission of animal pathogens into 
human beings in future clinical application, alternatives for FBS have been 
explored, e.g. human platelet lysate (PL). In Chapter 4, we aimed to analyze the 
effects of FBS- and PL-supplemented medium on osteogenesis in MSCs 
monocultures or cocultures with ECs. Cells from three donors of each type (i.e. 
BM-MSCs and AT-MSCs) were used and cell proliferation and osteogenic 
differentiation were evaluated. The results showed that cell metabolic activity and 
proliferation increased in PL- compared to FBS-supplemented medium in 
monocultures and cocultures for both BM-MSCs and AT-MSCs. On the other hand, 
calcium deposition was cell type-dependent and decreased for BM-MSCs, but 
increased for AT-MSCs in PL-supplemented medium in both mono- and cocultures. 
In view of the effects of cocultures, BM-MSCs/ECs enhanced osteogenesis 
compared to BM-MSCs monocultures in both FBS- and PL-supplemented media, 
whereas AT-MSCs/ECs showed similar results compared to AT-MSCs 
monocultures. From these data, it can be concluded that FBS-supplemented 
medium is more suitable for inducing BM-MSCs to mineralize, while PL-
supplemented medium favors AT-MSCs osteogenic differentiation, irrespective of 
monoculture or coculture conditions. 
4. What is the optimal cell loading method for osteogenesis of BM-MSCs, AT-
MSCs, and their cocultures with ECs in hydrogels? 
After the optimal culture medium for both BM-MSCs and AT-MSCs was determined 
in two-dimensional (2D) culture conditions in Chapter 4, a subsequent study was 
performed using three-dimensional (3D) culture conditions, in which cells were 
incorporated within hydrogels (Chapter 5). Hydrogels have attracted huge interests 
for minimally invasive surgical applications because of their injectability, among 
which collagen and oligo(poly(ethylene glycol)fumarate) (OPF) hydrogels are 
representatives of two main categories, i.e. natural and synthetic based hydrogels, 
respectively. Regarding cell loading methods (i.e. cell distribution) in hydrogels, 
single cells were often encapsulated and dispersed homogenously throughout the 
hydrogels, which is called dispersed- (D-) loading. However, due to the spatial 
distribution of the cells in this seeding method, cell-cell contact can be 
compromised and hamper cell performance. Therefore, both sandwich- (S-, cells 
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were l aded in between two hydrogel layers) and spheroid- (Sp-, sphero ds were 
encapsulated in hydrogels, r her than ingle c lls) loading were hypothe ized t  
induce higher osteogenesis because of the i proved cell-cell co tact. The cell 
behavior of both BM-MSCs and AT-MSCs in three loading methods, which are D-, 
S- and Sp-loading in two hydrogel systems (i.e. collagen and OPF), was compared. 
The results suggested that the cell behavior was influenced by the hydrogel type, 
meaning cells cultured in collagen hydrogels had higher proliferation and 
osteogenic differentiation capacity than in OPF hydrogels. In addition, AT-MSCs 
exhibited higher proliferation and osteogenic properties compared to BM-MSCs. 
However, no difference was observed for mineralization among the three loading 
methods, which did not confirm the hypothesis that S- and Sp-loading increases 
osteogenic capacity compared to D-loading. In conclusion, D- and Sp-loading 
represents two promising cell loading methods for injectable bone substitute 
materials that allow application of minimally invasive surgery for cell-based 
regenerative treatment. 
5. Will cocultures of AT-MSCs/ECs form more bone in comparison to AT-MSCs 
monocultures in an orthotopic implantation model? 
While the bone forming cap city of BM-MSCs ha  been proved b  a number of 
studies12-13, the feasibility of bone f rmation using AT-MSCs remains 
controver i l14-16. I  Chapter 6, the osteogenic capacity between AT-MSCs and 
AT-MSCs/ECs was compared both in vitr  and in vivo (i.e. rat cranial d fects). 
Fi stly, the optimal c ll ratio in cocultures f r osteogenic differe tiation was 
d termined by seeding AT-M Cs and ECs in ratios varyi g from 100:0 o 0:100 on 
tissue cult re plates. Aft rward , AT-MSCs and AT-MSCs/ECs were seeded on 
porous titanium fiber mesh scaffolds (Ti) for both in vitro and in vivo os eogenic 
evalu tio . For i  vit o evaluation, osteogenic differen i tion w s assessed by ALP-
activity and calcium ass y. For i  viv  evaluation, the scaffolds were implanted 
bilaterally into r t cranial defects (5 mm diameter) and bone formation was 
assessed histologically and histomorp ometrically after 8 weeks. The ratio of 50:50 
was chosen in the ocultures since th s cocultur  condition retained similar ount 
of calcium deposition while using the least number of AT-MSCs. Moreover, AT-
MSCs showed higher osteogenic differentiation in comparison to AT-MSCs/ECs on 
Ti in vitro. Further, superior bone formation wa  observed in AT-MSCs compared 
to AT-MSCs/ECs i  rat cran al defec s. In conclusion, AT-MSCs showed 
sign fica tly higher osteogenic potenti l compared to AT-MSCs/ECs both in vitr  
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and in vivo. However, a limitation of the study was that determination of the origin 
of the newly formed bone (i.e. donor or host) could not be performed. 
6. What is the effect of ectopic implantation site (i.e. subcutaneous and 
intramuscular) on bone formation of AT-MSCs and AT-MSCs/ECs? 
It has been postulated that the bone forming capacity of an engineered bone 
construct may be affected by the implantation site conditions, which can differ in 
blood flow and thus nutrition and oxygen supply and waste removal17. Therefore, in 
Chapter 7, we evaluated the effect of implantation site (i.e. subcutaneous, SQ vs. 
intramuscular, IM) on the bone forming capacity of cell-based and growth factor-
based constructs in athymic nude rats during an implantation period of 8 weeks. 
For this experiment, cell-based constructs consisted of porous 
hydroxyapatite/tricalcium phosphate (HA/TCP) blocks seeded with either human 
AT-MSCs monocultures or AT-MSCs/ECs cocultures and were pre-cultured in OM 
for 7 days. The growth factor-based constructs consisted of identical porous 
HA/TCP blocks with pre-adsorbed bone morphogenetic protein (BMP-2, 20 
ug/scaffold). Histological and histomorphometrical analyses were used to assess 
bone formation. An in vitro experiment was performed in parallel to compare the 
osteogenic capacity of the cell-based constructs. The cell-based constructs 
showed evident osteogenic differentiation in vitro, with only marginal differences 
between AT-MSCs monocultures and AT-MSCs/HUVECs cocultures. In vivo, none 
of the cell-based constructs showed bone formation, irrespective of the site of 
implantation. In contrast, all the growth factor-based constructs showed bone 
formation at both implantation sites without differences in the amount of formed 
bone. In conclusion, the results of this study demonstrated that the bone forming 
capacity of HA/TCP scaffolds with pre-adsorbed BMP-2 is equal at different ectopic 
implantation sites. Further, despite a similar in vitro osteogenic differentiation of 
AT-MSCs monocultures and AT-MSCS/HUVECs cocultures on HA/TCP scaffolds, 
a lack of ectopic bone forming capacity of these cell-based constructs was 
observed in vivo. 
7. Do AT-MSCs/ECs cocultures have equal angiogenic capacity compared to BM-
MSCs/ECs cocultures? 
Next to the comparison of osteogenic capacity between BM-MSCs and AT-MSCs 
and their cocultures with ECs, the angiogenic capacity of these cocultures using 
was evaluated both in vitro and in vivo at early time points (i.e. day 3 and 7) in 
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Chapter 8. In vitro, cells were either monocultured (i.e. BM-MSCs, AT-MSCs or 
ECs) or cocultured (i.e. BM-MSCs/ECs and AT-MSCs/ECs) on Thermanox® (2D) 
or in collagen gels (3D). For the in vivo experiment, cocultures were prepared in 
collagen gels and implanted subcutaneously in athymic nude mice. For both in vitro 
and in vivo experiments, samples were collected on day 3 and 7 and histologically 
processed for hematoxylin-eosin and CD31 (i.e. endothelial specific marker) 
staining. For in vivo samples, quantitative parameters for evaluating angiogenesis 
included CD31-positive staining percentage, total vessel-like structure (VLS) area 
percentage, VLS density, and average VLS area (i.e. the size of per VLS). In vitro 
results showed formation of VLS in both cocultures, while none of the 
monocultures (i.e. BM-MSCs, AT-MSCs or ECs) showed VLS formation, 
irrespective of 2D or 3D culture conditions. Although VLS formation occurred after 
in vivo implantation, no significant difference in angiogenic capacity was observed 
between the two cocultures, neither on day 3 nor on day 7. Further, VLS density 
decreased and anastomosis of the new human vessels with the murine host 
vasculature occurred over time. In conclusion, this study demonstrated that AT-
MSCs/ECs and BM-MSCs/ECs have equal angiogenic capacity both in vitro and in 
vivo, and that vessels from the donor origin can anastomose with the host 
vasculature within 7-day implantation. 
Closing remarks and future perspectives 
This thesis demonstrated that: 
(i) a cell ratio of 50:50 is optimal for osteogenesis for both BM-MSCs/ECs and AT-
MSCs/ECs cocultures, with FBS- and PL-supplemented OM to favor osteogenesis 
of BM-MSCs and AT-MSCs (regardless of monocultures or cocultures with ECs), 
respectively; 
(ii) AT-MSCs have at least equal osteogenic (in vitro) and angiogenic capacity (in 
vitro and in vivo) as BM-MSCs; and that 
(iii) bone formation was not observed in ectopic implantation sites using AT-MSCs 
monocultures or AT-MSCs/ECs cocultures. 
Although AT-MSCs and AT-MSCs/ECs showed high osteogenic capacity in vitro 
(Chapter 4), the bone forming ability of AT-MSCs in vivo has not been fully proven 
in this thesis. First, we tested the bone forming ability of AT-MSCs in an orthotopic 
model (i.e. a rat cranial defect). Although new bone tissue formation was found, we 
could not determine the origin (i.e. cell source, donor or host) of the newly formed 
bone tissue due to the impossibility of performing immunohistochemical staining on 
MMA-embedded specimens (Chapter 6). Later, when AT-MSCs were implanted 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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and in vivo. However, a limitation of the study was that determination of the origin 
of the newly formed bone (i.e. donor or host) could not be performed. 
6. What is the effect of ectopic implantation site (i.e. subcutaneous and 
intramuscular) on bone formation of AT-MSCs and AT-MSCs/ECs? 
It has been postulated that the bone forming capacity of an engineered bone 
construct may be affected by the implantation site conditions, which can differ in 
blood flow and thus nutrition and oxygen supply and waste removal17. Therefore, in 
Chapter 7, we evaluated the effect of implantation site (i.e. subcutaneous, SQ vs. 
intramuscular, IM) on the bone forming capacity of cell-based and growth factor-
based constructs in athymic nude rats during an implantation period of 8 weeks. 
For this experiment, cell-based constructs consisted of porous 
hydroxyapatite/tricalcium phosphate (HA/TCP) blocks seeded with either human 
AT-MSCs monocultures or AT-MSCs/ECs cocultures and were pre-cultured in OM 
for 7 days. The growth factor-based constructs consisted of identical porous 
HA/TCP blocks with pre-adsorbed bone morphogenetic protein (BMP-2, 20 
ug/scaffold). Histological and histomorphometrical analyses were used to assess 
bone formation. An in vitro experiment was performed in parallel to compare the 
osteogenic capacity of the cell-based constructs. The cell-based constructs 
showed evident osteogenic differentiation in vitro, with only marginal differences 
between AT-MSCs monocultures and AT-MSCs/HUVECs cocultures. In vivo, none 
of the cell-based constructs showed bone formation, irrespective of the site of 
implantation. In contrast, all the growth factor-based constructs showed bone 
formation at both implantation sites without differences in the amount of formed 
bone. In conclusion, the results of this study demonstrated that the bone forming 
capacity of HA/TCP scaffolds with pre-adsorbed BMP-2 is equal at different ectopic 
implantation sites. Further, despite a similar in vitro osteogenic differentiation of 
AT-MSCs monocultures and AT-MSCS/HUVECs cocultures on HA/TCP scaffolds, 
a lack of ectopic bone forming capacity of these cell-based constructs was 
observed in vivo. 
7. Do AT-MSCs/ECs cocultures have equal angiogenic capacity compared to BM-
MSCs/ECs cocultures? 
Next to the comparison of osteogenic capacity between BM-MSCs and AT-MSCs 
and their cocultures with ECs, the angiogenic capacity of these cocultures using 
was evaluated both in vitro and in vivo at early time points (i.e. day 3 and 7) in 
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Chapter 8. In vitro, cells were either monocultured (i.e. BM-MSCs, AT-MSCs or 
ECs) or cocultured (i.e. BM-MSCs/ECs an  AT-MSCs/ECs) on Thermanox® (2D) 
or in collagen gels (3D). For the in vivo experiment, cocultures were prepared in 
collagen gels and implanted subcutaneously in athymic nude mice. For both in vitro 
and in vivo experiments, samples were collected on day 3 and 7 and histologically 
processed for hematoxylin-eosin and CD31 (i.e. endothelial specific marker) 
staining. For in vivo samples, quantitative parameters for evaluating angiogenesis 
included CD31-positive staining percentage, total vessel-like structure (VLS) area 
percentage, VLS density, and average VLS area (i.e. the size of per VLS). In vitro 
results showed formation of VLS in both cocultures, while none of the 
monocultures (i.e. BM-MSCs, AT-MSCs or ECs) showed VLS formation, 
irrespective of 2D or 3D culture conditions. Although VLS formation occurred after 
in vivo implantation, no significant difference in angiogenic capacity was observed 
between the two cocultures, neither on day 3 nor on day 7. Further, VLS density 
decreased and anastomosis of the new human vessels with the murine host 
vasculature occurred over time. In conclusion, this study demonstrated that AT-
MSCs/ECs and BM-MSCs/ECs have equal angiogenic capacity both in vitro and in 
vivo, and that vessels from the donor origin can anastomose with the host 
vasculature within 7-day implantation. 
Closing remarks and future perspectives 
This thesis demonstrated that: 
(i) a cell ratio of 50:50 is optimal for osteogenesis for both BM-MSCs/ECs and AT-
MSCs/ECs cocultures, with FBS- and PL-supplemented OM to favor osteogenesis 
of BM-MSCs and AT-MSCs (regardless of monocultures or cocultures with ECs), 
respectively; 
(ii) AT-MSCs have at least equal osteogenic (in vitro) and angiogenic capacity (in 
vitro and in vivo) as BM-MSCs; and that 
(iii) bone formation was not observed in ectopic implantation sites using AT-MSCs 
monocultures or AT-MSCs/ECs cocultures. 
Although AT-MSCs and AT-MSCs/ECs showed high osteogenic capacity in vitro 
(Chapter 4), the bone forming ability of AT-MSCs in vivo has not been fully proven 
in this thesis. First, we tested the bone forming ability of AT-MSCs in an orthotopic 
model (i.e. a rat cranial defect). Although new bone tissue formation was found, we 
could not determine the origin (i.e. cell source, donor or host) of the newly for ed 
bone tissue due to the impossibility of performing immunohistochemical staining on 
MMA-embedded specimens (Chapter 6). Later, when AT-MSCs were implanted 
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ectopically (i.e. SQ and IM), no bone formation was observed, irrespective of 
mono- or cocultures systems (Chapter 7), which corroborates previous results18-19. 
In those previous reports, the authors hypothesized that two parameters were 
critically required for induction of osteogenesis by AT-MSCs, i.e. the osteogenic 
commitment of AT-MSCs and the presence of a mineral component in the 
scaffold20. Although our experimental design met these two requirements, no 
positive results were achieved. This suggests that other prerequisites are needed. 
Therefore, more studies on the (molecular) osteogenesis mechanisms of AT-MSCs 
as well as the enhancement of their bone forming efficacy are necessary for 
improvement of the use of this cell type in BTE applications. Firstly, the 
osteogenesis related gene expression and the secreted growth factors of AT-
MSCs should be screened over time and compared in parallel with BM-MSCs in 
vitro and in vivo. Secondly, since two-dimensional expansion of human MSCs can 
have unfavorable effects on osteogenic differentiation21, methods that can 
circumvent the expansion phase on tissue culture plastic, e.g. spheroids culture, 
are necessary to retain stemness of the MSCs. Third, increasing the pre-culture 
time of in vitro osteogenic priming may enhance bone formation ectopically as it 
has been reported that prolonged osteogenic pre-culture (i.e. from 1 week to 2 
weeks) can enhance bone formation orthotopically (i.e. in rat cranial defects)22. 
Finally, bone formation of human AT-MSCs can be increased by genetic 
manipulation with genes encoding growth factors, such as BMP-223. 
Another critical issue relates to the question whether cocultures can enhance 
osteogenesis and angiogenesis compared to monocultures, especially for AT-
MSCs. Interestingly, also in contrast to BM-MSCs/ECs, AT-MSCs/ECs cocultures 
did not improve osteogenesis in comparison to AT-MSCs monocultures. In this 
respect, research on cell-cell interactions between AT-MSCs and ECs in cocultures 
can aid in explaining why cocultures do not induce higher mineralization and bone 
formation compared to AT-MSCs monocultures. 
Despite attempts of several researchers to predict the in vivo bone forming 
capacity of MSCs from in vitro indices24-25, no consensus has been reached. 
Although no bone formation was observed (i.e. ectopic implantation) using human 
AT-MSCs in the applied experimental set-up in this thesis, several aspects can be 
considered to obtain solid data on the bone forming capacity of AT-MSCs: (i) stable 
and nondisruptive labeling of the committed cells can be applied for in vivo 
implantation to localize cells without affecting their normal genetic constitution and 
functions; (ii) bone formation can be observed continuously to dynamically evaluate 
the bone formation process; (iii) it would be interesting to address bioreactor 
system effects for cell seeding and in vitro culture. 
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As a general principle, cell-based approaches for BTE application should be 
clinically competitive or superior to existing therapies. In pre-clinical studies, large 
animal models should be used to assess graft functionality, as research on small 
animals does not provide relevant results due to major differences in defect size 
and healing properties. Furthermore, research on the underlying mechanisms of 
osteogenic differentiation of stem cells as well as enhancement of bone forming 
capacity remains a challenging topic. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Another critical issue relates to the question whether cocultures can enhance 
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respect, research on cell-cell interactions between AT-MSCs and ECs in cocultures 
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Despite attempts of several researchers to predict the in vivo bone forming 
capacity of MSCs from in vitro indices24-25, no consensus has been reached. 
Although no bone formation was observed (i.e. ectopic implantation) using human 
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and nondisruptive labeling of the committed cells can be applied for in vivo 
implantation to localize cells without affecting their normal genetic constitution and 
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fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Samenvatting 
Bot tissue engineering (BTE) is een veelbelovende aanpak voor botregeneratie, 
ook al blijven de uitdagingen groot. Het gebruik van mesenchymale stamcellen 
(MSCs)in BTE heeft bewezen waardevol te zijn voor het vergroten van de bot 
regeneratieve capaciteit in dierstudies1. Ten aanzien van de verschillende types 
MSCs zijn de MSCs verkregen uit beenmerg (BM) het meest gebruikt en het meest 
bestudeerd voor BTE doeleinden. Echter, het verkrijgen van grote aantallen cellen 
van een makkelijk bereikbare locatie blijft een uitdaging voor MSCs transplantatie2. 
Omdat BM-MSCs niet voldoen aan de wens voor een makkelijk bereikbare locatie, 
hebben MSCs verkregen uit vetweefsel (adipose tissue, AT) veel aandacht 
gekregen als mogelijk alternatief en cel-gebaseerde BTE. 
Het is bekend dat naast herkomst van cellen ook vascularisatie in geëngineerde 
constructen een voorwaarde is voor BTE strategieën. Onvoldoende vasculatisatie 
leidt tot een slechte overleving van cellen in het construct3,4 en beperkt daarmee 
het succes van botregeneratie, vooral voor grote botdefecten5,6. Daarom heeft 
onderzoek zich gericht op mogelijke strategieën om botregeneratie te verbeteren 
via betere vascularisatie in geëngineerde constructen. Verschillende technieken 
zijn hiervoor gebruikt, waaronder biofabricatie van scaffolds met angiogene 
eigenschappen, groeifactor afgifte om bloedvatvorming te stimuleren, en co-kweek 
van MSCs met endotheliale cellen (ECs). Het onderliggende principe voor het 
gebruik van co-kweek voor MSCs en ECs in BTE is gebaseerd op de ingewikkelde 
samenhang van osteogenese en angiogenese tijdens botvorming. Deze 
samenhang wordt aangetoond door het feit dat bot een sterk gevasculariseerd 
weefsel is, waarin bloedvaten en botcellen zowel ruimtelijk als temporeel met 
mekaar samenwerken7. Recente resultaten hebben aangetoond dat co-kweken 
van BM-MSCs en ECs de vorming van een vasculair netwerk8,9 en botweefsel10,11 
verbeteren in vergelijking met mono-kweken van BM-MSCs. Echter, slechts een 
beperkt aantal studies heeft zich gericht op het gebruik van AT-MSCs. 
Het doel van dit proefschrift was de effecten van MSC herkomst (i.e. BM of AT) op 
osteogenese en angiogenese te evalueren voor zowel MSC mono-kweken als co-
kweken met ECs. Hiertoe werden eerst de (co)kweek condities (e.g. kweekmedium, 
cell ratio) geoptimaliseerd. Hoofdstuk 1 omvat een korte introductie over BTE en 
de gerelateerde cel strategieën, alsook voor co-kweek systemen voor BTE 
toepassingen. Deze samenvatting evalueert de (sub)doelen zoals omschreven in 
het eerste hoofdstuk. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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Het is bekend dat naast herkomst van cellen ook vascularisatie in geëngineerde 
constructen een voorwaarde is voor BTE strategieën. Onvoldoende vasculatisatie 
leidt tot een slechte overleving van cellen in het construct3,4 en beperkt daarmee 
het succes van botregeneratie, vooral voor grote botdefecten5,6. Daarom heeft 
onderzoek zich gericht op mogelijke strategieën om botregeneratie te verbeteren 
via betere vascularisatie in geëngineerde constructen. Verschillende technieken 
zijn hiervoor gebruikt, waaronder biofabricatie van scaffolds met angiogene 
eigenschappen, groeifactor afgifte om bloedvatvorming te stimuleren, en co-kweek 
van MSCs met endotheliale cellen (ECs). Het onderliggende principe voor het 
gebruik van co-kweek voor MSCs en ECs in BTE is gebaseerd op de ingewikkelde 
samenhang van osteogenese en angiogenese tijdens botvorming. Deze 
samenhang wordt aangetoond door het feit dat bot een sterk gevasculariseerd 
weefsel is, waarin bloedvaten en botcellen zowel ruimtelijk als temporeel met 
mekaar samenwerken7. Recente resultaten hebben aangetoond dat co-kweken 
van BM-MSCs en ECs de vorming van een vasculair netwerk8,9 en botweefsel10,11 
verbeteren in vergelijking met mono-kweken van BM-MSCs. Echter, slechts een 
beperkt aantal studies heeft zich gericht op het gebruik van AT-MSCs. 
Het doel van dit proefschrift was de effecten van MSC herkomst (i.e. BM of AT) op 
osteogenese en angiogenese te evalueren voor zowel MSC mono-kweken als co-
kweken met ECs. Hiertoe werden eerst de (co)kweek condities (e.g. kweekmedium, 
cell ratio) geoptimaliseerd. Hoofdstuk 1 omvat een korte introductie over BTE en 
de gerelateerde cel strategieën, alsook voor co-kweek systemen voor BTE 
toepassingen. Deze samenvatting evalueert de (sub)doelen zoals omschreven in 
het eerste hoofdstuk. 
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1. Wat is de huidige state-of-the-art voor het gebruik van BM-MSCs en AT-MSCs, 
en hun co-kweken met ECs in BTE? 
Cellen vormen de basale component voor BTE. De huidige status van in vitro 
kweek condities en in vivo botvorming capaciteit van BM-MSCs en AT-MSCs en 
hun co-kweken met ECs zijn beschreven in Hoofdstuk 2, waarin de inconsistentie 
in de wetenschappelijke literatuur inzake de effecten van zowel preparatie van cel-
gebaseerde constructen als MSC herkomst op osteogenese en angiogenese zijn 
samengevat. Allereerst werd de variatie in de in vitro pre-kweek condities (e.g. 
kweekmedium, pre-kweek tijd) belicht omdat dit de experimentele resultaten 
beïnvloedt. Vervolgens werd de botvormende capaciteit van cel-gebaseerde 
constructen vergeleken met cel-vrije constructen, waarbij tevens onderscheid 
gemaakt werd tussen mono- en co-kweek aanpakken. De meeste gepubliceerde 
resultaten gebruiken BM-MSCs en slechts enkele publicaties gebruiken AT-MSCs. 
Er werd geconcludeerd dat cel-gebaseerde strategieën veelbelovend zijn omdat ze 
een gunstig effect hebben op in vivo botvorming. Echter, in vitro cel 
(co)kweekcondities vereisen standaardisatie en optimalisering om inter-experiment 
vergelijkingen te kunnen maken en de verwachtingen van cel-gebaseerde BTE/RM 
waar te kunnen maken. 
2. Wat is optimaal t.a.v. celkweekmedium en cel ratio in co-kweken van BM-
MSCs/ECs voor zowel osteogenese als angiogenese? 
Gebaseerd op het feit dat verschillende kweekmedia en cel ratio‟s zijn gebruikt in 
eerder BM-MSCs/ECs co-kweken en er geen consensus bestaat, werd in 
Hoofdstuk 3 gezocht naar optimalisatie van kweekmedium en cel ratio voor 
osteogenese en angiogenese. Cel (co-)kweken werden uitgevoerd in vier 
verschillende kweekmedia: MSCs proliferatie medium, osteogeen medium (OM), 
endotheelcel medium, en een 1:1 mix van de twee laatstgenoemde. Mineralisatie 
in de kweken werd enkel gezien in OM. Additionele experimenten met kweek in 
OM toonden dat alkalische fosfatase (ALP) activiteit, mineralisatie en percentage 
CD31 (platelet endothelial cell adhesion molecule, PECAM-1) positieve kleuring 
het hoogst waren voor co-kweken met een 50:50 BM-MSCs/ECs ratio. De 
resultaten van deze studie toonden dat een BM-MSCs/ECs ratio van 50:50 in OM 
de optimale conditie is voor co-kweken t.a.v. zowel osteogene als angiogene 
differentiatie. 
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3. Is humaan bloedplaatjeslysaat (PL) een ideaal alternatief voor foetaal bovine 
serum (FBS) om te gebruiken als toevoeging in kweekmedium voor BM-MSCs, AT-
MSCs en hun co-kweken met ECs? 
Zoals eerder aangegeven, zijn BM-MSCs en AT-MSCs de meest gebruikte 
stamcellen binnen BTE/RM. Voor gebruik in de kliniek is het noodzakelijk om een 
veilige en efficiënte manier voor celvermeerdering op grote schaal te vinden voor 
deze cellen. Tot dusver is FBS vooral gebruikt als voedingssupplement in 
celkweken. Echter, vanwege de risico‟s van verspreiding van dierlijke pathogenen 
in humane patiënten bij toekomstige klinische toepassing, zijn alternatieven 
gezocht, waaronder PL. In Hoofdstuk 4 hadden we als doel de effecten van FBS- 
en PL-verrijkte media op osteogenese in MSCs mono-kweken of co-kweken met 
ECs te analyseren. Cellen van drie donors (i.e. BM-MSCs en AT-MSCs) werden 
gebruikt en proliferatie en osteogene differentiatie werden geëvalueerd. De 
resultaten toonden dat het metabolisme en de proliferatie verhoogd waren in PL- 
t.o.v. FBS-verrijkt medium in mono- en co-kweken van zowel BM-MSCs als AT-
MSCs. Daarentegen was calcium depositie cel-type afhankelijk en verlaagd voor 
BM-MSCs, maar verhoogd voor AT-MSCs in PL-verrijkt medium voor zowel mono- 
als co-kweken. Het effect van co-kweken werd duidelijk voor BM-MSCs, welke een 
verhoogde osteogene differentiatie lieten zien bij co-kweek t.o.v. mono-kweek in 
zowel FBS- als PL-verrijkt medium, terwijl AT-MSCs voor mono- en co-kweek een 
gelijke osteogene differentiatie vertoonden. Uit deze data werd geconcludeerd dat 
FBS-verrijkt medium meer geschikt is voor BM-MSCs voor mineralisatie, terwijl PL-
verrijkt medium de osteogene differentiatie van AT-MSCs stimuleert, voor zowel 
mono- als co-kweken. 
4. Wat is de optimale cel-lading methode voor osteogenese van BM-MSCs, AT-
MSCs en hun co-kweken met ECs in hydrogels? 
Na de vaststelling van de optimale kweekmedia voor BM-MSCs en AT-MSCs twee-
dimensionale (2D) kweekcondities in Hoofdstuk 4, werd in Hoofdstuk 5 een 
studie uitgevoerd in drie-dimensionale (3D) kweekcondities, waarbij cellen werden 
geladen in hydrogels. Hydrogels zijn interessant voor minimaal invasieve 
toepassingen vanwege hun injecteerbaarheid en collageen en 
oligo(poly(ethyleneglycol)fumarate) (OPF) zijn vertegenwoordigers van de twee 
belangrijkste categorieën, i.e. natuurlijke en synthetische hydrogels. T.a.v. cel-
lading methoden (i.e. cel distributie) in hydrogels zijn individuele cellen vaak 
geladen en homogeen verdeeld in hydrogels, hetgeen dispersed-lading (D) 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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resultaten van deze studie toonden dat een BM-MSCs/ECs ratio van 50:50 in OM 
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genoemd wordt. Vanwege de ruimtelijke distributie van de cellen in deze cel-lading 
methode kan cel-cel contact verminderd zijn en celgedrag verminderen. Daarom 
werd als hypothese gesteld dat zowel sandwich- (S, cellen geladen tussen twee 
lagen hydrogel) als spheroid-lading (Sp, spheroid clusters van cellen homogeen 
verdeeld in hydrogels) zou leiden tot een hogere mate van osteogenese vanwege 
verhoogd cel-cel contact. Het celgedrag van BM-MSCs en AT-MSCs in deze drie 
cel-lading methodes werd vergeleken voor twee hydrogels, collageen en OPF. De 
resultaten suggereerden dat cel gedrag beïnvloedt wordt door type hydrogel, 
waarbij collageen een hogere proliferatie en osteogene differentiatie induceerde 
dan OPF. Bovendien vertoonden AT-MSCs hogere proliferatie en osteogene 
eigenschappen dan BM-MSCs. Echter, er werd geen verschil gevonden voor 
mineralisatie binnen de drie cel-lading methodes, waardoor de hypothese niet 
bevestigd kon worden. Concluderend kan gesteld worden dat D- en Sp-lading 
veelbelovende cel-lading methodes zijn voor injecteerbare botvervangende 
materialen, welke minimaal invasieve chirurgie toelaten voor cel-gebaseerde 
regeneratieve behandelingen. 
5. Laten co-kweken van AT-MSCs meer botvorming zien in vergelijking met AT-
MSCs mono-kweken in een orthotopisch implantatiemodel? 
Waar botvormende capaciteit van BM-MSCs in verschillende studies is 
aangetoond12,13, is die voor AT-MSCs minder eensluidend14-16. In Hoofdstuk 6 
werd de osteogene capaciteit van AT-MSCs en AT-MSCs/ECs vergeleken via in 
vitro en in vivo (i.e. rat craniaal defect) experimenten. Allereerst werd de optimale 
cel ratio in co-kweken voor osteogene differentiatie bepaald door AT-MSCs en ECs 
in verschillende ratio‟s te zaaien (100:0 – 0:100) op weefselkweek platen. 
Vervolgens werden AT-MSCs en AT-MSCs/ECs geladen op poreuze titanium 
vezelgaas scaffolds (Ti) voor zowel in vitro als in vivo osteogene evaluatie. In vitro 
werd gekeken naar ALP-activiteit en calcium, terwijl in vivo de scaffolds bilateraal 
geplaatst werden in rat craniale defecten (5 mm diameter) met evaluatie van 
botvorming via histologie en histomorfometrie na 8 weken. Een cel ratio van 50:50 
werd gekozen voor co-kweken omdat hiermee in vitro eenzelfde mate van 
mineralisatie werd behaald met een minimaal aantal AT-MSCs. Verder toonde in 
vitro onderzoek een hogere osteogene differentiatie voor AT-MSCs in vergelijking 
met AT-MSCs op Ti-scaffolds. Een superieure botvorming werd gevonden voor AT-
MSCs in vergelijking met AT-MSCs/ECs in de rat craniale defecten. Er werd 
geconcludeerd dat AT-MSCs een significant hoger osteogeen potentieel hebben 
t.o.v. AT-MSCs/ECs zowel in vitro als in vivo. Echter, een beperking in de studie 
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was dat de herkomst van het nieuwgevormde bot (i.e. donor of gastheer) niet kon 
worden bepaald. 
6. Wat is het effect van ectopische implantatie plek (i.e. subcutaan en 
intramusculair) op botvorming door AT-MSCs en AT-MSCs/ECs? 
Men heeft gesteld dat de botvormende capaciteit van een geengineered 
botconstruct beïnvloedt wordt door de condities op de implantatie plek, welke kan 
verschillen in bloedperfusie en dus voeding, zuurstof en afvoer van afvalstoffen17. 
Daarom werd in Hoofdstuk 7 het effect van implantatie plek (i.e. subcutaan, SC vs. 
intramusculair, IM) op de botvormende capaciteit van cel-gebaseerde en 
groeifactor-gebaseerde constructen bestudeerd in naakte ratten met een 
implantatie periode van 8 weken. Cel-gebaseerde constructen bestonden uit 
poreuze hydroxyapatiet/tricalciumfosfaat (HA/TCP) blokken geladen met humane 
AT-MSCs of AT-MSCs/ECs en 7 dagen voorgekweekt in OM. Groeifactor-
gebaseerde constructen bestonden uit identieke HA/TCP blokken met 
geadsorbeerd bone morphogenetic protein (BMP-2, 20 ug/scaffold). Histologie en 
histomorfometrie werden gebruikt om de botvorming te analyseren. Een parallel in 
vitro experiment werd uitgevoerd om de osteogene capaciteit van cel-gebaseerde 
constructen in vitro te vergelijken. Cel-gebaseerde constructen vertoonden een 
duidelijke osteogene capaciteit in vitro, met slechts marginale verschillen tussen 
AT-MSCs en AT-MSCs/ECs. In vivo werd voor geen van de cel-gebaseerde 
constructen bot gevonden, onafhankelijk van implantatie plek. Daarentegen 
toonden alle groeifactor-gebaseerde constructen botvorming op beide implantatie 
plekken met even grote hoeveelheden gevormd bot. Concluderend toonden de 
resultaten van deze studie dat de botvormende capaciteit van HA-TCP scaffolds 
met geadsorbeerd BMP-2 gelijk is op verschillende ectopische implantatie plekken. 
Ondanks een duidelijke en gelijke in vitro osteogene differentiatie van AT-MSCs en 
AT-MSCs/ECs op HA/TCP scaffolds, induceerden deze scaffolds geen botvorming 
in vivo. 
7. Hebben AT-MSCs/ECs co-kweken een gelijke angiogene capaciteit in 
vergelijking met BM-MSCs/ECs co-kweken? 
Naast de vergelijking van de osteogene capaciteit tussen BM-MSCs en AT-MSCs 
en hun co-kweken met ECs werd ook de angiogene capaciteit van deze co-kweken 
bestudeerd via zowel in vitro als in vivo experimenten met korte tijdspunten (i.e. 3 
en 7 dagen) in Hoofdstuk 8. Voor in vitro experimenten werden cellen in mono-
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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genoemd wordt. Vanwege de ruimtelijke distributie van de cellen in deze cel-lading 
methode kan cel-cel contact verminderd zijn en celgedrag verminderen. Daarom 
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dan OPF. Bovendien vertoonden AT-MSCs hogere proliferatie en osteogene 
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regeneratieve behandelingen. 
5. Laten co-kweken van AT-MSCs meer botvorming zien in vergelijking met AT-
MSCs mono-kweken in een orthotopisch implantatiemodel? 
Waar botvormende capaciteit van BM-MSCs in verschillende studies is 
aangetoond12,13, is die voor AT-MSCs minder eensluidend14-16. In Hoofdstuk 6 
werd de osteogene capaciteit van AT-MSCs en AT-MSCs/ECs vergeleken via in 
vitro en in vivo (i.e. rat craniaal defect) experimenten. Allereerst werd de optimale 
cel ratio in co-kweken voor osteogene differentiatie bepaald door AT-MSCs en ECs 
in verschillende ratio‟s te zaaien (100:0 – 0:100) op weefselkweek platen. 
Vervolgens werden AT-MSCs en AT-MSCs/ECs geladen op poreuze titanium 
vezelgaas scaffolds (Ti) voor zowel in vitro als in vivo osteogene evaluatie. In vitro 
werd gekeken naar ALP-activiteit en calcium, terwijl in vivo de scaffolds bilateraal 
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botvorming via histologie en histomorfometrie na 8 weken. Een cel ratio van 50:50 
werd gekozen voor co-kweken omdat hiermee in vitro eenzelfde mate van 
mineralisatie werd behaald met een minimaal aantal AT-MSCs. Verder toonde in 
vitro onderzoek een hogere osteogene differentiatie voor AT-MSCs in vergelijking 
met AT-MSCs op Ti-scaffolds. Een superieure botvorming werd gevonden voor AT-
MSCs in vergelijking met AT-MSCs/ECs in de rat craniale defecten. Er werd 
geconcludeerd dat AT-MSCs een significant hoger osteogeen potentieel hebben 
t.o.v. AT-MSCs/ECs zowel in vitro als in vivo. Echter, een beperking in de studie 
Chapter 9 
 
217 
 
was dat de erko st va  het nieuwgevormde bot (i.e. dono  of gastheer) niet kon 
worden bepaald. 
6. Wat is het effect van ectopische implantatie plek (i.e. subcutaan en 
intramusculair) op botvorming door AT-MSCs en AT-MSCs/ECs? 
Men heeft gesteld dat de botv mende cap iteit van ee  geengineered 
botconstruct beïnv oedt wordt door de condities op de implantatie plek, welke kan 
verschillen in bloedperfusi  en dus voeding, zuurstof en afvoer van afvalstoffen17. 
Daarom werd in Hoofdstuk 7 het effect van implantatie plek (i.e. u cutaan, SC vs. 
intramus ulair, IM) op de botvorm nde c paciteit van cel-gebaseerde en 
groeifactor-gebase rde c nstructen estudee d in n akte r tten met een 
implant tie periode van 8 weken. Cel- ebaseerde co s ructen bestonden uit 
poreuze hydroxyapatiet/t icalciumfosfaat (HA/TCP) blokken geladen met huma e 
AT-MSCs of AT-MSCs/ECs en 7 dagen voorgekweekt in OM. Groeifact r-
gebaseer e constructen bestonden uit ide tieke HA/TCP blokken met 
gead orbeerd bon  morphogenetic protein (BMP-2, 20 ug/scaffold). Hi tologie en 
histomorfometrie werden gebruikt om de botvorming te analyseren. Een parallel in 
vitro experiment werd uitgevoerd om de steogene capacitei  van cel-g baseerde 
constructen in vitro te vergelijken. C l-gebaseerde constructen vertoond n een 
duidelijke osteogene capaciteit in vitro, met slechts marginale ver chillen tussen 
AT-MSCs en AT-MSCs/ECs. In vivo werd voor geen van e cel-geba eerde 
constructen bot gevonden, onafhankelijk va  implantatie pl k. Daarentegen 
toonden alle groeifactor-gebaseerde constructen botvorming op beide implantatie 
plekken met even grote hoeveelhed n gevormd bot. Concluderend toonden de 
resultaten van deze st die dat de botvormende capaciteit van HA-TCP scaffolds 
me  geadsorb erd BMP-2 g lijk is op ver chillende ctopische implantatie plekken. 
O danks en duidelijke en gelijke in vitro osteogene differen i tie van AT-MSCs en 
AT-MSCs/ECs op HA/TCP scaffold , induceerden deze scaffolds g en botvorming 
in vivo. 
7. Hebben AT-MSCs/ECs co-kweken een gelijke angiogene capaciteit in 
vergelijking met BM-MSCs/ECs co-kweken? 
Naast de vergelijking van de osteogene capaciteit tussen BM-MSCs en AT-MSCs 
en hun co-kweken met ECs werd ook de angiogene capaciteit van deze co-kweken 
bestudeerd via zowel in vitro als in vivo experimenten met korte tijdspunten (i.e. 3 
en 7 dagen) in Hoofdstuk 8. Voor in vitro experimenten werden cellen in mono-
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kweek (i.e. BM-MSCs, AT-MSCs of ECs) of co-kweek systeem (i.e. BM-MSCs/ECs 
en AT-MSCs/ECs) bestudeerd op Thermanox© (2D) of in collageen hydrogels (3D). 
Voor het in vivo experiment werden co-kweken opgezet in collageen hydrogels en 
subcutaan geïmplanteerd in athymische naakte muizen. Voor zowel in vitro als in 
vivo experimenten werden monsters genomen op dag 3 en 7 en daarna 
histologisch verwerkt voor hematoxiylin-eosin en CD31 (i.e. endotheelcel marker) 
kleuring. In vivo werden hiermee de kwantitatieve parameters percentage CD31-
positieve kleuring, percentage totale bloedvat-achtige structuren (VLS), VLS 
dichtheid en gemiddelde VLS oppervlak (i.e. de grootte per VLS) bestudeerd voor 
angiogenese evaluatie. In vitro resultaten toonden vorming van VLS in beide co-
kweken, maar in geen enkele van de mono-kweken (i.e. BM-MSCs, AT-MSCs of 
ECs), onafhankelijk van 2D of 3D kweek condities. Hoewel VLS vorming 
plaatsvond na in vivo implantatie, werden geen verschillen in angiogene capaciteit 
waargenomen tussen beide co-kweken, niet op dag 3 en ook niet op dag 7. Voorts 
verminderde de VLS dichtheid en anastomosis van de nieuwe humane bloedvaten 
met muizen bloedvaten vond plaats in de tijd. Concluderend werd gesteld dat AT-
MSCs/ECs en BM-MSCs/ECs een gelijke angiogene capaciteit hebben in vitro en 
in vivo en dat nieuw-gevormde bloedvaten kunnen aankoppelen aan gastheer 
bloedvaten binnen 7 dagen. 
Afsluitende opmerkingen en toekomstperspectief 
Dit proefschrift heeft aangetoond dat: 
i. Een cel ratio van 50:50 optimaal is voor ostiogenese in zowel BM-
MSCs/ECs en AT-MSCs/ECs, waarbij FBS- en PL-verrijking van het 
medium respectievelijk BM-MSCs en AT-MSCs bevorderend werkt; 
ii. AT-MSCs tenminste een gelijke osteogene (in vitro) en angiogene 
capaciteit (in vitro en in vivo) hebben in vergelijking met BM-MSCs; en dat 
iii. Botvorming niet waargenomen werd na ectopische implantatie van cel-
gebaseerde constructen met AT-MSCs of AT-MSCs/ECs. 
Hoewel AT-MSCs en AT-MSCs/ECs de hoogste osteogene capaciteit hadden in 
vitro (Hoofdstuk 4), is de in vivo botvormende capaciteit van AT-MSCs niet 
volledig bewezen in dit proefschrift. Allereerst hebben we het vermogen tot 
botvorming van AT-MSCs onderzocht in een orthotopisch model (i.e. rat craniaal 
defect). Hoewel nieuw botweefsel gevormd werd, was het onmogelijk om de 
herkomst (i.e. donor of gastheer) te identificeren vanwege het onvermogen om 
immunohistochemische mogelijkheden te gebruiken voor MMA-specimens 
(Hoofdstuk 6). Vervolgens werd na ectopische implantatie (i.e. SC en IM) van AT-
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MSCs geen botvorming waargenomen, onafhankelijk van mono- of co-kweek 
systemen (Hoofdstuk 7), hetgeen overeenkomt met eerdere resultaten18,19. In 
deze eerdere literatuur, werd door de auteurs verondersteld dat twee parameters 
ernstig noodzakelijk zijn voor inductie van osteogenese door AT-MSCs, i.e. 
osteogene toewijding van AT-MSCs en de aanwezigheid van een minerale 
component in het scaffold20. Hoewel onze experimentele opzet voldeed aan deze 
vereisten, werden geen positieve resultaten bereikt. Dit suggereert dat andere 
vereisten noodzakelijk zijn. Derhalve zijn meer studies naar de (moleculaire) 
mechanismen van osteogenese in AT-MSCs noodzakelijk, evenals naar de 
verbetering van de botvormende werkzaamheid voor gebruik van dit celtype voor 
BTE toepassingen. Het is van belang dat men zich eerst richt op expressie van 
osteogene genen en afgegeven groeifactoren door AT-MSCs via het screenen 
hiervan in de tijd en het vergelijken met parallelle experimenten met BM-MSCs in 
vitro en in vivo. Daarnaast dienen methoden ontwikkeld te worden om de 
„stemness‟ van MSCs te waarborgen tijdens de in vitro expansie fase op 
weefselkweek plastic (bijv. via spheroids kweek) omdat is aangetoond dat twee-
dimensionale expansie van humane MSCs een ongunstig effect op osteogene 
differentiatie heeft21. Tevens zou verlenging van de voorkweek tijd voor in vitro 
osteogene priming de ectopische botvorming kunnen verbeteren, aangezien is 
aangetoond dat verlengde osteogene voorkweek (i.e. van 1 tot 2 weken) 
orthotopische botvorming kan verbeteren (i.e. in rat craniaal defecten)22. Tenslotte 
zou de botvorming van humane AT-MSCs kunnen worden verhoogd door 
genetische manipulatie met genen coderend voor groeifactoren, zoals BMP-223. 
Een ander kritisch punt hangt samen met de vraag of co-kweken de osteogenese 
en angiogenese kunnen verbeteren t.o.v. mono-kweken, vooral voor AT-MSCs. In 
tegenstelling tot hetgeen waargenomen voor BM-MSCs, werd de osteogenese niet 
verbeterd in AT-MSCs/ECs t.o.v. AT-MSCs. Hiervoor zou onderzoek naar cel-cel 
interacties tussen AT-MSCs en ECs in co-kweken kunnen helpen in het begrijpen 
waarom co-kweken niet meer mineralisatie en botvorming induceren bij AT-MSCs, 
maar wel bij BM-MSCs. 
Ondanks pogingen van verschillende onderzoekers om de in vivo botvormende 
capaciteit van MSCs te voorspellen via in vitro indicatoren24,25 bestaat er 
momenteel geen consensus. Hoewel geen botvorming werd waargenomen (i.e. 
ectopische implantatie) bij gebruik van humane AT-MSCs in de toegepaste 
experimentele opzet in dit proefschrift, kunnen verschillende aspecten overwogen 
worden om betrouwbare dat over botvormende capaciteit van AT-MSCs te 
verkrijgen: (i) stabiele en onverstorende labeling van toegewijde cellen kan worden 
gebruikt voor in vivo implantatie om localisatie van cellen mogelijk te maken; (ii) 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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kweek (i.e. BM-MSCs, AT-MSCs of ECs) of co-kweek systeem (i.e. BM-MSCs/ECs 
en AT-MSCs/ECs) bestudeerd op Thermanox© (2D) of in collageen hydrogels (3D). 
Voor het in vivo experiment werden co-kweken opgezet in collageen hydrogels en 
subcutaan geïmplanteerd in athymische naakte muizen. Voor zowel in vitro als in 
vivo experimenten werden monsters genomen op dag 3 en 7 en daarna 
histologisch verwerkt voor hematoxiylin-eosin en CD31 (i.e. endotheelcel marker) 
kleuring. In vivo werden hiermee de kwantitatieve parameters percentage CD31-
positieve kleuring, percentage totale bloedvat-achtige structuren (VLS), VLS 
dichtheid en gemiddelde VLS oppervlak (i.e. de grootte per VLS) bestudeerd voor 
angiogenese evaluatie. In vitro resultaten toonden vorming van VLS in beide co-
kweken, maar in geen enkele van de mono-kweken (i.e. BM-MSCs, AT-MSCs of 
ECs), onafhankelijk van 2D of 3D kweek condities. Hoewel VLS vorming 
plaatsvond na in vivo implantatie, werden geen verschillen in angiogene capaciteit 
waargenomen tussen beide co-kweken, niet op dag 3 en ook niet op dag 7. Voorts 
verminderde de VLS dichtheid en anastomosis van de nieuwe humane bloedvaten 
met muizen bloedvaten vond plaats in de tijd. Concluderend werd gesteld dat AT-
MSCs/ECs en BM-MSCs/ECs een gelijke angiogene capaciteit hebben in vitro en 
in vivo en dat nieuw-gevormde bloedvaten kunnen aankoppelen aan gastheer 
bloedvaten binnen 7 dagen. 
Afsluitende opmerkingen en toekomstperspectief 
Dit proefschrift heeft aangetoond dat: 
i. Een cel ratio van 50:50 optimaal is voor ostiogenese in zowel BM-
MSCs/ECs en AT-MSCs/ECs, waarbij FBS- en PL-verrijking van het 
medium respectievelijk BM-MSCs en AT-MSCs bevorderend werkt; 
ii. AT-MSCs tenminste een gelijke osteogene (in vitro) en angiogene 
capaciteit (in vitro en in vivo) hebben in vergelijking met BM-MSCs; en dat 
iii. Botvorming niet waargenomen werd na ectopische implantatie van cel-
gebaseerde constructen met AT-MSCs of AT-MSCs/ECs. 
Hoewel AT-MSCs en AT-MSCs/ECs de hoogste osteogene capaciteit hadden in 
vitro (Hoofdstuk 4), is de in vivo botvormende capaciteit van AT-MSCs niet 
volledig bewezen in dit proefschrift. Allereerst hebben we het vermogen tot 
botvorming van AT-MSCs onderzocht in een orthotopisch model (i.e. rat craniaal 
defect). Hoewel nieuw botweefsel gevormd werd, was het onmogelijk om de 
herkomst (i.e. donor of gastheer) te identificeren vanwege het onvermogen om 
immunohistochemische mogelijkheden te gebruiken voor MMA-specimens 
(Hoofdstuk 6). Vervolgens werd na ectopische implantatie (i.e. SC en IM) van AT-
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MSCs geen botvorming w a genom n, onafhankelijk van mo - f co-kweek 
systeme  (Hoofdstuk 7), he geen overeenkom met eerdere resultaten18,19. In 
deze eerdere literatuur, werd oor de auteurs verondersteld dat twee pa ameters 
ernstig noodzakelijk zijn voor inductie van osteogenese door AT-MSCs, i.e. 
osteogene toewijding van AT-MSCs en de aanwezigheid van een minerale 
component in het scaffold20. Hoewel onze experimentele opzet voldeed aan deze 
vereisten, werden geen positieve resultaten bereikt. Dit suggereert dat andere 
vereisten noodzakelijk zijn. Derhalve zijn meer studies naar de (moleculaire) 
mechanismen van osteogenese in AT-MSCs noodzakelijk, evenals naar de 
verbetering van de botvormende werkzaamheid voor gebruik van dit celtype voor 
BTE toepassingen. Het is van belang dat men zich eerst richt op expressie van 
osteogene genen en afgegeven groeifactoren door AT-MSCs via het screenen 
hiervan in de tijd en het vergelijken met parallelle experimenten met BM-MSCs in 
vitro en in vivo. Daarnaast dienen methoden ontwikkeld te worden om de 
„stemness‟ van MSCs te waarborgen tijdens de in vitro expansie fase op 
weefselkweek plastic (bijv. via spheroids kweek) omdat is aangetoond dat twee-
dimensionale expansie van humane MSCs een ongunstig effect op osteogene 
differentiatie heeft21. Tevens zou verlenging van de voorkweek tijd voor in vitro 
osteogene priming de ectopische botvorming kunnen verbeteren, aangezien is 
aangetoond dat verlengde osteogene voorkweek (i.e. van 1 tot 2 weken) 
orthotopische botvorming kan verbeteren (i.e. in rat craniaal defecten)22. Tenslotte 
zou de botvorming van humane AT-MSCs kunnen worden verhoogd door 
genetische manipulatie met genen coderend voor groeifactoren, zoals BMP-223. 
Een ander kritisch punt hangt samen met de vraag of co-kweken de osteogenese 
en angiogenese kunnen verbeteren t.o.v. mono-kweken, vooral voor AT-MSCs. In 
tegenstelling tot hetgeen waargenomen voor BM-MSCs, werd de osteogenese niet 
verbeterd in AT-MSCs/ECs t.o.v. AT-MSCs. Hiervoor zou onderzoek naar cel-cel 
interacties tussen AT-MSCs en ECs in co-kweken kunnen helpen in het begrijpen 
waarom co-kweken niet meer mineralisatie en botvorming induceren bij AT-MSCs, 
maar wel bij BM-MSCs. 
Ondanks pogingen van verschillende onderzoekers om de in vivo botvormende 
capaciteit van MSCs te voorspellen via in vitro indicatoren24,25 bestaat er 
momenteel geen consensus. Hoewel geen botvorming werd waargenomen (i.e. 
ectopische implantatie) bij gebruik van humane AT-MSCs in de toegepaste 
experimentele opzet in dit proefschrift, kunnen verschillende aspecten overwogen 
worden om betrouwbare dat over botvormende capaciteit van AT-MSCs te 
verkrijgen: (i) stabiele en onverstorende labeling van toegewijde cellen kan worden 
gebruikt voor in vivo implantatie om localisatie van cellen mogelijk te maken; (ii) 
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botvorming kan worden bestudeerd in een continue modus om het dynamische 
botvormingsproces te evalueren; (iii) het zou interessant zijn om effecten van 
bioreactor systemen op cel lading en in vitro kweek te evalueren. 
In het algemeen zouden cel-gebaseerde aanpakken voor BTE toepassingen 
klinisch competitief of superieur dienen te zijn aan bestaande therapieën. In pre-
klinische studies zouden derhalve grote proefdiermodellen moeten worden gebruikt 
om de werkzaamheid te evalueren, omdat onderzoek met kleine proefdiermodellen 
onvoldoende relevantie heeft vanwege grote verschillen in defect grootte en 
genezingseigenschappen. Bovendien blijft onderzoek naar onderliggende 
mechanismen van osteogene differentiatie van stamcellen evenals vergroting van 
de botvormende osteogene capaciteit een uitdagend terrein. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
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 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
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 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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botvorming kan worden bestudeerd in een continue modus om het dynamische 
botvormingsproces te evalueren; (iii) het zou interessant zijn om effecten van 
bioreactor systemen op cel lading en in vitro kweek te evalueren. 
In het algemeen zouden cel-gebaseerde aanpakken voor BTE toepassingen 
klinisch competitief of superieur dienen te zijn aan bestaande therapieën. In pre-
klinische studies zouden derhalve grote proefdiermodellen moeten worden gebruikt 
om de werkzaamheid te evalueren, omdat onderzoek met kleine proefdiermodellen 
onvoldoende relevantie heeft vanwege grote verschillen in defect grootte en 
genezingseigenschappen. Bovendien blijft onderzoek naar onderliggende 
mechanismen van osteogene differentiatie van stamcellen evenals vergroting van 
de botvormende osteogene capaciteit een uitdagend terrein. 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
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otherwise been a somewhat stressful laboratory environment. Dear Alexey, I miss 
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contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
Acknowledgements 
 
232 
 
上遇到挫折和困难，你都会耐心地倾听，劝解和开导我，给了我莫大的动力和克服
困难的勇气！老妹，谢谢你的付出和爱，我希望你在未来的道路上一帆风顺！ 
感谢所有的亲戚，在我这么多年的成长和求学生涯中给予我的无私关怀和帮助！ 
 
There are too much that I want to express, too many people that I would like to 
thank and too many things that I can vividly recall. Text is too much weak 
comparing to what is in my deepest heart and mind. Although the text stops here, 
my gratitude will continue forever…To those whom I mentioned or not, I wish you 
and your family all the best in the future. 
         
List of Publications 
233 
 
List of Publications 
Peer-reviewed publications 
1. Ma J, Both SK, Yang F, Cui FZ, Pan J, Meijer GJ, Jansen JA, van den Beucken 
JJ. Cell-based strategies in bone tissue engineering and regenerative medicine. 
Stem Cells Transl Med 2013 (in press). 
2. Ma J, van den Beucken JJ, Yang F, Both SK, Cui FZ, Pan J, Jansen JA. 
Coculture of osteoblasts and endothelial cells: optimization of culture medium 
and cell ratio. Tissue Eng Part C Methods 2010;17(3):349-57. 
3. Ma J, van den Beucken JJ, Both SK, Prins HJ, Helder MN, Yang F, Jansen JA. 
Osteogenic capacity of human BM-MSCs, AT-MSCs and their co-cultures using 
HUVECs in FBS and PL supplemented media. J Tissu  Eng Regen Med 2013 
(in press). 
4. Ma J, Yang F, Both SK, Kersten-Niessen M, Bongio M, Pan J, Cui FZ, Kasper 
FK, Mikos AG, Jansen JA, van den Beucken JJ. Comparison of cell-loading 
methods in hydrogel systems. J Biomed Mater Res A 2013 (in press). 
5. Ma J, Both SK, Ji W, Yang F, Prins HJ, Helder MN, Pan J, Cui FZ, Jansen JA, 
van den Beucken JJ. Ad pose tissue-derived MSCs as mono ultures or 
cocultures with human umbilical vein endothelial cells: performance in vitro and 
in rat cranial defects. J Biomed Mater Res A 2013 (in press). 
6. Ma J, Yang F, Both SK, Prins HJ, Helder MN, Pan J, Cui FZ, Jansen JA, van 
den Beucken JJ. Bone forming capacity of cell- and growth factor-based 
constructs at different ectopic implantation sites. Submitted to Eur Cell Mater 
2013. 
7. Ma J, Yang F, Both SK, Prins HJ, Helder MN, Pan J, Cui FZ, Jansen JA, van 
den Beucken JJ. In vitro and in vivo angiogenic capacity of BM-MSCs/HUVECs 
and AT-MSCs/HUVECs cocultures. Submitted to Biofabrication 2013. 
8. Ma J, Pan J, Tan B, Cui FZ. Determination of critical size defect of minipig 
mandible. J Tissue Eng Regen Med 2009;3(8):615-22. 
9. Ji W, Yang F, Ma J, Bouma MJ, Boerman OC, Chen Z, van den Beucken JJ, 
Jansen JA. Incorporation of stromal cell-derived factor-1alpha in PCL/gelatin 
electrospun membranes for guided bone regeneration. Biomaterials 
2013;34(3):735-45. 
List of Publications 
 
234 
 
10. Hoekstra JW, Ma J, Plachokova AS, Bronkhorst EM, Bohner M, Pan J, Meijer 
GJ, Jansen JA, van den Beucken JJ. The in vivo performance of CaP/PLGA 
composites with varied PLGA microsphere sizes and inorganic compositions. 
Acta Biomater 2013;9(7):7518-26. 
11. Leal AI, Caridade SG, Ma J, Yu N, Gomes ME, Reis RL, Jansen JA, 
Walboomers XF, Mano JF. Asymmetric PDLLA membranes containing 
Bioglass(R) for guided tissue regeneration: characterization and in vitro 
biological behavior. Dent Mater 2013;29(4):427-36. 
Curriculum vitae 
235 
 
Curriculum Vitae 
 
Jinling Ma was born on February 8th, 1982 in Zibo city in 
Shandong Province. In year 2000, she started her bachelor 
study as a medical student, with the major of dental science. In 
2005, she was enrolled as a master student with the major of 
oral and maxillofacial surgery in dentistry in China Capital 
Medical University. Her research topic was “Functional 
reconstruction of jaw defects”. During this period, she did her 
intership of dentist training, from which she realized the significance of repairing 
bone defects in clinics. 
In 2008, after she received her master degree, she did another internship in 
Department of Materials Science & Engineering in Tsinghua University, where she 
learned basic techniques and gained deeper understandings of tissue engineering 
and regenerative medicine. 
In November of 2008, she started working as a PhD student at Department of 
Biomaterials in Radboud University Nijmegen Medical Center. She participated in a 
China-Netherlands Programme Strategic Alliances (PSA) supported research 
project. During this period, she explored in vitro mineralization and in vivo bone 
formation capacities of different stem cell types under various culture conditions. 
She also compared the osteogenic capacity between mesenchymal stem cells 
monocultures and their cocultures with angiogenic cells. These studies were in 
collaboration with University of Amsterdam and VU University Amsterdam. This 
PhD research came to a successful end in April of 2013 and the results of the 
performed studies are described in this thesis. 
Now, she has been enrolled as a dentist by Beijing Stomatological Hospital which 
is affiliated to China Capital Medical University, where she will work as an 
implantologist. In her future clinical work, she will combine research with clinics to 
achieve better bone regeneration using tissue engineering approaches. 
Chapter 2 
 
28 
 
contribution to bone formation69 as well as vessel formation70 from both donor and 
host cells, among which most of the studies demonstrated that bone14,71 and blood 
vessel formation70,72 were mainly from the implanted donor cells. 
2.5. Clinical studies 
MSCs have been used in clinical trials in various fields of regenerative medicine 
such as treatment of graft versus host disease, diabetes mellitus, amyotrophic 
lateral sclerosis and liver failure. However, to our knowledge, human clinical trials 
addressing cell-based constructs for bone repair are limited to case reports (Table 
3), which emphasizes the need for randomized control trials and systematic clinical 
studies. The available case reports are about long bone defects, jaw defects, 
alveolar cleft regeneration and sinus augmentation. A search on clinicaltrials.gov 
using a combination of search terms revealed in total 24 relevant studies as listed 
below: 
 "bone marrow derived mesenchymal stem cells" AND "bone" 8 studies; 
 "adipose tissue derived mesenchymal stem cells" AND "bone" 2 studies; 
 "dental pulp stem cells" AND "bone" 0 study; 
 “mesenchymal stromal cells” AND “bone” 5 studies; 
 “mesenchymal stromal cells” AND “bone regeneration” 2 studies; 
 “stem cells” AND “bone regeneration” 7 studies. 
These studies are dedicated to the treatment of bone defects and diseases, such 
as bone cyst, osteoarthritis, osteonecrosis, spinal fusion, and atrophic nonunion 
fractures using human MSCs monocultures. Currently, some of these studies are 
still in the status of recruiting patients. To date, BM-MSCs are still the main source 
for clinical trials as well as case reports and reports on the use of coculture-based 
constructs for clinical bone regeneration is lacking. The clinical studies conducted 
so far have demonstrated that it is safe to use human MSCs for bone regeneration, 
but the outcomes are substantially less promising compared to those of animal 
studies. Only 34.5% and 25.6% of bone regeneration (of the original defect volume) 
for 2 patients was found after 4 months when BM-MSCs loaded demineralized 
bone matrix was used to restore the defects in human alveolar cleft73. Meijer et al. 
found that bone regeneration was observed in 50% (3/6) of the patients, and only 
in 1 patient bone formation was induced by the tissue-engineered construct when 
BM-MSCs seeded β-tricalcium phosphate granules were implanted in jaw defects. 
A remarkable finding of this study was that despite this low number of construct 
contribution to clinical bone formation, parallel conducted ectopic implantations 
with the constructs in nude mice showed bone formation in all specimens74. The 
List of Publications 
 
234 
 
10. Hoekstra JW, Ma J, Plachokova AS, Bronkhorst EM, Bohner M, Pan J, Meijer 
GJ, Jansen JA, van den Beucken JJ. The in vivo performance of CaP/PLGA 
composites with varied PLGA microsphere sizes and inorganic compositions. 
Acta Biomater 2013;9(7):7518-26. 
11. Leal AI, Caridade SG, Ma J, Yu N, Gomes ME, Reis RL, Jansen JA, 
Walboomers XF, Mano JF. Asymmetric PDLLA membranes containing 
Bioglass(R) for guided tissue regeneration: characterization and in vitro 
biological behavior. Dent Mater 2013;29(4):427-36. 
Curriculum vit e 
235 
 
Curriculum Vitae 
 
Jinling Ma was born on February 8th, 1982 in Zibo city in 
Shandong Province. In year 2000, she started her bachelor 
study as a medical student, with the major of dental science. In 
2005, she was enrolled as a master student with the major of 
oral and maxillofacial surgery in dentistry in China Capital 
Medical University. Her research topic was “Functional 
reconstruction of jaw defects”. During this period, she did her 
intership of dentist training, from which she realized the significance of repairing 
bone defects in clinics. 
In 2008, after she received her master degree, she did another internship in 
Department of Materials Science & Engineering in Tsinghua University, where she 
learned basic techniques and gained deeper understandings of tissue engineering 
and regenerative medicine. 
In November of 2008, she started working as a PhD student at Department of 
Biomaterials in Radboud University Nijmegen Medical Center. She participated in a 
China-Netherlands Programme Strategic Alliances (PSA) supported research 
project. During this period, she explored in vitro mineralization and in vivo bone 
formation capacities of different stem cell types under various culture conditions. 
She also compared the osteogenic capacity between mesenchymal stem cells 
monocultures and their cocultures with angiogenic cells. These studies were in 
collaboration with University of Amsterdam and VU University Amsterdam. This 
PhD research came to a successful end in April of 2013 and the results of the 
performed studies are described in this thesis. 
Now, she has been enrolled as a dentist by Beijing Stomatological Hospital which 
is affiliated to China Capital Medical University, where she will work as an 
implantologist. In her future clinical work, she will combine research with clinics to 
achieve better bone regeneration using tissue engineering approaches. 
